0001360865-12-000089.txt : 20120518 0001360865-12-000089.hdr.sgml : 20120518 20120518171213 ACCESSION NUMBER: 0001360865-12-000089 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20120331 FILED AS OF DATE: 20120518 DATE AS OF CHANGE: 20120518 FILER: COMPANY DATA: COMPANY CONFORMED NAME: COMPETITIVE TECHNOLOGIES INC CENTRAL INDEX KEY: 0000102198 STANDARD INDUSTRIAL CLASSIFICATION: PATENT OWNERS & LESSORS [6794] IRS NUMBER: 362664428 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-08696 FILM NUMBER: 12856437 BUSINESS ADDRESS: STREET 1: 1375 KINGS HIGHWAY EAST CITY: FAIRFIELD STATE: CT ZIP: 06824 BUSINESS PHONE: (203) 368-6044 MAIL ADDRESS: STREET 1: 1375 KINGS HIGHWAY EAST CITY: FAIRFIELD STATE: CT ZIP: 06824 FORMER COMPANY: FORMER CONFORMED NAME: UNIVERSITY PATENTS INC DATE OF NAME CHANGE: 19920703 10-Q 1 cttc10q1q2012.htm COMPETITIVE TECHNOLOGIES, INC. QUARTERLY REPORT ON FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2012 UNITED STATES

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


(Mark One)


[x]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended

March 31, 2012

or

[  ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from

 

to

 


Commission file number 1-8696

[cttc10q1q2012001.jpg]

COMPETITIVE TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)

www.competitivetech.net

Delaware

36-2664428

(State or other jurisdiction of incorporation or organization)

(I. R. S. Employer Identification No.)

 

 

1375 Kings Highway East, Suite 400 Fairfield, Connecticut

06824

(Address of principal executive offices)

(Zip Code)


(203) 368-6044

(Registrant’s telephone number, including area code)

 

 

(Former name, former address and former fiscal year, if changed since last report)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes [X]  No [   ]


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months.

Yes [X]

No [  ]


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "accelerated filer, large accelerated filer and smaller reporting company" as defined in Rule 12b-2 of the Exchange Act.


Large accelerated filer  [  ]

Accelerated filer  [  ]

Non-accelerated filer  [  ] (Do not check if a smaller reporting company)

Smaller reporting company  [x]


Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Exchange Act).

Yes [  ]

No [X]


The number of shares of the registrant’s common stock outstanding as of May 18, 2012 was 14,830,204 shares.



COMPETITIVE TECHNOLOGIES, INC.


INDEX TO QUARTERLY REPORT ON FORM 10-Q




PART I.  FINANCIAL INFORMATION

Page No.


Item 1.

Condensed Consolidated Interim Financial Statements (unaudited)


Condensed Consolidated Balance Sheets at March 31, 2012 (unaudited) and December 31, 2011

3


Condensed Consolidated Statements of Operations for the

three months ended March 31, 2012 and March 31, 2011(unaudited)

4


Condensed Consolidated Statement of Changes in Shareholders’ Interest for the three months

ended March 31, 2012 (unaudited)

5


Condensed Consolidated Statements of Cash Flows for the

three months ended March 31, 2012 and March 31, 2011(unaudited)

6-7


Notes to Condensed Consolidated Interim Financial Statements (unaudited)

8-19


Item 2.

Management's Discussion and Analysis of Financial Condition and

Results of Operations

20-25


Item 3.

Quantitative and Qualitative Disclosures About Market Risk

26


Item 4.

Controls and Procedures

26



PART II.  OTHER INFORMATION


Item 1.

Legal Proceedings

27


Item 1A.

Risk factors

27


Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

27


Item 3.

Defaults Upon Senior Securities

27


Item 5.

Other Information

27


Item 6.

Exhibits

27


Signatures

28


Exhibit Index

29



Page 2


PART I.  FINANCIAL INFORMATION


Item 1.  Condensed Consolidated Interim Financial Statements


COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARY

Condensed Consolidated Balance Sheets


 

March 31, 2012

 

December 31, 2011

Assets

(Unaudited)

 

 

Current Assets:

 

 

 

Cash and cash equivalents

$

1,570 

 

$

28,485 

Restricted cash

 

750,000 

Receivables, net of allowance of $101,154

at March 31, 2012, and December 31, 2011

112,015 

 

42,471 

Inventory, Finished Goods

4,440,156 

 

4,210,156 

Prepaid expenses and other current assets

56,245 

 

70,268 

Total current assets

4,609,986 

 

5,101,380 

 

 

 

 

Property and equipment, net

42,707 

 

26,169 

Security deposits

17,275 

 

17,275 

TOTAL ASSETS

$

4,669,968 

 

$

5,144,824 

 

 

 

 

Liabilities and Shareholders' Interest (Deficit)

 

 

 

Current Liabilities:

 

 

 

Accounts payable, general

$

1,326,862 

 

$

1,124,007 

Accounts payable, GEOMC

4,175,225 

 

3,865,225 

Accrued expenses and other liabilities

549,500 

 

1,228,473 

Notes payable

300,000 

 

100,000 

Deferred revenue

9,600 

 

12,800 

Derivative liability

88,960 

 

66,176 

Preferred stock liability

375,000 

 

375,000 

Total current liabilities

6,825,147 

 

6,771,681 

 

 

 

 

Commitments and Contingencies

 

 

 

Shareholders’ interest (Deficit):

 

 

 

5% preferred stock, $25 par value, 35,920 shares

authorized, 2,427 shares issued and outstanding

60,675 

 

60,675 

Series B preferred stock, $0.001 par value, 20,000 shares

authorized, no shares issued and outstanding

 

Series C convertible preferred stock, $1,000 par value,

750 shares authorized, 375 shares issued

outstanding at March 31, 2012 and December 31, 2011

 

Common stock, $.01 par value, 20,000,000 shares

authorized, 14,830,204 shares issued and outstanding

at March 31, 2012 and 14,715,789 shares issued

and outstanding at December 31, 2011

148,302 

 

147,157 

Capital in excess of par value

45,036,867 

 

44,771,128 

Accumulated deficit

(47,401,023)

 

(46,605,817)

Total shareholders’ interest (Deficit)

(2,155,179)

 

(1,626,857)

 

 

 

 

TOTAL LIABILITIES AND SHAREHOLDERS'

INTEREST (DEFICIT)

$

4,669,968 

 

$

5,144,824 

See accompanying notes



Page 3


PART I.  FINANCIAL INFORMATION (Continued)


COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARY


Condensed Consolidated Statements of Operations

(Unaudited)


 

Three months ended

 

Three months ended

 

March 31, 2012

 

March 31, 2011

Revenue

 

 

 

Product sales

$

329,746 

 

$

1,827,056 

Cost of product sales

150,571 

 

856,754 

Gross profit from product sales

179,175 

 

970,302 

 

 

 

 

Other Revenue

 

 

 

Gain on sale on rental assets

 

34,728 

Retained royalties

12,403 

 

10,610 

Investment income

1,497 

 

Other income

14,704 

 

10,910 

Total other revenue

28,604 

 

56,248 

 

 

 

 

Expenses

 

 

 

 

 

 

 

Selling expenses

86,940 

 

100,793 

Personnel and consulting expenses

331,370 

 

367,119 

General and administrative expenses

552,378 

 

516,637 

Interest expense

9,513 

 

9,616 

Unrealized loss on derivative instrument

22,784 

 

2,951 

Total Expenses

1,002,985 

 

997,116 

 

 

 

 

Income (loss) before income taxes

(795,206)

 

29,434 

Provision (benefit) for income taxes

 

 

 

 

 

Net income (loss)

$

(795,206)

 

$

29,434 

 

 

 

 

Basic income (loss) per share

$

(0.05)

 

$

(0.00)

 

 

 

 

Basic weighted average number

of common shares outstanding:

14,752,251 

 

13,826,055 

 

 

 

 

Diluted income (loss) per share

$

(0.05)

 

$

(0.00)

 

 

 

 

Diluted weighted average number

of common shares outstanding:

14,752,251 

 

14,466,787 


See accompanying notes





Page 4


 PART I.  FINANCIAL INFORMATION (Continued)


COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARY

Condensed Consolidated Statement of Changes in Shareholders' Interest (Deficit)

For the Three Months Ended March 31, 2012

(Unaudited)


 

Preferred Stock

 

Common Stock

 

 

 

 

 

 

 


Shares

outstanding

 



Amount

 


Shares

outstanding

 



Amount

 

Capital

in excess

of par value

 


Accumulated

deficit

 

Total

shareholders’

interest(deficit)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance – December 31, 2011

2,427

 

$

60,675

 

14,715,789

 

$

147,157

 

$

44,771,128

 

$

(46,605,817)

 

(1,626,857)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

-

 

-

 

-

 

-

 

-

 

(795,206)

 

(795,206)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares issued

to settle accounts

payable, general and

accrued expenses

-

 

-

 

114,415

 

1,145

 

127,109

 

 

128,254 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Compensation expense

from stock option

grants

-

 

-

 

-

 

-

 

138,630

 

 

138,630 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance – March 31, 2012

2,427

 

$

60,675

 

14,830,204

 

$

148,302

 

$

45,036,867

 

$

(47,401,023)

 

$

(2,155,179)

See accompanying notes



Page 5


 PART I.  FINANCIAL INFORMATION (Continued)


COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARY


Condensed Consolidated Statements of Cash Flows

(Unaudited)


 

Three months ended

 

Three months ended

 

March 31, 2012

 

March 31, 2011

Cash flows from operating activities:

 

 

 

Net income (loss)

$

(795,206)

 

$

29,434 

Adjustments to reconcile net income (loss) to net cash used in operating activities:

 

 

 

Depreciation and amortization

3,464 

 

8,154 

Share-based compensation – stock options

138,630 

 

4,720 

Accrued stock contribution (directors stock exp)

 

(10,083)

Gains on sale of rental assets

 

(34,728)

Unrealized loss on derivative instrument

22,784 

 

2,951 

Changes in assets and liabilities:

 

 

 

Receivables

(69,544)

 

(1,152,853)

Restricted cash

750,000 

 

Prepaid expenses and other current assets

14,022 

 

1,764 

Inventory

(230,000)

 

(870,228)

Accounts payable, accrued expenses and

other liabilities

(41,063)

 

1,708,077 

Net cash (used in) operating activities

(206,913)

 

(312,792)

 

 

 

 

Cash flows from investing activities:

 

 

 

Purchase of property and equipment

(20,002)

 

(14,415)

Proceeds from sale of rental asset

 

43,800 

Increase in security deposits

 

(2,275)

Net cash provided by (used in) provided by investing activities

(20,002)

 

27,110 

 

 

 

 

Cash flows from financing activities:

 

 

 

Proceeds from note payable

200,000 

 

50,000 

Proceeds from exercise of stock options

 

10,050 

Cash provided by financing activities

200,000 

 

60,050 

 

 

 

 

Net (decrease) in cash and cash equivalents

(26,915)

 

(225,632)

Cash and cash equivalents at beginning of period

28,485 

 

557,018 

 

 

 

 

Cash and cash equivalents at end of period

$

1,570 

 

$

331,386 

 

 

 

 



Supplemental disclosure of non-cash investing and financing transactions:


During February 2012, the Company issued 14,415 shares at $1.19 per share to settle $17,154 of accrued liabilities.


During March 2012, the Company issued 100,000 common shares at $1.111 per share to settle $111,100 of accrued liabilities.




Page 6


During February 2011, the Company canceled 10,000 common shares previously issued to Crisnic and canceled the related $9,000 receivable.   


During February 2011, the Company issued 10,000 common shares at $0.99 per share to settle $9,900 of deferred payroll.


During January 2011, the Company canceled 15,000 common shares previously issued to Crisnic and canceled the related $13,500 receivable.   


During January 2011, the Company issued 15,000 common shares at $1.09 per share to settle $16,350 of accrued liabilities.


See accompanying notes



Page 7


PART I.  FINANCIAL INFORMATION (Continued)


COMPETITIVE TECHNOLOGIES, INC. AND SUBSIDIARY


Notes to Condensed Consolidated Interim Financial Statements

(Unaudited)


1.

BASIS OF PRESENTATION


The interim condensed consolidated financial information presented in the accompanying condensed consolidated financial statements and notes hereto is unaudited.


Competitive Technologies, Inc. ("CTTC") and its majority-owned subsidiary, Vector Vision, Inc. ("VVI"), (collectively, "we" or "us") provide patent and technology licensing and commercialization services throughout the world, with concentrations in the U.S., Europe and Asia, with respect to a broad range of life and physical sciences, electronics, and nanotechnologies originally invented by individuals, corporations and universities.  


These consolidated financial statements include the accounts of CTTC and VVI.  Inter-company accounts and transactions have been eliminated in consolidation.


We believe we made all adjustments necessary, consisting only of normal recurring adjustments, to present the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S.  The results for the three months ended March 31, 2012 are not necessarily indicative of the results that can be expected for the next full fiscal year ending December 31, 2012.


The interim unaudited condensed consolidated financial statements and notes thereto, should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission ("SEC") on April 16, 2012.


During the three months ended March 31, 2012, and the three months ended March 31, 2011, we had a significant concentration of revenues from our Calmare® pain therapy medical device.  The percentages of gross revenue attributed to sales and rentals of Calmare® devices were 92% and 97% in the three months ended March 31, 2012 and March 31, 2011, respectively.  We continue to expand our sales activities for the Calmare® device and expect the majority of our revenues to come from this technology for at least the next two fiscal years.  However, we continue to seek revenue from new or existing technologies or products to mitigate the concentration of revenues, and replace revenues from expiring licenses and patents on other technologies.  


The Company incurred operating losses for the past three quarters, having produced marginal net income in the first quarter of 2011, after having incurred operating losses each quarter since fiscal 2006.  The Company has taken steps to significantly reduce its operating expenses going forward and expects revenue from sales of Calmare® medical devices to grow.  During the five month transitional period ended December 31, 2010; the Company undertook a major reduction of its operating expenses through staff reductions and reduced office space costs.  However, even at the reduced spending levels, should the anticipated increase in revenue from sales of Calmare® devices not occur the Company may not have sufficient cash flow to fund operating expenses beyond the fourth quarter of calendar 2012.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include adjustments to reflect the possible future effect of the recoverability and classification of assets or amounts and classifications of liabilities that may result from the outcome of this uncertainty.


The Company's continuation as a going concern is dependent upon its developing recurring revenue streams sufficient to cover operating costs.  The company does not have any significant individual cash or capital requirements in the budget going forward.  If necessary, CTTC will meet anticipated operating cash requirements by further reducing costs, issuing debt and/or equity, and/or pursuing sales of certain assets and technologies while we pursue licensing and distribution opportunities for our remaining portfolio of technologies.  There can be no assurance that the Company will



Page 8


be successful in such efforts.  Failure to develop a recurring revenue stream sufficient to cover operating expenses would negatively affect the Company’s financial position.


Our liquidity requirements arise principally from our working capital needs, including funds needed to sell our current technologies and obtain new technologies or products, and protect and enforce our intellectual property rights, if necessary.  We fund our liquidity requirements with a combination of cash on hand, cash flows from operations, if any, including royalty legal awards, short term borrowing, and sales of common stock.  At March 31, 2012, we had no outstanding long-term debt.  


During the fiscal 2011, the Company entered into a Factoring Agreement with Versant Funding, LLC ("Versant") to accelerate receivable collection and better manage cash flow.  Under the Factoring Agreement the Company will sell to Versant certain of the Company's accounts receivables.  For those accounts receivable the Company tenders to Versant and Versant chooses to purchase, Versant will advance 75% of the face value to the Company, and will submit a percentage of the remainder to the Company upon collection on the account.  The percentage is based on the time it takes Versant to collect on the account.   As part of the Factoring Agreement, the Company and Versant entered into a Security Agreement whereby the Company granted Versant a security interest in certain of the Company’s assets to secure the Company’s performance of the representations made with respect to the purchase of the accounts receivable.  At March 31, 2012, no receivables were factored.


Sales of our Calmare® pain therapy medical device continue to be the major source of revenue for the Company.  The Company acquired the exclusive, worldwide rights to the "Scrambler Therapy" technology in 2007.  The Company's agreement with Giuseppe Marineo, the inventor of "Scrambler Therapy" technology, and Delta Research and Development ("Delta"), authorizes CTTC to manufacture and sell worldwide the device developed from the patented "Scrambler Therapy" technology.  The "Scrambler Therapy™" technology is patented in Italy and applications for patents have been filed in the U.S. and internationally and are pending approval.  The Calmare® device has CE Mark certification from the European Union as well as U.S. FDA 510(k) clearance.


The agreement with Professor Marineo and Delta enabled the Company to establish an agreement with GEOMC Co., Ltd. ("GEOMC", formerly Daeyang E & C Co., Ltd.) of Seoul, South Korea, to manufacture the Calmare® pain therapy medical device, based on Prof. Marineo's "Scrambler Therapy™" technology.  The GEOMC agreement is for a period of ten (10) years, through 2017, and outlines each company's specific financial obligations.


The Company has entered into a number of international distribution agreements, at one time covering nearly 40 countries.  The Company conducted a review of its distribution partners during the five-month period ending December 31, 2010, leading to the termination of CTTC's agreement with Life Epistéme Group, srl ("LEG").  LEG had the distribution rights in 34 countries, but had not met its minimum obligations to CTTC, and the Company had no indication that LEG would meet its commitments in the foreseeable future.  



During the quarter ended March 31, 2011, CTTC negotiated a new distribution agreement with Life Episteme Italia ("LEI") for the countries of Italy and Malta. The distribution agreement with LEI contained quarterly and annual marketing and sales requirements which LEI must meet in order to retain continued exclusivity within LEI's territory.  


In 2010, the Company became its own distributor in the U.S, contracting with 15 commissioned sales representatives.  During 2011, the Company and its representatives developed plans to increase awareness of the Calmare device among critical medical specialties and have begun to implement those plans targeting specific customers and locations in fiscal 2012.


Over the past 18 months, the Company entered into several sales agreements for the Calmare® device, including sales to U.S. government entities within the U.S. Department of Defense and the U.S. Department of Veterans Affairs.  Sales to these physicians and medical practices and to others with whom the Company had existing sales agreements are generating revenue for the Company.  




Page 9


We earn revenue in two ways: retained royalties from licensing our clients' and our own technologies to our customer licensees, and sales of finished products.  We record revenue when the terms of the sales arrangement are accepted by all parties including a fee that is fixed and determinable, delivery has occurred and our customer has taken title, and collectability is reasonably assured.


In 2011 the Company took greater control of the sales process, worldwide.  We are the primary obligor, responsible for delivering devices as well as for training our customers in the proper use of the device.  We deal directly with customers, setting pricing and providing training; work directly with the inventor of the technology to develop specifications and any changes thereto and to select and contract with manufacturing partners; and retain significant credit risk for amounts billed to customers.  Therefore, all product sales are recorded following a gross revenue methodology.


2.

NET INCOME (LOSS) PER COMMON SHARE


The following sets forth the denominator used in the calculations of basic net income (loss) per share and net income (loss) per share assuming dilution:


 

Three  months ended

 

Three months ended

 

March 31, 2012

 

March 31, 2011

Denominator for basic net income (loss) per share, weighted average shares outstanding

14,752,251

 

13,826,055

Dilutive effect of common stock options

N/A

 

8,212

Dilutive Effect of Series C convertible preferred stock

N/A

 

632,520

Denominator for diluted net income (loss) per share, weighted average shares outstanding

14,752,251

 

14,466,787


Options to purchase 373,000 shares of our common stock outstanding at March 31, 2012 and 375 shares of convertible preferred stock at March 31, 2012 were not included in the computation of diluted net income (loss) per share because they were anti-dilutive.  


In the quarter ended March 31, 2011, those options with exercise prices less than $1.28, (average market price for the period) if exercised, would have resulted in dilution using the treasury stock method.  At March 31, 2011 the Company had 280,000 outstanding options to purchase its common stock, of which only 30,000 options had an exercise price less than $1.28.  In addition, 750 shares of convertible preferred stock were outstanding at March 31, 2011, with the dilutive effect of 632,520 shares of common stock.


3.

RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS



No new accounting pronouncements issued or effective during the three months ended March 31, 2012 has had or is expected to have a material impact on the consolidated financial statements.




Page 10



4.

RECEIVABLES


Receivables consist of the following:   


 

March 31, 2012

 

December 31, 2011

Calmare® Sales Receivable

$

102,850

 

$

24,444

Other Receivable

9,165

 

18,027

Royalties, net of allowance of $101,154

at March 31, 2012 and December 31, 2011

-

 

 

Total receivables

$

112,015

 

$

42,471


5.

AVAILABLE-FOR-SALE AND EQUITY SECURITIES


The fair value of the equity securities we held were categorized as available-for-sale securities, were zero, consisted of shares in Security Innovation and Xion Pharmaceutical Corporation.  We own 223,317 shares of stock in the privately held Security Innovation, an independent provider of secure software located in Wilmington, MA.


In September 2009 we announced the formation of a joint venture with Xion Corporation for the commercialization of our patented melanocortin analogues for treating sexual dysfunction and obesity.  CTTC currently owns 60 shares of common stock or 33% of the outstanding stock of privately held Xion Pharmaceutical Corporation.


6.

FAIR VALUE MEASUREMEMENTS


The Company measures fair value in accordance with Topic 820 of the FASB Accounting Standards Codification ("ASC"), "Fair Value Measurements and Disclosures" ("ASC 820"), which provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described as follows:


Level 1 -

Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.


Level 2 -

Inputs to the valuation methodology include:

Quoted prices for similar assets or liabilities in active markets;

Quoted prices for identical or similar assets or liabilities in inactive markets;

Inputs other than quoted prices that are observable for the asset or liability;

Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.


Level 3 -

Inputs to the valuation methodology are unobservable and significant to the fair value measurement.


The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.  Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.




Page 11


The Company values its derivative liability associated with the variable conversion feature on its Series C Convertible Preferred Stock (Note 12) based on the market price of its common stock.  For each reporting period the Company calculates the amount of potential common stock that the Series C Preferred Stock could convert into based on the conversion formula (incorporating market value of our common stock) and multiplies those converted shares by the market price of its common stock on that reporting date.  The total converted value is subtracted by the consideration paid to determine the fair value of the derivative liability.


The method described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value could result in a different fair value measurement at the reporting date.


The Company classified the derivative liability of $88,960 and $66,176 at March 31, 2012 and December 31, 2011, respectively, in Level 2 of the fair value hierarchy.


The carrying amounts reported in our Condensed Consolidated Balance Sheet for Cash and Cash Equivalents, Accounts Receivable, Accounts Payable, Notes Payable, Accrued Expenses and Other Liabilities and Preferred Stock Liability approximate fair value due to the short-term maturity of those financial instruments.


7.

PREPAID EXPENSES AND OTHER CURRENT ASSETS


Prepaid expenses and other current assets consist of the following:


 

March 31, 2012

 

December 31, 2011

Prepaid insurance

$

855

 

$

25,283

Travel and commission advances

35,500

 

35,500

Other

19,890

 

9,485

Prepaid expenses and other current assets

$

56,245

 

$

70,268


8.

PROPERTY AND EQUIPMENT


Property and equipment, net, consist of the following:


 

March 31, 2012

 

December 31, 2011

Property and equipment, gross

$

247,647

 

$

227,645

Accumulated depreciation and amortization

204,940

 

201,476

     Property and equipment, net

$

42,707

 

$

26,169


Depreciation and amortization expense was $3,464 and $8,154 for the three months ended March 31, 2012, and 2011, respectively.  


9.

ACCOUNTS PAYABLE, GENERAL


 

March 31, 2012

 

December 31, 2011

Legal fees payable

$

785,534

 

$

733,858

Accounting fees payable

103,397

 

39,285

Consulting fees payable

225,024

 

110,515

Other payables

212,907

 

240,349

Accounts Payable, General

$

1,326,862

 

$

1,124,007




Page 12


10.

ACCRUED EXPENSES AND OTHER LIABILITIES


 

March 31, 2012

 

December 31, 2011

Royalties payable

$

284,948

 

$

210,169

Deferred compensation

8,089

 

-

Accrued accounting fees

65,502

 

93,529

Arbitration settlement payable

-

 

775,000

Other accrued liabilities

190,961

 

149,775

Accrued Expenses and Other Liabilities

$

549,500

 

$

1,228,473


Deferred revenue includes 12 and 16 training days which were purchased but not conducted during the three months ended March 31, 2012 and year ended December 31, 2011, respectively.  


11.

NOTES PAYABLE


In December 2011, the Company issued a 90-day note payable to borrow $100,000.  That note was originally extended for an additional 30 days in March 2012.  The proceeds were used for general corporate purposes.  In January 2012, two additional notes were issued to borrow $50,000 each.  In April and May, 2012 additional notes totaling $125,000 were issued.  On May 10, 2012 all notes totaling $325,000 were combined into one note.  Note payable bears simple of interest at 6.00% per annum.  Principal amounts totaling $300,000 and $25,000 including all unpaid interest are due on July 2, 2012 and August 1, 2012, respectively.    


In March 2012, the Company issued a 24-month convertible promissory note to borrow $100,000 for general corporate purposes.  The convertible promissory note bears simple interest of 6.00% simple interest per annum and is payable monthly in advance. At any time on or after September 13, 2012 the holder of the note may elect by notice to the Company to convert this convertible promissory note into shares of Company’s common stock at the rate of $1.05 per share.


12.

SHAREHOLDERS’ INTEREST


On May 2, 2011 the Company adopted and executed the Employees’ Directors’ and Consultants Stock Option Plan (the “Plan”).  During the three months ended March 31, 2012, the Company granted 70,000 options to directors which were fully vested upon granting.  Also, 10,000 previously granted options were forfeited during the quarter ended March 31, 2012.  All outstanding options have been fully expensed.


During the three months ended March 31, 2012, the Board of Directors extended the expiration dates for all options previously granted to two departing Board members in recognition for their service during the period of managerial transition.  Those options will expire per their original term specified in each individual option agreement, typically either 5 or 10 years from the date of granting, rather than expiring within the specified time period, typically 90 days following the Board members’ termination dates.  The Company considered the extension as a modification to the option agreements recording incremental compensation of $80,000 for the three months ended March 31, 2012.


We estimated the fair value of each option on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions.


Three Months Ended March 31, 2012

Dividend yield (1)

  0.0%

Expected volatility (2)

86.7% - 87.1%

Risk-free interest rates (3)

  0.89%

Expected lives (2)

5 YEARS


(1)

We have not paid cash dividends on our common stock since 1981, and currently do not have plans to pay or declare cash dividends. Consequently, we used an expected dividend rate of zero for the valuations.



Page 13


(2)

Estimated based on our historical experience. Volatility was based on historical experience over a period equivalent to the expected life in years.

(3)

Based on the U.S. Treasury constant maturity interest rate with a term consistent with the expected life of the options granted.


During the three months ended March 31, 2012, the Company recognized expense of $58,630 for stock options issued to directors during the current period.   During the three months ended March 31, 2011, the Company recognized expense of $4,720, for stock options issued to employees.


On December 15, 2010 the Company issued a $400,000 promissory note.  The promissory note was scheduled to mature on December 31, 2012 with an annual interest rate of 5%.


On December 15, 2010, the Company's Board of Directors authorized the issuance of 750 shares of Series C Convertible Preferred Stock ($1,000 par value) with a 5% cumulative dividend to William R. Waters, Ltd. of Canada.  On December 30, 2010, 750 shares were issued.  The Company converted the above $400,000 promissory note into 400 shares and received cash of $350,000 for the remaining 350 shares.  These transactions were necessitated to replenish the Company's operating cash which had been drawn down by the $750,000 cash collateral previously posted by CTTC in a prejudgment remedy action styled John B. Nano v. Competitive Technologies, Inc., Docket No. CV10 5029318 (Superior Court, Bridgeport, CT), see Note 12 below for details.   


On June 17, 2011, William R. Waters, Ltd. of Canada, advised the Company of its intent to convert one half of its Series C Convertible Preferred Stock, 375 shares, to common stock, with a conversion date of June 16, 2011.  On July 14, 2011, American Stock Transfer & Trust Company was asked to issue the certificate for 315,126 shares of CTTC common stock.  In accordance with the conversion rights detailed below, the conversion price for these shares was $1.19, which is 85% of the mid-point of the last bid price ($1.35) and the last ask price ($1.45) on June 16, 2011, the agreed upon conversion date.


The rights of the Series C Convertible Preferred Stock are as follows:


Dividend rights – The shares of Series C Convertible Preferred Stock accrue a 5% cumulative dividend on a quarterly basis and is payable on the last day of each fiscal quarter when declared by the Company’s Board.  Dividends declared for the three months ended March 31, 2012 were $4,623.  At March 31, 2012, $14,075 dividends declared have not been paid, including the $4,623 declared in the current quarter, and are shown in accrued and other liabilities.


Voting rights – Holders of these shares of Series C Convertible Preferred Stock shall have voting rights equivalent to 1,000 votes per $1,000 par value Series C Convertible Preferred share voted together with the shares of common stock


Liquidation rights – Upon any liquidation these Series C Convertible Preferred Stock shares shall be treated as equivalent to shares of Common stock to which they are convertible.


Redemption rights – The redemption rights were associated with the $750,000 that had been held in escrow by the Company in the event that the funds were released and returned to the company.  However, the funds were withdrawn from escrow and paid out in accordance with the settlement agreement (see Note 13 for details).  Therefore the redemption rights no longer apply to the remaining Series C Convertible Preferred Stock.


Conversion rights – Holder has right to convert each share of Series C Convertible Preferred Stock at any time into shares of the Company's common stock at a conversion price for each share of common stock equal to 85% of the lower of (1) the closing market price at the date of notice of conversion or (2) the mid-point of the last bid price and the last ask price on the date of the notice of conversion.  The variable conversion feature creates an embedded derivative that was bifurcated from the Series C Convertible Preferred Stock on the date of issuance and was recorded at fair value.  The derivative liability will be recorded at fair value on each reporting date with any change recorded in the Statement of Operations as an unrealized gain (loss) on derivative instrument.



Page 14


On the date of conversion of the 375 shares of Series C Convertible Preferred Stock the Company calculated the value of the derivative liability to be $81,933 and recorded an unrealized loss of $15,678 for the six months ended June 30, 2011 related to the converted shares.  Upon conversion, the $81,933 derivative liability was reclassified to equity.  


The Company recorded a convertible preferred stock derivative liability of $88,960, associated with the 375 shares of Series C Convertible Preferred Stock outstanding at March 31, 2012, and $66,176, associated with the 375 shares of Series C Convertible Preferred Stock outstanding at December 31, 2011.  


The Company has classified the Series C Convertible Preferred Stock as a liability at March 31, 2012 and December 31, 2011 because the variable conversion feature may require the Company to settle the conversion in a variable number of its common shares.  


13.

CONTRACTURAL OBLIGATIONS AND CONTINGENCIES


As of March 31, 2012, CTTC and its majority-owned subsidiary, VVI, have remaining obligations, contingent upon receipt of certain revenue, to repay up to $199,006 and $203,478, respectively, in consideration of grant funding received in 1994 and 1995.  CTTC is also obligated to pay at the rate of 7.5% of its revenue, if any, from transferring rights to certain inventions supported by the grant funds.  VVI is obligated to pay at rates of 1.5% of its net sales of supported products or 15% of its revenue from licensing supported products, if any.  We recognize these obligations when we receive revenue related to the grant funds.  We recognized $425 and $345 of these obligations during the quarters ended March 31, 2012and March 31, 2011, respectively.  


On November 22, 2010, the Company terminated its operating lease and paid the landlord all existing obligations thereto.  The Company then entered into a new, three-year operating lease for new, more appropriately sized office spaces.  The obligations are significantly less that the previous lease, averaging $70,000 per year for the three-year term.  Under the previous lease, rent and utility obligations would have been approximately $300,000 per year for that same period.


In January 2011, the Company entered into a two-year lease effective February 1, 2011 for additional office space for the sales and training staff in Charlotte, NC.  Obligations under this lease average $27,000 per year for the two-year term.


Carolina Liquid Chemistries Corporation, et al. (Case pending) – On August 29, 2005, we filed a complaint against Carolina Liquid Chemistries Corporation ("Carolina Liquid") in the United States District Court for the District of Colorado, alleging patent infringement of our patent covering homocysteine assays, and seeking monetary damages, punitive damages, attorneys’ fees, court costs and other remuneration at the option of the court.  As we became aware of other infringers, we amended our complaint to add as defendants Catch, Inc. ("Catch") and the Diazyme Laboratories Division of General Atomics ("Diazyme").  On September 6, 2006, Diazyme filed for declaratory judgment in the Southern District of California for a change in venue and a declaration of non-infringement and invalidity.  On September 12, 2006, the District Court in Colorado ruled that both Catch and Diazyme be added as defendants to the Carolina Liquid case.  


On October 23, 2006, Diazyme requested the United States Patent and Trademark Office (the "USPTO") to re-evaluate the validity of our patent and this request was granted by the USPTO on December 14, 2006.  On July 30, 2009, the U.S. Patent and Trademark Office’s Board of Patent Appeals and Interferences (“BPAI”) upheld the homocysteine patent.  In September 2008, the examiner had denied the patent, but that denial was overruled by the BPAI.  While the examiner had appealed that BPAI decision, delaying further action, that appeal was also denied by the BPAI on December 13, 2010.  In June 2011, the examiner once again appealed the BPAI decision, was again denied.  In addition to responding to this new appeal, the Company had petitioned the Director of the USPTO to help expedite further action on the case within the USPTO, which was to have been handled with special dispatch according to USPTO requirements for handling reexamination proceedings of patents involved in litigation.  




Page 15


On March 13, 2012, the USPTO issued the Ex Parte Reexamination Certificate confirming the patentability of claims examined.  Future action on this case pends its return to the District Court in Colorado.  


Employment matters – former employee (case pends) – In September 2003, a former employee filed a whistleblower complaint with OSHA alleging that the employee had been terminated for engaging in conduct protected under the Sarbanes Oxley Act of 2002 (SOX).  In February 2005, OSHA found probable cause to support the employee’s complaint and the Secretary of Labor ordered reinstatement and back wages since the date of termination and CTCC requested de novo review and a hearing before an administrative law judge (“ALJ”).  In July 2005, after the close of the hearing on CTTC’s appeal, the U.S. district court for Connecticut enforced the Secretary’s preliminary order of reinstatement and back pay under threat of contempt and the company rehired the employee with back pay.  


On October 5, 2005, the ALJ who conducted the hearing on CTTC’s appeal of the OSHA findings ruled in CTTC’s favor and recommended dismissal of the employee’s complaint.  Although the employee abandoned his position upon notice of the ALJ’s decision, he nevertheless filed a request for review by the DOL Administrative Review Board ("ARB").  


In May 2006, the U.S. Court of Appeals for the Second Circuit vacated the order of the district court enforcing the Secretary’s preliminary order of reinstatement and back pay.  The employee also filed a new SOX retaliation complaint with OSHA based on alleged black listing action by CTTC following his termination.  OSHA dismissed the complaint and the employee filed a request for a hearing by an administrative law judge. Ultimately, the employee voluntarily dismissed the appeal.


In March 2008, the ARB issued an order of remand in the employee’s appeal of the October 2005 dismissal of his termination complaint, directing the ALJ to clarify her analysis utilizing the burden-shifting standard articulated by the ARB.  In January 2009, the ALJ issued a revised decision again recommending dismissal and once again the employee appealed the ruling to the ARB.  On September 30, 2011, the ARB issued a final decision and order affirming the ALJ’s decision on remand and dismissing the employee’s complaint.  The employee has appealed the ARB's decision before the U.S. Court of Appeals for the Second Circuit which has ordered the employee to file his opening brief by May 31, 2012.  Response briefs by the Solicitor's Office of the U.S. Department of Labor and CTTC are due by July 30, 2012.  No date has been set for oral argument.


John B. Nano vs. Competitive Technologies, Inc. - Arbitration (case completed) – On September 3, 2010, the Board of Directors of CTTC found cause consisting of violation of fiduciary duties to the Corporation and violation of the CTTC Corporate Code of Conduct and removed John B. Nano as an Officer of the Corporation, in all capacities.  On September 13, 2010, the Board of Directors also found cause consisting of violation of fiduciary duties to the Corporation and violation of the CTTC Corporate Code of Conduct removed John B. Nano as a Director of the Corporation, in all capacities, for cause, consisting of violation of his fiduciary duties.  Details of these actions are outlined in Form 8-K filings with the SEC on September 13, 2010, and September 17, 2010.  Mr. Nano was previously the Chairman of the Board of Directors, President and Chief Executive Officer of CTTC. 


On September 13, 2010, Mr. Nano brought an arbitration claim to the American Arbitration Association against CTTC.  Mr. Nano's employment contract with the Company had called for arbitration, which Mr. Nano had demanded to resolve this conflict.  Mr. Nano sought $750,000 that he claimed was owed under his contract and claimed that he had been terminated without cause. 


On September 23, 2010 the Company was served notice that John B. Nano, CTTC's former Chairman, President and CEO had filed a Notice of Application for Prejudgment Remedy/Claim of $750,000 and an Application for an Order Pendente Lite claiming we had breached Mr. Nano’s employment contract with us.  The applications were filed in the State of Connecticut Superior Court in Bridgeport, CT.  In November 2010, the Company funded $750,000 as a Prejudgment Remedy held in escrow with the Company's counsel and has included this amount as restricted cash on the December 31, 2011 and December 31, 2010 balance sheets.  The Company did not believe it was liable to the former Chairman, President and CEO, believing he was terminated for cause.  The case proceeded through the



Page 16


arbitration process.  The initial arbitration hearing began in April 2011; additional hearing dates were held in May and June 2011.  In July 2011, each party submitted a summary limited in length stating their positions.  


Prior to the conclusion of the arbitration hearings, the Company filed suit in Federal Court against the American Arbitration Association.  The Company requested a temporary restraining order to halt the arbitration, which was denied by the court.  The Company also requested a hearing before the court to review the arbitration proceedings.  In August 2011, the American Arbitration Association's assigned arbitrator gave award to the Company's former Chairman, President and CEO, despite the Company's strongly held belief that the Board of Directors properly exercised its reasonable discretion under the employment agreement in finding that the former executive engaged in willful misconduct and gross negligence and that the executive’s actions were cause for employment termination under the employment agreement and governing law.  The former executive had requested a payment of $750,000, which he believed was due under his employment agreement.  Following the notification of award, the former employee filed a motion with the State of Connecticut Superior Court in Bridgeport, CT to have the award confirmed.  CTTC followed with a motion to vacate the award.  A hearing on those two motions was held before a judge in October 2011.  


In January 2012, the judge denied the Company's motion to vacate the arbitration award in favor of its former CEO John B. Nano and granted Mr. Nano's application to confirm the award.  Following the decision, CTTC settled all disputes with its former Chairman and CEO, John B. Nano. Pursuant to the settlement, CTTC has released to Mr. Nano from escrow the $750,000 deposited by CTTC following Mr. Nano's application for a prejudgment remedy. CTTC paid an additional $25,000 as settlement of additional amounts of statutory interest.  These amounts ($775,000) had been accrued at December 31, 2011.  The settlement includes mutual general releases of any and all claims either party has or had against the other. The settlement agreement also includes a provision that neither CTTC nor Mr. Nano would disparage the other. Should any such disparagement occur and litigation ensue, they further agreed that the prevailing party would be entitled to recover its costs and expenses, including reasonable attorney's fees. CTTC's payments to Mr. Nano were completed in the quarter ended March 31, 2012.


Unfair Trade Practices; U.S. District Court of Connecticut (case completed) – In September 2011, the Company filed a complaint against an individual in U.S. District Court of Connecticut for (1) violation of the Connecticut Unfair Trade Practices Act, (2) tortious interference with business and economic expectancy, (3) libel and (4) injunctive relief.  The complaint noted that the individual named in the civil action has, for more than a year, engaged in a systematic campaign to destroy the Company's trades and business, interfere with the Company's expectations and contracts and libel the Company by disseminating materially false and libelous statements about the Company on message boards throughout the Internet and otherwise.  The Company sought punitive damages from the individual for his alleged unfair trade practices and wrongful interference with the Company's business.  The case was concluded in March 2012.  By the parties’ stipulation settling the matter, the defendant agreed to cease his posting of any statements on the Internet or publishing any statements elsewhere, orally or in writing, concerning CTTC, CTTC’s officers, directors, and employees, the Calmare device, Marineo (the inventor of the Calmare device), or any other person or entity in connection with their purchase or use of the Calmare device.


Summary – We may be a party to other legal actions and proceedings from time to time.  We are unable to estimate legal expenses or losses we may incur, if any, or possible damages we may recover, and have not recorded any potential judgment losses or proceeds in our financial statements to date, with the exception of the accrued expenses related to the Nano case, previously disclosed.  We record expenses in connection with these suits as incurred.


We believe we carry adequate liability insurance, directors and officers insurance, casualty insurance, for owned or leased tangible assets, and other insurance as needed to cover us against potential and actual claims and lawsuits that occur in the ordinary course of our business.  However, an unfavorable resolution of any or all matters, and/or our incurrence of significant legal fees and other costs to defend or prosecute any of these actions and proceedings may, depending on the amount and timing, have a material adverse effect on our consolidated financial position, results of operations or cash flows in a particular period.



Page 17


Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations


Forward-Looking Statements


Statements about our future expectations are “forward-looking statements” within the meaning of applicable Federal Securities Laws, and are not guarantees of future performance.  When used in herein, the words "may," "will," "should," "anticipate," "believe," "intend," "plan," "expect," "estimate," "approximate," and similar expressions are intended to identify such forward-looking statements.  These statements involve risks and uncertainties inherent in our business, including those set forth in Item 1A under the caption "Risk Factors," in our most recent Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission ("SEC") on April 16, 2012 and as amended on May 15, 2012, and other filings with the SEC, and are subject to change at any time.  Our actual results could differ materially from these forward-looking statements.  We undertake no obligation to update publicly any forward-looking statement.


Overview


Competitive Technologies, Inc. ("CTTC") was incorporated in Delaware in 1971, succeeding an Illinois corporation which had incorporated in 1968.  CTTC and its majority owned subsidiary (collectively, "we", "our", or "us") provide distribution, patent and technology transfer, sales and licensing services focusing on the needs of our customers, matching those requirements with commercially viable technology or product solutions.  We develop relationships with universities, companies, inventors and patent or intellectual property holders to obtain the rights or a license to their intellectual property or to their product.  They become our clients, for whom we find markets to sell or further develop or distribute their technology or product.  We also develop relationships with those who have a need or use for technologies or products.  They become our customers, usually through a license or sublicense, or distribution agreement.  


Our revenue fluctuates due to changes in revenue of our customers, upfront license fees, new licenses granted, new distribution agreements, expiration of existing licenses or agreements, and/or the expiration or economic obsolescence of patents underlying licenses or products.


We acquire rights to commercialize a technology or product on an exclusive or non-exclusive basis, worldwide or limited to a specific geographic area.  When we license or sublicense those rights to our customers, we may limit rights to a defined field of use.  Technologies can be early, mid, or late stage.  Products we evaluate must be working prototypes or finished products.  We establish channel partners based on forging relationships with mutually aligned goals and matched competencies to deliver solutions that benefit the ultimate end-user.


We earn revenue from retained royalties from licensing our clients' and our own technologies to our customer licensees and sales of finished products.  Our customers pay us license fees, royalties based on usage of a technology, or per unit fees, and we share that revenue with our clients.  


We earn revenue in two ways, retained royalties from licensing our clients' and our own technologies to our customer licensees and sales of finished products.  We record revenue when the terms of the sales arrangement are accepted by all parties, delivery has occurred and our customer has taken title, and collectability is reasonably assured.


In 2011 the Company took greater control of the sales process, worldwide.  We are the primary obligor, responsible for delivering devices as well as training our customer in the proper use of the device.  We deal directly with customers, setting pricing and providing training; work directly with the inventor of the technology to develop specifications and any changes thereto and to select and contract with manufacturing partners; and retain significant credit risk for amounts billed to customers.  Therefore, all product sales are recorded following a gross revenue methodology.  We record in Product sales, the total funds invoiced and received from customers and record the costs of the device as Cost of product sales, with Gross profit from product sales being the result.


Sales of our Calmare® pain therapy medical device continue to be the major source of revenue for the Company.  The Company acquired the exclusive, worldwide rights to the "Scrambler Therapy" technology in 2007.  The Company's agreement with Giuseppe Marineo, the inventor of "Scrambler Therapy" technology, and Delta Research and



Page 18


Development ("Delta"), authorizes CTTC to manufacture and sell worldwide the device developed from the patented "Scrambler Therapy" technology.  The "Scrambler Therapy™" technology is patented in Italy and applications for patents have been filed in the U.S. and internationally and are pending approval.  The Calmare® device has CE Mark certification from the European Union as well as U.S. FDA 510(k) clearance.


The agreement with Professor Marineo and Delta enabled the Company to establish an agreement with GEOMC Co., Ltd. ("GEOMC", formerly Daeyang E & C Co., Ltd.) of Seoul, South Korea, to manufacture the Calmare® pain therapy medical device, based on Prof. Marineo's "Scrambler Therapy™" technology.  The GEOMC agreement is for a period of ten (10) years, through 2017, and outlines each company's specific financial obligations.


The Company has entered into a number of international distribution agreements, at one time covering nearly 40 countries.  The Company conducted a review of its distribution partners during the five-month period ending December 31, 2010, leading to the termination of CTTC's agreement with Life Epistéme Group, srl ("LEG").  LEG had the distribution rights in 34 countries, but had not met its minimum obligations to CTTC, and the Company had no indication that LEG would meet its commitments in the foreseeable future.  


During the quarter ended March 31, 2011, CTTC negotiated a new distribution agreement with Life Episteme Italia ("LEI") for the countries of Italy and Malta.  As a part of that agreement, LEI purchased 53 of the 55 devices CTTC had taken back into inventory from LEG.  In addition to the purchase of the 53 devices, the distribution agreement with LEI contained quarterly and annual marketing and sales requirements which LEI must meet in order to retain continued exclusivity within LEI's territory.  


In 2010, the Company became its own distributor in the U.S, contracting with 15 commissioned sales representatives.  During 2011, the Company and its representatives developed plans to increase awareness of the Calmare device among critical medical specialties and have begun to implement those plans targeting specific customers and locations in fiscal 2012.


Over the past 18 months, the Company entered into several sales agreements for the Calmare® device, including sales to U.S. government entities within the U.S. Department of Defense and the U.S. Department of Veterans Affairs.  Sales to these physicians and medical practices and to others with whom the Company had existing sales agreements are generating revenue for the Company.  


Presentation


We rounded all amounts in this Item 2 to the nearest thousand dollars. Certain amounts may not total precisely.


The following discussion and analysis provides information that we believe is relevant to an assessment and understanding of our financial condition and results of operations.  This discussion and analysis should be read in conjunction with our Consolidated Financial Statements and Notes thereto.


Results of Operations – Three months ended March 31, 2012 vs. three months ended March 31, 2011


Summary of Results


We incurred a net loss of $795,000 or $0.05 per basic and diluted share for the three months ended March 31, 2012, compared to a nominal gain of $29,000 or $0.00 per basic and diluted share for the three months ended March 31, 2011.  As explained in detail below, the net loss reflects a decrease of $791,000 in gross profit from product sales, a decrease in other revenue of $28,000 and an increase in other expenses of $6,000.


Revenue and Gross Profit from Sales


Revenue from product sales:  In the three months ended March 31, 2012, we recorded $330,000 in revenue from the sale and shipment of six Calmare® pain therapy medical devices; with a cost of product sales of $151,000.  In



Page 19


the three months ended March 31, 2011, we recorded $1,827,000 in gross revenue from the sale and shipment of 71 (63 internationally, 8 domestic) Calmare® pain therapy medical devices, with a cost of product sales of $857,000.  


53 of the 71 medical devices sold in the quarter ended March 31, 2011 represent the sale to a new distributor of units the Company had brought back into inventory during the transition period ended December 31, 2010, following the cancellation of the earlier distribution agreement with Life Epistéme Group, srl.  


Other Revenue


Gain on sale of rental assets for the three months ended March 31, 2011 of $35,000 represents the gain on the sale of one Calmare medical device to a customer that had previously rented the device from the Company.  No sale of a rental asset occurred in the three months ended March 31, 2012.


Retained royalties for the three months ended March 31, 2012, were $12,000, which was $1,000 or 9% more than the $11,000 of retained royalties reported in the three months ended March 31, 2011.  


Investment income of $1,000 in the three months ended March 31, 2012 represents interest paid on the $750,000 restricted cash which was held in escrow per the legal case involving the former chief executive (See Note 13 for a discussion of that case).  No such income was received in the three months ended March 31, 2011.


Other income for the three months ended March 31, 2012, was $15,000, including payments for training and the sale of supplies such as electrodes and cables for use with our Calmare® devices ($7,000) and rental income ($8,000) from customers who were renting Calmare® pain therapy medical devices from us.  Approximately $8,000 of other income consisting of rental income from customers who were renting Calmare® pain therapy medical devices from us was reported in the three months ended March 31, 2011.  


Expenses


Total expenses were $1,003,000 in the three months ended March 31, 2012 compared to $997,000 in the three months ended March 31, 2011, an increase of $6,000.


Selling expenses were $87,000 in three months ended March 31, 2012, compared to $101,000 in the three months ended March 31, 2011. The decrease of $14,000 was due to a decrease of $5,000 in domestic patent legal expenses related to the joint venture with XION Corporation to develop the melanocortin technologies and a decrease of $34,000 in commission expenses due to fewer sales of Calmare® devices, offset by an increase of $25,000 in patent and translation fees related to working with the inventor of the Calmare® device.   


Personnel and consulting expenses were $331,000 in the three months ended March 31, 2012, as compared to $367,000 in the three months ended March 31, 2011, a reduction of $36,000 or 10%.  


Personnel related expenses were $187,000 in the quarter ended March 31, 2012 as compared to $233,000 quarter ended March 31, 2011, a reduction of $46,000 primarily due to the departure of two employees in January 2012.  In addition, there were increased consulting fees ($10,000), primarily due to work related to U.S. and Federal government sales of our Calmare® device, the management services of our current CEO, and the work of the contracted Managing Director for International Business Development.  


General and administrative expenses were $552,000 in the three months ended March 31, 2012, an increase of $35,000, or 7% from $517,000 in the three months ended March 31, 2011.  The change is primarily due to decreases in legal fees ($101,000) associated with the legal activity relating to the former CEO challenging his termination for cause. In addition, there were increases in legal fees associated with other litigation ($20,000), increases in corporate legal expenses ($32,000); increases in directors' fees and expenses ($161,000, which includes $139,000 in stock option expense for directors); and increases in rent and associated expenses related to opening another office during the quarter ended March 31, 2011 ($5,000).  The increases were offset by decreases in investor and public relations expenses due primarily to the shift of emphasis in the duties of the investor relations/public relations consultant to management



Page 20


services ($14,000); decreases in audit and compliance expense primarily due to timing of activities ($21,000); a reduction in travel expenses ($19,000) due to fewer employees traveling in 2012; decreased insurance expenses ($1,000); decreases in marketing expenses ($9,000); decreases in supply expenses ($9,000); a reduction in banking fees, miscellaneous taxes and other fees ($4,000); and a reduced depreciation expense of ($5,000) due to having less property and equipment to depreciate.


Interest expense was essentially unchanged, $10,000 in the three months ended March 31, 2012, compared to the three months ended March 31, 2011.


Unrealized loss on derivative instruments The variable conversion feature related to the Company’s Series C Convertible Preferred Stock (“Series C”) creates an embedded derivative that is required to be recorded at fair value at each reporting period.  During the three months ended March 31, 2012, the Company recorded $23,000 loss related to the embedded derivative’s change in fair value, which was an increase of $20,000 from the $3,000 loss related to the embedded derivative’s change in fair value recorded in the three months ended March 31, 2011.  


Financial Condition and Liquidity


Our liquidity requirements arise principally from our working capital needs, including funds needed to find and market new or existing technologies or products, and protect and enforce our intellectual property rights, if necessary.  We fund our liquidity requirements with a combination of cash on hand and cash flows from operations, if any, including royalty legal awards, short term debt, and sales of common stock.  At March 31, 2012, we had no outstanding long-term debt.  


During the third quarter of fiscal 2011, we entered into a Factoring Agreement with Versant to accelerate receivable collection and manage cash flow.  Under the Factoring Agreement the Company will sell to Versant certain of the Company's accounts receivables.  For those accounts receivable the Company tenders to Versant and Versant chooses to purchase, Versant will advance 75% of the face value to the Company, and will submit a percentage of the remainder to the Company upon collection on the account.  The percentage is based on the time it takes Versant to collect on the account.   As part of the Factoring Agreement, the Company and Versant entered into a Security Agreement whereby the Company granted Versant a security interest in certain of the Company’s assets to secure the Company’s performance of the representations made with respect to the purchase of the accounts receivable.  At March 31, 2012, the Company had no factored receivables.


Our future cash requirements depend on many factors, including results of our operations and marketing efforts, results and costs of our legal proceedings, and our equity financing.  To achieve and sustain profitability, we must increase the number of distributors for our products, broaden the base of technologies for distribution, license technologies with sufficient current and long-term revenue streams, and add new licenses.  Obtaining rights to new technologies, granting rights to licensees and distributors, enforcing intellectual property rights, and collecting revenue are subject to many factors, some of which are beyond our control.  


In fiscal 2010, the Company incorporated revenue from the sale of inventory into its revenue stream.  That source of revenue is expected to continue as sales of its Calmare® pain therapy medical device continue to expand and other products are added to the Company's portfolio of technologies.


Cash and cash equivalents consist of demand deposits and interest earning investments with maturities of three months or less, including overnight bank deposits and money market funds.  We carry cash equivalents at cost.


At March 31, 2012, the Company's balance sheet showed cash and cash equivalents of $2, 000.  This is compared to $28,000 cash and cash equivalents at December 31, 2011.  In addition, at December 31, 2011, the Company had $750,000 of restricted cash held in escrow as a Prejudgment Remedy associated with the arbitration case involving our former Chairman, President and CEO.  Those funds are no longer held in escrow, having been paid out as part of the settlement of that case during the quarter ended March 31, 2012 (See Note 13 for details regarding that case).  The net loss of $795,000 for the three months ended March 31, 2012 contained non-cash inflow of $165,000 and net cash inflow related to changes in assets and liabilities of $423,000, resulting in cash used in operations of $207,000.  During



Page 21


the three-month period ending March 31, 0212, the company issued notes payable to borrow $200,000 and issued 114,000 shares of common stock to pay down $128,000 in accrued liabilities.


We currently have the benefit of using a portion of our accumulated NOLs to eliminate any future regular federal and state income tax liabilities.  We will continue to receive this benefit until we have utilized all of our NOLs, federal and state.  However, we cannot determine when and if we will be profitable enough to utilize the benefit of the remaining NOLs before they expire.


Going Concern


The Company incurred operating losses for the pastfour quarters, having produced marginal net income in the first quarter of fiscal 2011, after having incurred operating losses each quarter since fiscal 2006.  During the three month periods ended March 31, 2012 and March 31, 2011, we had a significant concentration of revenues from our Calmare® pain therapy medical device technology.  We continue to seek revenue from new technologies or products to mitigate the concentration of revenues, and replace revenues from expiring licenses on other technologies.  


Although we have taken steps to significantly reduce operating expenses going forward, even at these reduced spending levels, should the anticipated increase in revenue from sales of Calmare® medical devices not occur the Company may not have sufficient cash flow to fund operating expenses beyond the fourth quarter of 2012.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  


The Company's continuation as a going concern is dependent upon its developing recurring revenue streams sufficient to cover operating costs.  The company does not have any significant individual cash or capital requirements in the budget going forward.  During the transitional period ended December 31, 2010, the Company undertook a major reduction of its operating expenses through staff reductions and reduced office space costs.  If necessary, the Company will meet anticipated operating cash requirements by further reducing costs, issuing debt and /or equity, and / or pursuing sales of certain assets and technologies while we pursue licensing and distribution opportunities for our remaining portfolio of technologies.  There can be no assurance that the Company will be successful in such efforts.  Failure to develop a recurring revenue stream sufficient to cover operating expenses would negatively affect the Company’s financial position.


Capital requirements


We continue to seek revenue from new technology licenses to mitigate the concentration of revenue, and replace revenue from expiring licenses.  We have created a new business model for appropriate technologies that allows us to move beyond our usual royalty arrangement and share in the profits of distribution.


All purchases under $1,000 are expensed.  We expect capital expenditures to be less than $50,000 in 2012.


Contractual Obligations and Contingencies


On November 22, 2010, the Company terminated our operating lease for office space and paid the landlord all existing obligations thereto.  The Company then entered into a new, three-year operating lease for new, more appropriately sized office spaces.  The obligations are significantly less that the previous lease, averaging $70,000 per year for the three-year term.  Under the previous lease, rent and utility obligations would have been approximately $300,000 per year for that same period.


In January 2011, the Company entered into a two-year lease effective February 1, 2011 for additional office space for the sales and training staff in Charlotte, NC.  Obligations under this lease average $27, 000 per year for the two-year term.


Contingencies.  Our directors, officers, employees and agents may claim indemnification in certain circumstances.  We seek to limit and reduce our potential financial obligations for indemnification by carrying directors and officers’ liability insurance, subject to deductibles.



Page 22



We also carry liability insurance, casualty insurance, for owned or leased tangible assets, and other insurance as needed to cover us against claims and lawsuits that occur in the ordinary course of business.  


Many of our license and service agreements provide that upfront license fees, license fees and/or royalties we receive are applied against amounts that our clients or we have incurred for patent application, prosecution, issuance and maintenance costs.  If we incur such costs, we expense them as incurred, and reduce our expense if we are reimbursed from future fees and/or royalties we receive.  If the reimbursement belongs to our client, we record no revenue or expense.


As of September 30, 2011, CTTC and its majority-owned subsidiary, VVI, have remaining obligations, contingent upon receipt of certain revenue, to repay up to $199,006 and $203,478, respectively, in consideration of grant funding received in 1994 and 1995.  CTTC is also obligated to pay at the rate of 7.5% of its revenue, if any, from transferring rights to certain inventions supported by the grant funds.  VVI is obligated to pay at rates of 1.5% of its net sales of supported products or 15% of its revenue from licensing supported products, if any.  We recognize these obligations when we receive revenue related to the grant funds.  We recognized $425 and 345 of these obligations during the quarters ended March 31, 2012 and March 31, 2011, respectively.  


Critical Accounting Estimates


There have been no significant changes in our accounting estimates described under the caption “Critical Accounting Estimates” included in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in our Annual report on Form 10-K /A for the year ended December 31, 2011.


Item 3.  Quantitative and Qualitative Disclosures About Market Risk


Not applicable.  


Item 4.  Controls and Procedures  


(a)

Evaluation of disclosure controls and procedures


Our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Securities Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2012.  Our disclosure controls and procedures are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Act (15 U.S.C. 78a et seq.) is recorded, processed, summarized, and reported, within the time periods specified in the Commission’s rules and forms.  Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.  Based on this evaluation, management concluded that our disclosure controls and procedures were effective as of March 31, 2012.


(b)

Change in Internal Controls


During the period ending March 31, 2012, there were no changes in our internal control over financial reporting during that period that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.



Page 23


PART II – OTHER INFORMATION


Item 1.

Legal Proceedings


See Part I, Item 1, Note 13 to the accompanying unaudited condensed consolidated financial statements of this Quarterly Report on Form 10-Q.


Item 1A.

Risk Factors


We disclosed the risk factors related to our business and the market environment in our Annual Report on Form 10-K/A for the fiscal year ended December 31, 2011.  Since September 2010, the Company has taken several actions that we believe will reduce the Company's risk.  These include lowering costs through staff reductions and office relocation, developing additional sales, and obtaining additional capital.


Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds


There were no unregistered sales of equity securities in the quarter ended March 31, 2012.


Item 3.

Defaults Upon Senior Securities


None


Item 5.

Other Information


None.


Item 6.

Exhibits


31.1

 

Certification by the Chief Executive Officer of Competitive Technologies, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

 

 

 

31.2

 

Certification by the Chief Financial Officer of Competitive Technologies, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

 

 

 

32.1

 

Certification by the Chief Executive Officer of Competitive Technologies, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) (furnished herewith).

 

 

 

32.2

 

Certification by the Chief Financial Officer of Competitive Technologies, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) (furnished herewith).

 

 

 

101

 

Interactive Data Files.



Page 24


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



COMPETITIVE TECHNOLOGIES, INC.

(the registrant)


By /s/ Johnnie D. Johnson.

Johnnie D. Johnson

Chief Executive Officer,

Chief Financial Officer, Chief Accounting

Officer and Authorized Signer

May 18, 2012




Page 25







[cttc10q1q2012002.jpg]








www.competitivetech.net




Page 26



INDEX TO EXHIBITS


Exhibit No.

 

Description

31.1

 

Certification by the Chief Executive Officer of Competitive Technologies, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

 

 

 

31.2

 

Certification by the Chief Financial Officer of Competitive Technologies, Inc. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)).

 

 

 

32.1

 

Certification by the Chief Executive Officer of Competitive Technologies, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) (furnished herewith).

 

 

 

32.2

 

Certification by the Chief Financial Officer of Competitive Technologies, Inc. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350) (furnished herewith).

 

 

 

101

 

Interactive Data Files.






Page 27


EX-31 2 cttc10q1q2012x312.htm EXHIBIT 31.2 Converted by EDGARwiz

Exhibit 31.2

CERTIFICATIONS

I, Johnnie D. Johnson, certify that:

1.

I have reviewed this report on Form 10-Q of Competitive Technologies, Inc. for the period ending March 31, 2012;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting procedures;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.


Date: May 18, 2012


/s/ Johnnie D. Johnson

Johnnie D. Johnson

Chief Financial Officer



EX-31 3 cttc10q1q2012x311.htm EXHIBIT 31.1 Converted by EDGARwiz

Exhibit 31.1

CERTIFICATIONS

I, Johnnie D. Johnson, certify that:

1.

I have reviewed this report on Form 10-Q of Competitive Technologies, Inc. for the period ending March 31, 2012;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting procedures;

(c)

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the Company’s most recent fiscal quarter (the Company’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions):

(a)

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

any fraud, whether or not material, that involves management or other employees who have a significant role in the Company’s internal control over financial reporting.


Date: May 18, 2012


/s/ Johnnie D. Johnson

Johnnie D. Johnson

Chief Executive Officer



EX-32 4 cttc10q1q2012x321.htm EXHIBIT 32.1 Converted by EDGARwiz

Exhibit 32.1



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Report of Competitive Technologies, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Johnnie D. Johnson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:


1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Johnnie D. Johnson

Johnnie D. Johnson

Chief Executive Officer


May 18, 2012


A signed original of this written statement required by Section 906 has been provided to Competitive Technologies and will be retained by Competitive Technologies and furnished to the Securities and Exchange Commission or its staff upon request.




EX-32 5 cttc10q1q2012x322.htm EXHIBIT 32.2 Converted by EDGARwiz

Exhibit 32.2



CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002




In connection with the Report of Competitive Technologies, Inc. (the "Company") on Form 10-Q for the period ended March 31, 2012, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Johnnie D. Johnson, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 that:


1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



/s/ Johnnie D. Johnson

Johnnie D. Johnson

Chief Financial Officer


May 18, 2012


A signed original of this written statement required by Section 906 has been provided to Competitive Technologies and will be retained by Competitive Technologies and furnished to the Securities and Exchange Commission or its staff upon request.




EX-101.INS 6 cttc-20120331.xml XBRL INSTANCE DOCUMENT 10-Q 2012-03-31 false Competitive Technologies Inc. 0000102198 --12-31 14715789 20707445 Smaller Reporting Company Yes No No 2012 Q1 1570 28485 750000 112015 42471 4440156 4210156 56245 70268 4609986 5101380 42707 26169 17275 17275 4669968 5144824 1326862 1124007 4175225 3865225 549500 1228473 300000 100000 9600 12800 88960 66176 375000 375000 6825147 6771681 60675 60675 148302 147157 45036867 44771128 -47401023 -46605817 -2155179 -1626857 4669968 5144824 329746 1827056 150571 856754 179175 970302 -34728 12403 10610 1497 14704 10910 28604 56248 86940 100793 331370 367119 552378 516637 9513 9616 22784 2951 1002985 997116 -795206 29434 -795206 29434 -0.05 -0.00 14752251 13826055 -0.05 -0.00 14752251 14466787 60675 148302 45036867 -47401023 -2155179 2427 14830204 -795206 -795206 1145 127109 128254 114415 138630 138630 3464 8154 138630 4720 -10083 -69544 -1152853 750000 14022 1764 -230000 -870228 -41063 1708077 -206913 -312792 -20002 -14415 43800 -2275 -20002 27110 200000 50000 10050 200000 60050 -26915 -225632 557018 331386 60675 147157 44771128 -46605817 -1626857 2427 14715789 <!--egx--><p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">Supplemental disclosure of non-cash investing and financing transactions:</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">During February 2012, the Company issued 14,415 shares at $1.19 per share to settle $17,154 of accrued liabilities.</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">During March 2012, the Company issued 100,000 common shares at $1.111 per share to settle $111,100 of accrued liabilities.</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">During February 2011, the Company canceled 10,000 common shares previously issued to Crisnic and canceled the related $9,000 receivable.&nbsp;&nbsp; </p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">During February 2011, the Company issued 10,000 common shares at $0.99 per share to settle $9,900 of deferred payroll. </p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">During January 2011, the Company canceled 15,000 common shares previously issued to Crisnic and canceled the related $13,500 receivable.&nbsp;&nbsp; </p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">During January 2011, the Company issued 15,000 common shares at $1.09 per share to settle $16,350 of accrued liabilities.</p> <!--egx--><p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:27.0pt"><b><font style="LETTER-SPACING:-0.15pt">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BASIS OF PRESENTATION</font></b></p> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">The interim condensed consolidated financial information presented in the accompanying condensed consolidated financial statements and notes hereto is unaudited.</p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">Competitive Technologies, Inc. ("CTTC") and its majority-owned subsidiary, Vector Vision, Inc. ("VVI"), (collectively, "we" or "us") provide patent and technology licensing and commercialization services throughout the world, with concentrations in the U.S., Europe and Asia, with respect to a broad range of life and physical sciences, electronics, and nanotechnologies originally invented by individuals, corporations and universities.&nbsp; </p> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:54.75pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">These consolidated financial statements include the accounts of CTTC and VVI.&nbsp; Inter-company accounts and transactions have been eliminated in consolidation.</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">We believe we made all adjustments necessary, consisting only of normal recurring adjustments, to present the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&nbsp; The results for the three months ended March 31, 2012 are not necessarily indicative of the results that can be expected for the next full fiscal year ending December 31, 2012.</font></p> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">The interim unaudited condensed consolidated financial statements and notes thereto, should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission ("SEC") on April 16, 2012.</font></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">During the three months ended March 31, 2012, and the three months ended March 31, 2011, we had a significant concentration of revenues from our Calmare<sup>&#174;</sup> pain therapy medical device.&nbsp; The percentages of gross revenue attributed to sales and rentals of Calmare<sup>&#174; </sup>devices were 92% and 97% in the three months ended March 31, 2012 and March 31, 2011, respectively.&nbsp; We continue to expand our sales activities for the Calmare<sup>&#174;</sup> device and expect the majority of our revenues to come from this technology for at least the next two fiscal years.&nbsp; However, we continue to seek revenue from new or existing technologies or products to mitigate the concentration of revenues, and replace revenues from expiring licenses and patents on other technologies.&nbsp; </font></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">The Company incurred operating losses for the past three quarters, having produced marginal net income in the first quarter of 2011, after having incurred operating losses each quarter since fiscal 2006.&nbsp; The Company has taken steps to significantly reduce its operating expenses going forward and expects revenue from sales of Calmare<sup>&#174; </sup>medical devices to grow.&nbsp; During the five month transitional period ended </font>December 31, 2010<font style="LETTER-SPACING:-0.15pt">; the Company undertook a major reduction of its operating expenses through staff reductions and reduced office space costs.&nbsp; However, even at the reduced spending levels, should the anticipated increase in revenue from sales of Calmare<sup>&#174; </sup>devices not occur the Company may not have sufficient cash flow to fund operating expenses beyond the fourth quarter of calendar 2012.&nbsp; These conditions raise substantial doubt about the Company&#146;s ability to continue as a going concern.&nbsp; The financial statements do not include adjustments to reflect the possible future effect of the recoverability and classification of assets or amounts and classifications of liabilities that may result from the outcome of this uncertainty.</font></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">The Company's continuation as a going concern is dependent upon its developing recurring revenue streams sufficient to cover operating costs.&nbsp; The company does not have any significant individual cash or capital requirements in the budget going forward.&nbsp; If necessary, CTTC will meet anticipated operating cash requirements by further reducing costs, issuing debt and/or equity, and/or pursuing sales of certain assets and technologies while we pursue licensing and distribution opportunities for our remaining portfolio of technologies.&nbsp; There can be no assurance that the Company will be successful in such efforts.&nbsp; Failure to develop a recurring revenue stream sufficient to cover operating expenses would negatively affect the Company&#146;s financial position.</font></p> <p style="LINE-HEIGHT:12pt; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">Our liquidity requirements arise principally from our working capital needs, including funds needed to sell our current technologies and obtain new technologies or products, and protect and enforce our intellectual property rights, if necessary.&nbsp; We fund our liquidity requirements with a combination of cash on hand, cash flows from operations, if any, including royalty legal awards, short term borrowing, and sales of common stock.&nbsp; At March 31, 2012, we had no outstanding long-term debt.&nbsp; </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">During the fiscal 2011, the Company entered into a Factoring Agreement with Versant Funding, LLC ("Versant") to accelerate receivable collection and better manage cash flow.&nbsp; Under the Factoring Agreement the Company will sell to Versant certain of the Company's accounts receivables.&nbsp; For those accounts receivable the Company tenders to Versant and Versant chooses to purchase, Versant will advance 75% of the face value to the Company, and will submit a percentage of the remainder to the Company upon collection on the account.&nbsp; The percentage is based on the time it takes Versant to collect on the account.&nbsp;&nbsp; As part of the Factoring Agreement, the Company and Versant entered into a Security Agreement whereby the Company granted Versant a security interest in certain of the Company&#146;s assets to secure the Company&#146;s performance of the representations made with respect to the purchase of the accounts receivable.&nbsp; At March 31, 2012, no receivables were factored. </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; tab-stops:189.0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">Sales of our <font style="LETTER-SPACING:-0.15pt">Calmare<sup>&#174;</sup> pain therapy medical device continue to be the major source of revenue for the Company.&nbsp; The Company acquired the exclusive, worldwide rights to the "Scrambler Therapy" technology in 2007.&nbsp; The Company's agreement with Giuseppe Marineo, the inventor of "Scrambler Therapy" technology, and Delta Research and Development ("Delta"), authorizes CTTC to manufacture and sell worldwide the device developed from the patented "Scrambler Therapy" technology.&nbsp; The "Scrambler Therapy&#153;" technology is patented in Italy and applications for patents have been filed in the U.S. and internationally and are pending approval.&nbsp; The Calmare<sup>&#174;</sup> device has CE Mark certification from the European Union as well as U.S. FDA 510(k) clearance.</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">The agreement with Professor Marineo and Delta enabled the Company</font><font style="LETTER-SPACING:-0.15pt"> to establish an agreement with GEOMC Co., Ltd. ("GEOMC", formerly Daeyang E &amp; C Co., Ltd.) of Seoul, South Korea, to manufacture the Calmare<sup>&#174;</sup> pain therapy medical device, based on Prof. Marineo's "Scrambler Therapy&#153;" technology.&nbsp; The GEOMC agreement is for a period of ten (10) years, through 2017, and outlines each company's specific financial obligations.</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">The Company has entered into a number of international distribution agreements, at one time covering nearly 40<b> </b>countries.&nbsp; The Company conducted a review of its distribution partners during the five-month period ending December 31, 2010, leading to the termination of CTTC's agreement with Life Epist&#233;me Group, srl ("LEG").&nbsp; LEG had the distribution rights in 34 countries, but had not met its minimum obligations to CTTC, and the Company had no indication that LEG would meet its commitments in the foreseeable future.&nbsp; </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">During the quarter ended March 31, 2011, CTTC negotiated a new distribution agreement with Life Episteme Italia ("LEI") for the countries of Italy and Malta. <font style="LETTER-SPACING:-0.15pt">The distribution agreement with LEI contained quarterly and annual marketing and sales requirements which LEI must meet in order to retain continued exclusivity within LEI's territory.&nbsp; </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">In 2010, the Company became its own distributor in the U.S, contracting with 15 commissioned sales representatives.&nbsp; During 2011, the Company and its representatives developed plans to increase awareness of the Calmare device among critical medical specialties and have begun to implement those plans targeting specific customers and locations in fiscal 2012. </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">Over the past 18 months, the Company entered into several sales agreements for the Calmare<sup>&#174;</sup> device, including sales to U.S. government entities within the U.S. Department of Defense and the U.S. Department of Veterans Affairs.&nbsp; Sales to these physicians and medical practices and to others with whom the Company had existing sales agreements are generating revenue for the Company.&nbsp; </font></p> <p style="MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">We earn revenue in two ways: </font>retained royalties from licensing our clients' and our own technologies to our customer licensees, and sales of finished products.&nbsp; We record revenue when the terms of the sales arrangement are accepted by all parties including a fee that is fixed and determinable, delivery has occurred and our customer has taken title, and collectability is reasonably assured.</p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In 2011 the Company took greater control of the sales process, worldwide.&nbsp; We are the primary obligor, responsible for delivering devices as well as for training our customers in the proper use of the device.&nbsp; We deal directly with customers, setting pricing and providing training; work directly with the inventor of the technology to develop specifications and any changes thereto and to select and contract with manufacturing partners; and retain significant credit risk for amounts billed to customers.&nbsp; Therefore, all product sales are recorded following a gross revenue methodology. </p> <!--egx--><p style="MARGIN:0in 0in 0pt; tab-stops:27.0pt 1.0in 1.5in"><b><font style="LETTER-SPACING:-0.15pt">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NET INCOME (LOSS) PER COMMON SHARE</font></b></p> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:.5in"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">The following sets forth the denominator used in the calculations of basic net income (loss) per share and net income (loss) per share assuming dilution:</font></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:.5in"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <table width="612" style="MARGIN:auto auto auto 41.75pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:12pt"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:211.5pt; PADDING-RIGHT:5.75pt; HEIGHT:12pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:12pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><b><font style="LETTER-SPACING:-0.15pt">Three&nbsp; months ended</font></b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:13.5pt; PADDING-RIGHT:5.75pt; HEIGHT:12pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:12pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><font style="LETTER-SPACING:-0.15pt">Three months ended</font></p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:12pt"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:211.5pt; PADDING-RIGHT:5.75pt; HEIGHT:12pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="156" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:12pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><b><font style="LETTER-SPACING:-0.15pt">March 31, 2012</font></b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:13.5pt; PADDING-RIGHT:5.75pt; HEIGHT:12pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="156" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:12pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><font style="LETTER-SPACING:-0.15pt">March 31, 2011</font></p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:25.55pt"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:211.5pt; PADDING-RIGHT:5.75pt; HEIGHT:25.55pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-INDENT:-7.75pt; MARGIN:0in 0in 0pt 7.75pt">Denominator for basic net income (loss) per share, weighted average shares outstanding</p></td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:25.55pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:right 99.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14,752,251</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:13.5pt; PADDING-RIGHT:5.75pt; HEIGHT:25.55pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:25.55pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:right 99.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13,826,055</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:14.85pt"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:211.5pt; PADDING-RIGHT:5.75pt; HEIGHT:14.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-INDENT:-7.75pt; MARGIN:0in 0in 0pt 7.75pt">Dilutive effect of common stock options</p></td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:14.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:right 99.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N/A</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:13.5pt; PADDING-RIGHT:5.75pt; HEIGHT:14.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:.5in">&nbsp;</p></td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:14.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:right 99.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8,212</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:14.85pt"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:211.5pt; PADDING-RIGHT:5.75pt; HEIGHT:14.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-INDENT:-7.75pt; MARGIN:0in 0in 0pt 7.75pt">Dilutive Effect of Series C convertible preferred stock</p></td> <td width="156" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:14.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:right 99.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; N/A</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:13.5pt; PADDING-RIGHT:5.75pt; HEIGHT:14.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="156" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:14.85pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:right 99.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 632,520</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:45pt"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:211.5pt; PADDING-RIGHT:5.75pt; HEIGHT:45pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="TEXT-INDENT:-7.75pt; MARGIN:0in 0in 0pt 7.75pt">Denominator for diluted net income (loss) per share, weighted average shares outstanding</p></td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:45pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:right 99.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14,752,251</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:13.5pt; PADDING-RIGHT:5.75pt; HEIGHT:45pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="156" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.75pt; WIDTH:117pt; PADDING-RIGHT:5.75pt; HEIGHT:45pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:right 99.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14,466,787</p></td></tr></table> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="BACKGROUND:white">Options to purchase 373,000 shares of our common stock outstanding at March 31, 2012 and 375 shares of convertible preferred stock at March 31, 2012 were not included in the computation of diluted net income (loss) per share because they were anti-dilutive.&nbsp; </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="BACKGROUND:white">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="BACKGROUND:white">In the quarter ended March 31, 2011, those options with exercise prices less than $1.28, (average market price for the period) if exercised, would have resulted in dilution using the treasury stock method.&nbsp; At March 31, 2011 the Company had 280,000 outstanding options to purchase its common stock, of which only 30,000 options had an exercise price less than $1.28.&nbsp; In addition, 750 shares of convertible preferred stock were outstanding at March 31, 2011, with the dilutive effect of 632,520 shares of common stock.</font></p> <!--egx--><p style="MARGIN:0in 0in 0pt"><b>3.</b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS </b></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="BACKGROUND:white">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="BACKGROUND:white">No new accounting pronouncements issued or effective during the three months ended March 31, 2012 has had or is expected to have a material impact on the consolidated financial statements.</font></p> <!--egx--><p style="MARGIN:0in 0in 0pt"><b>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RECEIVABLES</b></p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:.5in">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">Receivables consist of the following:&nbsp;&nbsp; </p> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:.5in">&nbsp;</p> <table style="MARGIN:auto auto auto 45.75pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="300" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:225.15pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">&nbsp;</p></td> <td width="126" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:94.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><b>March 31, 2012</b></p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.85pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center">&nbsp;</p></td> <td width="146" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:109.65pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center">December 31, 2011</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="300" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:225.15pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Calmare<sup>&#174;</sup> Sales Receivable</p></td> <td width="126" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:94.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 77.0pt"><b>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 102,850</b></p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.85pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="146" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:109.65pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 92.0pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 24,444</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="300" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:225.15pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Other Receivable</p></td> <td width="126" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:94.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 77.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9,165</b></p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.85pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="146" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:109.65pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 92.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18,027</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="300" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:225.15pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Royalties, net of allowance of $101,154 </p> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; at March 31, 2012 and December 31, 2011</p></td> <td width="126" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:94.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 77.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</b></p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.85pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="146" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:109.65pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="300" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:225.15pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Total receivables</p></td> <td width="126" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:94.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 77.0pt"><b>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 112,015</b></p></td> <td width="16" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:11.85pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="146" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:109.65pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 92.0pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42,471</p></td></tr></table> <!--egx--><p style="MARGIN:0in 0in 0pt"><b>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AVAILABLE-FOR-SALE AND EQUITY SECURITIES</b></p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">The fair value of the equity securities we held were categorized as available-for-sale securities, were zero, consisted of shares in Security Innovation and Xion Pharmaceutical Corporation.&nbsp; </font>We own 223,317 shares of stock in the privately held Security Innovation, an independent provider of secure software located in Wilmington, MA.</p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">In September 2009 we announced the formation of a joint venture with Xion Corporation for the commercialization of our patented melanocortin analogues for treating sexual dysfunction and obesity.&nbsp; CTTC currently owns 60 shares of common stock or 33% of the outstanding stock of privately held Xion Pharmaceutical Corporation.</p> <!--egx--><p style="MARGIN:0in 0in 0pt"><b>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; FAIR VALUE MEASUREMEMENTS </b></p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; tab-stops:.7in 62.85pt 303.8pt decimal 5.1in left 398.85pt decimal 6.4in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; tab-stops:.7in 62.85pt 303.8pt decimal 5.1in left 398.85pt decimal 6.4in">The Company measures fair value in accordance with Topic 820 of the FASB Accounting Standards Codification ("ASC"), "Fair Value Measurements and Disclosures" ("ASC 820"), which provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described as follows:</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; tab-stops:.7in 62.85pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-49.5pt; MARGIN:0in 0in 0pt 99pt; tab-stops:.7in 99.0pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in">Level 1 - &nbsp; Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; tab-stops:.7in 62.85pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:50.25pt; MARGIN:0in 0in 0pt; tab-stops:99.0pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in">Level 2 - Inputs to the valuation methodology include:</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-13.5pt; MARGIN:6pt 0in 0pt 112.5pt; TEXT-AUTOSPACE:; tab-stops:99.0pt 112.5pt decimal 5.1in 6.4in">&#149;<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Quoted prices for similar assets or liabilities in active markets;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-13.5pt; MARGIN:6pt 0in 0pt 112.5pt; TEXT-AUTOSPACE:; tab-stops:99.0pt 112.5pt decimal 5.1in 6.4in">&#149;<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Quoted prices for identical or similar assets or liabilities in inactive markets;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-13.5pt; MARGIN:6pt 0in 0pt 112.5pt; TEXT-AUTOSPACE:; tab-stops:99.0pt 112.5pt decimal 5.1in 6.4in">&#149;<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Inputs other than quoted prices that are observable for the asset or liability;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-13.5pt; MARGIN:6pt 0in 0pt 112.5pt; TEXT-AUTOSPACE:; tab-stops:99.0pt 112.5pt decimal 5.1in 6.4in">&#149;<font style="FONT:7pt 'Times New Roman'">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>Inputs that are derived principally from or corroborated by observable market data by correlation or other means.</p> <p style="TEXT-ALIGN:justify; MARGIN:6pt 0in 0pt 99pt; tab-stops:62.85pt 94.5pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in">If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.</p> <p style="TEXT-ALIGN:justify; MARGIN:0in 0in 0pt; tab-stops:.7in 62.85pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-48.6pt; MARGIN:0in 0in 0pt 99pt; tab-stops:49.5pt 99.0pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in">Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:-48.6pt; MARGIN:0in 0in 0pt 99pt; tab-stops:49.5pt 99.0pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in">&nbsp;</p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; tab-stops:49.5pt 99.0pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in"><font style="LETTER-SPACING:-0.1pt">The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&nbsp; Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.</font></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; tab-stops:49.5pt 99.0pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; tab-stops:49.5pt 99.0pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in"><font style="LETTER-SPACING:-0.1pt">The Company values its derivative liability associated with the variable conversion feature on its Series C Convertible Preferred Stock (Note 12) based on the market price of its common stock.&nbsp; For each reporting period the Company calculates the amount of potential common stock that the Series C Preferred Stock could convert into based on the conversion formula (incorporating market value of our common stock) and multiplies those converted shares by the market price of its common stock on that reporting date.&nbsp; The total converted value is subtracted by the consideration paid to determine the fair value of the derivative liability.</font></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; tab-stops:49.5pt 99.0pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-ALIGN:justify; TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; tab-stops:49.5pt 99.0pt 303.8pt decimal 5.1in left 397.4pt decimal 6.4in"><font style="LETTER-SPACING:-0.1pt">The method described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value could result in a different fair value measurement at the reporting date.</font></p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">The Company classified the derivative liability of $88,960 and $66,176 at March 31, 2012 and December 31, 2011, respectively, in Level 2 of the fair value hierarchy.</p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">The carrying amounts reported in our Condensed Consolidated Balance Sheet for Cash and Cash Equivalents, Accounts Receivable, Accounts Payable, Notes Payable, Accrued Expenses and Other Liabilities and Preferred Stock Liability approximate fair value due to the short-term maturity of those financial instruments.</p> <!--egx--><p style="MARGIN:0in 0in 0pt"><b><font style="LETTER-SPACING:-0.15pt">7.</font></b><font style="LETTER-SPACING:-0.15pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>PREPAID EXPENSES AND OTHER CURRENT ASSETS</b></font></p> <p style="MARGIN:0in 0in 0pt"><b><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></b></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">Prepaid expenses and other current assets consist of the following:</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <table width="572" style="MARGIN:auto auto auto 41.4pt; WIDTH:429.2pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:211.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:0in .5in 208.6pt 297.4pt 390.65pt 7.0in"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="142" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:0in .5in 208.6pt 297.4pt 390.65pt 7.0in" align="center"><b><font style="LETTER-SPACING:-0.15pt">March 31, 2012</font></b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:0in .5in 208.6pt 297.4pt 390.65pt 7.0in" align="center"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="130" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:97.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:0in .5in 208.6pt 297.4pt 390.65pt 7.0in" align="center"><font style="LETTER-SPACING:-0.15pt">December 31, 2011</font></p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:211.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:.5in">Prepaid insurance</p></td> <td width="142" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:7.0pt right 1.25in"><b><font style="LETTER-SPACING:-0.15pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 855</font></b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:7.0pt right 81.0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="130" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:97.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:7.0pt right 81.0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 25,283</font></p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:211.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">Travel and commission advances</p></td> <td width="142" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 1.25in"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35,500</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 81.0pt">&nbsp;</p></td> <td width="130" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:97.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 81.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 35,500</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:211.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">Other</p></td> <td width="142" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 1.25in"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19,890</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 81.0pt">&nbsp;</p></td> <td width="130" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:97.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 81.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 9,485</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:211.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">Prepaid expenses and other current assets</p></td> <td width="142" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:7.0pt right 1.25in"><b><font style="LETTER-SPACING:-0.15pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 56,245</font></b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:7.0pt right 81.0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="130" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:97.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:7.0pt right 81.0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 70,268</font></p></td></tr></table> <!--egx--><p style="MARGIN:0in 0in 0pt"><b>8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; PROPERTY AND EQUIPMENT</b></p> <p style="MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">Property and equipment, net, consist of the following:</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <table width="572" style="MARGIN:auto auto auto 41.4pt; WIDTH:429pt; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:211.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:0in .5in 208.6pt 297.4pt 390.65pt 7.0in"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="142" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><font style="TEXT-DECORATION:none; text-underline:none"><strong><u>March 31, 2012</u></strong></font></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12.9pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><font style="FONT-WEIGHT:normal; TEXT-DECORATION:none; text-underline:none"><u>&nbsp;</u></font></p></td> <td width="130" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:97.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center"><font style="FONT-WEIGHT:normal; TEXT-DECORATION:none; text-underline:none"><u>December 31, 2011</u></font></p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:211.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">Property and equipment, gross</p></td> <td width="142" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 1.25in"><b>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 247,647</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12.9pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 81.0pt">&nbsp;</p></td> <td width="130" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:97.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 81.0pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 227,645</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:211.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">Accumulated depreciation and amortization</p></td> <td width="142" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 1.25in"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 204,940</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12.9pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 81.0pt">&nbsp;</p></td> <td width="130" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:97.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 81.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 201,476</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="282" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:211.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp; Property and equipment, net</p></td> <td width="142" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:7.0pt right 1.25in"><b><font style="LETTER-SPACING:-0.15pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 42,707</font></b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:12.9pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:7.0pt right 81.0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p></td> <td width="130" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:97.8pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:12pt; MARGIN:0in 0in 0pt; tab-stops:7.0pt right 81.0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 26,169</font></p></td></tr></table> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">Depreciation and amortization expense was $3,464 and $8,154 for the three months ended March 31, 2012, and 2011, respectively.&nbsp; </p> <!--egx--><p style="MARGIN:0in 0in 0pt"><b>9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACCOUNTS PAYABLE, GENERAL</b></p> <p style="MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <table style="MARGIN:auto auto auto 0.5in; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="289" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:216.9pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">&nbsp;</p></td> <td width="141" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:105.55pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt; tab-stops:5.1pt decimal 68.1pt" align="center"><b>March 31</b><b>, 2012</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.85pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt; tab-stops:5.1pt decimal 68.1pt" align="center">&nbsp;</p></td> <td width="135" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:101.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt; tab-stops:5.1pt decimal 68.1pt" align="center">December 31, 2011</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="289" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:216.9pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Legal fees payable</p></td> <td width="141" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:105.55pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 88.0pt"><b>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 785,534</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.85pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="135" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:101.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 83.0pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 733,858</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="289" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:216.9pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Accounting fees payable</p></td> <td width="141" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:105.55pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 88.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 103,397</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.85pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="135" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:101.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 83.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 39,285</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="289" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:216.9pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Consulting fees payable</p></td> <td width="141" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:105.55pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 88.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 225,024</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.85pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="135" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:101.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 83.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 110,515</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:5.4pt"> <td width="289" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:216.9pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Other payables</p></td> <td width="141" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:105.55pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 88.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 212,907</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.85pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="135" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:101.1pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 83.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 240,349</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:5.4pt"> <td width="289" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:216.9pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Accounts Payable, General</p></td> <td width="141" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:105.55pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 88.0pt"><b>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,326,862</b></p></td> <td width="18" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.85pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="135" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:101.1pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 83.0pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,124,007</p></td></tr></table> <p style="MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <p style="MARGIN:0in 0in 0pt"><b>10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ACCRUED EXPENSES AND OTHER LIABILITIES</b></p> <p style="MARGIN:0in 0in 0pt"><b>&nbsp;</b></p> <table style="MARGIN:auto auto auto 0.5in; BORDER-COLLAPSE:collapse" cellpadding="0" cellspacing="0"> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="291" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:218.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">&nbsp;</p></td> <td width="142" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.4pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt; tab-stops:5.1pt decimal 68.1pt" align="center"><b>March 31</b><b>, 2012</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt; tab-stops:5.1pt decimal 68.1pt" align="center">&nbsp;</p></td> <td width="133" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:99.4pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="TEXT-ALIGN:center; MARGIN:0in 0in 0pt" align="center">December 31, 2011</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="291" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:218.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Royalties payable</p></td> <td width="142" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.4pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 89.0pt"><b>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 284,948</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="133" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:99.4pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 82.0pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 210,169</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="291" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:218.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Deferred compensation</p></td> <td width="142" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.4pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 89.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 8,089</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="133" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:99.4pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 82.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid"> <td width="291" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:218.5pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Accrued accounting fees</p></td> <td width="142" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.4pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 89.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 65,502</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="133" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:99.4pt; PADDING-RIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 82.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 93,529</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:5.4pt"> <td width="291" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:218.5pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Arbitration settlement payable</p></td> <td width="142" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.4pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 89.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:.5in">&nbsp;</p></td> <td width="133" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:99.4pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="LINE-HEIGHT:normal; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:ideograph-numeric; tab-stops:7.0pt right 82.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 775,000</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:5.4pt"> <td width="291" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:218.5pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Other accrued liabilities</p></td> <td width="142" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.4pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 89.0pt"><b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 190,961</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="133" style="BORDER-BOTTOM:windowtext 1pt solid; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:99.4pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 82.0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 149,775</p></td></tr> <tr style="PAGE-BREAK-INSIDE:avoid; HEIGHT:5.4pt"> <td width="291" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:218.5pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="bottom"> <p style="MARGIN:0in 0in 0pt; tab-stops:.25in .5in .75in">Accrued Expenses and Other Liabilities</p></td> <td width="142" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:106.4pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 89.0pt"><b>&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 549,500</b></p></td> <td width="17" style="BORDER-BOTTOM:#f0f0f0; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:13.1pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt">&nbsp;</p></td> <td width="133" style="BORDER-BOTTOM:windowtext 1.5pt double; BORDER-LEFT:#f0f0f0; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:5.4pt; WIDTH:99.4pt; PADDING-RIGHT:5.4pt; HEIGHT:5.4pt; BORDER-TOP:#f0f0f0; BORDER-RIGHT:#f0f0f0; PADDING-TOP:0in" valign="top"> <p style="MARGIN:0in 0in 0pt; tab-stops:7.0pt right 82.0pt">&nbsp; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,228,473</p></td></tr></table> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="MARGIN:0in 0in 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Deferred revenue includes 12 and 16 training days which were purchased but not conducted during the three months ended March 31, 2012 and year ended December 31, 2011, respectively.&nbsp; </p> <!--egx--><p style="MARGIN:0in 0in 0pt"><b>11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES PAYABLE</b></p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">In December 2011, the Company issued a 90-day note payable to borrow $100,000.&nbsp; That note was originally extended for an additional 30 days in March 2012.&nbsp; The proceeds were used for general corporate purposes.&nbsp; In January 2012, two additional notes were issued to borrow $50,000 each.&nbsp; In April and May, 2012 additional notes totaling $125,000 were issued.&nbsp; On May 10, 2012 all notes totaling $325,000 were combined into one note.&nbsp; Note payable bears simple of interest at 6.00% per annum.&nbsp; Principal amounts totaling $300,000 and $25,000 including all unpaid interest are due on July 2, 2012 and August 1, 2012, respectively.&nbsp; &nbsp;&nbsp;</font></p> <p style="MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">In March 2012, the Company issued a 24-month convertible promissory note to borrow $100,000 for general corporate purposes.&nbsp; The convertible promissory note bears simple interest of 6.00% simple interest per annum and is payable monthly in advance.</font> At any time on or after September 13, 2012 the holder of the note may elect by notice to the Company to convert this convertible promissory note into shares of Company&#146;s common stock at the rate of $1.05 per share.</p> <!--egx--><p style="MARGIN:0in 0in 0pt"><b>12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHAREHOLDERS&#146; INTEREST </b></p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">On May 2, 2011 the Company adopted and executed the Employees&#146; Directors&#146; and Consultants Stock Option Plan (the &#147;Plan&#148;).&nbsp; During the three months ended March 31, 2012, the Company granted 70,000 options to directors which were fully vested upon granting.&nbsp; Also, 10,000 previously granted options were forfeited during the quarter ended March 31, 2012.&nbsp; All outstanding options have been fully expensed.</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">During the three months ended March 31, 2012, the Board of Directors extended the expiration dates for all options previously granted to two departing Board members in recognition for their service during the period of managerial transition.&nbsp; Those options will expire per their original term specified in each individual option agreement, typically either 5 or 10 years from the date of granting, rather than expiring within the specified time period, typically 90 days following the Board members&#146; termination dates. &nbsp;The Company considered the extension as a modification to the option agreements recording incremental compensation of $80,000 for the three months ended March 31, 2012.</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">We estimated the fair value of each option on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions.</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">Three Months Ended</font> March 31, 2012<font style="LETTER-SPACING:-0.1pt"></font></p><pre style="MARGIN-LEFT:0.5in">Dividend yield (1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 0.0%</pre><pre style="MARGIN-LEFT:0.5in">Expected volatility (2) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 86.7% - 87.1%</pre><pre style="MARGIN-LEFT:0.5in">Risk-free interest rates (3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp; 0.89%</pre><pre style="MARGIN-LEFT:0.5in">Expected lives (2) &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 5 YEARS</pre><pre>&nbsp;</pre><pre style="TEXT-INDENT:-0.5in; MARGIN-LEFT:1in">(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; We have not paid cash dividends on our common stock since 1981, and currently do not have plans to pay or declare cash dividends. Consequently, we used an expected dividend rate of zero for the valuations.</pre><pre style="TEXT-INDENT:-0.5in; MARGIN-LEFT:1in">(2)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Estimated based on our historical experience. Volatility was based on historical experience over a period equivalent to the expected life in years.</pre><pre style="TEXT-INDENT:-0.5in; MARGIN-LEFT:1in">(3)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Based on the U.S. Treasury constant maturity interest rate with a term consistent with the expected life of the options granted.</pre> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; TEXT-AUTOSPACE:">During the three months ended March 31, 2012, the Company recognized expense of $58,630 for stock options issued to directors during the current period.&nbsp;&nbsp; During the three months ended March 31, 2011, the Company recognized expense of $4,720, for stock options issued to employees.</p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">On December 15, 2010 the Company issued a $400,000 promissory note.&nbsp; The promissory note was scheduled to mature on December 31, 2012 with an annual interest rate of 5%.</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">On December 15, 2010, the Company's Board of Directors authorized the issuance of 750 shares of Series C Convertible Preferred Stock ($1,000 par value) with a 5% cumulative dividend to William R. Waters, Ltd. of Canada.&nbsp; On December 30, 2010, 750 shares were issued.&nbsp; The Company converted the above $400,000 promissory note into 400 shares and received cash of $350,000 for the remaining 350 shares.&nbsp; These transactions were necessitated to replenish the Company's operating cash which had been drawn down by the $750,000 cash collateral previously posted by CTTC in a prejudgment remedy action styled <i>John B. Nano v. Competitive Technologies, Inc.,</i> Docket No. CV10 5029318 (Superior Court, Bridgeport, CT), see Note 12 below for details.&nbsp;&nbsp; </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">On June 17, 2011, William R. Waters, Ltd. of Canada, advised the Company of its intent to convert one half of its Series C Convertible Preferred Stock, 375 shares, to common stock, with a conversion date of June 16, 2011.&nbsp; On July 14, 2011, American Stock Transfer &amp; Trust Company was asked to issue the certificate for </font>315,126 shares of CTTC common stock.&nbsp; In accordance with the conversion rights detailed below, the conversion price for these shares was $1.19, which is 85% of <font style="LETTER-SPACING:-0.1pt">the mid-point of the last bid price ($1.35) and the last ask price ($1.45) on June 16, 2011, the agreed upon conversion date.</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">The rights of the Series C Convertible Preferred Stock are as follows:</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="MARGIN:0in 0in 0pt 0.5in"><i><font style="LETTER-SPACING:-0.1pt">Dividend rights &#150; </font></i><font style="LETTER-SPACING:-0.1pt">The shares of Series C Convertible Preferred Stock accrue a 5% cumulative dividend on a quarterly basis and is payable on the last day of each fiscal quarter when declared by the Company&#146;s Board.&nbsp; Dividends declared for the three months ended March 31, 2012 were $4,623.&nbsp; At March 31, 2012, $14,075 dividends declared have not been paid, including the $4,623 declared in the current quarter, and are shown in accrued and other liabilities.</font></p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><i><font style="LETTER-SPACING:-0.1pt">Voting rights</font></i><font style="LETTER-SPACING:-0.1pt"> &#150; Holders of these shares of Series C Convertible Preferred Stock shall have voting rights equivalent to 1,000 votes per $1,000 par value Series C Convertible Preferred share voted together with the shares of common stock</font></p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><i><font style="LETTER-SPACING:-0.1pt">Liquidation rights</font></i><font style="LETTER-SPACING:-0.1pt"> &#150; Upon any liquidation these Series C Convertible Preferred Stock shares shall be treated as equivalent to shares of Common stock to which they are convertible.</font></p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><i><font style="LETTER-SPACING:-0.1pt">Redemption rights</font></i><font style="LETTER-SPACING:-0.1pt"> &#150; The redemption rights were associated with the $750,000 that had been held in escrow by the Company in the event that the funds were released and returned to the company.&nbsp; However, the funds were withdrawn from escrow and paid out in accordance with the settlement agreement (see Note 13 for details).&nbsp; Therefore the redemption rights no longer apply to the remaining Series C Convertible Preferred Stock.</font></p> <p style="MARGIN:0in 0in 0pt">&nbsp;</p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><i><font style="LETTER-SPACING:-0.1pt">Conversion rights </font></i><font style="LETTER-SPACING:-0.1pt">&#150; Holder has right to convert each share of Series C Convertible Preferred Stock at any time into shares of the Company's common stock at a conversion price for each share of common stock equal to 85% of the lower of (1) the closing market price at the date of notice of conversion or (2) the mid-point of the last bid price and the last ask price on the date of the notice of conversion.&nbsp; The variable conversion feature creates an embedded derivative that was bifurcated from the Series C Convertible Preferred Stock on the date of issuance and was recorded at fair value.&nbsp; The derivative liability will be recorded at fair value on each reporting date with any change recorded in the Statement of Operations as an unrealized gain (loss) on derivative instrument. </font></p> <p style="MARGIN:0in 0in 0pt 0.5in"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="MARGIN:0in 0in 0pt 0.5in"><font style="LETTER-SPACING:-0.1pt">On the date of conversion of the 375 shares of Series C Convertible Preferred Stock the Company calculated the value of the derivative liability to be $81,933 and recorded </font>an unrealized loss of $15,678 for the six months ended June 30, 2011 related to the converted shares.&nbsp; Upon conversion, the $81,933 derivative liability was reclassified to equity.&nbsp; </p> <p style="MARGIN:0in 0in 0pt 0.5in">&nbsp;</p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">The Company recorded a convertible preferred stock derivative liability of $88,960, associated with the 375 shares of Series C Convertible Preferred Stock outstanding at March 31, 2012, and $66,176, associated with the 375 shares of Series C Convertible Preferred Stock outstanding at December 31, 2011.&nbsp; </font></p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="MARGIN:0in 0in 0pt 0.5in; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">The Company has classified the Series C Convertible Preferred Stock as a liability at March 31, 2012 and December 31, 2011 because the variable conversion feature may require the Company to settle the conversion in a variable number of its common shares.&nbsp; </font></p> <!--egx--><p style="MARGIN:0in 0in 0pt"><b><font lang="FR">13</font></b><font lang="FR">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <b>CONTRACTURAL OBLIGATIONS AND </b></font><b>CONTINGENCIES</b></p> <p style="MARGIN:0in 0in 0pt"><font lang="FR">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt; BACKGROUND:white"><font style="LETTER-SPACING:-0.1pt">As of March 31, 2012, CTTC and its majority-owned subsidiary, VVI, have remaining obligations, contingent upon receipt of certain revenue, to repay up to $199,006 and $203,478, respectively, in consideration of grant funding received in 1994 and 1995.&nbsp; CTTC is also obligated to pay at the rate of 7.5% of its revenue, if any, from transferring rights to certain inventions supported by the grant funds.&nbsp; VVI is obligated to pay at rates of 1.5% of its net sales of supported products or 15% of its revenue from licensing supported products, if any.&nbsp; We recognize these obligations when we receive revenue related to the grant funds.&nbsp; We recognized $425 and $345 of these obligations during the quarters ended March 31, 2012and March 31, 2011, respectively.&nbsp; </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">On November 22, 2010, the Company terminated its operating lease and paid the landlord all existing obligations thereto.&nbsp; The Company then entered into a new, three-year operating lease for new, more appropriately sized office spaces.&nbsp; The obligations are significantly less that the previous lease, averaging $70,000 per year for the three-year term.&nbsp; Under the previous lease, rent and utility obligations would have been approximately $300,000 per year for that same period. </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.1pt">In January 2011, the Company entered into a two-year lease effective February 1, 2011 for additional office space for the sales and training staff in Charlotte, NC.&nbsp; Obligations under this lease average $27,000 per year for the two-year term.</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><b><i>&nbsp;</i></b></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><b><i>Carolina Liquid Chemistries Corporation, et al</i></b><b>. (Case pending)</b><i> </i>&#150; On August 29, 2005, we filed a complaint against Carolina Liquid Chemistries Corporation ("Carolina Liquid") in the United States District Court for the District of Colorado, alleging patent infringement of our patent covering homocysteine assays, and seeking monetary damages, punitive damages, attorneys&#146; fees, court costs and other remuneration at the option of the court.&nbsp; As we became aware of other infringers, we amended our complaint to add as defendants Catch, Inc. ("Catch") and the Diazyme Laboratories Division of General Atomics ("Diazyme").&nbsp; On September 6, 2006, Diazyme filed for declaratory judgment in the Southern District of California for a change in venue and a declaration of non-infringement and invalidity.&nbsp; On September 12, 2006, the District Court in Colorado ruled that both Catch and Diazyme be added as defendants to the Carolina Liquid case.&nbsp; </p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">On October 23, 2006, Diazyme requested the United States Patent and Trademark Office (the "USPTO") to re-evaluate the validity of our patent and this request was granted by the USPTO on December 14, 2006.&nbsp; On July 30, 2009, the U.S. Patent and Trademark Office&#146;s Board of Patent Appeals and Interferences (&#147;BPAI&#148;) upheld the homocysteine patent.&nbsp; In September 2008, the examiner had denied the patent, but that denial was overruled by the BPAI.&nbsp; While the examiner had appealed that BPAI decision, delaying further action, that appeal was also denied by the BPAI on December 13, 2010.&nbsp; In June 2011, the examiner once again appealed the BPAI decision, was again denied.&nbsp; In addition to responding to this new appeal, the Company had petitioned the Director of the USPTO to help expedite further action on the case within the USPTO, which was to have been handled with special dispatch according to USPTO requirements for handling reexamination proceedings of patents involved in litigation.&nbsp; </p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">On March 13, 2012, the USPTO issued the Ex Parte Reexamination Certificate confirming the patentability of claims examined.&nbsp; Future action on this case pends its return to the District Court in Colorado.&nbsp; </p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><i>&nbsp;</i></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><b><i>Employment matters &#150; former employee (case pends) &#150; </i></b>In September 2003, a former employee filed a whistleblower complaint with OSHA alleging that the employee had been terminated for engaging in conduct protected under the Sarbanes Oxley Act of 2002 (SOX).&nbsp; In February 2005, OSHA found probable cause to support the employee&#146;s complaint and the Secretary of Labor ordered reinstatement and back wages since the date of termination and CTCC requested de novo review and a hearing before an administrative law judge (&#147;ALJ&#148;).&nbsp; In July 2005, after the close of the hearing on CTTC&#146;s appeal, the U.S. district court for Connecticut enforced the Secretary&#146;s preliminary order of reinstatement and back pay under threat of contempt and the company rehired the employee with back pay.&nbsp; </p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">On October 5, 2005, the ALJ who conducted the hearing on CTTC&#146;s appeal of the OSHA findings ruled in CTTC&#146;s favor and recommended dismissal of the employee&#146;s complaint.&nbsp; Although the employee abandoned his position upon notice of the ALJ&#146;s decision, he nevertheless filed a request for review by the DOL Administrative Review Board ("ARB").&nbsp; </p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">In May 2006, the U.S. Court of Appeals for the Second Circuit vacated the order of the district court enforcing the Secretary&#146;s preliminary order of reinstatement and back pay.&nbsp; The employee also filed a new SOX retaliation complaint with OSHA based on alleged black listing action by CTTC following his termination.&nbsp; OSHA dismissed the complaint and the employee filed a request for a hearing by an administrative law judge. Ultimately, the employee voluntarily dismissed the appeal.</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">In March 2008, the ARB issued an order of remand in the employee&#146;s appeal of the October 2005 dismissal of his termination complaint, directing the ALJ to clarify her analysis utilizing the burden-shifting standard articulated by the ARB.&nbsp; In January 2009, the ALJ issued a revised decision again recommending dismissal and once again the employee appealed the ruling to the ARB.&nbsp; On September 30, 2011, the ARB issued a final decision and order affirming the ALJ&#146;s decision on remand and dismissing the employee&#146;s complaint.&nbsp; The employee has appealed the ARB's decision before the U.S. Court of Appeals for the Second Circuit which has ordered the employee to file his opening brief by May 31, 2012.&nbsp; Response briefs by the Solicitor's Office of the U.S. Department of Labor and CTTC are due by July 30, 2012.&nbsp; No date has been set for oral argument.</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><b><i>John B. Nano vs. Competitive Technologies, Inc. - Arbitration (case completed)</i></b> &#150; On September 3, 2010, the Board of Directors of CTTC found cause consisting of violation of<sub> </sub>fiduciary duties to the Corporation and violation of the CTTC Corporate Code of Conduct and removed John B. Nano as an Officer of the Corporation, in all capacities.&nbsp; On September 13, 2010, the Board of Directors also found cause consisting of violation of<sub> </sub>fiduciary duties to the Corporation and violation of the CTTC Corporate Code of Conduct removed John B. Nano as a Director of the Corporation, in all capacities, for cause, consisting of violation of his fiduciary duties.&nbsp; Details of these actions are outlined in Form 8-K filings with the SEC on September 13, 2010, and September 17, 2010.&nbsp; Mr. Nano was previously the Chairman of the Board of Directors, President and Chief Executive Officer of CTTC.&nbsp; </p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">On September 13, 2010, Mr. Nano brought an arbitration claim to the American Arbitration Association against CTTC.&nbsp; Mr. Nano's employment contract with the Company had called for arbitration, which Mr. Nano had demanded to resolve this conflict.&nbsp; Mr. Nano sought $750,000 that he claimed was owed under his contract and claimed that he had been terminated without cause.&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">On September 23, 2010 the Company was served notice that John B. Nano, CTTC's former Chairman, President and CEO had filed a Notice of Application for Prejudgment Remedy/Claim of $750,000 and an Application for an Order Pendente Lite claiming we had breached Mr. Nano&#146;s employment contract with us.&nbsp; The applications were filed in the State of Connecticut Superior Court in Bridgeport, CT.&nbsp; <font style="LETTER-SPACING:-0.15pt">In November 2010, the Company funded $750,000 as a Prejudgment Remedy held in escrow with the Company's counsel and has included this amount as restricted cash on the December 31, 2011 and December 31, 2010 balance sheets.&nbsp; The Company did not believe it was liable to the</font> former Chairman, President and CEO, believing he was terminated for cause.&nbsp; The case proceeded through the arbitration process. <font style="LETTER-SPACING:-0.15pt">&nbsp;The initial arbitration hearing began in April 2011; additional hearing dates were held in May and June 2011.&nbsp; In July 2011, each party submitted a summary limited in length stating their positions.&nbsp; </font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">Prior to the conclusion of the arbitration hearings, the Company filed suit in Federal Court against the American Arbitration Association.&nbsp; The Company requested a temporary restraining order to halt the arbitration, which was denied by the court.&nbsp; The Company also requested a hearing before the court to review the arbitration proceedings.&nbsp; In August 2011, the American Arbitration Association's assigned arbitrator gave award to the Company's former Chairman, President and CEO, despite the Company's strongly held belief that the Board of Directors properly exercised its reasonable discretion under the employment agreement in finding that the former executive engaged in willful misconduct and gross negligence and that the executive&#146;s actions were cause for employment termination under the employment agreement and governing law.&nbsp; The former executive had requested a payment of $750,000, which he believed was due under his employment agreement.&nbsp; Following the notification of award, the former employee filed a motion with the State of Connecticut Superior Court in Bridgeport, CT to have the award confirmed.&nbsp; CTTC followed with a motion to vacate the award.&nbsp; A hearing on those two motions was held before a judge in October 2011.&nbsp; </p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">In January 2012, the judge denied the Company's motion to vacate the arbitration award in favor of its former CEO John B. Nano and granted Mr. Nano's application to confirm the award.&nbsp; Following the decision, CTTC settled all disputes with its former Chairman and CEO, John B. Nano. Pursuant to the settlement, CTTC has released to Mr. Nano from escrow the $750,000 deposited by CTTC following Mr. Nano's application for a prejudgment remedy. CTTC paid an additional $25,000 as settlement of additional amounts of statutory interest.&nbsp; These amounts ($775,000) had been accrued at December 31, 2011.&nbsp; The settlement includes mutual general releases of any and all claims either party has or had against the other. The settlement agreement also includes a provision that neither CTTC nor Mr. Nano would disparage the other. Should any such disparagement occur and litigation ensue, they further agreed that the prevailing party would be entitled to recover its costs and expenses, including reasonable attorney's fees. CTTC's payments to Mr. Nano were completed in the quarter ended March 31, 2012.</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><b><i>Unfair Trade Practices; U.S. District Court of Connecticut (case completed</i></b><i>) </i>&#150; In September 2011, the Company filed a complaint against an individual in U.S. District Court of Connecticut for (1) violation of the Connecticut Unfair Trade Practices Act, (2) tortious interference with business and economic expectancy, (3) libel and (4) injunctive relief.&nbsp; The complaint noted that the individual named in the civil action has, for more than a year, engaged in a systematic campaign to destroy the Company's trades and business, interfere with the Company's expectations and contracts and libel the Company by disseminating materially false and libelous statements about the Company on message boards throughout the Internet and otherwise.&nbsp; The Company sought punitive damages from the individual for his alleged unfair trade practices and wrongful interference with the Company's business.&nbsp; The case was concluded in March 2012.&nbsp; By the parties&#146; stipulation settling the matter, the defendant agreed to cease his posting of any statements on the Internet or publishing any statements elsewhere, orally or in writing, concerning CTTC, CTTC&#146;s officers, directors, and employees, the Calmare device, Marineo (the inventor of the Calmare device), or any other person or entity in connection with their purchase or use of the Calmare device.</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt">&nbsp;</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><i>Summary</i> &#150; We may be a party to other legal actions and proceedings from time to time.&nbsp; We are unable to estimate legal expenses or losses we may incur, if any, or possible damages we may recover, and have not recorded any potential judgment losses or proceeds in our financial statements to date, with the exception of the accrued expenses related to the Nano case, previously disclosed.&nbsp; We record expenses in connection with these suits as incurred.</p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">&nbsp;</font></p> <p style="TEXT-INDENT:0.5in; MARGIN:0in 0in 0pt"><font style="LETTER-SPACING:-0.15pt">We believe we carry adequate liability insurance, directors and officers insurance, casualty insurance, for owned or leased tangible assets, and other insurance as needed to cover us against potential and actual claims and lawsuits that occur in the ordinary course of our business.&nbsp; However, an unfavorable resolution of any or all matters, and/or our incurrence of significant legal fees and other costs to defend or prosecute any of these actions and proceedings may, depending on the amount and timing, have a material adverse effect on our consolidated financial position, results of operations or cash flows in a particular period.</font></p> 1145 127109 128254 114415 0000102198 2012-01-01 2012-03-31 0000102198 2012-03-31 0000102198 2011-06-30 0000102198 2011-12-31 0000102198 2011-01-01 2011-03-31 0000102198 us-gaap:CommonStockMember 2012-01-01 2012-03-31 0000102198 us-gaap:AdditionalPaidInCapitalMember 2012-01-01 2012-03-31 0000102198 us-gaap:RetainedEarningsMember 2012-01-01 2012-03-31 0000102198 us-gaap:ComprehensiveIncomeMember 2012-01-01 2012-03-31 0000102198 us-gaap:PreferredStockMember 2012-03-31 0000102198 us-gaap:CommonStockMember 2012-03-31 0000102198 us-gaap:AdditionalPaidInCapitalMember 2012-03-31 0000102198 us-gaap:RetainedEarningsMember 2012-03-31 0000102198 us-gaap:ComprehensiveIncomeMember 2012-03-31 0000102198 2010-12-31 0000102198 2011-03-31 0000102198 us-gaap:PreferredStockMember 2011-12-31 0000102198 us-gaap:CommonStockMember 2011-12-31 0000102198 us-gaap:AdditionalPaidInCapitalMember 2011-12-31 0000102198 us-gaap:RetainedEarningsMember 2011-12-31 0000102198 us-gaap:ComprehensiveIncomeMember 2011-12-31 iso4217:USD shares iso4217:USD shares net of allowance of $101,154 at March 31, 2012, and December 31, 2011 $25 par value, 35,920 shares authorized, 2,427 shares issued and outstanding $0.001 par value, 20,000 shares authorized, no shares issued and outstanding $1,000 par value, 750 shares authorized, 375 shares issued and outstanding at March 31, 2012 and December 31, 2011 $.01 par value, 20,000,000 shares authorized, 14,830,204 shares issued and outstanding at March 31, 2012 and 14,715,789 shares issued and outstanding at December 31, 2011 EX-101.CAL 7 cttc-20120331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 cttc-20120331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 cttc-20120331_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Accounts payable, general Inventory, Finished Goods Property, Plant, and Equipment Accrued stock contribution (directors stock exp) Adjustments to reconcile net income (loss) to net cash used in operating activities: Total shareholders' interest (Deficit) Accounts payable, GEOMC Security deposits Receivables Net loss - year ended December 31, 2011 Statement [Line Items] Capital in excess of par value Entity Current Reporting Status Share-based compensation - stock options Commitments and Contingencies {1} Commitments and Contingencies Loss on disposal of property and equipment Deferred rent Diluted income (loss) per share Basic income (loss) per share Income (loss) before income taxes Selling expenses Series C convertible preferred stock Exercise of stock options (Shares) 2011 Accumulated deficit Entity Central Index Key Related Party Transactions Disclosure [Text Block] Compensation Related Costs, Retirement Benefits Accounts Payable and Accrued Liabilities Disclosure [Text Block] Business Description and Basis of Presentation [Text Block] Statement of Cash Flows, Supplemental Disclosures Proceeds from sale of stock Proceeds from exercise of stock options Net income (loss) attributable to common shareholders Unrealized gain on derivative instrument Investment income Equity Components [Axis] Document Fiscal Year Focus Proceeds from note payable Derivative liability {1} Derivative liability Deferred revenue {1} Deferred revenue Related Party Disclosures Commitments and Contingencies Disclosure [Text Block] Restructuring and Related Activities Disclosure [Text Block] Investments, Debt and Equity Securities Revenue Total shareholders' interest(deficit) Share Balance - December 31, 2011 Share Balance - December 31, 2011 Share Balance - December 31, 2011 Payables and Accruals Significant Accounting Policies [Text Block] Net (decrease) in cash and cash equivalents Increase in security deposits Proceeds from sale of rental asset Changes in assets and liabilities: Other income TOTAL LIABILITIES AND SHAREHOLDERS' INTEREST (DEFICIT) Restricted Shares Purchased in Private Placement 2011 Common shares issued to settle accounts 2011 Return of shares to Crisnic (Shares) 2011 Compensation expense from stock option grants Entity Filer Category Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Debt Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Cash Flow, Supplemental Disclosures [Text Block] Supplemental Cash Flow Information Cost of product sales Shareholders' interest (Deficit): Preferred stock liability Deferred revenue Accounts payable Inventory Conversion of Class C Convertible Preferred Stock 2011 Common shares issued to settle accounts payable, general and accrued expenses {1} Common shares issued to settle accounts payable, general and accrued expenses Gains on sale of rental assets Restricted cash {1} Restricted cash Condensed Financial Information of Parent Company Only Disclosure [Text Block] Fair Value Disclosures [Text Block] Earnings Per Share Pension and Other Postretirement Benefits Disclosure [Text Block] Proceeds from sale of preferred stock Bad Debt Expense Basic weighted average number of common shares outstanding: Receivable from Crisnic Common stock Current Liabilities: Cash and cash equivalents Cash and cash equivalents at beginning of year Cash and cash equivalents at end of year Balance Sheets Conversion of Class C Convertible Preferred Stock (Shares) 2011 Entity Common Stock, Shares Outstanding SEC Schedule, Article 12-04, Condensed Financial Information of Registrant Organization, Consolidation and Presentation of Financial Statements Statements of Operations Capital in excess of par value {1} Capital in excess of par value Liabilities and Shareholders' Interest (Deficit) Common shares issued to Directors 2011 Document Fiscal Period Focus Accounting Changes and Error Corrections Purchase of property and equipment Stock based compensation, common stock Diluted weighted average number of common shares outstanding: General and administrative expenses Current Assets: Preferred stock dividend Restricted Shares Purchased in Private Placement (Shares) 2011 Statement [Table] Entity Well-known Seasoned Issuer Document and Entity Information Debt Disclosure [Text Block] Restructuring and Related Activities Cash Paid for interest Cash flows from financing activities: Total Expenses 5% preferred stock Common shares issued to settle accounts (Shares) 2011 Entity Public Float Prepaid expenses and other current assets {1} Prepaid expenses and other current assets Equity Property, Plant and Equipment Disclosure [Text Block] Proceeds from issuance of note payable Statements of Cash Flows Other Revenue Gross profit from product sales Accrued expenses and other liabilities Share Balance - August 1, 2010 Share Balance - August 1, 2010 Share Balance - March 31, 2012 Document Type Fair Value Measures and Disclosures Accounting Policies Nature of Operations [Text Block] Retained royalties Preferred Stock New Accounting Pronouncements and Changes in Accounting Principles [Text Block] Total other revenue {1} Total other revenue Deferred Costs, Capitalized, Prepaid, and Other Assets Net income (loss) Personnel and consulting expenses Accumulated deficit {1} Accumulated deficit Total current liabilities Derivative liability Notes payable TOTAL ASSETS Prepaid expenses and other current assets Common shares issued to settle accounts payable, general and accrued expenses (Shares) Entity Voluntary Filers Notes payable {1} Notes payable Long-term Debt [Text Block] Accounts payable, accrued expenses and other liabilities Cash flows from operating activities: Interest expense Expenses Commitments and Contingencies Total current assets Exercise of stock options 2011 Statement of Stockholders' Equity Entity Registrant Name Earnings Per Share [Text Block] Compensation Related Costs, Share Based Payments Stockholders' Equity Note Disclosure [Text Block] Net cash (used in) operating activities Product sales Series B preferred stock Property and equipment, net Restricted cash Assets {1} Assets Common shares issued to settle accounts payable, general and accrued expenses Common Stock Document Period End Date Common shares issued to settle accounts payable, general and accrued expenses (Shares) {1} Common shares issued to settle accounts payable, general and accrued expenses (Shares) Receivables, net Unrealized loss on derivative instrument Net (loss) for the period Total other revenue Gain on sale of rental assets Common shares issued to Directors (Shares) 2011 Receivable From Crisnic Amendment Flag Balance - December 31, 2011 Balance - December 31, 2011 Balance - December 31, 2011 Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] Receivables, Loans, Notes Receivable, and Others Cash provided by financing activities Repayment of note payable Net cash provided by (used in) provided by investing activities Cash flows from investing activities: Stock option compensation expense Depreciation and amortization Provision (benefit) for income taxes Return of shares to Crisnic 2011 Balance - August 1, 2010 Balance - August 1, 2010 Balance - August 1, 2010 Current Fiscal Year End Date EX-101.PRE 10 cttc-20120331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 11 cttc-20120331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000250 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000200 - Disclosure - Earnings Per Share link:presentationLink link:definitionLink link:calculationLink 000230 - Disclosure - SEC Schedule, Article 12-04, Condensed Financial Information of Registrant link:presentationLink link:definitionLink link:calculationLink 000270 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Organization, Consolidation and Presentation of Financial Statements link:presentationLink link:definitionLink link:calculationLink 000030 - Statement - Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 250000 - Disclosure - Accounting Changes and Error Corrections link:presentationLink link:definitionLink link:calculationLink 000260 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Equity link:presentationLink link:definitionLink link:calculationLink 000150 - Disclosure - Commitment and Contingencies link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000180 - Disclosure - Compensation Related Costs, Share Based Payments link:presentationLink link:definitionLink link:calculationLink 000130 - Disclosure - Payables and Accruals link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Deferred Costs, Capitalized, Prepaid, and Other Assets link:presentationLink link:definitionLink link:calculationLink 000210 - Disclosure - Fair Value Measures and Disclosures link:presentationLink link:definitionLink link:calculationLink 000190 - Disclosure - Compensation Related Costs, Retirement Benefits link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Consolidated Statements of Changes in Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 000060 - Statement - Statement of Cash Flows, Supplemental Disclosures link:presentationLink link:definitionLink link:calculationLink 000170 - Disclosure - Equity link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000120 - Disclosure - Property, Plant, and Equipment link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Investments, Debt and Equity Securities link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000140 - Disclosure - Restructuring and Related Activities link:presentationLink link:definitionLink link:calculationLink 000220 - Disclosure - Related Party Disclosures link:presentationLink link:definitionLink link:calculationLink 000160 - Disclosure - Debt link:presentationLink link:definitionLink link:calculationLink 000240 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Receivables, Loans, Notes Receivable, and Others link:presentationLink link:definitionLink link:calculationLink GRAPHIC 12 cttc10q1q2012001.jpg IMAGE begin 644 cttc10q1q2012001.jpg M_]C_X``02D9)1@`!`0$`W`#<``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,# M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_ MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`$#`@D#`2(``A$!`Q$!_\0` M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4% M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$! M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$" M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_****`"B MBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*** M*`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH M`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@` MHHHH`****`"BBB@`HHHH`****`"BFI,LCNJLI9#A@#DK]?2G4`%%%%`!1110 M`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`! M1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%% M%%`!1110`4444`%%%%`!1110`4444`%%%!.!F@`)`ZD"O#/VR_VS--_9G\.& MSM6AO_%>H1YM+0G*VZG($TF/X01PO5C[`FF?MF_MGZ7^S9X::RLF@OO%M]&? MLMKD,MJ/^>LH'0>B]6(],FOS+\7^+M2\>^);S5]8NY[_`%&_D,L\TK99V)_E MT``X`Z4`>J_`7]MKQ;\'_BU=^([Z^NM:MM;F#ZQ;329%V.@9?[KJ/NX``'RX MQQ7Z9?"GXK:'\9_!-IK_`(?OH[[3[L8R.'B<`;HW'577/(/\B#7XSYY[Y%>G M_LO?M2:Y^S'XW%_8,]YI-VRKJ.G,V([E,]1_=<!+*/3GA?XC[:OJ]W/>ZA?R&6::5B6=B<_@!Z=`!C`Z4`+XM\7:GX[\1WF ML:Q>7%_J-_(99IY6)=S_`$&,<#@8`["LWMGICTKH?"'PC\4^/I%70_#FM:J6 MY!M;.24?7@5Z'HW[`'Q=UN-)$\&W5NK]#-G(P`,&ALC@Y M_&O=I/\`@FW\78HRP\.6[D#[JZA!G_T*N>U_]B#XK^&E)N/`^LRJ/^?55NOQ M_=EC0!#^R]^U%KO[,7CE;^P9[G2;LA=1TYW(BNT'\0_NR*"=K=NG()%?J/\` M"+XN:'\;?`UIX@T"[6ZL;H8(/RR6\@`+1NO\+C/(^A&00:_'C7?#&I>%;HP: MGIU[ITP_Y9W$#Q-^3`&N]_9@_:>UW]F/QNNHZJ>,]20"TL MU&\6X;($D@!SU^ZHY8^U7_VHOVJ;?X2R0>&M"EL;KQGJPV0K<3".WTQ&'_'Q M.QX``Y"DY;'Y^=?"/X3?#CP)K[>*-5^)]EJWC>]S)>:F]Q;.!(W+")9%?8!T M!&#@=NE`'@W@[]@_XF_&CQ*?$7C2PUJ&WU5S<7$H>W:_D)]8YY8]G'3/3ICH M*^F_A9^R)X$^%ENJ1?"?7=GGP?H+9S\'@<\_\`'EI'_P`?JC_PM'PM_P!%<'_?^Q_^-4?\+1\+?]%< M'_?^Q_\`C5`%X>#]!7./@\!G_IRTC_X_1_PB&@@$#X/``_\`3EI'_P`?JC_P MM'PM_P!%<'_?^Q_^-4?\+1\+?]%<'_?^Q_\`C5`$U[\.?"^I`"X^"MO/@8&_ M3]'8CZ9GXKQ?XR_\$^O"OQ!26XT'P5XN\)ZBV2OV:?3I;5CCO$UUQSC[K#Z& MO8O^%H^%O^BN#_O_`&/_`,:H_P"%H^%O^BN#_O\`V/\`\:H`^-O!?AWXM?\` M!._Q>FNW.C7<_AF\<)?1)(LUO'[M;JRN/E=#@2VT@`W1R+_``N,CCW!&00:XF\^(WA#4K26WN/BO#<0 M3*4DCDEL6213U!!BY!%>+7NB>'OV8O$LGC#X6>--(U&.5M^L>&[B_ACBU./E MB82N%CD'.T8P.@XRK`'V117*_!WXR:'\AW(FAE`6:%AMEM),?-'(I MY#`\>AZC(KJJ`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"BB@D#KQ0`5Y'\?_P!H2Z\,:W:^"?!L$.K_`!`U MI?W$!^:#2XCUN;@C.U5Z@8Y^G7F_VU_VT[']G;13H^CM#?\`C*_C_<0?>6R5 MA@2R#UY^5>YYZ=?//V9?A=H>C>&Y_$/CO2O'VJ^./$$C75]=166I1-$K'(B# M0[0PX!/4M737.H3>K'[) MPJY(51PH]\D]GYOQ%_Z%[P!_X.+K_P"1*XG[!X`_Z%_XE_\`?.L__%T?8/`' M_0O_`!+_`.^=9_\`BZ`.V\WXB_\`0O>`/_!Q=?\`R)1YOQ%_Z%[P!_X.+K_Y M$KB?L'@#_H7_`(E_]\ZS_P#%T?8/`'_0O_$O_OG6?_BZ`.V\WXB_]"]X`_\` M!Q=?_(E'F_$7_H7O`'_@XNO_`)$KB?L'@#_H7_B7_P!\ZS_\71]@\`?]"_\` M$O\`[YUG_P"+H`[;S?B+_P!"]X`_\'%U_P#(E'F_$7_H7O`'_@XNO_D2N)^P M>`/^A?\`B7_WSK/_`,72C3O`!&?^$?\`B6!]-9_^+H`[7S?B+_T+W@#_`,'% MU_\`(E)YWQ%_Z%[P#_X.+K_Y$JKX:^"?@_Q3HT5[!8>);>.;.$N]4U&WF&#C ME'E##IZ5Z#I.E0:)IT-I;1F."!0J*6+$#W)R2?O]U>_4\=?S4\1>(K_P`7Z[=ZIJ=U/?W]]*TL\\S%WE*`/9_P!D#X>7W[0GQ\GU[6==LK:72'75;B]U0"9+B?=^[4J77=D@G&<8 M0^PK[X&J^(QT^)/@K_P6+_\`)->%?L'_``HNO"WP'L[^Z^&EKXDFU^1KU+NY MGL\^5]U%"R_,!A<^^:]I_L*3_HBFD?\`?[3J`+G]J^)/^BE>"O\`P6+_`/)- M']J^)/\`HI7@K_P6+_\`)-4_["D_Z(II'_?[3J/["D_Z(II'_?[3J`+G]J^) M/^BE>"O_``6+_P#)-']J^)/^BE>"O_!8O_R35/\`L*3_`*(II'_?[3J/["D_ MZ(II'_?[3J`+G]J^)/\`HI7@K_P6+_\`)-']J^)/^BE>"O\`P6+_`/)-4_[" MD_Z(II'_`'^TZC^PI/\`HBFD?]_M.H`MMJWB0`D?$KP5_P""Q?\`Y)KI?`UC MXE:Z6ZU/Q)HVM:>Z$(MEII@W-G[V_P`UP1UXQ7+:9X72_P!2MX;GX/:)96\C MA9)W>PD$*]VVJ"3CT%>FZ7I5KHMA%:V=M;VEM",)##&(XT'H%'`H`L`8]311 M10`4444`%%%%`!1110`444C$A210!E^-/&^D?#KPW>:UK^IZ?HNCZ?&9;J]O M9U@M[=1_$[L0%'U-?&WC+_@X._9N\)^(I-/AU[7]:CB?:UW8:/*]N>.JE]I8 M?05\/_\`!QS^V/K7C;]H6V^$>GW\UMX8\)6L-UJ%O%*P6_OI5WJ9`#@B.,IM M!'!9CSD8\?\`V`/^"*7Q!_;Q^$\WC>UUW1?"GAN6:2VT^>]CDFEU!XV*R%43 M[J*P*[B>2K`#C-?J&3\&Y;3RV&9YU6<(SM9+3?;HVVUK9=#\US;B[,*F82R[ M)Z2E*%[MZ[;]4DD]-=V?NQ^S'^U1X,_:_P#A;!XQ\"ZC+J>B33-;EY;=X)(Y M5QN1E<`Y&1TR/>O*_P!IC_@KU\!_V5/$4NB>(O&45_KMNVRXT[1X6OY[5L=) M"GRHW^RS;O:OB+QG+\2_^"-'_!)CQ1X.U"]MK'QMXE\7RZ=HNI:=_O[^^D80V=N MK*'FD(!9CN=0`.69@,CJ#*>"LOQ'M\=6K-8:$FHNZNTNK=MNFUWY"S7C''X? MV.#HTD\1.*LVL MH&;/W?..8U/^\P'OFOKZSO(M0M(IX)8YH9E#QR(P9'4C(((X((K^:W_@H?\` M\$O_`!O_`,$Z]8T0^(=0TO7]#\0AULM3L`Z)YJ`%HI$<91L'(Y((!YR"!^@/ M_!MG^V5KWQ#\/^*?A%X@U&YU*+PI9IJVA//(7>VM3((Y8`3SL1WC*CL'(&`` M*QXAX-P5/+_[6RBJYTUNGKI>UT[+9[IHVR#B[&5,?_9F:TU"H]FM-;7LU=[K M9H^H_C__`,%J/@5^S3\7M:\#^*-8UR/7]`E6&\CM=)DGBC=D5PH<<$[67IZU M[)^S7^UWX(_:O^"O_"P/"&I23^&UEGAEEN8C!);M"?W@=3RN!AN?X2#WK^;7 M]M[XACXN_MD_%+Q''+)/;ZQXJU&:V9OO>1]I<1+^$80?A7T__P`$]/VYS\"/ M^":7[2'A`WK6^JRVL$NB*)"'#WW^AS.F.GEC8^?4K7HYEX=T:>6TJV&ENC??8\_+^/JT\PJ4<0HJFE.S5[^[=K6_5+[S]&KO_@X5_9KM+F6 M(Z]XD:U\.0Z9(7; M+%K758[;)^OE9^A%9\2\"X/`2POL)2:J5(PE=IZ2[:*W7N:<.\;8O'+$*NHI MPIRG&R?3OKZ'K@_X.&OV:F&1KGB<8]=#F%>H_LW?\%:O@/\`M4>);;0_"_C> MVBUZ\)%MINIPO8W-T1_#&)`%=NX56+$=J_GT_8W^"/A_]HS]HKP_X/\`%'BR MT\#Z'JQF%QK5R8UBL@D+R+GS&1?F90O+#[U9'QW\%67P%^/VOZ)X5\5P^)++ MPUJ9BT[7]/;RUNO+(*S1E2<$'NI(RO!/6O9K^'&42JRPE&I-5%'F5[-6O;7W M4GKT3N>11\0_\%3OA)^P[\0=.\,> M/]1U>SU;5-/75($M-.DN5,#221@DKT):)QCVKREO^#AO]FL#C6O%!_[@8<Y_;&_9#^!)^&?CW39_"7A'0;Z6WU'6;&6V MN;]+J9)T/DINV8"L""?2OR$TS3'U75[>R5E62XF6%6/0%F`S].:SR'@W(\=VE=EYWQ=GF`J04J<%&:5G:]WRQGU[6O.^RQW&DR0QGRH))WRYX'R1M]3Q7PS?_P#!+#Q; M_P`$]_\`@GY^T+JWB+Q#H6MV?BSP_I\5LM@)5DB*72NV\.`/X\#!/2OE/_@B MG9-J'_!3CX8VZ$*T[:E&">F3I=X*Y:/"&38C!XO&86I*4:5^5W6MH*6ON][K MIH=-;BO-Z&+PN%Q,(QE4MS*W>;CI[W:Q^LMU_P`'"?[-ME=RP2ZUXG$D+%&` MT.4@$'!J-O\`@X=_9J4$_P!M>*?_``12_P"-?E+_`,%(_P#@EAXL_P"">VF^ M']:\1^(M!UN+Q?>W,4,>GI*IMVC"N=V\#((<=/2L+_@GG_P32\4?\%&KWQ=: M^&=>T31)_",-M-+_`&BLA6X\\RA0I0'&#$'OV?\`1/B;/J/B%O". MOZG/H]K<1Z1*SBYA4,R.O\.0<@GK@^E?D9_P74\'S>`/VRM$T*ZDCFN-%\#Z M+8RO%G8[Q0LC,N><$KGFOJ7]B;]E]?VM/^#?_P`5>&H+83ZU9ZOJ&K:.0N76 M[MRDBJ/]]0T9]I#WKPZW"F5TK5K)Z]3[P_8^_X*B?"3]N3QMJ?AWP#JVI76K:39?VA-!>6#VI:' MS%C++N^]AG0''3<*A_:\_P""JGP@_8B^(%GX8\=ZKJEOK%[9+?I#96#W6R)G M906*_=)*G@]N:_$7_@CE\>F_9X_X*'>`+V65K>RU^[/AR]!8JI2[(C4-Z@2^ M4W/`*@]JRO\`@JS\>)/VE_\`@H'\0]:M7DNK&WU+^QM,527W06P$"[1U^=E9 M\>LAKTEX=8?^V7A7*7L.3FO=7O>UKVMY[;'`^/\`$?V0L2E'VW/RVL[6M>]K M_+?<_:JT_P""U'P-N_@/=_$D:CXDC\)VFN1>'6N7T:8,][)!).(U7N!'&23T M&5'<5R'_`!$-?LU<_P#$[\3G'?\`L.7%?(__``4E_9;3]D/_`((8_"/PI-:+ M;:S<>,;+5=9PH#M>W&GW[R!B.K(-D>3GB,#H!7YU_LZ^%?A_XP^(#67Q)\7: MKX,\.BU=QJ&GZ4VI3><"NR/R@PX(W?-GC'O1DW!63XW#5<7S5'&,Y)6:;:3T M=E%MM^0LWXQS;!XBGA;04I1BW=-)-[J[DDDO,_I!_8W_`."@7PY_;NL=:G>0^'I8HKPWEDUL5:0,5P&Z\*:]MK\_\`_@@E\)?A?X"^&OCO4_A=XZU[ MQQINI:E!;WDNIZ(=+:VECB+!54LV\$2=?PK]`*_-L]PN'PV/J4,+SDL@ MZ%O[J=^IXZM_;=_;>L_V>-(DT/19(+WQA>Q_(APT>G*1Q)(/[W=5[]3QU_-C M7M?O_%6M76I:C=7%Y?7TK33S2,6>1RW] MXYEGGF8L\CGJ2>_;\JK6\?FS(@4L7(7`!R&X2)0J@84?9N!Z"M#_`(2_P5_T6#XE?]\7'_R-7H(_X6X``9/A@?PO*/\` MB[G_`#T^&!_\#*`//O\`A+_!7_18/B5_WQGPP_\G*,_%O_`)Z?##_R"O^BP?$K_OBX_\`D:O0?^+N?\]/A@/_``,HS\7/^>GPP_\`)R@#S[_A M+O!7_18/B7_WQGPP_\`)R@M M\7`#^\^&&/\`M\H`F_9\_LK5WO\`4='\:>*O%5N@%L\>JLP2%N&RJM&ASCOR M,$UZ;6%\/5UX:"3XC.BG4C*W.E^9Y&SC;]_YMW7/:MV@`HHHH`****`"BBB@ M`HHHH`*1SA3QFEH.,C@^N-O\`X)??\%S[;]B;X`I\.?%_A#4O$&DZ5-//H]YI MDT230B5S(T,B/@%?,9F#ALC=C:0!C]>?VF/!/P?_`&E/`.H>"?B'=>$]5TV1 M\2VUSJ$,<]I*I(WHVX/%(IR,C!Z@\$@_GIXN_P"#>KX$ZAKDDVC?'BYTS3FY M6VN;BQNY$]?W@>/(]/ES[FOUS*^),KQF50RW.Z.^%DV;=JE`5QCYL="37S/\`M/\`_!%/ M]F/X\^*;S7/#WC>R^'6I7S[Y8-)U.SDTTL>I6W<_(3Z(ZK_LU.3\3972IU\J MQ%*7U:4GRM)NT7T?7I>^]QYMP[F52=#,Z%2/UF,5S)M:M=5TV>J>ECX)_P"" MM_\`P5HM_P#@HLOAG1="\,W?AWPUX8EDO%:_F22\O)W4+DA/E1%7(`!8DG.1 MTKVG_@@-\*]1^$GPK^-WQ[U-9K'0])\+7>FV,S#"W)B7[3<2`]PGD1#([LPX MQ7O_`,`/^#<7X)Z;?P:SK/C;Q!\1+&*3=%!;2P6EE-CJKF+>[#/99%]Z^Q?V M@?A#\.]._9(U[X:7NLZ)\,O!>JZ-+HPFCG@L(K&W="K[/,(3[I.2>N3GK49O MQ1E<,#')GE>5\-9E+&RS?-)+G2?*KK5VLKM:)(_ MGC_8-\'1?&G]NGX;:3J<:7,6N>)[P//0X-!%CR=^6!9$52!_=SU)KZ)^(&"CF6BDZ7(D_==U M)-M:;VMU/!7`N,EEZNX^UY[_`!*SBTKZ][]#\O?VU_V2YOV9_P!CO]G:_O+3 M[/JWC;3]2US4#LPP,[6KP(_^T("F1QCD8!!S]&?LH?$8>)?^#>/X[:`TKR2> M&M615!)(CCGN;*0*/;<'/U8U^AG_``49_P""=WP[_;4\"^#=.\7>+)_!6G^$ MY'73YK>6WB$H:-5\O,HQ@*@(`]*\T^`/_!(7X6^`?V=?BE\+M!^*>JZ[H_Q' MAM'U%X[JTEFTT6TN\2($!`W':"6&,**\&?&.%Q66TEB6_:1JJ;]UV252^_E% MV_`]N'">)PN85'ATO9RIN"]Y7OR6VWUDK_B?BC^RA^S/K7[7WQ[T+X>^'KNP ML=7U\RB":]9E@3RXGE;<5!/W4/0>E?HA\`O^#8_Q./']A<_$CQSX?3PW;2K) M=6>C)--=7J`C]T'=46,,.-PW$>GTZ2\U"\M+&TAQOGN)5BC3) MP,LQ`'.!S4\3^(.*E65/*9N,''5N-I7N[VOY6+X;X$P\:+J9G%.:?25U:RWM MYW/PN_X.2/"VG^!OVM/ASH>D6L-CI>C_``\L;*SMHAA+>&.]OD1%'HJJ`/I7 MR[^RWX3^`'B+PSJ4GQ>\6_$/P]J\5R!8Q>'M,@NX98=HRSF3D-NR,#M7[0?M MU_\`!,7X4_\`!3'XWZ-XEU#XEW%EJ^FZ0ND0V6C7=I.)HDEFFW[3N;=F9LXX MP!7D5S_P;%_"NS@>63XD>-HHT!9G=+4*H]22E>CD_&66T,JI8'$U)PG%:N*= M[WONT]SSLVX2S&MF=7&8>G"<&]+M6V2V36Q];_\`!.?QMX*\:_L%^%!\/;_6 M]3\)Z+ITND6=UJULMM>3_9RT;,Z+P#D'I7\V'A$X\YOXN/\`MH*_H]_8 MPT#X.?L9?!>P^#NB?%?POK$]C-]>/PSQ#@,JKXQUW)1JM_P#*4SX3_P#7QJ'_`*;+NOW6_:]^&7@SX\?`/7/A=XH\76GANV\0 M64<$DOVR"*[2-74AU60XY*8R1CK7S/\`L2?\$/OAA^S3\?O#7Q1\)_$3Q!XF MN?#,MQY,3/:RVLK26\D#*S1KG(64G`/4"N3AWB'"8+(\5@Z]U.IS\NCL^:%E MKMN=.?Y#BL9G6&Q="SC3Y>;57TE=Z>AY/_P=)\_"GX1?]A;4/_1,-<7_`,&L MQ_XK#XSG'2STC_T.\K[W_P""B_\`P3=\.?\`!1CPYX8TSQ%X@UK0(O"]S/=0 M-IR1L96E15(;>#P-HZ5YY^Q+^QE\&?\`@DCK?BF23XM:?%<^,([:":/Q+JUC M9&/R#*5V`E"2?-.GB+4/YQU9_;#_ M`."/?PT_X*0?&9OB7/\`$'68GN+""Q5=%EM;FU*1!MK!L-DD-ZU[_P#L-?L: MZ+^PE\"8?`.@:MJ>LZ?#?3WWVF_""8M*1D80`8&T8J,YXBP=?AVAED&_:P<; MIII:)WU^9649!BZ&?ULQFE[.?-9IZZM=/D?@Q_P5I_9LG_8]_;X\5Z?IL;V& MFZISMVOS>FOJ M>%'@F:SSVEU[#FYK75^]N7??3T/)?^#F=1_PP1X6`XQX[L__`$@U"OQI_9KT M7X:Z]\1#;_%76O$^@^%S:R,+G0K2.YN_/!78NU^-I&[)Z\"OZ,/^"A_[%'AG M]O#X%6GA/Q9X@U#PSI.D:M%KAO;5HE*O'#-%AC("H3;,Q)]0*^(M-_X-W?@+ MK%]#:V?QJUJZNIVV1Q0W>GR22-Z!0,D^PK'@[BK+\%E+PF(E*,KMWC%NR=M4 M[-7-^+.&<=C,T6*P\8RC9*TFE>W1K1V/5?\`@@_XA^"FC^#O'/A'X/\`B+QM MXCCM;R#5M1F\0Z?':/$94,2*GE\,/W1)XS7Z!U\>?L"_L!?"W_@F'XH\6'2_ MB,U_J'B:*VANK?6KVT@>W$6]EPJ[3DB0GGMBOIS_`(7;X,SC_A+O#&3_`-12 M#_XJO@>()T\3CZE?".4X2LTY+5Z*]]%U/N,AC/#X&%'$J,)QNFHO1:NUM7T. MGHJ.VO8;VUCGAFBF@F4.DB,&1U(R""."".])"G.;M%-^A[4ZL(J\FD=I145EJ$&HVR36\\-Q#( M,K)&X=6'J".#4M2T4F%%%%(84444`%%%%`!1110`4444`?!G_!0[]A^[TG5- M2^(7A>.YOK*Y8W&K6A8O):MCF92O@G]O7]@9O"4EYXU\$V3/I3EIM1TZ%239DG)EC`_Y9^JC[O7IT M`/CPC'`[UT/PFFAA^)_A]KFRN-1M_P"T(1):P$B6Y4N!L7!!W-G`Y'-<^Q`) M.`,].U6=$U:;0]:L[VWD>&XLYTN(Y%`)C9&#!A[@@'TH`_0I=-\'[1CX%?$O M'^Y/_P#'Z7^S?!__`$0KXE_]\S__`!^KEMXQ%Q;QR+^U!X?574$!ETI6'L03 MP?:G_P#"5G_HZ+P[^6E?XT`4/[-\'_\`1"OB7_WS/_\`'Z/[-\'_`/1"OB7_ M`-\S_P#Q^K__``E9_P"CHO#OY:5_C1_PE9_Z.B\._EI7^-`%#^S?!_\`T0KX ME_\`?,__`,?H_LWP?_T0KXE_]\S_`/Q^K_\`PE9_Z.B\._EI7^-'_"5G_HZ+ MP[^6E?XT`4/[-\'_`/1"OB7_`-\S_P#Q^D;3?!X!/_"B_B7Q_L3_`/Q^M#_A M*S_T=%X=_+2O\:/^$K/?]J'PX?PTK_&@#V3X"&R'P]A33_#FL>%;2*:14L-3 M#"=>\&Z!J7B36Y8GG2RL8C+,Z(,LP4=@.37[O_`/!P\H3_`()J:V1D$:WI MO_HZOS=_X-X\'_@I3HH.?^0)J7_HFOZ$X>XEKU.':N.<%S44TEK9\L5:_K?4 M_!<]X1E64_0BO%_P!F3]BGQ/\`M7:=JMSX>UGP/I4>CR)% M,->UZ#3&0PQDYJFY.4FV MFTKU).UKI];;G!G>`4,[GA(P=11459.S=H16]GVOL?KE^SWX[U+_`()`?\$< MYM8\3#0-;UVQO[D:3%INHK>66H7%S.1"HF3AE&&9]O($;=Z_'OQK\0/BK^W_ M`/'1)-0NM?\`'GC+7IBMK:1!IBN>?+AB'RQQJ!T```'/K7Z&?M]?`O5?!/\` MP0B^&>C6^L:'XC_X5[KJKK5QH-^E_91B66Y"MYB<$*T\2GT,E?+/_!%[]KWP M9^QI^V,OB#QW$8M%U?2Y=(_M$1&4Z1)))&PG*@%MN$*,5Y`&Z<:># MQF;4(*K7_-9:N]NQZ^?U)5,5A,KK2=*BH0OK>U]VWLVMKO3J M>T_\$BOV//BW^R#_`,%-_`T7CWP/K?ANUUS3]4MQ<3HLMO*/L,LNT2QLT>[* M+\I;/7BO@7Q-+'9?&;49)"D4<>M2,Q/`4"_^)^M0 M1()))M4GC09QN)F8"M^$OPXO3T_Z;PU\U?M/_\`!./X ML?L=^!M(\1^/=!M=+TG7)Q;VLL5]%<%W*%P"$)(^4$\U]+?\&\_'Q>^-`''_ M`!;>^_\`1\%%?+\)A.&:U'!U?:0O?FT>KDK[::!0QV*Q7$=*KBZ?LY[6UVY7 M;?74_/CS7M[L/$[1R1N&1EX*D'@@]CFOUP^(?[>4?[<7_!!KQR=4N?/\=>#1 MINFZ^K$L\Q^V1"&Z^DJ+DG^^KBOR]^`?@^Q^(WQ[\'>'=261M/\`$.N6>EW& MQBCJD\Z1%E/8C?D=1DN"&4]Z^ASO+\/CJ]"FW:K3<:D?-*2YE_76QX.3X_$8.C6J M)7I5$X2\FXOE?]=+GL?_``0'4)_P4^\$$G`%CJF?_`"?^"JWB[]JG MXTZ_X-\-ZS>Z-\-/#UW)806EG*T7]L-&=KSSD??4NK;5^Z%QP3DUB?\`!!>! MKK_@I=X-B0X>33=64'W.GSBOE3QIX-U#X4_$K5-!URS9=2\/ZA)9WMO*"N9( MG*NIS@X)'IT-FK?R.WF_8A^+MM\%4^(K_#SQ.O@EXOM`U9K1A#Y)`(FQ][RR""'QM/K M7TK_`,$A?^"K?C#]E[XS:!X,\3ZQ?ZY\-_$-W%ITMM>3-,=%:1]J3P$Y*J&8 M;D'!&2`"*_136?\`@M-^SG/^QK-J`\06=S=SZ";/_A$I+9A>M*8-GV5H]I79 M_"7R4QW/2OPB^%/@G4?B1\3?#WAW2(IYM4UO4;>QM4A4M(9))%5<`/ M/'NG>'-=/B"\NS:3VUQ(WE.L05\QQLO.T\9S7SF<82M7X0PM/#PA?\%Z_P#@J!X@_95L=*^&'@&]DTGQ9XFT M\ZAJ&JQ'$VFV;.\2+$?X9)&CD^8_P#"7A;Q M-XYO+1O-U&\B5IR'8$C?(YP7(!P,DGTZ5]*_\%]FB\9?MC:+\0M(O'UCP?\` M$'PK8ZAHFHK&ZP2QIOB9$W`'(*AR"`1YRDCFOI#_`((0?\%&_@Y^SY^S!JW@ M;QSXCL/!VMV>KSZD+B^C98M1BD5`-KJ#EDV8VGGD8SV]#*^?)N'(8O+J'M*L MK_7[C\Y_@1^TI M\4_V"/C"\_AW4]9\+ZQHUYLU+1[G>D-P58;X+B`X!!Q@Y&1P00<&OV6_:@_X M+%6O@W_@E_X;^,'A6VBA\5?$`?V9I=I*#(FG7R[UN&8$?,(O+#%<^'[W[/;V\[1>4;PPP)$TVT\@,RDC(!QC-=S M^T/\!/$_AK_@C[\"/%%W!=0Z3+XFUNX,11@%CNQ`+>5LC@-]CEVD]1(",[J[ MLYR?!YA+`XK&TU"I.45)=[Q!CC,-@ZCG"$6XOM[R7, MNVC;_'H>(>&/#/Q9_P""@WQU-G9#7_B+XYUC?.QFN`[A`?F9GD81Q1*6`R2J M+D#CBO2O"O\`P3L_:E^"/QZM=$\/>!_&VA^-(HUN(;K2;Q%BC0G`8WD4GD*, MCG,@QCG%>U?\&^7[0?@SX.?&?XA:'XIU?3=`U'QEH"6FCWU_,EO`TR.Q,'FL M0$9]ZD`D!C'CK@5\F_'G1?'_`.SQXZ_X1[6O'<>I:E#$))3HOB@ZE#;D]$>2 M)RH?')7.0",XS7K2Q>*GCZN6T(PA"$8\JE%OFNM6K-+ECLU;?JCREAL-'!4L MPK2G*1SRZ M?(_^";O[6OB?5]2U;4-+D\/)IENUW<2S)YR))))L+$C(5TSC^\,]17S M5_P2T_Y2+?!DXQ_Q55G_`.AU\]DF!>#PN:8=M-J[]U62;IWLE=VM>VY[^;XQ M8O$Y;62:3Y5[SN[*=KMZ7O8[S_@N@@3_`(*=?$<8!R;+\?\`0H:XGX'_`/!- M?QM\?_AEI_BG1_$'PRL-.U/S!';ZKXJM;*[78[(=\3GH(/>O>P>)6'R3"S]JJ?N0U<>9?#M9-?TCQ,7AO;YSB8^R=3W MIZ*7*_BWNTS[V_X+3_M;>-_V1?V7/A#\%=`U*30]5U3PO;IX@U"QE(E>*"". MW:WCD7!".X_A!^T9\//AE=>)_B3HO@+Q-J$CV/ MAG6KC_2--OHVB$C+.ZG"0[O+(FSA2XSD-Q^2_P"V+^PAXC_8MGT236O$_@3Q M+:^(%9[&Y\.:RMZLJJ`2Y7"NJ_,,,5P<]:\'@K&8>66PP^'E[.O-R;;C?F:; M;MLFK:63NK'M<882O',95Z\?:48J*24KLZO/&):W[`S>$6O?&O@FU+:629M2TR%>-?!-DSZISG->B?\(QXT_Z(-\-?_!M!_P#(]?%/[)WBOPMI^O7^F^,-8\::583Q MA[/^P+R6,F;.J#NW+SD#(VX[U[W]L^#?_`$-OQQ_[_77_`,;H`];_`.$8 M\:?]$&^&O_@V@_\`D>C_`(1CQI_T0;X:_P#@V@_^1Z\D^V?!O_H;?CC_`-_K MK_XW1]L^#?\`T-OQQ_[_`%U_\;H`];_X1CQI_P!$&^&O_@V@_P#D>C_A&/&G M_1!OAK_X-H/_`)'KR3[9\&_^AM^./_?ZZ_\`C='VSX-_]#;\C_A&/&G_`$0;X:_^#6#_`.1Z\D^V?!O_`*&W MXX_]_KK_`.-T?;/@W_T-OQQ_[_77_P`;H`][^&B>./#_`(LM0WPE\&>&[&Z< M17E[IVKQ&:.(G).U85WX.#MS7LZ$%017P[]K^#70^+?CB1_UVNO_`(W7T1^S MC\?/"/C*UMO"V@ZAXBO;C2[7*2:S:R1SSQJ0.9&50[#(]\<\\F@#UNBBB@`H MHHH`****`"BBB@`HHHH`^:_^"L/[)/BG]MG]C[4?`?@^;1[?6KK4K.[1]3N' M@M]D4FY@61'.<=/EKY"_X)1?\$7_`(N?L3_MB:=X]\7W_@JXT2UTZ[M'73=1 MGFN"\L>U<*\"#&>OS5^B/Q[^.R_`Z;P0C:8=3'C+Q39>&1BX\G[(;A93Y_W6 MWA?+^[QG/48I?!OQP_X2SX]^-_`QTPP'P;9:;>?;?/WB[%XLQV[-HV;/)_O' M=N[8Y^CP6?X_"Y=4P%)+V52][K76R=G?T/`Q>08+%8^&.J7]I3M:STT;:T^\ M^-O^"UG_``2Y^)'_``4'\<^`M2\"W?A6VM_#5A=VUV-7O9;=F:62-EV!(GR, M(NK?#(?]Q>Y_^1J_8GX.?MN_#?X^^*K?1_"NNW=_=7MO M<7=E)-I%Y:6^I16\JQ7#6\TT21S^5(R*_ELVTL,]:O?"S]I*R^('_"S)K^TA MT'3_`(:>(KG0KNZGN@\FB7Z'AO\`P38_X)WZE^SU^PAJGPA^ M*MMX=UV/6[^\DO;>RF>XM9K>8*`NYT0[AC/`X(!!KX/_`&H/^#:7Q]X?\8WE MU\*/$&B>(/#TSE[>RU>X-I?VRGI&7VF.3'3=E<@#BOUH^!O[5?@C]HN;4(?" MFJ7-U^W3O% M>E:YJ^EQZ;&TEY)+;6$YA:\D9(PMO'(W"B0@%OE5G-=;X=^.VG:UXT^(&DRR M64*?#Z:WCOI(Y999$66SCN\R(8E"$))P$:3*X)*D[1VOC?.(8JIB6HJ4HI/W M=+)NUM>\GJ<:X+RN6'AA_>Y8MM>]K=I7Z=DCYK_X*]_L`^.?VZ/V/?B) MJ?C"^\&W%MXJ\(W&A68TV_FG=;B22-@7#PIA,(>02>G%?WTLVF0ZU:_:M(O+!=0L)3MCN[=KB*,3PE@5WQ[@#P<9&:ND?MR_#37 M/C);>`[;Q!<2>(;^^N=+LQ_95X+.^N[9&>Y@ANS%]GD>%5.\+(=I^4_-Q7EX M?B',*.7RRR"7LWJ]-=T]_D>E7X?P-7'1S&;?M%HM=-K;?,_*;X"_\&\?QX^& MGQX\%>)M1U3X=/I_A[Q!8:I=+!JMRTIBAN8Y7"@VX!;:IP"0,]Q7VM_P6)_X M)1W'_!0'PMH.L^#Y=&TOX@>'G-NMQ?NT,%]9L_&32_#^JFS\#?V^'TV^CELI+MM+GN(CAY( MA@2B`-E58)O*G+(P'76XMS7%XREC;KGIZ*RLO>Z/76YRT>%,LPV$JX2SY)ZN M[N].JTZ'Q'_P2T_X(F_&#]C/]L_PU\0/%VH^"+C0M(MKV&9--U&>:X)FM9(E MVJT"`_,XSEAQGK7L'_!3S_@AKH7[:?BVY\=^#-5M?"7CRZ4?;A/$6L-7*J%5 MI-OS1R8`&\9R!RN>:^M?V??VJ_"7[2>FW#3/AG^U[X"^+WCI_#FA:Q<7.HM%//:--IMU;6 MVJQ02".>2TGEC6*Z2-R%9H6<`^W-9XCBO-IX]9ASEC\5E_X-ROVC/[<%KY?@9;8?\`+Z=:/D_EY?F? M^.5]^_\`!,?_`((;Z!^Q-XK@\;^+]7MO&/CNW4BQ,4!2QTMM+9=4OYH)S+'-<.Q"I"XVXE7!SG@\5\K_P#$-5^T'@#^ MU?AE_P"#BZ_^1J_9/XF?MC?#WX0?$:V\*^(-=:SUB9+:28)8W$]OIZ7,IAMF MNIXT:*V$TJE$,S)N88%)\0/VH]+^'W[37P_^&%QIVIW&J_$&QU.^MKN*UF:V MM5LEA9E=U0H"_F\988VC/+H&O+N.U\4>"M)AM[76]+/FOI]TJ;6 M:-G52\3<;D(7<`.A`(_-_P")?_!MM\>/"VMRQ^'K_P`&>*=.+XBG74&LY2OJ MTFW4UC8W%R0+>WN+M(S M!!-+E=D*3;%&6!9FQ@+;35?C+XFTI=)M'$CZ+H4CS27F,$)).ZJ M$4]#M4DC@$9R/U&^+/[,'@KXT_`>Z^&NN:%92>$+FS2Q2RB01K:(@'E&+`^1 MHRJE2.A`K(^-O[7.@?!67X8E[74-9MOBIXBM=`TVXL+>6>&+SX)9TN&:-&`3 M;&.N,A]V0JL1U%O\7+>?XZ7?@<"R^UVN@P:Z<3R&X*27$T',?E[`F8N&\PL2 M2-@`#'@S;/\`,\PJPQ.)F[QUC;1*W56ZWZ[G;E>0Y=@:4L/AX*TM)7U;TZWZ M>6Q^.O[0W_!M!\3?"WB6YD^&WB;P]XIT)F+01:G,VGWT:]D;Y6C<@<;MR@]< M#H(O@%_P;0_%+Q5XAMW^(GB3PYX2T56!F33IFU"^<YDC6&=XB?G6-V(Y_N MMBY\*_CJOQ.^*?Q(\,IIALC\/-5M=,:X,_F"^,]C!=[PNT;,"?9C+9VYR,X' MO2\0<^A2]E*23M\3BN;M?M^!XJX"R657VBB[7VYM/3O^)YEX_P#V!M*\(?\` M!/#Q7\$OA?9V.EKJ>B7%A9M>R%%N+F4#=-<2*I)9B,EMI/08P`*_/K]BK_@@ M;\;_`-GS]K/X>^-]=U'X?R:-X6UNWU&\6TU2XDG:.-\D(K6Z@MCH"1]:_7/X MI_%30/@MX&O?$GB;48M+T>PV"69D:1F9W")&B("\DCNRJJ("S,P`!)`KE='_ M`&KO"7BCX->)/&^DSZE?Z=X3BN3J=F=-N8=2LYH(_,DMY+5T$Z2[<'8R9(92 M,@@UXV7<2YEA:-:E2=U6;YFU=MM6>O?4];'\-X#$U:56HFG22Y4G9))W6A^; M_P#P4N_X(??&/]KO]L[Q=\0/"VH^!8-"US[-]G34-2GAN!Y=O'&VY5@8#YD. M,,>,5X./^#:G]H,'_D*_#+_P<77_`,BU^RW['OQ[O?VGOV&3YHU9IX86+[",D)L)Y1G7#&[XU^.@\(?M#>"/`/]F&X;QGI MNJ:B+[[1M%I]B^R_)Y>T[]_VGKN7;L[YX]?"<>YQAJ4<)3Y;4U;;I%>O9'EX MO@3*L15EB:G->;N]>K?IYGY_?MU?\$3/BA^U#\*OA3!I7C7PW#J/P[\(VF@/ MHUVLJ6AN(U'FS1W"J2=Y`'S1C`1?4U\H^&?^#<#]H35_$*VM_+X'TBR#@/>O MJS3*5[LJ)&6)]B%K]E/$O[;_`,-_"?QAF\"7VN7[1-(O)+6QN[ MU$>SAFNEB,$;S"6,(&D&YF"]>*E^.?[9GP]_9QU\:5XJUB_MM3&F2:VUM9:- M>ZC)%81OLENG^SQ2!(D/WF;`422AAJ2P]!*,8K1=COZ*Y/3OC?X8U>P\67=KJT,UIX'N9;/6YA')Y=A-%"D M\J%MN&*1R*6V;L$X/((&-\#?VI?!_P"T7/K$'A>[U-[S01;O>VNI:1=Z7TBTR_M+:>]%^]TP6 MW2-(4=V:1F55`7.2!UJM8?M<>$?$/P0UCQWH\NI:EIVBS2V5Q9M82V>H)>I( M(OL;07"QO',9&5-L@7!8$D#FDJ-3^5[VVZA[2/<]0HKY8_9\_P""D5S\7_B! M'I.K^#;?1+"XOX]-6\M-7-[]DGD>>.%9E:&(8DDMY4!C9R'"@J%97/U#YS>U M57H3HRY*BL_5?H*E5C47-$FHHHK$T"BBB@`ILT8EC*D!E88(/((]*=10!\-_ MMI?L47WPM\3+\2_AO"]N-/G6^O+"!,FR=2&\Z)1_!D$LO;G'!(&_\'/C+\5O MC'X#M=!P<%6'KWR,@YK[#EB656#`,K#!!&0:^//V MD?V,]!^%GCB?XA:;X0A\5>&75WUKP^CO$]N3\QN8"I!`!'*<@`G`QT`.I.I_ M&('!^*'P>!'_`$R6D_M3XQ?]%0^#W_?I:\@\-Q>%_%VA6VIZ7^RUK.H:?>+O M@N(-3N9(Y%R1D$)@CBKO_"+Z-_T:=XA_\#[K_P"(H`]2_M3XQ?\`14/@]_WZ M6C^U/C%_T5#X/?\`?I:\M_X1?1O^C3O$/_@?=?\`Q%'_``B^C?\`1IWB'_P/ MNO\`XB@#U+^U/C%_T5#X/?\`?I:/[4^,7_14/@]_WZ6O+?\`A%]&_P"C3O$/ M_@?=?_$4?\(OHW_1IWB'_P`#[K_XB@#U+^U/C#W^*'P>_P"_2TY=7^,2'*_% M'X/J?41J#7E?_"+Z-_T:=XA_\#[K_P"(H_X1?1O^C3O$/_@?=?\`Q%`'UO\` M#+XBF7PY9V_B7Q%X/NM>/[N1M,OE,5P<\%58Y!/ISST]*[@$'D&='4 M@K^R?XB5AR"+^ZR/_'*]2\._M8>//"^D6]A9_`+QNEI:J$C5[V69U7TW21%C MCW-`'TY17G_PX^/1\;Q1IJ/A'QIX:O&X,5_I$S1Y]I(U9<>[8KT!6##(S0`4 M4F><<4M`!1110`4444`>7_M7_`&__:`\!:5;:+K4/A[Q)X8UNS\1:)?3VOVN MVAN[9R56:'T?7O&?C9[2. M[.CV$ECIEG;VL;1P10QR2RR9^=V9GD.6[=.*]GHH>(J-WO_5[_F'LHVM;^MCPS]F_]E[Q+\.?B7>>,?&GB+1M=UU? M#EEX1L%TC39+"VBL+66:59)%DED+3N\N6((10H"CDFH/V;?V7/&?P"\0V^E- MXRTJ^^'>A2:C+I&G1:1Y>I3&\N3<;;NY:1E982SJGE1QE@07)(Y]ZHHJ8B*+4V[>5J]M'OV:VT/QM\8]8.JB3_`(6M);.(O)Q_9WDZ M9%8XSGY\^5O[=<>]>K4553%59N\GK:WR3NON_0(T(1T2\SP[X%?L?/\`!;Q% M\.[\ZV+]?`?P[M_`>S[/Y?VLQ&W/VGJ=N?(^[SC=UKYZ^%7P`^)-E^U_X(T* M/1]5L/AK\-_&'B'Q-"]_I$4:D7Z7F"M\MPXN0TMXQ1%@C9%9Q(244G[V(R,& MFB/'^MU;7YK[]6*5"+MTM_P/\D&#Y8'?%?/NB?L7:G;?L>_$CX0W MFOV+6/C&7Q"-/U"&T99;*'5KFZN2)5+D.T7R9Y=X!_9U;P5\:?$/BQ]2%S%KOAG2?#WV41;#%]A:[ M)EW9YWBY`QCC9WS7C/[%W_!,:/\`9*^)6G:DMWX0O=,\,6-WI^D7-MHDD.M7 M4<[KM:[N7G=-R1J$_<1Q^9GBK6*JJ,H\VDK)_+8ET(-IVVV(KBW-Q M9R19V^8A7/7&17CO[(G[$O@W]E#X:>&],T_P]X6?Q+HNG+8W7B"UT:"UO=0/ M\3O(J[R6/)RQS7L]%9QJSC%P3T>_G;_ARI0BVI-:H^:/VA/V$=8^,'Q"\93: M9XHTW2O"GQ2MM+M?%UG<:<]Q?%;!V*FSF655B,D9$;;T?:5W+R<5Z/\`$SX$ M:CXR_:1^&?CVQU.RM8O`]MJ]A>6<\#2->PWT=N,QNK#8Z/:QGD,"K,,`X->H M457UBIIKLFOO5G^&A/L8:Z>?W._YGR1\0_\`@F)!XJ_:JU+QY:W'A"?2O$FM MV'B#4X]7T22]U.TN+584*6DPF6)$D6WA_P!9$[1MO92"1M]6^+W[+4GQ1^*F MJ^)EU@67]I>`-2\$B#R-_EF[FBD^T9SSM\O&WC.>M>PT5<\76E;FELK+T_I! M&A!7LM]3PWQM^R;J6L?##X+:)I>MV4%Y\(=9TK4Q-=6K/%J26EE-9R)M5P49 MXYW93DA6"Y##-=?;?`TV_P"U)??$@7X/VWPK;>&C9>7]WR;N>X\W?GOY^W&/ MX22VNI-3O;?4/,V13S2W#QHL`9$188HT*KR!P![G\)_@8_PQ^*WQ+\2G4! M>#XA:M:ZF(/+V_8O)L+>TV9S\V?(W9XQNQVKT2BKK8JK5LYN^EOE>_YBIT80 MORK=W^=K'G?[4'P+?]H3X7)HUMJ2:3JFFZKI^O:9=20&>&.\L;J.Z@\V,,I> M(O$`RAE)4G!!P:YOX._LPZMX1\'?$AO$FMZ?J/BOXIWDM_J]QIUH]M86KFRB MLHT@B=W?:L4"$EG)9BQX&`/:**4<34C#V:>G_#?Y+[@=&#GSM:_U_FSD_@+\ M,C\%?@9X+\&F[%^?"6A6.BFYV;/M'V:W2'S-O.-VS.,\9K*\;?`]O%O[17@; MQX-0\D>#M-U73_LGEY^T_;3:_-NSQL^S=,<[_:O0:*A59_K7M-%5] M8J::[?\``7Z(GV4>QX?\3_V6=:UCP#\+HO"VO:;IWBGX3W$%QIESJ=D]U8WN MVQDLI8YHTD1PKQRLP*N"K*O49!@T?]B6S;]B[7?A'K.JMJ3>*+;4GU/5(X1! MF^OIY;F6>*/)\M4GF+1KN)4(H))RU>[T4_K-2R5]G?\`7]6'LHW;[GAWPK_9 M*U7X:_L;ZS\.(_&-Y_PEOB*QU0WWBV"$17/]IWYE>2^1`?E9))=R+N^41HN< M`5S/["7["6I_LE>.?''B'4M7\/W]WXYL=*M[F'2[.ZB6.6Q^U#SFDN;B>65Y M1<[F+-P5XXKZ7HIRQ51J46_B=V)4(73MML?/.D_L4ZE#^QEX\^$=WX@LF3Q1 M!S70_'7]GCQ-XK\=^"?&G@C7M% MT;Q;X*M;S38QK.G27VGWMI=K")5=(I8G5PT$3JRO_"5((8X]EHI/$U'+F;ZM M_?H_O&J4;!OB7H-_JUT\'Q!\177B!+BU18KC2Y)!"8RA8,I M>.2%7!((R!D$5[)13EBJKWEUO\[W_,2H06R\OD?,OP0_8+U#X?>.;'4-8U3P MX=,TV>*^>UT33IK4ZY>1/.\-U=^;+(NY#.[`(-Q98\OA`M?2GE/Z"IJ*BM6E M4?-,J$%%604445D6%%%%`!1110`4V1`Z%2`0>".QIU%`'R#^UM^S/XD^&3-X MF^'VN^)-'\-&8W&L:/I$[@VF3\]Q!$&"D=2RY':0?M+7FJ:HL,'@OX6VQN)#L5_#=HD:9/`+N,`>['\:[R2#Q M]#'&S^!_@O&)5#INMM%4LI&0?]9T-`%__A-_#_\`T<;XW_\``*[_`/CE'_"; M^'_^CC?&_P#X!7?_`,*?$?C'P;H;:EJ'@K MX-QV:-LW16&D3LS8SM"HY8GV`H`Z'_A-?#XQ_P`9&>..>G^@W?\`\74&H>)) M]9@2S\'?&GX@>+?$=W(L-EIL%M<1F9VS\S,TF%0<;CS@'IWKA/#WQMU?XENW MAK2_A]\/;S6=<=(;22U\-6R7$)YW;!MVY(ZLPX`SQ7W/^QC^QAIG[-GAW[?? M+;7_`(NOTQ=7@0%;93UAB)&0N>IXW<>E`'1?LK?`[7?@[X/=O%'B35/$GB'4 MPCW;W%Y)/!;; M"&Z''/X5^W,D8D4@@$$8((S7PW^WS^P)]B-[XX\#V7[D[IM3TN!,;.I::%1V M[LHZ=1W%`'Q4CX8%@SC/3.#73:+J7A!8P-0TKQ#(_&6@U&)![\&$_P`ZYE@0 M0,G(_"D(X_B'Z4`=Q<:E\.A$QBTOQ@SCH&U&!1^?E'^5<]X@O-$GR-*L]2ML MG@W-VDW'_`8UK()XY)&:7MGG\#0`F3_>;\JTO"/A#4_'WB2STC1[.XO]2OY! M'##"I+,2?;MW)[`&G>"_!>J_$/Q38Z+HMG/?ZEJ$GEP01@LSGJ?H`,DD\``G MI7Z:?L8_L::;^S3X8^V7JP7WBW4$`N[L*"+=3@F&,XX7(Y/5B!V`%`"?L9?L M8Z7^S7X;6^O4BO\`Q;J$8^UW6W*VX(_U4?H!G!;JWMTKW7ITHHH`****`"BB MB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`**** M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH` M****`"BBB@`HHHH`****`"D=05/&S)!W3Z MII<*\CJ6FA4#IW9/Q'<4`?$8(.3P`?QK5\%^"=4^(OBBQT;1K.6^U+4)1%#" MG)8GN2>`!W)X`Y)'9_@7P'K'Q*\766A:)93WVIW\GEQ0J,_4D]`H'))X`!-? MIO\`L>?L:Z5^S+X:-Q/]GU'Q5?+B\O@,B-?^>461D(#U/5N_0``%/]D_]D30 M/V4/`D^JZK+;2^(9;8S:GJN#_9?^'>H_";]GCP5X:U8Q'4M$ MTBWM;D1OO2.14&Y%.!E5/RCV`KO*AE!1110`4444`%%%%`!1110`4444`%%% M%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444 M`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110` M4444`%(4#9R`ZE1>GJ$'\"D\D+ M@$_08[(#`P***``C/7-)L'O2T4`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` M!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`% M%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`44 M44`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!111 M0`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%%%%` 7!1110`4444`%%%%`!1110`4444`?_]D_ ` end GRAPHIC 13 cttc10q1q2012002.jpg IMAGE begin 644 cttc10q1q2012002.jpg M_]C_X``02D9)1@`!`@$`2`!(``#_X0Q<17AI9@``34T`*@````@`!P$2``,` M```!``$```$:``4````!````8@$;``4````!````:@$H``,````!``(```$Q M``(````<````<@$R``(````4````CH=I``0````!````I````-``"OR````G M$``*_(```"<0061O8F4@4&AO=&]S:&]P($-3,B!7:6YD;W=S`#(P,#@Z,3$Z M,#,@,3,Z,C8Z,3```````Z`!``,````!``$``*`"``0````!```"[J`#``0` M```!```!=P`````````&`0,``P````$`!@```1H`!0````$```$>`1L`!0`` M``$```$F`2@``P````$``@```@$`!`````$```$N`@(`!`````$```LF```` M`````$@````!````2`````'_V/_@`!!*1DE&``$"``!(`$@``/_M``Q!9&]B M95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)#!$+"@L1%0\, M#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P, M#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,#!$,#`P,#`P, M#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`4`"@`P$B``(1`0,1`?_=``0` M"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$``04!`0$!`0$` M`````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!``(1`P0A$C$% M05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D M1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F M]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#(3$2!$%187$B M$P4R@9$4H;%"(\%2T?`S)&+A7U5F9VAI:FML;6YO8G-T=7 M9W>'EZ>WQ__:``P#`0`"$0,1`#\`]522224I))!S,S'PL=V1D.V5LY/Y)29)]RP MWVVWAWB0PC_-A&Z?C=1Z+[ M-QS>GDRYC6$6U$G5]5(-GK5?Z2JMV_\`PE5?^DOBO<8#9)_D#^]6&8E;8+@' M'^J`/N24E8]EC`]C@YCA+7`R"#W!4E%E==;=M;0QLDPT0))W.X_>X.]J7">Q58[AM)*F>L=)#0\YN.&NF'&UD';]+\[\U2?U7I;)WY ME#=KMAFQ@AP&[9]+Z6UR7#+L?L5Q1[AM)*K^U.F2!]KHDEC0/49J;!NI;]+_ M``K?YK_2)6=4Z94YS;,RACJW;'AUC`6NC=L=+O:[:EPGL5<0[AM)*+'LL8VR MMP>QX#FN:9!!U:YK@I()4DDDDI__T?3LS,Q\+'=D9+]E;?O)/T6,;^<]RXZW M/NZSU;&]?VT^J/3IG1K0=SMT?2L>UOO/8\E^*;1Z=_&GYU=L?1M:S_`+=^G_I*ZTIZ,O)))+9.O=-N/BW\ M4$V`&-_'\L?W)O4;^_\`],?W)*='"$ASS$SM$*TJ/3KFDOJW2?I#W`_R7*\D MI22222GS1O1[#;UG'/V-]V8K_A M?T2#1T?.IP\KJ-.)B]-I/37]-#&9=+F9619^B=<;O4;17M_G7LMN]3?5_A5H M9OU*RPSZQ#"Z=6W[2[&;TL-=6V:Q8RW-:R7_`*%OZ/>_U/3_`.#4+?JQUCT. MEWV='9G,PVY%5_2K;,>H%UIGW8-/V_#SF'.H-F+ZGV)S6?: M;'LQ/2W4V6?Z3UU_P"@ M:U_ZOOL]/^<5#,^K^??T7I^4&4Y.9G9]N7G;;<;:;;?9534^]SL6]^QO\S^G MKW^HCGZG=FUK+19]FVTM M;2[V/]-C*5=Q\G&RJA=C6LOJ=]&RMP>TQX/9+5YWC?5+K#W,<7 M5FJ[$KYV[<^I5LN.`!E&8D;V!'5EQSD2`8D:=G<2224#*_ M_]+U5"R<:C*H?CY#!958(>P]T5))3S]U5^"YM%SW6-/MIN.V7@#1C^/UAC![ M_P#2_P`__I*ZH>N?%WW!;^1CTY-+Z+VA]5@AS3_>/6@'_B;16UK&VM_\&_Z%:4Z+\V1N(`D/:Y MGMC]'^FN?[_])_Q:C;TC&M;8Q[[=EPL#FBPC2UC:7!CA[Z]C6?HMGOJ5Y)&S MW531RNE59#+!ZMM3[6%AL8[4!SFVNHZ70RRD>K'\Y[;W?^!J\DE9[JIHNZ/C&DTM?;6"&MW,L(=#?1'\Y]+Z. M-6U$NZ=CW,;6\OV-=8XM#B`[U0\6!_[W\Z[:K225GNJFL_I^.]['^YI9Z>T- M<6B*2]U38;^;^E?N0V])H8&AMEP#6L:`+'<,L^TZGZ7O=^CL_P"`_1*ZDE94 MTF]*QVM<-]I<_?+R\EWZ0W//N_D?:K/2_<_1_N)G='Q'EA>;'&NRNULO)]]3 M?2K=K_(^FKR25GNJG__3]522224I#R,>G)I?1>P656"'-*(DDIYG&^J);GN^ MT6"S!9#JQ^?9/^#N_=V?G[?Y[_@UM8N/FU9=[K;6NQ71]GJ`C8``-L;6[=O] M=7$DE*22224I))))2DDDDE*22224I))))2DDDDE*22224__9_^T15E!H;W1O M0`@`&P`:0!G`&@`=``@`&(`;`!U`&4````! M``````````````````````````$``````````````NX```%W```````````` M``````````$`````````````````````````$`````$```````!N=6QL```` M`@````9B;W5N9'-/8FIC`````0```````%)C=#$````$`````%1O<"!L;VYG M``````````!,969T;&]N9P``````````0G1O;6QO;F<```%W`````%)G:'1L M;VYG```"[@````9S;&EC97-6;$QS`````4]B:F,````!```````%7!E96YU;0````I%4VQI8V54>7!E`````$EM9R`````&8F]U;F1S3V)J M8P````$```````!28W0Q````!`````!4;W`@;&]N9P``````````3&5F=&QO M;F<``````````$)T;VUL;VYG```!=P````!29VAT;&]N9P```NX````#=7)L M5$585`````$```````!N=6QL5$585`````$```````!-'1415A4`````0``````"6AOD%L:6=N````!V1E9F%U;'0````)=F5R=$%L:6=N96YU;0````]% M4VQI8V5697)T06QI9VX````'9&5F875L=`````MB9T-O;&]R5'EP965N=6T` M```115-L:6-E0D=#;VQO)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;& MUN;V-T=79W>'EZ>WQ]?G]Q$``@(!`@0$`P0%!@<'!@4U`0`"$0,A,1($05%A M<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]B7I[?'_]H`#`,!``(1`Q$`/P#U5))))2DDD',S,?"QW9&0[96SD]R> MS6C\Y[DE)DERN+];;OMSGY3`W"L@-:!+J@/\(XM_G=W^&_\``O\`A>H8]CV- M>QPH6`_G66;F5^N[\[;ZBO4^O?&5E-++GB64EN MX5,=]&O]WUMO](?_`-:_FT78/W1_VV/[TE.6?JGA[?;;>'>)#"/\V$;I^-U' MHOLW'-Z>3+F-81;42=7U4@V>M5_I*JW;_P#"55_Z2^*]Q@-DG^0/[U89B5M@ MN`UP9&I]1S3[/ M[2-'LBQW3I*O7GX-AJ;7DU/=D`F@->TFP-^F:H/Z39^=L46=4Z996^UF70^N MH`V/;8PM:#PY[@[VI<)[%5CN&TDJ9ZQTD-#SFXX:Z8<;60=OTOSOS5)_5>EL MG?F4-VNV&;&"'`;MGTOI;7)<,NQ^Q7%'N&TDJO[4Z9('VNB26-`]1FIL&ZEO MTO\`"M_FO](E9U3IE3G-LS*&.K=L>'6,!:Z-VQTN]KMJ7">Q5Q#N&TDHL>RQ MC;*W!['@.:YID$'5KFN"D@E22222G__1].S,S'PL=V1DOV5M^\D_18QOYSW+ MCK<^[K/5L;U_;3ZH].F=&M!W.W1]*Q[6^]R[/)QJ,JE]&0P65/$.:?\`7VN_ ME+CLOIMO1>IX]CR7XIM'IW\:?G5VQ]&UK/\`MWZ?^DKK2GHR\DDDMDZ]TVX^ M+?Q038`8W\?RQ_W^=>RV[U-]7^ M%6AF_4K+#/K$,+IU;?M+L9O2PUU;9K%C+ZZ@9]E5F!3@UNH;OL?:UWIW MYK+O3RK=C/4JH?[ZOT?^B5^WZH]?/4K,EM1^SGK%.4,;?5L-33N.=O<_U-]+ M?T/I?SK_`/1J&+]4?K%1D8=@I(QSU49>507U$5BJW]!G5>_;[\6VQEM7\[^B MJ]B/N]?=A?I/^+ZN%`@?W)=1OW_28U?5I^5B]-Z?=@T_;\/.8S$]+=399_I/5S'_`.D4<[ZM969TWK%^/C47!_4C?A7-MHVC''LO>V[U M-E+/38UME=CD7IGU/ZY1U'`99@U4OPLUV3D=;;=NLR*R[>ZHU3ZWZ5OL_2?^ MEO7C1]6OK,_ZLCHUO36U#$R6Y8K=>S;E-+WNMPGMI=^AV[F/]1]O_;:'N4;& M2.X_YTO57K3P6*,#L?Y?*V_#9`:Q[7_ M`*!K7_J^^ST_YQ4,SZOY]_1>GY093DYF=GVY>=MMQMIMM]E5-3[W.Q;W[&_S M/Z>O?ZB.?J=URW%S+FX%6+3=FX^2.A-N&Q]=(>VZOUV?H6.NWM_.V?\`;>.C M8OU7^L#::"_#JIK'6,?,;B5C'8ZJFLW>M?=9CBJJU^VRJME=>_V5_HZTA,1V MR1-$;_W."OF28DGY9"P=O[W%;UW2,[!'3Z*/6I9;C8[/7H;9435Z;6LM%GV; M;2UM+O8_TV,I5W'R<;*J%V-:R^IWT;*W![3'@]DM7G>-]4NL-Q^K8^5TNQ[< MQQ=6:KL2MSF_:*K]K+W-MO\`YMGJ^E?9]E]G\W7=^D76_4[`ZG@=']#J=55% MQM>]E=+:VD,`-&/X_6& M,'O_`-+_`#_^DKJAZY\7?<%OY&/3DTOHO:'U6"'-/]X]S7?REQ_5L3,Z5;M? M%V/8?T-Y:`?^)M%;6L;:W_P;_H5I3HMR'-<'-UON\"!'X%:G1>EW]3C(R0*\'@,`$W:_O1O93_*9_._U$E/ M3X^13DU"ZAP?6Z=KAP8.THJ9K0T!K0`T"`!H``G24TSTO&+GN)>=[S9&X@"0 M]KF>V/T?Z:Y_O_TG_%J-O2,:UMC'OMV7"P.:+"-+6-I<&.'OKV-9^BV>^I7D MD;/=5-'*Z55D,L'JVU/M86&QCM0'.;:YS6G]'NW,_<1;<#'NR&Y#]WJ,+"TA MQ$%@M:WC^3DVMZ8V^H]SOIV*+.D8[/1( MLMFF(=ZCI=#+*1ZL?SGMO=_X&KR25GNJFB[H^,:32U]M8(:WZJ:S^GX[WL?[FEGI M[0UQ:(I+W5-AOYOZ5^Y#;TFA@:&V7`-:QH`L=PRS[3J?I>]WZ.S_`(#]$KJ2 M5E32;TK':UPWVES]\O+R7?I#<\^[^1]JL]+]S]'^XF=T?$>6%YL<:[*[6R\G MWU-]*MVO\CZ:O))6>ZJ?_]/U5))))2D/(QZ[[18+,%D.K'Y]D_X.[]W9^?M_GO^#6UBX^;5EWNMM:[%='V>H"-@``VQM;M MV_UU<224I))))2DDDDE*22224I))))2DDDDE*22224I))))3_]DX0DE-!"$` M`````%4````!`0````\`00!D`&\`8@!E`"``4`!H`&\`=`!O`',`:`!O`'`` M```3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S`&@`;P!P`"``0P!3`#(````! M`#A"24T$!@``````!P`&`````0$`_^$ZL6AT='`Z+R]N&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI M2'IR95-Z3E1C>FMC.60B/SX*/'@Z>&UP;65T82!X;6QN#IX;7!T:STB,RXQ+C$M,3$Q(CX*("`@/')D9CI21$8@>&UL M;G,Z&UL;G,Z>&%P34T](FAT='`Z+R]N&%P+S$N,"]M;2\B"B`@("`@("`@("`@('AM;&YS.G-T4F5F/2)H='1P.B\O M;G,N861O8F4N8V]M+WAA<"\Q+C`O&%P34TZ1&]C=6UE;G1)1#X*("`@("`@("`@ M/'AA<$U-.DEN&%P34TZ26YS=&%N8V5)1#X*("`@("`@("`@/'AA<$U- M.D1E&%P.DUE=&%D871A1&%T93XR,#`X+3$Q+3`S5#$S.C(V.C$P M+3`U.C`P/"]X87`Z365T861A=&%$871E/@H@("`@("`@("`\>&%P.D-R96%T M;W)4;V]L/D%D;V)E(%!H;W1O&%P.D-R96%T M;W)4;V]L/@H@("`@("`\+W)D9CI$97-C&UL;G,Z9&,] M(FAT='`Z+R]P=7)L+F]R9R]D8R]E;&5M96YT&UL;G,Z=&EF9CTB:'1T M<#HO+VYS+F%D;V)E+F-O;2]T:69F+S$N,"\B/@H@("`@("`@("`\=&EF9CI/ M`",`*``M`#(`-P`[`$``10!*`$\`5`!9 M`%X`8P!H`&T`<@!W`'P`@0"&`(L`D`"5`)H`GP"D`*D`K@"R`+<`O`#!`,8` MRP#0`-4`VP#@`.4`ZP#P`/8`^P$!`0&!YD'K`>_!]('Y0?X M"`L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$`DE"3H)3PED"7D)CPFD";H) MSPGE"?L*$0HG"CT*5`IJ"H$*F`JN"L4*W`KS"PL+(@LY"U$+:0N`"Y@+L`O( M"^$+^0P2#"H,0PQ<#'4,C@RG#,`,V0SS#0T-)@U`#5H-=`V.#:D-PPW>#?@. M$PXN#DD.9`Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1`F$$,081!^ M$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,3 M0Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%>`6`Q8F M%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA`&&48BABO&-48^AD@&449 M:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:'`(<*AQ2''LP>%AY`'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!(&P@ MF"#$(/`A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D321\ M)*LDVB4))3@E:"67)<`^(#Y@/J`^X#\A/V$_HC_B0"-`9$"F0.=!*4%J0:Q![D(P M0G)"M4+W0SI#?4/`1`-$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?`2`5( M2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,%W)7AI>;%Z]7P]?85^S8`5@5V"J8/QA3V&B8?5B26*<8O!C M0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/VB6:.QI0VF::?%J2&J? M:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"MPAG#@<3IQE7'P,QY*GF)>>=Z1GJE M>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*B!"H%K@%JX8.AG*&UX<[AY^(!(AIB,Z),XF9B?Z*9(K*BS"+EHO\ MC&.,RHTQC9B-_XYFCLZ/-H^>D`:0;I#6D3^1J)(1DGJ2XY--D[:4()2*E/25 M7Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KYP0)ZN MGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:FF&J:+IOVG;J?@J%*H MQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[``L'6PZK%@L=:R2[+" MLSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NCNZM;LNNZ>\(;R;O16] MC[X*OH2^_[]ZO_7`<,#LP6?!X\)?PMO#6,/4Q%'$SL5+QHM\I MWZ_@-N"]X43AS.)3XMOC8^/KY'/D_.6$Y@WFENV<[BCNM.]`[\SP6/#E\7+Q__*,\QGSI_0T],+U4/7>]FWV^_>* M^!GXJ/DX^7I[?'U^?W M.$A8:'B(F*BXR-CH^"DY25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOH1``(" M`0(#!04$!08$"`,#;0$``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`H&_W9T^W]M5]<8J[%78J[%78J[%78J[%78J[%78J[%78J[%7 M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7 M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7 M8J[%78J[%78J[%78J[%78J[%7__6^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5 MV*NQ5V*NQ5V*NQ5Y)^;7YM:-^5VC":?A?>8;]6&BZ+RH7IL9I2/LQ)W/[1^$ M;[A5^7?F7S)K?F_6;W7=?O7O]2OF#SSML$_WVD<8^PD8_9Q5(O\`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`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`D6*2Y@C_T M="W3G<2'TTK3]M\5>LZ7_P`XV?F;--QUSR]?:?;#I)8RZ5>/4#;]W)J=KWZ_ MO,5>KZ/_`,XY^7K9%.K^2_/NJ3@UD"WGEZV@;Y(FI.X_Y&8JSRU_*#\N[5%( M_(+S)/(J\2TVJ:9Q5!W?Y6 M?E]<\N?_`#C]KHY;GZOJ&FP5_P"1>N)BK$-0_('R5>4^K?EEY\T@#H+34]!; M_J(U&;%7D^N_\XT^;$4R^6M%U^X8?9L]4&B0_3Z\&KR?\0PJ\P\P_DW^9_E6 MW-[K7D^^CM5_>27-JT-VBCI622T>3AO_`#X%>95IT/W'K]S"OW8J^_?R"_/X M:\+'R/YXO::Z0L.@>8)VVOJ[);W#FG[^GV&/][T/[S^\5?7^*NQ5V*NQ5V*N MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_T_OYBKL5=BKL5=BKL5=BKL5= MBKL5=BKL5=BKR3\VOS:T;\KM&$TW"^\PWZ-^A=%Y4YD=9IB/LQ)W/[1^%=^B MKX#T?R7^:/YZZ[?>8$@DO3=S<;WS%?-Z5A#3;TXG'7T]O@C1^.%7T=Y&_P"< M<;SRJR76N^5?+OG?48WY1R7VN7D=HM*4I:_HF4/WKZCN,"OHNWF_,"SAAM;/ MR9Y6M;6$<8X(=>NXT1?!4710!BJ(^O\`YC_]2IY;_P#"@O/^\-BKOK_YC_\` M4J>6_P#PH+S_`+PV*N^O_F/_`-2IY;_\*"\_[PV*N^O_`)C_`/4J>6__``H+ MS_O#8J[Z_P#F/_U*GEO_`,*"\_[PV*N^O_F/_P!2IY;_`/"@O/\`O#8J[Z_^ M8_\`U*GEO_PH+S_O#8J[Z_\`F/\`]2IY;_\`"@O/^\-BKRKSK^4TOGP3S:Q^ M7/EBTU2?1YH='EGN)K>,`&LB-!$S]_B1/^`[JO??R"_/Q=:%CY$\\78CUM>-OY=UZ5 MAQONT=M.]:>O3[#?[MZ?WG]XJ^P,5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5= MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5= MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5= MBKL5=BKL5=BK_]3[^8J[%78J[%78J[%78J[%78J[%78J[%7E'YJ_FKI/Y:Z4 ME4_2GF?5!PT#R_'4O,Y(4.X7=4!/S8_"N_15\[Z'^0'GOSOJD7G_`/,K4K-] M4U!Q5+*TM M0$M[2#3+J&)$'[*1I=T7Z,51/H?F1_U=/+7_`$@7G_99@5WH?F1_U=/+7_2! M>?\`99BKO0_,C_JZ>6O^D"\_[+,5=Z'YD?\`5T\M?](%Y_V68J[T/S(_ZNGE MK_I`O/\`LLQ5WH?F1_U=/+7_`$@7G_99BKO0_,C_`*NGEK_I`O/^RS%7>A^9 M'_5T\M?](%Y_V68J[T/S(_ZNGEK_`*0+S_LLQ5WH?F1_U=/+7_2!>?\`99BK MO0_,C_JZ>6O^D"\_[+,5=Z'YD?\`5T\M?](%Y_V68J\+_,7_`)QXO_/UU+K7 MU[0-#\P$-)+=Z?97,*WDAIM<\KB0"NYYJG.O7EV*HO\`*W\T]=T/55_*W\WA M+IWFFVX1Z!KMT>4>H1[1HCS='9//,47GR^0R7*R:=#J$=BS'X8[=I9!&I2/X:JE%)/`T)+&U> MH_X3_,W_`,NT/^X!9_\`53`KO\)_F;_Y=H?]P"S_`.JF*N_PG^9O_EVA_P!P M"S_ZJ8J[_"?YF_\`EVA_W`+/_JIBKO\`"?YF_P#EVA_W`+/_`*J8J[_"?YF_ M^7:'_<`L_P#JIBKO\)_F;_Y=H?\`<`L_^JF*N_PG^9O_`)=H?]P"S_ZJ8J[_ M``G^9O\`Y=H?]P"S_P"JF*N_PG^9O_EVA_W`+/\`ZJ8J[_"?YF_^7:'_`'`+ M/_JIBKO\)_F;_P"7:'_<`L_^JF*N_P`)_F;_`.7:'_<`L_\`JIBKO\)_F=_Y M=H?]P"S_`.JF*N_PG^9O_EVA_P!P"S_ZJ8JQ'SA^3'F+S[90:?YJ_,5-1M[6 M99[.5=#M(KB!Z48PS(X=.?>G7%6:?EA9_F'I6F:EHOY@3P:H^D77H:#YA27U M)K^TX@B6=>JL":?%\1[UIR95Z;BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5 M=BKL5?_6^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5Y+^;/YM:-^5^CK)*%U#S'J(*Z M'H2GXI&Z&66A!6-.YZL?A7?HJ\S\C?DMK^L3C\QO/OFS6])_,#6`[\=,>WB- MG;2KP6&D]O-P;AUX!>(^#^:IM7J?_*L]0_\`+K>=_P#I+T__`+(,"N_Y5GJ' M_EUO._\`TEZ?_P!D&*N_Y5GJ'_EUO.__`$EZ?_V08J[_`)5GJ'_EUO.__27I M_P#V08J[_E6>H?\`EUO._P#TEZ?_`-D&*N_Y5GJ'_EUO._\`TEZ?_P!D&*N_ MY5GJ'_EUO.__`$EZ?_V08J[_`)5GJ'_EUO.__27I_P#V08J[_E6>H?\`EUO. M_P#TEZ?_`-D&*N_Y5GJ'_EUO._\`TEZ?_P!D&*N_Y5GJ'_EUO.__`$EZ?_V0 M8J[_`)5GJ'_EUO.__27I_P#V08J[_E6>H?\`EUO._P#TEZ?_`-D&*N_Y5IJ' M_EU?._\`TEZ?_P!D&*IOHWD:32YC->>=O-'F$4IZ.HWT:ITZTM(;8_CBK/,5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_7^_F*NQ5V*NQ5 MV*NQ5V*NQ5V*O)/S;_-K1ORNT833<+[S#?HPT71>5"Y&QFF(W6).Y_:/PC?< M*OEK\GO)/_*W]?UG\QOS1OCJ%F9!!I\#7,EF\UT*$-TB@'V.-/CZ&J," M5?3_`/RJS\J_&Z_\*+5?^R[`KO\`E5GY5^-U_P"%%JO_`&78J[_E5GY5^-U_ MX46J_P#9=BKO^56?E7XW7_A1:K_V78J[_E5GY5^-U_X46J_]EV*N_P"56?E7 MXW7_`(46J_\`9=BKO^56?E7XW7_A1:K_`-EV*N_Y59^5?C=?^%%JO_9=BKO^ M56?E7XW7_A1:K_V78J[_`)59^5?C=?\`A1:K_P!EV*N_Y59^5?C=?^%%JO\` MV78J[_E5GY5^-U_X46J_]EV*HF'\G_RVN%+V]G?3JK<2T>N:JP!&]#2\.*L@ MT'\N?*'EJ\_2&DZ=<+=A>*275_>WH3W1;J>55/N`#C:LXQ5V*NQ5V*NQ5V*N MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*N MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__0^_F*NQ5V*NQ5V*NQ5V*N MQ5Y)^;7YM:-^5VC>M-POO,-^C?H71>5.9'6:8C[,2=S^T?A7?HJ_-*74=6_, MGSK!<>9-?@M[W7KQ$OM8U"2.&WM8?Y_C^!$C3]C%7Z!6.B?\XRV=I:VJW/D2 MZ%O&D0N+B]T^660QK0,[M)\34WKBJ)^H_P#.,W^_OR__`.DO3_\`JIBKOJ/_ M`#C-_O[\O_\`I+T__JIBKOJ/_.,W^_OR_P#^DO3_`/JIBKOJ/_.,W^_OR_\` M^DO3_P#JIBKOJ/\`SC-_O[\O_P#I+T__`*J8JU]1_P"<9O\`?WY?_P#27I__ M`%4Q5OZC_P`XS?[^_+__`*2]/_ZJ8JU]1_YQF_W]^7__`$EZ?_U4Q5OZC_SC M-_O[\O\`_I+T_P#ZJ8J[ZC_SC-_O[\O_`/I+T_\`ZJ8J[ZC_`,XS?[^_+_\` MZ2]/_P"JF*IWI'D[\B?,,DT&@:-Y/UN:V4-/%IWU.X>->@+"$L5'OBKT;0?+ M/E[RO;S6GEW1;/1+:XD,T\%G"L*NYVY,%`J<53S%78J[%78J[%78J[%78J[% M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[% M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[% M78J[%78J[%78J[%78J[%78J[%78J[%78J__1^_F*NQ5V*NQ5V*NQ5V*O)/S: M_-K1ORNT833\+[S#?JPT71>5"]-C-*1]F).Y_:/PC?<*OR[\R^9=:\W:U>:[ MK]\U_J=^W.>9NB_[[2.,?82,?LXJ^C?^<"VEC/J/Q4;\JJU?M8J^I/^5A?DWU_1[5\?\,:E_P!D&*M_\K"_ M)O\`ZM[?^$QJ7_9!BKO^5A?DW_U;V_\`"8U+_L@Q5W_*POR;_P"K>W_A,:E_ MV08J[_E87Y-_]6]O_"8U+_L@Q5W_`"L+\F_^K>W_`(3&I?\`9!BKO^5A?DW_ M`-6]O_"8U+_L@Q5W_*POR;_ZM[?^$QJ7_9!BKO\`E87Y-_\`5O;_`,)C4O\` ML@Q5W_*POR;_`.K>W_A,:E_V08J[_E87Y-_]6]O_``F-2_[(,55K3SO^3^H7 MEK8VVFK)=74B0VROY;OT4O(W!%YO8A14[;G#S5ZU9Z;IVG"1=/L+:P64AI5M MXDB#$="W`"N!4;BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKYK_YR#_YR ME_+;_G'BP@C\QS2ZYYNU.!I]$\E:<5-W+&"56>X=OAMX2XX\VJ31O31^#`;C MLKL/4=HG]V*B.3E(_`#[C][Q>? MVRU4CZ(QB/B?Q\GMO_.-O_.?'YD?FC^:7E7\M_.?D_R\\/FJXDMX=9TCZU9R M6WI6\LQ9XIY;I9:F,"@*=GQG)D-1#\JOS._Y^>W4=_+8_D_Y M"M9K&WD*KYA\U&5OK"C:J6%I+"T8-*@M.2:[HN=UH?8%^4O-FG2?EOYSU6 M5;;38KF<7.EWMPVR10WG&,QR2'[*2HH)(17=R`>3[5]E-1HXF<#QP'=L1[Q^ MJWJ>S/:C!JY"$QP3/Q!^/ZWWMG+/3/S<_P"&70;?5=4N]9CNY9$N+B>XC$*BWN;<`".)&J:_:SL?9_P!F?#EQJ*5S=Y?8C3B!,)R,J-77/Y.FQ>V>]7^M^ MQ_G;SAIOD?R/YI\]WP^M:7Y6T:[UF:.)A6>.U@:?A&VXK)QXK[D9YUI]/+-E MCBCSD0'O\^HCAQ2R2Y1%OQ?'_/SK\\]R?)OD7?M]3U/;V_XZ.^>D?Z!M+_JD M_L_4^>_Z--3OZ(?;^M]M_P#.&7_.5WFS_G(N^\_:5YUTC0]&O_+,&GW>C)HL M=S$)H;AITN#*+FXG_NV2*G$C[1KVSF/:/L&'9@@<S_;D^T3 M,3B`8UR\[[RF/_.9_P#SDWYU_P"<<8/RZ?R;HFBZQ+YP?51?'68[B1(EL!9\ M/3%O/`:M]8-:D],A[.=B8^TY9!.1B(UR\[_4S]H.V9]G"!A$$ROGY5^M\*C_ M`)^=_GA^UY+\C5[4M=3_`.\CG4?Z!M/_`*I+[/U/-#VUU'^IQ^W]:::-_P`_ M0/S6@O5D\P?EWY3U/30/CM-/-]83D^T\MQ>*/^1>"?L+@(].60/F`?U)A[:Y M@?5CB1Y$C];]%_\`G';_`)RM_+[_`)R*M+JUT.&?RYYRTF!;C7/)NHNC3+`> M*M24A^GN+UO97;F#M"Q"Q(

5]0T?R_'IQ@O-5@O9;AVN[""[@S?=B>RV'7Z6.:2S;_Z!M+_`*I/[/U.K_T::G^9#[?ULH\C?\_'OSH\ MS>=O)_EN_P#*7DR&Q\PZYIVF7DMM::@)4BNKE(7,9?4''*C[5!'ME&J]B]-B MQ2F)SN()Z=![FW3>U^IRY8P,(T2!U[_>]*_YR2_YSL_-7\FOSL\Z?EOY<\M> M5-1T/RX=.^IW6IV]Z]T_US3;2\?F\-["FSSL!1.E.N8/8WLK@UVDAFE.0E*^ M55L2.YSNU_:?-HM7+#&,3&-<[O<`][PS_HIQ^>8J3Y/\BFO;ZGJ5!\O]R6;; M_0-I/Y\_L_4ZH>VFJOZ(?;^MW_13K\\MQ_@WR+7M_H>I_P#>2P?Z!M+_`*I/ M[/U,O]&FJ_F0^W];ZF\]_P#.9OYB^6?^<8?RA_.O3O+OEM_-'Y@ZM=Z=JVF7 M,-Y)81):R7L?.!([I)`3]54T:4TJ?HT&A]G,.?7Y=-*4A'&-B*L\O+S[G>:W MV@S8=#BU$8Q)F=QO77S\N]\L_P#13K\\M_\`G3?(O_2'J?\`WDLWY]AM+_JD M_L_4Z,>VFJ_F0^W];Z<_YRT_YS0_,K\A?S4A\C>4O+WEK4M,DT*SU-Y]8@O) M;@37$DZ,`;>[@7B!&M-O'?-'V#[-8.T-/XLYR!LC:NGO#N.V_://H-1X<(@B M@=[_`$%\Q_\`13G\\_\`J3O(G_2'J?\`WDLWO^@;2?ZI/[/U.F_T::K^9#[? MUN/_`#\Z_/,?],=Y$_Z0]3_[R6/^@;2?ZI/[/U+_`*--5_,A]OZWU*/^IZ?UGU>8!_P!^T[^VU M/RG$>"KO:^5]U?8[\^T&0=G#4T..^6]4O+E[I' MYH:%:W>OMJ4%[*MCJ5S907J01F*Z@HDB22<`U6_=M7.;['[!P:S49<,YD&!/ M*MP"1?(^7S>B[6[;S:33X\T(`B8'.]B0#73S^3Y7T?\`Y^<_FZVK:4NO>3?) M_P"@_KEO^F6LK;4%NOJH=?7]$O?2*'*5XU4@'L:P)0CS%G?EUZOVVAN(;B"*ZAE62WGC66*8'X61AR#`^!!KGFIB0:/-]#$ M@1?1^*?F?_GYK^:D/F/7X/*?E3RA<>5HM1NH_+MW?6NHM=RV*RN+>24K>0KS M9.)(],?+/2=/[$83CB;%CC,GQ)`;U8%@=P[^\.X[*[?S:O#ER2B!X<;V! MW-'S/=W%\T?]%._SO(H/)GD8-W/U34R/N_2.;\>PVFO^\G7P_4Z0^VFHK^[C M]OZVO^BG/YY?]2;Y%/RL]3_[R62/L-I?]4G]GZF`]M-3_,A]OZWVI_SAE_SE M1Y]_YR+U;S_8^=-%T'28O*MIIT^GG18;F(NUU)<*_J?6+FXK01"E*9S/M'V% MA[,C`XY2/$3SKI7<`]'[/]MY>T93$X@<('*_TE]\9RKT[L5=BKL5=BKL5=BK ML5=BKL5=BKL5=BKL5=BKL5=BKL5?_]+[^8J[%78J[%78J[%7DGYM?FUHWY7: M,)I^%]YAOU8:+HO*A>FQFE(^S$G<_M'X1ON%7Y=^9?,NM^;M:O=>U^^>_P!2 MOFYW$QI\(_W6D7 M_+,/Y>>=6&D6:13R+HYI).?CFDVD'VY&9L593_RM(?\`EN_._P#W!S_U5Q5W M_*TA_P"6[\[_`/<'/_57%7?\K2'_`);OSO\`]P<_]5<5=_RM(?\`EN_._P#W M!S_U5Q5W_*TA_P"6[\[_`/<'/_57%7?\K2'_`);OSO\`]P<_]5<5=_RM(?\` MEN_._P#W!S_U5Q5W_*TA_P"6[\[_`/<'/_57%7?\K2'_`);OSO\`]P<_]5<5 M=_RM(?\`EN_._P#W!S_U5Q5W_*TA_P"6[\[_`/<'/_57%69^7-?;S%9RWAT/ M5=!$;M/\@>2O-GGC58WFT_REI%YJUW;QD!Y4M(6E]-"=N3\>*U[G M+M/@EGR1QQYR--.HS1P8Y9):=8E>WL?K)4.+>,QQS22R!6!8(A"`KS*\ MEKK.U.WM-V<1'(29'>ASKO[OQL['L[L34:\&6,5$;6>]]-_EM_SB)^=GY%_\ MY!?D]KWF+2+76_*L?F2T2\\VZ#-)=6=L9>:!;@-%%/$&-%Y/$(RS*O.K9S_: MGM)I-;H,L8$B1`V.QYCES!_!=]V9[/:K1Z['*8!B"=QN.1Y]R6?\_%?SDU/S M?^;!_*NRO)(_*?Y;I#]9LE;]U=:Q=0K-+<.%-&,,4JPIR%4/JTV:SV8UFFQ^( M0)`*ZQ_S[Z_*Z,7+'6_/HL/*M^CS5N73R[(Z7MRYJ21(]A'R!/285ZYYQV;V M7P=N9!7IAT>TN/L;&;]4ZC_`*7G]WVOR0!ST=\^?>G_`#[C M\RPZ)_SD9'I4K4_QAY:U/2;9?&6$PZB#_P`!9OG(>VF'CT0D/X9`_H_2]5[( M9A#6<)/U1(_3^A]#?\_4-H/R-_XR>9?U:7FG]@_KS>Z/^^=O[;_3A]\OT/RE M\HZ%_BKS7Y7\L?6_J0\R:O9:5]>X>IZ'UR=(/4*`@MQYUI45ST#4YO!Q2R5? M""?D'A=/A\7)&'+B('S?3O\`SE/_`,XG77_.-:>4;L>=X/.-AYL>ZA2ME]0G MMY+41,1Z7UBX]12)/M`K3H1OF@[!]H?Y3E*)APF._.Q]SN^VNPOY-$9>?/>B^5O-WG>U_ M+GR]J0N3?>2:,/&TL`/J.BQBKC=OHS;=H:G+I\1GBQG)(5L#7 M7XNJT6GQY\HADF(`]2^]_P`MO^<4?R(C_,'R1-Y>_P"#RU-';WD6H736TDDLJ%U6+]TZ$T'[3+FE[4[>T_9TXPR\5D7L+_2[CLW ML34:^!EBJ@:W-/K3_G*#\O/,GY5?\X:?\X_^0O-\4$/F+R_YIU$:E%:RB>)3 M=-J5U&%D``;X)5K[YS_L_J\>K[4SYL=\,HBKY]!][O>W=+DTO9N#%.K$C=?$ MOS$/X>.=T7B@_9[_`)S`_P"<0OS@_/+\X(O.'DO]")H47EVRT\W&HWK6\C7$ M$L[N!&D,AZ2"AZ9YG[.^T>FT&G\+*)7Q$["^?Q?1.WO9[4:W/XF,@^D#8_*6KK&NK^5M4O-(U586YQBYL9W@F"-0-GJ_P"2/_.//Y@?\Y`77F*Q\A-I:S>6(;>? M4SJ=R]N.%TTBQ\.$4G(_NSF!VIVQ@[.$3EOU>X;QHK29;B,0W#GA^\&V_&M!G'=G:^&M[;&7 M'?"8]?*+UG:&@GI.QO#G7$)??)^5=`!3OVST4O`OZ#O.7Y6C\WO^<&_*?E>W MM!>:]:?EUY?UGRHL:AI/TEI^F030QP\J`&=0T%?Y9#GCFBUOY+M4S)H<<@?< M20?UOK6MT@U?98A6_`"/>!?['\^>U,]D?)'[AZ'^?GH?\^\IO.?K\/,.C^6W M\AQ^C)^^COPXT>UF#-0F18)([D_3USRK-V4#VYX(^DRXOA]1'Z/U=/3L/:9_ MD7Q3]0CP_'Z1^O\`6_#L$$?PSU5\Q?NY^3WY8C\K_P#G`KSU'>6_U?7/.?D7 MS)YHUT-7D'U#2I?JJ$,`5*6J0JR]GY>.>2=I:[\YVO$@[1G&(^!_79?4^S]& M-)V5(2V,H2D?B.7RH/PB`%2<]:?+;?4GY*_DC^4?YD>4K[7_`#W_`,Y%:+^4 MNKVNJ364/EO4+2*XFEMHX8)%NE9[ZW/%VD=`.'[!W[#G^T^U=7I5"]-C- M*1]F).Y_:/PC?<*OR[\R^9=;\W:U>Z[K]^U]J=^W*>9NB_[[2.,;HL8_9Q5( MNOR_#^.*O0/ROLK^[\^>6Y=.T*3S-1ZA^AX'2)YS9GUQ^\D_=\?@Q5^A M_P#RL;\S?_+&ZG_W%['%7?\`*QOS-_\`+&ZG_P!Q>QQ5W_*QOS-_\L;J?_<7 ML<5=_P`K&_,W_P`L;J?_`'%['%7?\K&_,W_RQNI_]Q>QQ5W_`"L;\S?_`"QN MI_\`<7L<5=_RL;\S?_+&ZG_W%['%7?\`*QOS-_\`+&ZG_P!Q>QQ5K_E8WYF_ M^6-U/_N+V.*M_P#*QOS-_P#+&ZG_`-Q>QQ5W_*QOS-_\L;J?_<7L<5:_Y6-^ M9O\`Y8W4_P#N+V.*O;L5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKYB M_P"E&.OQ&7+B M_1M]KI^WXREH;X[=/Z`O^?>GG+RIKG_./&@>5='O M(!YB\E7>H0>:=+Y*+A'O+V>[@N&3[126.4*KD4JK(#\!SR'VMTN7%KI3D#PS MJCTY`5^/>^K>RVIQY-'&$2.*-V.O,[OLW5?,WE[0Y=+@UC6;33+C6[Z/3-&M M;F58YKN\E-%@@C8AI&(!:B@T4%S\()SFXXIR!(!(&Y\O>]`C^:S_ M`)RFTZ_TK_G(K\Y[;4CRN9/-5_>1DFO^CWDGUFW'T0RIGM'L],2[/Q$?S:^3 MY!V]$QUV4'^=?S>\_P#/N;S+Y;\N_P#.06;S2/+4L^ROJ#W M-I.L*M2BM)%#(%)(J?@&[`9JO;/#DR:,&/*,@3[MQ]Y=C[(YL>/5GCV)B0/? ML_=+SAY@\N^5/*VO>8_-M[!I_EK1;*6ZUJ[N=XE@C6K!E_;Y?9""I><>W9_,6J:K$=Z<+V[EG6G+>E'&=Y MV?A\'38X$5PQ`^QXC79?%SSF#=R)^U/=<_+VYTG\HO('YD"$O#YMUW7=,FN% M#\8UT^.R^KHY/P\G9IR./9=SX4X=:)ZO)@O>,8GYW?Z/T-F72&.FAFK:1(OW M>:M2OO*&@>3)R&TORYJFJ:KIY))82:M%8Q3)OL%'U%6`'=F\U>,#]]YEL]+E))7C%JQ.G2M7_)CN"P^- MH><_-FL^;;NSC,5GDTTH7^\F*`\CL3[OO.W>[OV<[,GJM3&=>B!LGW;@>_[AOW-_\`.>FW_.5' MYFG_`"-$_P"Z+8X?9+_C-Q^^7^Z*/:G_`(T,GNC_`+D/E70?+^O>:=4MM#\K MZ'J'F/6[WG]3T;2K66\NY?30R/Z<,"N[<44L:#8"N;_-GQX8\67#`&1/0;E]<_P#.,GY+_G'H/Y__`)3ZQKOY2^=M&TC3_,$$U_JM]H&I M6MM;Q@-5YII8$1%'70Y(0RQE(T``03S\OO>E[![+U>/6XYRQ M2B!N210Y5U^Y_0YGD[ZB_D;G_OI?]=OUG/H2'TCW/@T_J/O?LQ_SZX_Y0G\U MO^VWI_\`U#/GF?MS_C&/^K^DOHOL5_B^3^M^A.O^?G__`)*C\O?_``+?^Q"Y MP>PW^,Y/ZGZ0GVU_Q?'_`%OT%^(YZ'MGIY?-P_KJSYY?>W\N/_.0'_D^?SN[ M?\[_`.9?;_I:W.>Z=C_XCA_X7'_NLY+V[^C#[Y?H>J]B/KS>Z/Z7U#_S\8_\`6;[S_P`"/2O^)29S_LA_ MQHP]TON=[[5_XA+WQ^]^`F>OOE#^I+\A_P#R1WY,_P#@"^7?^Z9;YX+VC_C6 M7^O+[R^X=G_XMC_J1^X/P#_YR[_*N/\`*/\`/KSIH-C:-:>7M;F_Q#Y63@J1 M_4M29I&CB5>D<%P)8$]H\]<]F]=^;T4"3H> MX_ML/+(?S'U:/\I;S\HS0Z'/YM@\VQ,"0PN4L9;&12.A#(T9'^K]V<=!$ZL: MCJ(&/VW^MPAK9#2G!TXN+[*_4S[_`)Q<_*D_G'^=WDORCP]#^T--ICPY2/ M*'YF6WG7R=K?D^>_UBRDL;?7-.N=.EG5+=E9XTN8HRZ@FE16ASS;VQUF'4YX M'%,2`CT(/7R?0O9+29M/AF,D3&Y=01T\WZ29Q[UKL5=BKL5=BKL5=BKL5=BK ML5=BKL5=BKL5=BKL5=BKL5?_U/OYBKL5=BKL5>2?FU^;6C?E=HPFGX7WF&_5 MAHNB\J%Z;&:4C[,2=S^T?A&^X5?EWYE\RZWYNUJ]UW7[]K[4[]N4\S4HO^^T MCC&Z+&/V<52*O@?N/]&.*NZ?/V_AN#BKZ&_YQRLO.Q\U:UJ_DC3M'O[ZPTX6 MMQ^F&EBABCN)(_CC]`'X_P!S3_@\5?9/UW_G(7_JR>1_^DF__IBKOKO_`#D+ M_P!63R/_`-)-_P#TQ5WUW_G(7_JR>1_^DF__`*8J[Z[_`,Y"_P#5D\C_`/23 M?_TQ5WUW_G(7_JR>1_\`I)O_`.F*N^N_\Y"_]63R/_TDW_\`3%7?7?\`G(7_ M`*LGD?\`Z2;_`/IBKOKO_.0O_5D\C_\`23?_`-,5=]=_YR%_ZLGD?_I)O_Z8 MJ[Z[_P`Y"_\`5D\C_P#23?\`],5:^N_\Y#?]63R/_P!)-]_3%4Y\NW?YSR:S M9)YITCRK!H+&07\VG7%TUTH"/P*+("I^/C7VQ5ZKBKL5=BKL5=BKL5=BKL5= MBKL5=BKL5=BKL5=BKL52W6='TWS#H^K:!K%JE]I&N6<^GZK8R"J36US&T4T; M#P9&(.3QSECD)1-$&Q[PPR0$XF,MP11^+^9W_G(7\AO-/_./WGV_\K:U;37/ ME^\EEF\E^:.!]#4K$$<2'XA1-$'59T_8;?=&1V]K[&[6Q]H8!,?4/J'ASF!^GG$]X_'-Y!H/F'S!Y4U&'6?*^OZCY;U>`%8-6TJZEL[E`W4 M+-`R.*]Z'-EFT^/-'AR1$AY@'[W`Q9\F*7%`D'R-/I+_`)QFU_S7YX_YRE_) M_4_,GF'4_-&M#6XV?4]7O)[VX,,$4LCJ99W=Z!0=JYH>W]+BP]FY1"(B*'(` M=1W.Z[#U.7+VAB,Y&1OJ;Z'O?;O_`#\+_P"<9]8U^[A_//R!HD^JW,%JMG^8 MVE6,1>=^ M3T7M7V-+(1J,423_`!`#_9?H+\>1VH?<'/2.;Y]R9AYA_,/\P?-MA::7YJ\\ M^8/,VF6#*]CIVK:G=WL$+*O%3''/*ZJ0NPH.F8^+18,1XH8XQ/>`!]S=/59< M@J4Y$>9)2SROY5\R>=_,&F>5?*.C76O^8M:E^KZ7I-HO*21Z%B?!5106=FHJ M*"S$`$X=3J(:?&9]" M\M:SYE\Q:A"Q"3ZTUD[@(Q[)Z<4"&FX0&E2<\@UFL/:O:,9=)2$1Y1O^TOJ^ MDT8[+T$A_$(DGS-?@/YUQM7Y9[,'R(OURA_*P>;_`/GV;HSI85UKRJ=2\ZV+ M.2"!::K>FXDV['3WDH#MT^>>=3[0\'V@)OTDB!^,1_OGOH:#Q>PAMN+F/@3R M_P`U^2"J[NB1JTCR,%1%%26/0`#/19&A;P,19I^Q_P#SE;^3T7Y9_P#.#?Y< M^3+:(+<>0M9TB_U^1`91)?WL-VE])S-"JM=7K%:]!Q3PSS3L#M"6I[8ED/\` M&)#X"J^P?I?1.W-!'3]DQ@!]!B?B>?VG]#\?M+U2[T75=,UBP<1WVDW4-[92 M']F6!Q)&>HZ,HST?-C&2$H'D01\WS_#,XYB8Y@@_)^K_`/S]`O[75-)_YQ_U M*RE$UGJ,7F"ZM)1^U%-'I3HP^8.>?^PL3&><'^C_`+Y[KVUD)0PD?TOT/S'_ M`"SLK+5?S(_+S3-1MH[S3]2\S:1:7]I,O*.6&>\B21'7N&5B",[K7Y#CT^20 M-$1/W/%:+&)YX1.X,A][^D"#_G&/_G'BWE2=/R6\G/(G3U=(M95/S1T93](S MQB7;>ME_EI?,OKT.QM'&OW4=O(/9-*TG2M"T^UTG1-,M-'TJQ01V6F6,*6]O M"@Z+'%&%50/`#-;.:-&] M;]&ZGZ$%SZ?UB%[>7]UY\&G]1] M[]F/^?7'_*$_FM_VV]/_`.H9\\S]N?\`&9?^ZK7WE]__`//K M3_E(OSB_[9NC_P#)ZZSDO;OZ,/OE^AZKV(^O-[H_I?4/_/QC_P!9OO/_``(] M*_XE)G/>R'_&C#W2^YWOM7_B$O>/O?@)GL#Y0_J2_(;;\C?R8KL?\"^7:C_M MV6^>#=I?XUE_KR^\OM_9W^+8OZD?N#XD_P"?EWY6?I_\NO+?YJZ?!6^\@7GU M#7'6@Y:9JCI&CMM4^E="-5%?]VN)IQF' M.!W]Q_:_$;O7/4GS5^T7_/LO\JCI7E+S?^;^IV@6[\V7'Z#\L3.GQC3[%^5W M)&]=TFN:(1_-!GF7MOK^/-'3@[1%G^L>7R'WOHOL;H>#%+.1O(T/<.?V_<^\ MOSY_\D;^\/B+W7 M\L?^Q-'K9\>:'%("KN0V^!#LM'VOJM''APSX0?('[P7Z.?\`."?_`#DE M^=7YR_FKYF\M_F3YT_Q)HVG>5+C4[.T&G:=9\+E+ZRA5^=G;0,?@E84)(WSB MO:OL;2:'!"6"'"3*CN3T/>2]C[,=KZK6YY1S3X@(WR`ZCN`?JUG"/;NQ5V*N MQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__5^_F*NQ5V*O)/S:_-K1OR MNT833\+[S#?JPT71>5"]-C-*1]F).Y_:/PC?<*ORZ\R^9=;\W:U>Z[K]^U]J M=^W*>9NB_P"^TCC&Z+&/V,52.OO3Z?\`F[%7=>N_SZ?C7%7=?$K_`)_,5Q5] M6?\`.-6E^?[VW\X3^1_,.F:(IDL4U,:A:M<-*5$_IE/Y:5;%7U#^@?S\_P"I M\\M_]PQ_ZXJU^@?S\_ZGSRW_`-PQ_P"N*M_H'\_/^I\\M_\`<,?^N*N_0/Y^ M?]3YY;_[AC_UQ5WZ!_/S_J?/+?\`W#'_`*XJ[]`_GY_U/GEO_N&/_7%6OT#^ M?G_4^>6_^X8_]<5;_0/Y^?\`4^>6_P#N&/\`UQ5WZ!_/S_J?/+?_`'#'_KBK MOT#^?G_4^>6_^X8_]<5=^@?S\_ZGSRW_`-PQ_P"N*LI\H:;^9UGJ>5O.N@6?F30;ZAGTZ]B$B!UKQD0G=' M6OPNI##L]\4:[_P`^V?\`G'C5[^2\L+WS M=Y8MG'PZ3IFI6\ENA\0U_:7OQBCPR]X_40\YE]D-%,V.*/N/Z MP7H7Y2_\X0_DA^3_`)FTOSEH<>NZYYGT25YM(U76-0#&W>2)H6XPVD5K$PXN MWVT;K\LQ-?[3ZS68SCF8B)Y@#]=ERM#[-Z323&2-F0Y$G]5/K_.>=^^4?S*_ MYPJ_YQZ_,Z\OM6U'RIS>Z M+VCUVE`$9V!TEO\`M^UTFL]GM%JC

^.W[/L>0Z?\`\^T/^Q^B!LF9]Y'Z`' MUY^6GY+?E;^3]G-9?EQY+L/+(NE"7M[$'FO+A0Q8+->7#23R`$D@,Y`[4SGM M;VCJ-9*\TS+[A[@-G?:/L_!I(UBB(_>?>60^??).B?F/Y/\`,'D?S']8_0?F M6U:SU,6LGHS&)B"0CT-#MX91I]1+!D&2'.)L-VHP0SXSCGR.Q?'_`/T3F_YQ MO_Y9/,?_`'%3_P!4LZ'_`$7]H_SA_I0Z$>RF@_FGYE]<^5?R]\K>3_(6F?EK MI5B9/*6EZ8=(BL+IC,9;5U99%E8TY%PQY>-&'&, M<1Z0*^#Y<\N?\^__`/G'GRQK^A^8["QUV>]\OW]MJ-C#=:D98&FM95FC$B>F M.2\D%17<;9N\GM3K\F,XS(401R'5TN/V9T4,@R")L&^9Z/I?\T?RQ\K?G!Y+ MU+R%YRBN9M`U62WEN5M)C!,'MIDGC*2`&GQ(*[=,T^BUN71Y1EQ&I!VVLT>/ M5XSCR"XE\H_]$Y?^<;]O]$\QFG_:U/\`U2S>_P"B_M#^^5?-\.K7&F?EEIYTSRQ);WS0S"$PV\!,SA3S8K: MI4T&]:'VAUFCQC'BD!$>0/-TNM[`TFKR')D M!,CYE@7_`$3G_P"<;_\`ED\Q_P#<5/\`U2S+_P!&':/\X?Z4.)_H3T'\T_Z8 MKH_^?=/_`#CA')'(+3S&QC*L%;530\37>D0._3K@E[7=H$5QC_2AE'V4T`-\ M)_TQ?=NE?E_#?PVOF"ZCN]1^OW373&2) M2B<2P'$!3].:GM#M+-KI"68V0*=IH.SL.BB8XA0)M$?G-^1?D/\`/C1-)\O^ M?X;Z;3M%OOTC9+87)M6]?TGAJS`&HXN=L>S^T\^@F9X31(KE:Z_L[#K8"&46 M`;[GSB?^?8R#V_2K?]4\VY]KNT"*XA_I0ZH>RF@!OA/S+[PSF M7HWQ5YI_YP&_(#S?YF\Q>;=7M_,'Z7\T:I=ZOJI@U+A&;B]F>>7@GI'BO-S0 M5VSHL'M3KL,(PC(5$`#8KU;\E?\`G&K\LOR#NM?O M?R_@U*&X\RPV\.J&_NVN05MFD:/@"HX[R&N87:/;.I[0`&8@\/+:G-[/[(T^ MA).(49<][9C^;GY2>4/SK\H2>2/.\=W)HLME/\`5Y?5MR2E'HVWQ&HI MF)H]9DTF3Q,9J0/2/+6FVNE:5'(Q=UMK M.%8(0SG=B$05/?.7H<6...`A'D``/<$+YR\IZ)Y[\J>8?) MOF2T-[H7F:PGT[5+96X.T4Z%24?]EQ6JMV(!PX,\\$QDA]4381FPQS0,)BP1 M1?&O_1.;_G&__ED\QCY:J?\`JEG0_P"B[M'^>/\`2AT'^A30?S3_`*8OL+R' MY(\N_EOY/\O^1O*EF;'R_P"6K1;33H&/)R`2SR2-0/(<3&,D3$\B*^;XI'_/N;_G&\=+3S'M_VM3_U M2SHQ[7=H#^(?Z4//R]E-`?X3\RW_`-$Y_P#G'#K]5\R#_MZG_JEA_P!%_:/\ MX?Z4(_T)Z#^:?F7KWY-?\XJ?E+^1/F/4_-7D*UU2+5]6TYM+N9+^]:Y06SS1 MSLJ*56A+PKO[9KNT>V]5KXB.:0(!OE7DY^@[&TVAD98@02*W-OI'-2[5V*NQ M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*O_UOOYBKL5=BK\M/S[\G>= M?+OG2^U/S;>RZY;:Y(\FD^8:!()(0/[C@#2)XA2BC;PVQ5X=7WI]/_-V*NK[ MGZ#_`,W'%7=/G[?PW!Q5W3KU_'\:'_,8J^M_^<;?+GFCS#I7F?\`P]^8%UY/ M6SN[_4_^X59_UQ5W_*N/S+_\O?J?_<*L_P"N*N_Y5Q^9?_E[]3_[A5G_`%Q5 MW_*N/S+_`/+WZG_W"K/^N*N_Y5Q^9?\`Y>_4_P#N%6?]<5=_RKC\R_\`R]^I M_P#<*L_ZXJ[_`)5Q^9?_`)>_4_\`N%6?]<5=_P`JX_,O_P`O?J?_`'"K/^N* MN_Y5Q^9?_E[]3_[A5G_7%6O^5U'R[J$_G2QMI;W3+N:TF:%K# M4'9"\+HQ4LBU&=5[(889M88S`(X2=Q?4/,>U>>6+2`P)!X@-C70OQ3'YO?FS MT_Y6AYN_[CE__P!5L]/_`).TW^IQ_P!*/U/FWY[4?ZI+YG];O^5N_FQW_-#S M:?\`M]W_`/U6P_R=I?\`4H?Z4?J7\_J?]4E\S^M]Q_\`.`WGWSYYC_-+\PK3 M7_.FNZ_;6GY;:Q=6]MJ6I75S''.E[IX655FD=5<X/3^R^JSYM1D$IDCPSS)/4/AL_FY^:]0?^5H>;MO^UY?_P#5;.I/ M9NE)!\..W]$?J>9':.I`(\26_F?UN_Y6Y^;%/_)G^;C_`-ON_P#^JV'^3M,? M\E#_`$H_4HU^H'+)+YE^@G_/N'SUYX\S_G/YMT_S)YRUWS#80^3+JZCL]3U" MYO(EF74+"-75)Y'`;B["HSC?;/28,.GA*$(Q/%6P`VH_J>M]D=5FS:B49SD0 M(WN2>H'Z7WA_SE5_SE3H'_..?EZWM;2W@\P_F3YA@>3RSY9DF[;[;AV=`=9GD/TGR?A=^ M8O\`SD/^=/YIW=[<>B+96YCAZ&G)E+$?:8YZC MHNQ-)I(U#&+[R+/S/Z'S35]KZK52N?RIYRUSRQ,W MQ--I.HW-FQ.VY,$B$],R\VAP9!ZX1/O`+C8M;FQGTSD/<2'ZM_\`.<7YA>:X M_P`B_P#G'+S1Y>\VZSH]WYIM(;Z]OM/O)[&6Z%QI=M/6<0/'R)9^6XV)SSWV M5T>.>LS0R1!X0=CN+XJ>]]I]9.&DQ2A(CB(W&VU6_.+R;^:_YI3^;_*D$_YE M^:Y89=8L4ECDUJ^96#7,=0P,VX.=OKNS]-'3Y",<=HGH.YXO1Z[42SP'B2WD M.I[W[_\`_.5^I:EI'_..OYL:EI%_=:7J5IHQ>TU"RF>">)O6B'))8R&4T)W! MZ9Y'V+CCDUN*,A8,@^J]L9)8]'EE$T1$OYW#^;WYL*0!^9_FW?\`[7=__P!5 ML]F_D_3#_)0_TH_4^0_GM0>>27S/ZWZQ'S?YL_Z)F?XK_P`3ZP/-'U8#_$GU MR?\`2'_*6_5_]Z>?JT]+X*\OL;=-L\[&FQ#M_P`/A'#Q MPO$XCQ5SZ_77/W/R=/YO?FR?_*G^;C_V^[__`*K9Z)_)VF_U*'^E'ZG@1K]0 M/\I+YE^R7_/OG_G(:\_,KR;J/Y8^<=6EU+SMY$C%QI>H7DK2W.H:-*_$,\CN MS2/:RL(V8T^!HAN>1SS7VL[&&CRC-B%0G]DOV\_F^A^R_;!U6,XLAN<>7G'] MGZGRI_S\+\^^>_+?Y^6VG>7?.VOZ%IY\K:=-^C].U*[M81(T]UR81Q2(M305 M(SH?9#1XYT/M7J\V/6`0F0.$D7DB\XII'0T901ML>F7^U.BT^/03E M&$0015`#J.YI]FM9GR:Z$93D00;LWT/>_6#_`)R9_P"H3W?F'\P-3TZPD)$'ES1+B;3].A0 MFH000N#)3^:9G?\`RL]4T78.CTL:CC!/>0)'[ONI\PU?;6KU,KE,CR!H?CWV M\>T?S9YH\NWOZ2\O^9M5T'4:\OTAIU[/:S5ZU]2%U;\8#A8 M]5FQFXS(]Q+[X_YQ]_Y^"_F'Y,U/2_+_`.;U_)YZ\D2.L,^O3IRUFP0D`2^L M@K=(M2760-*?V9/AX-RG:WL?@RP,].."?=_"?U'[/+J]/V9[5Y\4A#.>*/?_ M`!#]8^WSZ/VIN-:0QF&41D*((!'Q?19Y!/$91-@@T?@_F`'YN_FP`!_RM#S?4_M?IN_\`^JV> MXCL[357AQ_TH_4^+G7ZB[\27S/ZW[3?\^X/,7F+S-^2?FV_\RZ]J/F*]B\\7 MEO#?:G=S7DJ1KINFOZ:O,[L%#.6IXDYYG[8X,>'61$`(^@'85U+Z+[(Y\F72 MR,R3ZB`2;Z!^@>-;F M.QN$+(]M91.#%)+&P^-W#(OV.):O#N?9_P!E8ZB(S:F^$\H\K\SUKY=[Q/;W MM-+!(X=/7$.[S^;\F?-7YF?F+YZF>Y\X^>]>\S22.7*ZEJ%Q/&I)K1(G M2OS M#U[0$M'+PV$5[+)9$D$'U+*8O;R=>CQG*\_9&DS@B>.)ORW^?-LP=J:K"089 M)"O/;Y/V'_YQ%_YS>3\X-2B_+G\SXK31OS`F0MY?U:T1HK/5Q$C/)&4-1#.J M)SI7@_Q<>!XH?.?:#V:EH1XN&Y8^O?']8\WT#L+VB&L/AYJ$^GM=N@#2R,S!(X84)'.21V"JM=R>VCU>JQZ7&J7YU^G.B_*8>'A MX(UW4*>?_,Y3+BXS??9M]%?EE_SF1_SD%^6%RIL_/5WYMTHFLN@^:9)=5MSM M10LDL@N(@.M(I4!/4'-1K?9K0ZH;PX3WQV/ZC\0[32>T.LTW*?$.Z6_[7[C_ M`/..O_.0_E+_`)R)\FR^8M`B?2M:T>2.U\U^5[B1))[&>5.:$,M/4ADHWIR\ M5Y\6^%65E'EW;'9.3L[-P2W!Y'O_`&CJ'TOLCM2':&'CCM(G;/2O9 M_0Z?)H,4I8XDDI\GSOMS69\>MR1C.0`/0GN'F^C/^?<7GGSQYG_.CS9I MWF3SEKGF&PA\F75REGJFH7-Y$LJ:A8(KJLTC@-20BO@X/G#_E;OYL?^71\W?+].7_\`U6S>?R=IO]3C_I1^ITOY_4?ZI+YG M];UC\@_S0_,S4?SR_)S3[_\`,3S1>V%]YTT.UO=/GUB]DAF@FOX5D22-YBK* M5.X(S5]M:'3QT>60A$$1/0=WN=GV/K<\M7CB9R(,A>Y[_>_9?_G+;_G)VS_Y MQT\IV!TRTAUGS_YJ]:+ROH\]3;Q)$!ZM[=!*-Z<19550REV:@-% MTLI!VA&N(]??YO_F9"P`84(2R@].W0'N%C&>JZ7LC2:85CQQ'G5GYFR^8ZGM75:@ MWDR$_&A\A02?RE^:OYF^1)H9O)OY@>8/+8@8.D%AJ-Q#`2&Y<9(%?TW6O564 M@]QD\W9NES@B>.)OR'WL,/:&HPD&&20(\R_I-_('5//VN?DW^7FN?F?=1WGG M;7-(AU'6)X[9+,D759K<201T1)!"Z"0*JCE7X5Z9XKVC#%#43CB^@&AO?+S_ M`![SS?8NSYY9Z>$LOU$6=JY_C]@Y/8,PG,=BKL5=BKL5=BKL5=BKL5=BKL5= MBK__U_OYBKL5=BK'O-/E;1/.6B7OE_S!9+>Z=>K1E.SQN/LRQ-U5U.X(_5BK M\N/S4_*S7?RNUOZG>%[O1KQW?0]=5?@G3^5^G"5/VU[C>M,5>5]>N_SZ?C7% M7=?$C]?ZQBKOD?NZ?A7I_3%7T?\`\X^>1M!\\R>:[76/-&L>6IM,%E+9C2KV M*S]<2>MZOJ!XY.?I\%W_`,IL5?2__0OWDO\`\N7YP_[C4'_9/BKO^A?O)?\` MY2_P#RY?G#_N-0 M?]D^*N_Z%^\E_P#ER_.'_<:@_P"R?%7?]"_>2_\`RY?G#_N-0?\`9/BK-_R_ M_+/R[Y'U:XU'2O..N>8+F\M#:&SU74(;J(+S1RZ1QQ1T8%.ONWCBKU_%78J[ M%78J[%78J[%78J[%78J[%78J[%78J[%78J\8_/3\C/*7_.0/D^R\D^<]0U;3 M=*L=6@UB&XT::"&X,\$,T*J6N(+A>!6=J@*#6F_CG]G=HY-#E\7'1-5O=?80 MX7:&@QZW'X>2ZN]OV@OQ%_YS,_YQ[\E?\X]>;?)^@^2=1UC4;/7](EO[Q]9G M@GE61)S$`A@MX`!0=QGI_LQVSF[1A,Y0+B1R\_B7S7VC[(Q=GS@,9)$@>?D^ M=?RH\K:=YX_-#\NO)NKRSPZ7YL\R:7H^HS6K*DZ07MW'!(T3.KJ&"N:54BO; M-UVEJ):?39,L><8DCX.H[/T\=1J(8I9=2U35/*VH:)/:ZOX[_-].T'8�&4X$DF)&]56WEY/YX/;/97R1]+?DA^<_Y5?EGH M6L:9Y^_YQ_T?\WM1U"_%U9:SJ5W'`]K!Z2)]759+*YJ.2EJU'7IFB[5[,U6J MF)8L^0 M_P`A=$_*#5O*MOIMI=ZAILT-Q+>0:H]S(8B\=I:E%1K)21O4TZ<=^!]I=%JM M&(1S9CE$KY].&O,_SGN?9W6:;5F?F3^?'YE M^8[BY:XM(M9N=*T)2[,D>GZ:[6ML(P?L!UC]0@; M=_V/!=MZHZG69)=`:'N&S,/^<2?^<;V_YR-\\ZEIFJ:C=Z-Y+\K6J7GFC5+$ M1FY+3N4MK6%I0ZH\O!V#,C`*C;5IF-[0]M'LS"#$`SD:%\MN9^&WS;^P>R!V MCF,9$B$19KGY#\6_2WSU_P`^V?R6UK0FM_(^I:UY*\Q6\)%GJ4ER=0M9Y=J& M[@F'(C8C]T\=*UH:4SB=-[9ZV$KR5./=5?(C]KV>H]D-'.-0N)[[O[#^L/#O M^<^O+=UY-_(3_G&CRAJ#Q2:CY7MH])OGA/[MIK+2[:"5DK^R73;-C[(9O&UV M?)_.!/SDZ_VKP>!HL./^::^Q^4VE:E=:/JFG:M:JC7.EW4-Y;+(O)#)!(LB! MA45%5WWST'-C&6$H'E($?-X3%D\.8F.8(/R?:WYE?\Y]?F[^:?D3S)^7VO>6 M/*-CI'F>V%I?7EA;7R7*H'60E#+>RH"2G=3G+Z+V0T^ESQRQG(F)L`U^IZ/6 M>U6?4X3BE&($A1(O];X<[YUKR[]@?_E5O_/#_P`7//-O^_C^/_3M]#_[]_X? M[]^/M/B.>D=7SWH]`_*[\Q_,'Y1^?_+7Y@>6W(U'R[>).]F6*QW=N?AN+66@ M/P31ED)I45Y#<#,+M#10UN"6*?*0Y]QZ$>YR]#JYZ3-'+'G$\N_R+Z8_YSM\ MVZ!^87YH>1OS#\KWJWV@>=?(&EZCI\@`#1\;Z_MY(9:$@2Q/$4D%?A8%>V:/ MV4T\M/IYXIBI1F0?D#?V[.Y]I]3'49X9(&XR@*^9_!2C_G`W_P!:I_++_4UO M_NBWV6^UO_&;D]\?]T&OV5_XT(>Z7^Y+&_\`G,GS]>?F!_SD9^9-W/+(;/RO MJ4GE?2+9R"(8-&8VL@2G:2X667YN MD3PCX;?>EO\`SC#^05W_`,Y$?F5#Y0.I2:)Y?TNRDU;S3K,48DECM(G2-8H` MWP>K-)(JKR-%')^+\.!N[=[7'9N#CJY$U$>?ZA^SJU=B=E'M'/P740+D?+]9 M_;T?HK^;G_/MO\OK?R)JVI?E5JVOQ^=-"TY[BPT[4KB&[@U62W0N8G"PQ&.: M:G%61@@8CX*=.*T'MGJ?&`SB)A(]UR.G&(G"9"41U-W[_?Y M4'XP#MVSTX/F[]KO^?>OGV?7_P`@?S(\CWL[SR?E_8>U^E&/7XY@?6!?O!K[J?2/934&>BR0/\!/R(O[[?BAVIUS MT]\X?NC_`,^Q:?\`*AO.%/\`RX%__P!TK2L\J]MO\>C_`%!]\GT[V-_Q.7]< M_=%]:?\`.1'GNX_+3\D/S-\ZV5PUIJ6CZ'<)HUVM*Q7]W2ULY!6OV9YD.<]V M7IAJ-5CQG<&0OW=?L=]VGJ#I]-DR1V(B:]_1_+U\523\R._SSW8;/B?-^FG_ M`#B)_P`X/^6OS@\C6_YH_F3JNHPZ+K%U/#Y9T#2I8X#-#:2O;S3W,S)(U&F1 ME5$"D<>18AN(X?VB]J,FCS'!@`X@-R=^=$5\.=_M>R[!]FX:O$,V8GA)V`\K M!^WE7[&`_P#.9?\`SB%I?_./MMH'G+R3JU]J?DC7[TZ7;[:>^CDDN+%;?ZRR6]IE3YWI>U^U^U, MLY:8B,8UZ?3M=UN19Y?V/>:OLGLOLW%&.<&4I==]ZJ]AL.?F^2O(VD_\X+Z' MJM[>^=?./GSSS9K:O/VUD` MCBQQAMN;!-^5[#[?>Z72X>R<9XLF24NX41UZUORZ_8_2[_G'?_G(;_G%/4O, MNE?E3^27EJ3RMJVNQS-##'HRV0N?J-O).S7-UR:29Q'$U&D9F/^T/^/Y??^@/IG_GV+_Y/'SGX_X%N_\`NIZ=FE]N?\6Q_P!?]!=S[%?X MQD_J_I#P'_G-`?\`63WYN?\`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`JQ_YQ8_ZF'0__``HT_P"RC%7?\JQ_YQ8_ZF'0_P#PHT_[*,5=_P`J MQ_YQ8_ZF'0__``HT_P"RC%7?\JQ_YQ8_ZF'0_P#PHT_[*,5=_P`JQ_YQ8_ZF M'0__``HT_P"RC%7?\JQ_YQ8_ZF'0_P#PHT_[*,5=_P`JQ_YQ8_ZF'0__``HT M_P"RC%7?\JQ_YQ8_ZF'0_P#PHT_[*,5=_P`JQ_YQ8_ZF'0__``HT_P"RC%7? M\JQ_YQ8_ZF'0_P#PHT_[*,5=_P`JQ_YQ8_ZF'0__``HT_P"RC%61>5O*_P#S MCGY0U^P\P^7O-&A6VL6/J_5)F\P12U]6*2)ZH]PP;X';KBKZ2Q5V*NQ5V*NQ M5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5^*G_/T3_R8WY9?^`W<_\`48V>D>PG M]WF]X_2^>^VWUXO'V7(+B?<_DO&?03X.7TY^ M1G_.-H_.O0M:UL_FGY5\A_H>_%C^C]>G]*::L2R^J@Y+\'Q4^8/AG/=L=NGL M^<8#$9V+V/["[WLGL8:Z)D0[GN.P. MR8:`SK()F5*X?\`.%W_`#DC MI?\`SCYYWUF+S5;2R>1_/45I;:_?VL?JW%C-9O(;6Y$8-7B43R"1%^*A#+R* M>F^M]I>Q9]HX8^']<+JS0-\Q[]A7X(V'L]VM'09CQ_3+G0OE^/QR/U:\U_\` M.>/_`#C5Y=W\VWDL/K6&@:3979NIMP.+&XBACA.]:3.A]L\_T_LMV MAEGPG'PCJ35??O\`"WN\_M+H<4.(3XCW"[^[;XODO_GX5YH'G7\DO^<<_.7U M86+>;5&L_4`_/T?KVFV]P8PU!RX*Y&A8_:[_`%GLQJM-B.67#41O1_8^..TJN2:R M*,Y7L/M83SY=)([PE+A_J@G;_-^.WN>D[8[+./!CU0&TXCB\I$<_C\-_M\<3 MZQJ5YINFZ/=7DD^FZ/)/)I=H^X@-T4:8(>H5F0-QKQY5:E6:O31Q1$C(#Z7^Y+!O^A-C_`#M_V,O_`.<-OS]T M;\@?S3GU;S7;SS>4/->G'1M58RA5T4\N+%E#LJHU' MM)V/+M'3@8_KB;%]>\-WL_VK'L_.93'HD*/EYOU._-?_`)SR_(SRQY&U._\` M(WF^+SIYOO[*1?+6C65K+"3"8G(C8#]/=^-G\_?2GCTSUX/E#]G?^?=7DR[T MC\COS:\[W=O);Q^=+N6TTTNK+ZUMI%I*OK(3LR^M9>V&H$]=C MQ@_2!?O)_53Z/[)8##1Y)D?437N`_7;\8:;?JSTY\Y?JY_S@K_SDK^2GY-_E M)YE\L?F/YT_PWKM]YNN]4M+,Z;J5Z'M9=/L($DYV=M,@J\#CB6#;>%,\_P#: MKL36:W4QG@AQ1$`.<1O9/4CO#W/LSVSI-'IY0S3X29$\B=J'<#W/JK\S?S3_ M`"G_`.G^6GUA=+BT[4K65Y+"1;JV6/ZS:P"1I9H M%0*I)JXBDDLK MVUN[B:]/*6)&]*6-Y74AZ*R\.)9RRCSGVF]G=1EU!U&$<0ES'4$`#X@_9[GO M_9SM_!BP#!F/"8\CT(-GX4\U_P"<\O\`G*?\OOS=T/R]^6GY;7C^8=-TG6!K M6M^:!%+!;F:"&>VBMK<3*CRBD[L[\0NR<&?DW'.]E.PE[BOQ]M[?-"VMKF\N;>SLK>2[N[N18;6UA0R2 MR2R,%1$102S,2``!USMY2$02=@'CHQ,B`-R7Z+?\Y\?E-J/D/0?^<<;Z=6NE MT7R-:>1M5OXU9H5N=#BC>,%MU'J^M*4%=PC>&<3[(:X9\FH'\Z7&!_6)O]#V M/M5H?`A@(Z1X2?=5?I?"GY=^:D\B^?\`R/YUDMFOH_*&OZ;K4MDA"M,EA=1W M#1@G8%PA7?.NUNG_`#&">+^=$CYAY329O!S0R?S9`_(OUZ_YRV\GZ-_SEEY4 M_*WSW^67YJ^0]-\K>4K?6)](1J*V#QI(JP3&)XQ;-ZBRA&7;8]O M.?9_52['S9,6?',RD0*B+Y7YCG8I]`[?T\>U,6/+AG'AB";)KG7ZGXO7]M#9 MW]]9V]_;ZI;VL\D,&IVHE6"Y1&*K-$+B.&4(X')>:*U#\2J=L]-A(R`)%7TZ MCWUM]I?.9"C5V^Z?^?'7A&_U3R-H&HZC-I]D,!GK..MHQ/V[?I>(_P#.6/\`ZTA^ M<=!_TT=S7[ES9>S7_&=B]Q^\NN]H?\?RWW_H#Z9_Y]B_^3R\Y_\`@"W?_=3T M[-)[<_XMC_K_`*"[GV*_QC)_5_2'@/\`SFA_ZT]^;G_;2M?^H"VS=>S'_&=B M]Q^\NH]I/^-#+[Q]P>;_`),_E7_RN#SD?*(\WZ-Y(I83WPUK79?1MCZ+(OH@ MU%7;G4#P!S*[6[1.@P^*(&>X%#\%Q>R]`-;E\,S$-KL_@/T@_P"<1?,%MH4E]&VC:?>+]9G>_TZXLHQ%S<`T>X4T'7.'[9]I9 M:W2RP^#*/%6Y\B#W>3V?9'L_'1ZJ.7QHRX;V'F"._P`WU-_SF3-_SCK=>7O) M'EC_`)R`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`_Y9=._[A>J?]D^!7?I[_G$#_EET[_N%ZI_V3XJ[]/?\X@?\LNG?]PO M5/\`LGQ5WZ>_YQ`_Y9=._P"X7JG_`&3XJ[]/?\X@?\LNG?\`<+U3_LGQ5WZ> M_P"<0/\`EET[_N%ZI_V3XJ[]/?\`.('_`"RZ=_W"]4_[)\5=^GO^<0/^673O M^X7JG_9/BKOT]_SB!_RRZ=_W"]4_[)\5=^GO^<0/^673O^X7JG_9/BKOT]_S MB!_RRZ=_W"]4_P"R?%6QY@_YQ!'2VTX=O^.7JO\`U0Q5].^4_./EOSQI9UKR MMJ0U73%G>V:X$4L)$J!2R%)D1P0&';%638J[%78J[%78J[%78J[%78J[%78J M[%78J[%78J[%7XJ?\_0R/^5D?EB*BO\`ANYV_P"CQL]']A#Z,OO'W%\]]MOK MQ>X_H?$/_./!`_/[\E#7_INO+Q\?^EC!G5=M_P"(YOZDON>9['VUF$_TQ][^ MF[S+_P`HYK__`&S;K_DRV>)X/[R/O'WOL>;^[E[B_DL5EXH=CMXTSWZ,A0?# M)1-E?4GMDF-/OS_GVY_ZT7/_`.`CJG_)^TSD/;7_`!(?UA^EZOV._P`/_.9__.(,OYXP0^?OR_2"V_,W1K3ZM<:?*Z00ZU:Q$M'"TC41)TJ1'(Y" MD41R%"LG*>S?M`.SR<67^[D?]*>_W=X^/OZ?VA[".N`R8O[P#_3#N]_:?)&K2Z%YP\NZEY8U>&O/3M3MI+:4J&*\U$@')20:,M0>QSU+3:O%J M(\6*0D/)\TU&FRX)<.2)B?-CRQO,ZQ0JTLLI"11(.3,S;!0!U->V73D(@DF@ MU0B20`+?JY_SGCIQT3_G'G_G%_1"LT1T>Q@L2MPO&4?5M)MHJ./YOAWIGG?L ME(RU^3]^NN:_HO_P"/HE? MZP5Y?[]^/I.QZ`4V.>E$[/G@&[^EO\NO(GEW\R_^<3_RR\B^:;-;S0_,_P"6 MGERUODHO-&.E6ICGC)!`DB=5=&[,H/;/$M5JLFG[0R9<9J498B+_0;IHX;P)PCO+5CRM[N M(5-$FCHX%:KNK492,]@[/UL-9@CEB>8W\CU'P?)M;I)Z;-+'+H=O,=_Q>_?\ MX%FO_.57Y9U%/W>MT'_;EOLU/M:?];LGOC_N@[7V6'^N$/=+_AF6'Z["5@GX]6M[A>44R[_`&HW8>^>KZ3M#!JX\6*8E]_Q M',/E^JT6;32XU?:C3:2)&,B<^@'+XG ME\.;T79GLWJ-5(&8,(=2?T#]-4_>2P\G^7OR_P#RS/DSRMIZ:;Y=\MZ%/9Z; M9*>D:0N69V&[/(Q+NYW9B6.YSRLZB>HU'B3-RE*S\WTX8(8,'AP%1C&A\G\J M:L"`:]1UJ,]YC*P^(2%%=M2F28OT_P#^?79_Y"-^9P'0>6[8U_Z/%S@/;H_N M\7O/W![GV)'[S*?(?>47_P`Y;_\`."GF73M=UG\ROR2T5M>\O:M,][KGD*P6 MM[I\TE7EDL(/]W0NU2(H_C0GBB%/L/L_[5PX!AU)HC82Z'W]Q\^17MWV8D)' M-IQ8.YCU'N[QY/+#(.*)!'>'BLF.>,\,@0?-&:%Y>U_S3J,&C>6=#O\`S%J]Q7ZOI.EVTMW< MO3KQB@5W/7L,AFU&/!'BR2$1WDT&6'!DS2X81,CY"WZZ?\X=?\X-Z[Y2\Q:/ M^;7YS6<-EJ>C'ZUY0\AL4GEM[L$&&^O71FC5XZ0O-D M1%K>TGTO4XU#3Z??1@^C=P5Z.G(@_P`R,R'X6.]_/C^=7_.+?YO_`)'ZC??XC\M7&J>5897%AYZTR-KC39H0 M1Q>5DY-:L:TX3<34'CR4W\B>3KV]TZ9^$_F>Z1K; M28`'".TEY(`A*UJ4CY2$`\4-,UFO[9TNB!\28ON&\OE^MV6B[(U.L(\.!KOY M#YOWX_YQI_YQW\O_`/..ODB70+":/5O,VMR1W7F_S.(^#7D\:D1QHI)*PPKZEV/V5#L_%P#_P#LWI^$G_.6 M#*/^DA_7_07:^QFVJG_4_2'@7_.:!I_SD_\`FW3>FI6M M?IL+;-O[,?\`&=B]Q^\NJ]H_\?R^\?<'S!].;]T;T+\HZ#\UORP.VWFW1:5_ MYCX?&F8?:%?ELE_S9?<7*T-_F,=?SA]X?=7_`#\0\K_G)YD_-=O,-QY$UN3\ ML_+&D06/EO7[2-[RQ*4$]YZXR-'IMET+/=7C#TTXJ>7&I=A]A6-! MFOU_:NGT,;RR`/=U/N'X#GZ'LS/K)5CB3Y]!\7]%?_./GY,:5^0WY7Z)Y`T^ MY&HWD#27OF+60G#Z[J%Q0S2\>RJ`L:`[A%6N]<\=[5[1EK]1+++:^0[AT_'> M^L]E]GQT.`8AN>I[R]LS6NQ=BKL5=BKL5=BKL5=BKL5=BKL5=BK_`/_2^_F* MNQ5V*NQ5V*NQ5CWFGRMHGG+1+WR_Y@LUO=-O5HZ'9XW'V9(V_9=3N#_#%7Y; M_FK^5>N_E=K?U.[Y7NCW;.^A:XBT69.R/O\`#(G5E'7J-L5>6?+Z/<^.WZQB MK[?\M?\`.1?Y56F@:'::_P"2+R?6K*QBAU6\M]/L)(9+B)`CR(TDT3GU*<_L M=\53G_H9/\D?^I#U'_N&:9_V58J[_H9/\D?^I#U'_N&:9_V58J[_`*&3_)'_ M`*D/4?\`N&:9_P!E6*N_Z&3_`"1_ZD/4?^X9IG_95BKO^AD_R1_ZD/4?^X9I MG_95BKO^AD_R1_ZD/4?^X9IG_95BKO\`H9/\D?\`J0]1_P"X9IG_`&58J[_H M9/\`)'_J0]1_[AFF?]E6*N_Z&3_)'_J0]1_[AFF?]E6*N_Z&3_)'_J0]1_[A MFF?]E6*N_P"AD_R1_P"I#U'_`+AFF?\`95BK+?*'_.2'Y6:EJ^G>6]+T;4O+ MGZ7NA%#<3VMG;VGKR`!#(8+ER.>RAN/TXJ^E\5=BKL5=BKL5=BKL5=BKL5=B MKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL50&HZ5I>L6S6>KZ;:ZK9O]NTO(4G MC/S20,/PR49RCR)#&4(RY@%":3Y;\NZ"&&AZ!IVC!Z\Q8VL-O6M*U])5\!AE MDE(422@8X@V`$ZR#-V*NQ5V*NQ5V*NQ5V*NQ5V*J,]O!=1/!1(82QQEN0"KZ;I.EZ-;"STC3;72K1=UM;.%((Q\DC"C\,$I MRE]1)3&$8\@`F&19.Q5V*L9F\E^3KB]_25QY3T:?4?\`EODL+=I_^1A0M^.6 MC/D'\1^9:C@QG^$?(,E`"BB@*!T`VRIL``%!O%+L5=BKL5=BKL5=BK'[_P`I M>5=5N5O=3\LZ5J-XAY)=W5E!-*#XAW0D??EHS9`*$C\VLX8'Z=>K1E.SQN/L2Q- MU5T.X(_5BK\N/S5_*O7?ROUOZG>%KS1[QG?0]=5:),O9'_ED3JZ]]B,59E^1 MOYS:C^7(U70$\NW7FB#6YDGT_2K:0QSK8__`"R?F7_DK_V2 MXJ[_`*&,\Q_^63\R_P#)7_LEQ5W_`$,9YC_\LGYE_P"2O_9+BKO^AC/,?_ED M_,O_`"5_[)<5=_T,9YC_`/+)^9?^2O\`V2XJ[_H8SS'_`.63\R_\E?\`LEQ5 MW_0QGF/_`,LGYE_Y*_\`9+BKO^AC/,?_`)9/S+_R5_[)<5=_T,9YC_\`+)^9 M?^2O_9+BKO\`H8SS'_Y9/S+_`,E?^R7%7JGY;_F5+Y]748K[RCJWE"_L"K): MZC%)PFA:@#I*T<8J&J"I%>AWWXJO4L5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL M5=BKL5?.G^//-7_0VW_*L?TK_P`Z1_RJ+_%'Z$]"#_CJ_I[ZE]8]?T_7_N/@ MX<^'?CRWS/&FC^3.;^+C$?APDG;Y.(<\OS(Q=."_C8`W^:MY;\[^:K[_`)R< M_-3\O;S5A/Y.\O\`D7RKK.B:-Z$"_5[W4+S5H;N7UUC69_42VB'%F95XU6A9 MAE4\,1@C/J21\OQW?'NR!+UD>0_2N\]?\Y`V_E7\SD_)KRW^6OFW\ROS%E\K M0^<$TS0AI=O9II^U34+**)A+;L.+?:Y+QK\7$0TW%C\0R`%UUNZO MH#S82RU/AHDU?3OKO>A?E9^9?ES\WO(?E[\P_*J7D&C>8DN/1LM1B$%Y;S6= MQ)9W5O<1*SJLD$\+QOQ9EJOPL10Y#4X)8,AQRJQW;LL6498B0NCW[/-_^<5/ M/7FK\R?R/\N>>_WL5_Z&]\E_7_TE_@SS4/RD/F3_!X_ M/7T+/_#GZ8^N?H^E/K?USZI]:_IMRX_%DQV?D),=N*KX>OZKZ\^3 M$ZB(WWJZOI_9TOO>[?F=^8_EO\I/(NO_`)A>;6NAH7EZ.$W$-E";BZGEN9X[ M6VM[>($<]`TVTULZ'YB6QE6[TN^EEA@NK:[TN[O;<_O(61XW=9%;8KU(EEP MF`!!L&]QWCG^CYA89!+;D>[WO$]8_P":GIK6]C)<-PA:66SFG@*[*9&B9Q3DR&N8.'&U@D2U2 MXE522B.(U<\58+OC+$8Y#CZ@UU[Z[K^R_)8Y`85ITDN"4@0>'F.HOKOT^[JQ\8<0!!WY=WS_`!?1Z7^:_P";NE?E7;>6 MH7\O:SYU\U^=]3.C^2O(_E^."34=1NUA>XD(-U-;P0PPQQEY9I9%1%ZFI`,, M&GEELB@(BR2RR9!"KZF@DWY.?GOHGYQZA^8.AV?E+S'Y+\Q_E=J=MHWG+0_, M<-I%)#>W-N+CA"]I=722HH-.8(5MF3DC*Q<^GEBHD@@C8@VN/*)WL17>]RRA ML?+&I_G-YSM/^5=3N/(^H?EUJ.OWNJPP6/I?7TU"SBBO7GDO%F% MM!&7@94BY^M*GPNGQIF#!$ZP_E-^;.F_FOIWF22+R]J_DWS'Y)UJ7R[YU\F:\ML+[3M2AAAN"A>SGN8) MHGCG1XIHI&21353U`P>'YH>=_+T&G-8:/,(1<20*E[?6MQ>RV\3+)<+:12>DC`M\1 MXY?#12D(DD`S^D'F=ZOROI?.BU'4Q!D*)X>?ROX[=W>'T-HVL:7YBT?2?,&B M7L6IZ+KEG!J&D:E`>45Q:W4:RPRH>ZNC!A[',,@@T7(!M,L"ORW\C?FIYW\Q M?DQJ_P":?FO_`)S9B\B^9K*7S/(WE&\T_P`E_5+1=)U6_L[..6"73H[QQ)%! M"=I0SEOA)Y+F^S:>&+)PC`9`5O^AT?>OY5^>M M3\T?DO\`E_\`F3Y[L8?*>J:[Y0TWS%YLLWY106,EQ9)=7-1*2T:)4FCGDHV; M<'-+EB!,B/*_Q^/LNH^#XOAR_)HS`$\0)%6`> M_P"S;K\*MKCF$B!1%WS\OU]&O^(\6RS0Z+\R)[UPQ)^77W#KUW M&QW:M5J?!,=OJD!\^GO[NFW,;/;_`,Q_S#\O?E;Y0U+SGYF^MRV%B\%M::9I MUNUW?ZA?7DR6UE8V5LGQ2SW,\B11KL.358JH+#&P8)9IB,?[`.9_'PW>X-'7S#IWE[S$=.G&H:5ZPMY+FTN MM*O+Z!C#*Z++&[K(I=?A(J1;ETAA#Q(R$HW5CH?,'?=A',#+A((-7NA_/_Y] M6/DGS_I/Y5Z;^7WFOS]^8'F#RY<^9-#T?0(K`6\MO:W*6LB37NH7MG#;D%^9 M>4JG$<0QE>.)XX=++)C.0D"(.]_H[TSRB,A&B2?Q\&6_E+^:>B?G!Y1_Q7HN MFZGH4EIJ>H:)K_EO68HX=1TS5-+N'M;RSNDBDFC#QR(?LNPH1WJ!#/@.&?"2 M#L#8Y&Q:<>3C%U7/GY/)?^<9/SE\Y?F[<_GDOF_ROJ?EY/(WYC:IH'EUKV&P MBC6PMEC2.R/U.[N6>XMRA>=F^&LJ>F["JQY.NTGY<8_Z40?GU]QZ>[<=33IM M1XIG_1D1\NGO^SS>@^0?.R^8/S3_`#W\ICS!JVJ/Y!U30;9M&O;&QMK'3!J& MB6UZ(["YMR;BZ67U#+(US\2.Q2/]VHRC+BX<4)5]5_8:_%-T9W*0[OU,8_,C M_G(9_(&K^;;"P_*'SQYXTG\N]-BUC\PO-6DPZ;;:?IUG+"UR3`VJ7UE)?2)" MA=UM4D"_99@_PY?@T/B"),XQX[`L]1W]U]/[+KR:C@XO23PBSM]UU?P[WHGF M+SI#>?D_KOYB>4+\M;W7DZZ\Q^5]3]'3;Q@PXAN*M+_R#\S:WYU_(O\`);SEYFO?TEYC\V^1/+FL^8-1].*+ MZQ?7^F6]QOHV0\N_ICZY^CZ<3=_7?JGUK]Q];^K^CZFW+C M\>9WY"=\-CBJ^'>_NK]'G>S1X\>?2ZO:OO[]OV;IW_SE]^:?F[\FO^F-.P3Z_<174L:M'%6GPK(>;)6)DYT/9N"&;/ M&,^7=RORV_%(U624,9,>?W>?X^YZC^4MMK%K^7GEM-?O/-=]K,D,LVH3>=_T M8->5Y9I'$=XNC?Z$#&"$00DC@%Y,[\F.'DKB-5\.3?'D]&R"7SM_SBIYZ\U? MF3^1_ESSAYUU3],^8[_6?--I>:@(8+<-%IWF/4K"V41V\4,8$<%O&@/`$TJQ M+$L5M-@\^:Y'^5OGR\\@_E5YN MO_)OYF?F,+?2X]-TN\TZ]^HS3I$^I"\NH%3 MK/Z]J=II<<4MX\?J+'2%)I88RU7'VG7YYC8,,LTQ"/,MV28A$R/1Y_Y1_P"< M@[+S%^8>D_EUKOY;^;_R[OO-ND7FN_E[JGF6&PBM]]0&8&0C1W%W\OC>_=T9%^ M:?YQ6'Y:7_DWRU9^5-;_`#`\^_F%/>1>3O(N@?4H[NZBTV)9[ZY>XU*ZLK2& M&W21.;23`DNH56J:0Q:2-=\]:QI.K7=GY?TYM0O-#TNU-_J?GU_C'\P+W\KO- M'Y9>:/RK\[1^7SYKTK2/,3Z7<"^T9;F.S>XBFTJ^OHE>.:9%>)F#+45R_+IN M"'&)`BZ\[_'XW%PCEN7"00:O\?C]+&?S-_.?S?Y1_P"EZK>HB68--')@R3) MWC5?;=^_IYL@_F=YT7RQYQ_)'0SK^L:.WGKS;/I*V6F6-C M=V^H>EI-]>&VOY;O][;0CT.8DM_WA=53[#,;M6BT'R9Y,T&."74]5U&:.240P"YFMX45(XGDD MDEE1$459N@(PZ(@@"(LD_=[ST",F00K8FS6WXY#F4%^5'YQ:7^:,OF_1Y M/+>L^1?.WY?7\.G^=O(?F!;;Z_8274(N+64265Q=6\T-Q&2T4L4K*U&ITPYM M-+%&,SO&8L'W$?JNFTY8B''TJWP]+^:OYU2_ MF=J/D?S%^:?Z#\[:?YFT7RS=:)Y:U#R])!:7FNZ;I>HI):^5;_1I-2U#3K0Z MDJ7%PVI+(4BGE3T>/!=M#!ICAX@.42;((NOZ7%PCBK8<)Y@;\W`.3,,FYZ@4 M".O]'ANA>YXN0,MN3ZFL_P`V_/=_^3>JZ[:Z%HLGYNZ+YC7R'J.DA[K]!Q^8 M7UJ'0Q=EJ?6?J-9TO*4]3T#Q^WOFL\/!XU<1\.KOKRNN[BZ=UN7QY/#NO5R\ MN=7[NO?7F__4^_F*NQ5V*NQ5V*NQ5V*NQ5CWFGRMHGG/1+SR_P"8+);W3KU: M,IV>-Q]F2-OV74[@C]51BK\POS$_+GS1^3/FJRFCF>2T%TMWY9\QQ#CR>*3F MG^K*G[:]^HVQ5]&^7/SV_.[S9IYU/R]^6NG:Q8I(]O)=VHF:-9TH62OUCL&7 M%4]_Y6C_`,Y&_P#EG[;_`("?_JMBKO\`E:/_`#D;_P"6?MO^`G_ZK8J[_E:/ M_.1O_EG[;_@)_P#JMBKO^5H_\Y&_^6?MO^`G_P"JV*N_Y6C_`,Y&_P#EG[;_ M`("?_JMBKO\`E:/_`#D;_P"6?MO^`G_ZK8J[_E:/_.1O_EG[;_@)_P#JMBKO M^5H_\Y&_^6?MO^`G_P"JV*N_Y6C_`,Y&_P#EG[;_`("?_JMBKO\`E:/_`#D; M_P"6?MO^`G_ZK8J[_E:/_.1O_EG[;_@)_P#JOBKO^5H_\Y&_^6?MO^`G_P"J M^*O<_P`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`P@`7RQ_RH;\[ MC^4!_P"<0SY3TK_E7/Z?$O\`RO/],1;^7?\`$/Z;*?HCT?K'Z0]+]S2GH<_B M]3CFTCK\4,XU0/KKZ.';BJN_Z?.[!_A[M?+23EA_+F^'^=Q;\-WW?5Y57])] M8?\`.1OY9Z]^:_Y5ZEY:\IWME8>;M-U31O,?E.74@QLI-1T'4K?4X(+HQ@NL M3L1K728K+2?)XU.'7-6N]6,QDGOWO+18X(;98J1)&>3NU7;TP`KPF,8B.$ MDGKY>7Z;OKR6)D9&]AT_7^ROB^G>4 M+K_G'GSPURY6UU+2(KM=4MKVWC.]O>*8H)@Z-6)CQ_:7-K@[1CCPPQ'>)XA, M5?/D0?U4XN33&>0SY$5PFR-^H-?IM]4^==)\V_F#^17G'0+G0XM`\\^=/(^I MZ;+Y?DNXYH+75-0TZ6#T/K<=5>-9GH)`-U^*@Z9KH9!@SB<-Q&5CI=';W6Y$ MX'+B,9;<0H]:L?:QK_E7?F7_`*%8_P"53>E;_P",/^55?X1]'UOW'Z2_0?U# MCZW\GK;6+G2W,'3UO])D4?+XJ;99#4[9;YS_7?XM?"KA`Y1_40I?\` M.3BS:#YU_P"<>OS)T'4?+_\`CGR?Y@UBP\L>4?,U^^D66OQ:SI,L5[8V^I"" M:*WO.$*O!ZU$HQW.$QSB3]H/E^IB M?_.(FI^:?-'YG?\`.6_G/S5::/;7VM^<]#M'&@78U'3XGT[0+6+ZFE]QC^L2 MVD;1PSLJ*GJA^&Q-+>TH0QPQPC=`'GL=^M=+YCRICI3*1F95=].6WGY=?.WW M7FI0-4\C^9[R*]M[:?3);G5;+4 MH+QX)V4SQTMV3C%5@6)(V`.9'+'\L<9._%==^U-)@?$$JZ4G'YB?ESYE\R_G MM_SCI^8&F1V[>7?RS_Q=_BAY)>$R_IG2XK2T]*/]NLB'EX#?+--JH8]-FQ&[ MGPUW>DV;W_06G/IY3SX\@JH<5_$5MM^D*WY1?E_YE\G>>_\`G(77M";U'>SCT73[-VE7]AO6@D%/#?WRG/GX\<(_P`T$?:Y$(49'O/Z M`'QAYS_YQ3\RZ5^8'YQ7^G_\X^>5/SPA_-#S!=^9O)7GC6?,MQHPT.ZU6)1< MVFLV495YK:"Y!E3ZH&=T+`\7I39X.TY<$8G(8<(J@/JKE1WKD+->=$C?`R:* M/$2("7$;L]+Y^_F=K\K'3Z1>2O+Z>4_)OE+RK%:V-E'Y9T6PTJ.RTN.6*QA6 MRMXX!':QS22R+$H2B!W9@M`S,=\TDY<4B>]V410ID^12^1?^<<_^<:/*?D/\ MN=!M?S"_++RA>_F/IVN>8-1N?,3Z987MYQN]>OKVPD%Z83(66VEAI\54H%_9 MS9ZSM'+.9X,DN$@;60.0O;WN)ATF..YB.*^="_+?W/I/SOY7M_._DSS=Y+O+ MF2SM/-VBW^BW5Y$`9(H]0MI+9Y$!H"5$A(S70F82$AS!MR91$@0>KXJ\O?E; M^>_FJQ_YQS_*_P`_>2]&\H^5?^<>-:T+6M:_,*QUI+Y?,4GEBPFM-/CTRQ6% M9X5GE:.28W/IE4#*G(TS8Y<^*!G/&;,P=J^F_JOS_FT9;0-!B\TZU^6WYE>7O.EQY;>\AL'OK3 M2VG$T,-Q9="TO6FD73KRZTJX6X^HWSVQ,BQ7"+`QV^.X^(V>7_P#.._Y,W?EC\Q+_`,ZS_P#. M./EC\B=-L]`DTJR]/79?,&O7=[=3PRSLL\,QM(K,)'QXLAE9PK?`HXG)UVNE MEAPG(9[WRH4-AM5V>?.JKK=4Z73C&;$!#;I\_D.7+G?3GV*Z_+[S++_SE'HG MYK)%;_X/L?RLU3RGO#);B!>7->+/^E(R^=)[^6GY=^8O*WYS?\`.2/G?5(K=-#_`#0U?RU> M^6)(I`\KQZ7Y?M=-N/60?8(FA(6O4;Y7FRQEBQQ'.-W\3^INA$B4B>M?<^3_ M`,\_^<>/S6_,GSW^<]MJ?D2/\S])\\6<$?Y/^;-9\WW.GZ#Y10Z4+6>*?R_" MQ]61;I3.KK#()69>;1<2AUT,$(5(1H^H<.\A?25'ISWCW=SAZG3G*9`@F MQL>+8;=1WWRVEW[/KS0?(WF*T_YQLT;\M;J"&'S9:_EI;^6;BV]56A744T=; M-D]45!42BG(;4WS6YLT9:F605-8\A_DI^3_ M`)&\PI''K_DSR3Y?T+7(X7$L:WFG:;;VTX20;,HDC-#W&^499"4R1U);8"H@ M/4LK9/S:/Y#?G?\`\J@7_G$-?*6EC\N/\0>HWYY'6HO^4=_Q#^F^'Z)]'ZQ^ MD/2_<\:>AS^+U>.=`.TX?F/SE_O*^FMKKA.]_37G=]._4?R?^X_+5Z/YU[U? M%W<_A7GT?5'_`#E)^7GF/\V/^;_`,UO/OG'S%Y- MM6O56&6RU?61>V/K3':)GA4\DO? MO^)I5GBDH\IV4$(>NV8 MNBS##FC,\A?W-N>!G`Q'5?YY_+OS%Y@_YR`_(+\QK!(3Y;_+K2/.MIYAD>8) M*LVNPZ9'9B./JX)M9.7\NWCD<>;AQ3A_.K[+_'S3*%S$NZTA_.3R9^85M^9O MY6_G9^6GEVT\[ZGY&L-;\O>9_(]QJ$>EW%]I6M_59!+8W4ZF`36]Q:1L4F*J MZ%@&5@*W:;+C\*>*9KBH@]Q'?UH^7+GOR:\HF)"4=ZNQWW7(WT\^?ES3'_G' M[R#YR\J0_F;YV_,6TLM(\Y_G#YOD\SZAY7TV?Z]!H]J+2UT^QL6NECC$\L<- MLK32*H3FS\4_,/_G&S MSOYC_P"IID26['C)!L`B)\I5?Q'0[]S1DTTCE$@=B03N?X>7E7>-N_W^B_\` MG(CRU^8_G#\F//?ES\I=7.B>?]2M(%T.]2\?3I'2.ZAEN[:&]C5VMI;FV26& M.6G[MW5S0"N8&DR1QY8RD+`/7DY&:)E`B)HOEW\AOR$\V>3/^G7YN_E_YE\X^?/\` MG'K7M#AMI--_+KSK>7TW2RDT74+)3$O[;>M<1[?3TKE>',(8\D?YP` M^VVR<;(/=;UK\G_S0_+33[#S!YR_)CS#>:HGE'4KPV$.K:9J MNF7&F:A;0W/IR)%<^G,K0M(.%00Q`-1+39XQC.$N4P/A1_'W>8CE@21(HQKQEJL\)8X8X61"]^5\1OE9_7]PAAQR$I3E_%6W=7FUY M8_*[S7I7YN?\Y1^<;N.V71?S9L?+,'E"1)@TC/I6CS65SZR?[KI*XI7J-\GF MU49X,.,HZO;_S.NO..E^;=)_.?3-?L=*TT7.GZ M)IN@RM/!+"U];0WMGI[)8/BP\3BX?3RK;E5=U7UNN M>[?X9X:O?G?G=]_+ROEL_P#_U?OYBKL5=BKL5=BKL5=BKL5=BK'O-/E;1/.6 MB7OE_P`P6:WNG7JT93L\;C[$L3=5=#N"/U8J_/S58/S+_P"<:?,5_::)>1SZ M!YA*_4=5GB]2WG6*H3FF_"5.7Q^/R.*O;(=1_P"#3]`FAF4/#/$]D MZ.CBJ.A$]"*??A54^M?\Y;?]6W0_^#L_^JF!7?6O^?R]YS\LZ5YNT"Z*M=:'K5E!?VX M%=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL M5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_];[^8J[%78J[%78 MJ[%78J[%78J[%6/>:?*VA^<]$O/+_F&R2^TZ]6C(:+J=P1^K%7 MP;YFT/\`-O\`+CS#H7D.+\QIM`\IW3O#Y4\RW-S/:V7%WY^A.\$ M77T\-J]#_P"51_\`.3'_`)=:V_[B^I?]DF!7?\JC_P"*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V M*NQ5V*NQ5__7^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L>\T^5M$\Y:)>^7_,%F MM[IUZM&4[/&X^Q+$W570[@C]6*OS<\[?E?KOD'SC::'Y@\SSZ9Y9U:5UT;S< MZS2V[1GHLZ1_89!N^_\`PF%68M^1$T9"O^=WEQ6^UP>^&_\`P^!5O_*C!_Y? M7RU_TGG_`+*,5=_RHP?^7U\M?])Y_P"RC%7?\J,'_E]?+7_2>?\`LHQ5W_*C M!_Y?7RU_TGG_`+*,5=_RHP?^7U\M?])Y_P"RC%7?\J,'_E]?+7_2>?\`LHQ5 MW_*C!_Y?7RU_TGG_`+*,5=_RHP?^7U\M?])Y_P"RC%7?\J,'_E]?+7_2>?\` MLHQ5W_*C!_Y?7RU_TGG_`+*,5=_RHP?^7U\M?])Y_P"RC%7?\J,'_E]?+7_2 M>?\`LHQ5W_*C!_Y?7RU_TGG_`+*,5=_RHP?^7U\M?])Y_P"RC%6!^9/R\U;2 MM?T?RGY;\[Q^>_,VM,G#2](,SK%&\8D222X,GI_Y5:TX`N_`85?=GY-_E1%^ M6FC327MX^I^:-:6)]>OB[-&#&/@AB!.ZI6G(BK==N@"O9<5=BKL5=BKL5=BK ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK ML5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK ML5=BKL5=BKL5=BKL5=BKL5=BK__0^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5 MCWFGRMHGG+1+WR_Y@LUO=.O5HR]'C[A;LLD5O=R\/=A\#>^%5W^!OR:_\OR__A+:C_S7@5W^!OR:_P#+\O\` M^$MJ/_->*N_P-^37_E^7_P#"6U'_`)KQ5W^!OR:_\OR__A+:C_S7BKO\#?DU M_P"7Y?\`\);4?^:\5=_@;\FO_+\O_P"$MJ/_`#7BKO\``WY-?^7Y?_PEM1_Y MKQ5W^!OR:_\`+\O_`.$MJ/\`S7BKO\#?DU_Y?E__``EM1_YKQ5W^!OR:_P#+ M\O\`^$MJ/_->*N_P-^37_E^&_P#"6U'_`)KQ5,=,_*_\I=7DNHK/\^K9?JEN MUW.]UH-S:*$CK6KW%Q$CL.?V15SBKRE_+:ZMYG@\N>1;R[\UF^D$.G7#V?U$ MS.?^*3<2<$_RW=/\OCA5^DGY.?DWI/Y8:4L\XCU'S9?QC]*:OPIZ2D`_5H!4 MT1#^UU;O10JJ%>V8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7 M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7 M8J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__1 M^_F*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L>\T^5M$\Y:)>^7_,%FM[IUZM& M7H\;C[,D;=5=3N"/U8J_+C\U?RKUS\K]<^IWA:\T>\:1M#UQ5^"=*?8?;X)$ MZNO0C?%6"Z&WE];U1YE@OY=-?[G^0'_+7Y_\`^D;2 M/^J^*N]/\@/^6OS_`/\`2-I'_5?%7>G^0'_+7Y__`.D;2/\`JOBKO3_(#_EK M\_\`_2-I'_5?%7>G^0'_`"U^?_\`I&TC_JOBK&/-J?EM"4A\CMY@O7(/JWVL M&UA0$=(XX($+OM_EIBK&='T?4_,.IVFC:/8R:EJ=W(8[6UC7XBP\>W^R\,5? MI]^3GY-Z3^6&E+/.(]1\VW\8_2NK\:>FI`/U:"I/P(?VNK]30!555[9BKL5= MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5= MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5= MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_]+[^8J[%78J[%78J[%7 M8J[%78J[%78J[%78J[%6/>:?*VB>-Q]F2-NJNIW! M'ZL5?EQ^:OY5ZY^5^N-9W@:]T:\:1]"UM1\,Z=DDV^&5*U91U&X[8J\KV'@# M]`_YI.*NJ3T)/R)_@Q_5BJ)M;BWAE+75HMW#6DB>HZ?\/'BK,[/6?R]5&^O> M2M5FE)VF@UU(1W[/83$_?A5./TQ^3_\`U)_F,_\`;[M_^R#`J`N=9_+"LBVG MDG7:4_=/-KT0/SX1Z;O_`,'BK$-1NM,G/'3=*;35'4S7+W#_`(^E_P`0Q5*: M_P"5^/\`S=BKJ_Y7SW_YN.*IEH^C:EYAU.RT?1[*2_U*^E]*VMD'%V;N3_S5 MBK]/OR<_)O2?RQTI;BX$>I>;;^,?I36.%/34@'ZM#N:(AK\75^IHO%55>V8J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J__3^_F*NQ5V*NQ5 MV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*L>\T^5M$\YZ)>>7_,%FM[IUZM&4[/&X^S M+$W574[@C]6*ORX_-3\J]<_*W6_J=V7N]%O'=]#UM1\$R?R/_)*@^VO0]ML5 M>5^Y^BO]I_4<5=7W^_\`VS_M8JZM.]/IW_XD,5=4GO\`B?ZG%7=>WPCI_GN, M5=T\`>_;^*G%75/8U/S)_4QQ5,M'TC4_,&I6>CZ/:2W^IWLGI6MM&*.S?3_Q M/%7Z?_DY^3>D_EAI0GF$>H^;-0C'Z5U?C01J0#]6@!)HB'JW5SN:#BBJO:\5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BK_]3[^8J[%78J M[%78J[%78J[%78J[%78J[%78J[%78J[%6/>:?*VB>OT_\W8J[\3V_KX_=VQ5U/'Z2?ZD?KQ5U?`_ M(`_P#8JF6CZ/J?F'4[31='M)-1U2]D,5K;1#XBZ]R2?^'Q5^G?Y.?D]HGY9: M\T^5M$\Y:)>>7_`#!9+>Z=>K1E-`\;C[,D M;;\74[@C]6*ORX_-3\J]<_*[7#9WO*\T:\=WT+7%6J3IUXR5^S*G[:C8C?IB MKRNI/?\`$_U.*NZ]OA'3_/<8J[I['O3:GZB/IQ5-M$T/5?,NKZ?H>C6CW^IZ MG*(K6V2@#/\`,D>FG^6_V,*OT]_)K\GM+_+#1Q-,$OO-VI1<=;U8$E54MS%M M`#2D:'Z6.^RA54*B_P`SOSH\K?EA/I>DW=EJ?FGS=KL;S:+Y*T"!+G4)H(V6 M-[F3U)(H;>!&8`RS2(O6A)!&3C`ROR8F5,*L/^-Q]F6)NJNIW!'ZL5?EQ^:GY5Z[^5^M_4[QFO-'O&D;0];5? M@G3^1_Y94_;7OUW!&*O*Z>WS)_B>/Z\5370]%U;S'JEGHVB6,NH:I>MQM;:, M49J=?]1/\O%7Z=_DY^36D_EAI0GG]/4O-E^@.J:OQIZ:D`_5H*DT1#7XNK]3 M0<555[9BK\R_SWMX]4L_^_+/3=)TR]8^F_EV2^TF2TA1RKE M8+B\>Z]3B*<^5155_RBTG3_(T=CYH_*G0 M9)GT^\L2ES=Q>9/6FCM[=R`6AC>%><;J_J\'X5,B2;[R@"MGVK^1\^O77Y,_ ME/<^:'DD\Q7/E#19=9DFY>LUP]C"SF;E0^H2?C_RJY`\V0>I8%=BKL5=BKL5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5 M=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5?_]?[^8J[%78J[%78J[%78J[% M78J[%78J[%78J[%78J[%78J[%78JQ[S3Y6T3SGHEYY?\P62WNG7JT93L\;C[ M,D;?LNIW!'ZJC%7YH>=?R)\Y>6O.EIY4TZPEUN'7I&3RYJD2@),@%292=HVB M&\E3M]O[&&E?=_Y0?E!I'Y6Z00#'J/F?44'Z:UL+2O0^A`#NL2D5[%C\1`^% M5"O8<5=BKQ+\U?R1TC\RKW3/,=EK5SY.\\:+"+73_,]G;VUXD]JLZW26>HV5 MY')#>6Z3HLR1N`4E`=&5M\D)5L@AA#?\X[Z_YQUNRU3\[?S-3\R=.TWTQ!Y9 MT[R]9:!9W:12"=(-2D22[NKJ`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` end XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Investments, Debt and Equity Securities
3 Months Ended
Mar. 31, 2012
Investments, Debt and Equity Securities  
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

5.         AVAILABLE-FOR-SALE AND EQUITY SECURITIES

 

The fair value of the equity securities we held were categorized as available-for-sale securities, were zero, consisted of shares in Security Innovation and Xion Pharmaceutical Corporation.  We own 223,317 shares of stock in the privately held Security Innovation, an independent provider of secure software located in Wilmington, MA.

 

In September 2009 we announced the formation of a joint venture with Xion Corporation for the commercialization of our patented melanocortin analogues for treating sexual dysfunction and obesity.  CTTC currently owns 60 shares of common stock or 33% of the outstanding stock of privately held Xion Pharmaceutical Corporation.

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]C,C=D-&)F,%\S,3%A7S0P-V1?.34Y.5\Q-38W M8C$T9&-A8F8B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I%>&-E;%=O#I.86UE/@T* M("`@(#QX.E=O#I% M>&-E;%=O#I.86UE/E)E8V5I=F%B;&5S7TQO86YS M7TYO=&5S7U)E8V5I=CPO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/DEN=F5S=&UE;G1S7T1E8G1?86YD7T5Q=6ET>5]393PO>#I.86UE M/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D1E9F5RF5D7U!R93PO>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E!R;W!E#I7;W)K#I7;W)K#I%>&-E;%=O#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D5Q=6ET>3PO>#I.86UE/@T*("`@(#QX M.E=O#I%>&-E;%=O M#I.86UE/D5A#I. M86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?0F%L86YC93PO M>#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/D-O;F1E;G-E9%]#;VYS;VQI9&%T961?4W1A=&5M M93$\+W@Z3F%M93X-"B`@("`\>#I7;W)K#I%>&-E;%=O#I%>&-E;%=O M#I! M8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E M;%=O7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,3`M43QS<&%N/CPO M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!0=6)L:6,@1FQO870\ M+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!6;VQU;G1A'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@ M(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]C,C=D-&)F M,%\S,3%A7S0P-V1?.34Y.5\Q-38W8C$T9&-A8F8-"D-O;G1E;G0M3&]C871I M;VXZ(&9I;&4Z+R\O0SHO8S(W9#1B9C!?,S$Q85\T,#=D7SDU.3E?,34V-V(Q M-&1C86)F+U=O'0O:'1M;#L@8VAA&-E'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$3PO=&0^#0H@("`@("`@(#QT9"!C;&%S M'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R M(&-L87-S/3-$2!D97!O'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT+"!N970\+W1D/@T*("`@("`@("`\=&0@8VQA6%B;&4L($=% M3TU#/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT+#$W-2PR,C4\ M'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$&-E'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%SF5D+"!N;R!S:&%R97,@:7-S=65D(&%N9"!O=71S M=&%N9&EN9SPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y;,UT\ M+W1D/@T*("`@("`@("`\=&0@8V]LF5D+"`Q-"PX,S`L,C`T('-H87)E'1087)T7V,R-V0T8F8P7S,Q,6%? M-#`W9%\Y-3DY7S$U-C=B,31D8V%B9@T*0V]N=&5N="U,;V-A=&EO;CH@9FEL M93HO+R]#.B]C,C=D-&)F,%\S,3%A7S0P-V1?.34Y.5\Q-38W8C$T9&-A8F8O M5V]R:W-H965T'0O:F%V87-C3X-"B`@ M("`\=&%B;&4@8VQA6%L=&EE7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAAF%T:6]N/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XD(#,L-#8T/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'`I/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\F5D(&QO M'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$2!A;F0@97%U:7!M96YT/"]T9#X-"B`@("`@("`@/'1D(&-L M87-S/3-$;G5M/B@R,"PP,#(I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!D97!O'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%S2`H=7-E9"!I;BD@<')O=FED960@8GD@:6YV97-T:6YG(&%C M=&EV:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN M(#!I;B`P<'0G/D1U2!I6QE/3-$)U1%6%0M24Y$14Y4.C`N M-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/D1U2`R,#$Q M+"!T:&4@0V]M<&%N>2!C86YC96QE9"`Q,"PP,#`@8V]M;6]N('-H87)E6QE M/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB2`R,#$Q+"!T:&4@0V]M<&%N>2!C86YC96QE9"`Q-2PP,#`@ M8V]M;6]N('-H87)E6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!- M05)'24XZ,&EN(#!I;B`P<'0G/D1U3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]C,C=D-&)F,%\S,3%A7S0P-V1?.34Y.5\Q-38W8C$T9&-A8F8-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(W9#1B9C!?,S$Q85\T,#=D M7SDU.3E?,34V-V(Q-&1C86)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R'0@0FQO8VM=/"]T M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@6QE M/3-$)TQ)3D4M2$5)1TA4.C$R<'0[($U!4D=)3CHP:6X@,&EN(#!P="<^/&9O M;G0@6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ M,&EN(#!I;B`P<'0G/E1H92!I;G1E2P@5F5C=&]R(%9I2!A8V-O=6YT6QE/3-$)TQ)3D4M2$5)1TA4.C$R<'0[(%1%6%0M24Y$14Y4.C`N M-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$3$545$52 M+5-004-)3D2P@8V]N'!E8W1E9"!F;W(@=&AE(&YE>'0@9G5L;"!F:7-C86P@ M>65A2XF;F)S<#L@5V4@8V]N M=&EN=64@=&\@97AP86YD(&]U2!O9B!O=7(@2!F;W(@870@;&5A'0@='=O(&9I'!I6QE/3-$)TQ)3D4M2$5)1TA4.C$R<'0[(%1%6%0M M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$3$545$52+5-004-)3D2!N;W0@ M:&%V92!S=69F:6-I96YT(&-A'!E;G-E2!D;V5S(&YO="!H879E(&%N>2!S:6=N:69I8V%N="!I;F1I=FED=6%L(&-A M2!F M=7)T:&5R(')E9'5C:6YG(&-O2P@86YD+V]R('!U'!E;G-E6QE/3-$)U1%6%0M24Y$14Y4 M.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$3$54 M5$52+5-004-)3D6QE M/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$3$545$52+5-004-)3D2P@86YD('=I;&P@2!A;F0@5F5R2!!9W)E96UE M;G0@=VAE2!T:&4@0V]M<&%N>2!G2!I;G1E6QE/3-$)U1%6%0M24Y$14Y4 M.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0[('1A8BUS=&]P2!M961I M8V%L(&1E=FEC92!C;VYT:6YU92!T;R!B92!T:&4@;6%J;W(@2!A M8W%U:7)E9"!T:&4@97AC;'5S:79E+"!W;W)L9'=I9&4@2!A;F0@87)E('!E;F1I;F<@87!P6QE M/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF M;VYT('-T>6QE/3-$3$545$52+5-004-)3D6QE M/3-$3$545$52+5-004-)3D6QE/3-$)U1%6%0M24Y$14Y4 M.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$3$54 M5$52+5-004-)3D2!H860@;F\@:6YD:6-A=&EO;B!T:&%T($Q%1R!W;W5L9"!M965T(&ET2!A;F0@86YN=6%L(&UA&-L=7-I=FET>2!W:71H:6X@3$5))W,@=&5R6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN M.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$3$545$52+5-0 M04-)3D2!H860@97AI2XF;F)S<#L@/"]F;VYT/CPO<#X@/'`@6%L=&EE2!A;&P@<&%R=&EE2!H87,@;V-C=7)R960@86YD(&]U M2!I2!T;V]K(&=R96%T97(@8V]N=')O;"!O9B!T:&4@2!C:&%N9V5S('1H97)E=&\@86YD('1O('-E;&5C="!A;F0@8V]N M=')A8W0@=VET:"!M86YU9F%C='5R:6YG('!A'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S M/3-$=&5X=#X\(2TM96=X+2T^/'`@6QE/3-$ M)TQ)3D4M2$5)1TA4.FYO6QE/3-$)TQ)3D4M M2$5)1TA4.FYO6QE/3-$)TU!4D=)3CIA=71O(&%U=&\@875T;R`T M-2XW-7!T.R!"3U)$15(M0T],3$%04T4Z8V]L;&%P6QE M/3-$)T)/4D1%4BU"3U143TTZ=VEN9&]W=&5X="`Q<'0@6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!-05)'24XZ,&EN(#!I;B`P M<'0G(&%L:6=N/3-$8V5N=&5R/B9N8G-P.SPO<#X\+W1D/B`\=&0@=VED=&@] M,T0Q-#8@6QE/3-$)T)/4D1%4BU"3U143TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z(V8P M9C!F,#L@4$%$1$E.1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R M86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z-2XT<'0[(%=)1%1(.C(R-2XQ-7!T M.R!0041$24Y'+5))1TA4.C4N-'!T.R!"3U)$15(M5$]0.B-F,&8P9C`[($)/ M4D1%4BU224=(5#HC9C!F,&8P.R!0041$24Y'+51/4#HP:6XG('9A;&EG;CTS M1'1O<#X@/'`@6QE/3-$)T)/4D1%4BU"3U143TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z(V8P M9C!F,#L@4$%$1$E.1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R M86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z-2XT<'0[(%=)1%1(.CDT+C5P=#L@ M4$%$1$E.1RU224=(5#HU+C1P=#L@0D]21$52+51/4#HC9C!F,&8P.R!"3U)$ M15(M4DE'2%0Z(V8P9C!F,#L@4$%$1$E.1RU43U`Z,&EN)R!V86QI9VX],T1T M;W`^(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S M.C6QE/3-$ M)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P M=#L@=&%B+7-T;W!S.C6QE/3-$4$%'12U"4D5!2RU)3E-) M1$4Z879O:60^(#QT9"!W:61T:#TS1#,P,"!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B-F,&8P9C`[($)/4D1%4BU,1494.B-F,&8P9C`[(%!!1$1)3D6QE/3-$ M)TU!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S.BXR-6EN("XU:6X@+C6QE/3-$)T)/4D1%4BU"3U143TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z M(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2 M.G1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z-2XT<'0[(%=)1%1(.CDT+C5P M=#L@4$%$1$E.1RU224=(5#HU+C1P=#L@0D]21$52+51/4#HC9C!F,&8P.R!" M3U)$15(M4DE'2%0Z(V8P9C!F,#L@4$%$1$E.1RU43U`Z,&EN)R!V86QI9VX] M,T1T;W`^(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T M;W!S.C6QE/3-$)T)/4D1%4BU"3U143TTZ(V8P9C!F,#L@0D]21$52+4Q% M1E0Z(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/ M3$]2.G1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z-2XT<'0[(%=)1%1(.C$P M.2XV-7!T.R!0041$24Y'+5))1TA4.C4N-'!T.R!"3U)$15(M5$]0.B-F,&8P M9C`[($)/4D1%4BU224=(5#HC9C!F,&8P.R!0041$24Y'+51/4#HP:6XG('9A M;&EG;CTS1'1O<#X@/'`@6QE/3-$4$%' M12U"4D5!2RU)3E-)1$4Z879O:60^(#QT9"!W:61T:#TS1#,P,"!S='EL93TS M1"="3U)$15(M0D]45$]-.B-F,&8P9C`[($)/4D1%4BU,1494.B-F,&8P9C`[ M(%!!1$1)3D6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S.BXR M-6EN("XU:6X@+C6%L=&EE6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P M=#L@=&%B+7-T;W!S.BXR-6EN("XU:6X@+C6QE/3-$ M)T)/4D1%4BU"3U143TTZ=VEN9&]W=&5X="`Q<'0@6QE/3-$)T)/4D1%4BU"3U143TTZ=VEN9&]W=&5X="`Q<'0@ M6QE/3-$)TU!4D=) M3CHP:6X@,&EN(#!P="<^)FYB6QE M/3-$4$%'12U"4D5!2RU)3E-)1$4Z879O:60^(#QT9"!W:61T:#TS1#,P,"!S M='EL93TS1"="3U)$15(M0D]45$]-.B-F,&8P9C`[($)/4D1%4BU,1494.B-F M,&8P9C`[(%!!1$1)3D6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T M;W!S.BXR-6EN("XU:6X@+C'0@,2XU<'0@9&]U8FQE.R!"3U)$15(M3$5&5#HC9C!F,&8P.R!0 M041$24Y'+4)/5%1/33HP:6X[($)!0TM'4D]53D0M0T],3U(Z=')A;G-P87)E M;G0[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ=VEN9&]W=&5X="`Q+C5P="!D;W5B M;&4[($)/4D1%4BU,1494.B-F,&8P9C`[(%!!1$1)3D6QE/3-$)TU!4D=)3CHP M:6X@,&EN(#!P=#L@=&%B+7-T;W!S.C7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$ M=&5X=#X\(2TM96=X+2T^/'`@6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!- M05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$3$545$52+5-004-) M3DF5R;RP@8V]N2!);FYO=F%T:6]N(&%N9"!8:6]N(%!H87)M86-E M=71I8V%L($-O2!);FYO=F%T:6]N+"!A;B!I;F1E<&5N9&5N="!P6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB'5A;"!D>7-F M=6YC=&EO;B!A;F0@;V)E2XF;F)S<#L@0U140R!C=7)R96YT;'D@;W=N M3X-"CPO:'1M;#X- M"@T*+2TM+2TM/5].97AT4&%R=%]C,C=D-&)F,%\S,3%A7S0P-V1?.34Y.5\Q M-38W8C$T9&-A8F8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(W M9#1B9C!?,S$Q85\T,#=D7SDU.3E?,34V-V(Q-&1C86)F+U=O'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$6QE/3-$3$545$52+5-004-)3D6QE/3-$3$545$52+5-004-)3D'!E;G-E M6QE/3-$)T)/ M4D1%4BU"3U143TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z(V8P9C!F,#L@4$%$ M1$E.1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT M.R!0041$24Y'+4Q%1E0Z-2XT<'0[(%=)1%1(.C(Q,2XU<'0[(%!!1$1)3D6QE/3-$3$545$52+5-004-)3D6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!, M24Y%+4A%24=(5#HQ,G!T.R!-05)'24XZ,&EN(#!I;B`P<'0[('1A8BUS=&]P M6QE/3-$3$545$52+5-004-)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(V8P9C!F,#L@ M0D]21$52+4Q%1E0Z(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ,&EN.R!"04-+ M1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z-2XT<'0[ M(%=)1%1(.C$S+C%P=#L@4$%$1$E.1RU224=(5#HU+C1P=#L@0D]21$52+51/ M4#HC9C!F,&8P.R!"3U)$15(M4DE'2%0Z(V8P9C!F,#L@4$%$1$E.1RU43U`Z M,&EN)R!V86QI9VX],T1T;W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N M=&5R.R!,24Y%+4A%24=(5#HQ,G!T.R!-05)'24XZ,&EN(#!I;B`P<'0[('1A M8BUS=&]P6QE/3-$3$545$52+5-004-) M3D6QE/3-$)TQ)3D4M2$5) M1TA4.FYO6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^5')A=F5L M(&%N9"!C;VUM:7-S:6]N(&%D=F%N8V5S/"]P/CPO=&0^(#QT9"!W:61T:#TS M1#$T,B!S='EL93TS1"="3U)$15(M0D]45$]-.B-F,&8P9C`[($)/4D1%4BU, M1494.B-F,&8P9C`[(%!!1$1)3D6QE/3-$4$%'12U"4D5!2RU)3E-) M1$4Z879O:60^(#QT9"!W:61T:#TS1#(X,B!S='EL93TS1"="3U)$15(M0D]4 M5$]-.B-F,&8P9C`[($)/4D1%4BU,1494.B-F,&8P9C`[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ=VEN9&]W=&5X="`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`Z,&EN)R!V86QI9VX],T1T M;W`^(#QP('-T>6QE/3-$)TQ)3D4M2$5)1TA4.C$R<'0[($U!4D=)3CHP:6X@ M,&EN(#!P=#L@=&%B+7-T;W!S.C6QE/3-$)T)/4D1%4BU"3U14 M3TTZ=VEN9&]W=&5X="`Q+C5P="!D;W5B;&4[($)/4D1%4BU,1494.B-F,&8P M9C`[(%!!1$1)3D6QE/3-$3$545$52+5-004-)3D7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA2P@4&QA;G0L M(&%N9"!%<75I<&UE;G0\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H M(&-L87-S/3-$=&@@8V]L2P@4&QA;G0L(&%N9"!%<75I<&UE M;G0\+W-T6QE M/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/E!R M;W!E6QE/3-$4$%'12U"4D5! M2RU)3E-)1$4Z879O:60^(#QT9"!W:61T:#TS1#(X,B!S='EL93TS1"="3U)$ M15(M0D]45$]-.B-F,&8P9C`[($)/4D1%4BU,1494.B-F,&8P9C`[(%!!1$1) M3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z(V8P9C!F,#L@4$%$1$E.1RU"3U14 M3TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0041$24Y' M+4Q%1E0Z-2XT<'0[(%=)1%1(.C$R+CEP=#L@4$%$1$E.1RU224=(5#HU+C1P M=#L@0D]21$52+51/4#HC9C!F,&8P.R!"3U)$15(M4DE'2%0Z(V8P9C!F,#L@ M4$%$1$E.1RU43U`Z,&EN)R!V86QI9VX],T1T;W`^(#QP('-T>6QE/3-$)U1% M6%0M04Q)1TXZ8V5N=&5R.R!-05)'24XZ,&EN(#!I;B`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`Z,&EN)R!V86QI9VX],T1T;W`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`Q<'0@6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$3$545$52+5-004-)3D6QE/3-$ M3$545$52+5-004-)3D'!E;G-E('=A2XF;F)S<#L@/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P M="<^/&(^.2XF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF M;F)S<#LF;F)S<#L@04-#3U5.5%,@4$%904),12P@1T5.15)!3#PO8CX\+W`^ M(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&(^)FYB6QE/3-$)TU!4D=)3CIA=71O(&%U=&\@875T;R`P M+C5I;CL@0D]21$52+4-/3$Q!4%-%.F-O;&QA<'-E)R!C96QL<&%D9&EN9STS M1#`@8V5L;'-P86-I;F<],T0P/B`\='(@6QE/3-$)T)/4D1%4BU" M3U143TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z(V8P9C!F,#L@4$%$1$E.1RU" M3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0041$ M24Y'+4Q%1E0Z-2XT<'0[(%=)1%1(.C(Q-BXY<'0[(%!!1$1)3D6QE/3-$ M)T)/4D1%4BU"3U143TTZ=VEN9&]W=&5X="`Q<'0@6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!- M05)'24XZ,&EN(#!I;B`P<'0[('1A8BUS=&]P6QE/3-$)T)/4D1% M4BU"3U143TTZ=VEN9&]W=&5X="`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`N)FYB6QE M/3-$)TU!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S.BXR-6EN("XU:6X@ M+C6QE/3-$)T)/4D1% M4BU"3U143TTZ=VEN9&]W=&5X="`Q<'0@6QE/3-$)TU! M4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S.BXR-6EN("XU:6X@+C6%L=&EE6QE/3-$4$%'12U"4D5!2RU)3E-)1$4Z879O:60^(#QT M9"!W:61T:#TS1#(Y,2!S='EL93TS1"="3U)$15(M0D]45$]-.B-F,&8P9C`[ M($)/4D1%4BU,1494.B-F,&8P9C`[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z(V8P M9C!F,#L@4$%$1$E.1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R M86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z-2XT<'0[(%=)1%1(.C$S+C%P=#L@ M4$%$1$E.1RU224=(5#HU+C1P=#L@0D]21$52+51/4#HC9C!F,&8P.R!"3U)$ M15(M4DE'2%0Z(V8P9C!F,#L@4$%$1$E.1RU43U`Z,&EN)R!V86QI9VX],T1T M;W`^(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$ M4$%'12U"4D5!2RU)3E-)1$4Z879O:60^(#QT9"!W:61T:#TS1#(Y,2!S='EL M93TS1"="3U)$15(M0D]45$]-.B-F,&8P9C`[($)/4D1%4BU,1494.B-F,&8P M9C`[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U14 M3TTZ(V8P9C!F,#L@0D]21$52+4Q%1E0Z(V8P9C!F,#L@4$%$1$E.1RU"3U14 M3TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0041$24Y' M+4Q%1E0Z-2XT<'0[(%=)1%1(.C$P-BXT<'0[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(V8P9C!F M,#L@0D]21$52+4Q%1E0Z(V8P9C!F,#L@4$%$1$E.1RU"3U143TTZ,&EN.R!" M04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z-2XT M<'0[(%=)1%1(.C$S+C%P=#L@4$%$1$E.1RU224=(5#HU+C1P=#L@0D]21$52 M+51/4#HC9C!F,&8P.R!"3U)$15(M4DE'2%0Z(V8P9C!F,#L@4$%$1$E.1RU4 M3U`Z,&EN)R!V86QI9VX],T1T;W`^(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@ M,&EN(#!P="<^)FYB6%B;&4\+W`^/"]T9#X@/'1D('=I M9'1H/3-$,30R('-T>6QE/3-$)V)O6QE/3-$)TU!4D=) M3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S.C6QE/3-$)V)O6QE/3-$)TQ)3D4M2$5)1TA4.FYO6QE/3-$)V)O6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T M;W!S.BXR-6EN("XU:6X@+C6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^ M)FYB7,@=VAI8V@@=V5R92!P=7)C:&%S M960@8G5T(&YO="!C;VYD=6-T960@9'5R:6YG('1H92!T:')E92!M;VYT:',@ M96YD960@36%R8V@@,S$L(#(P,3(@86YD('EE87(@96YD960@1&5C96UB97(@ M,S$L(#(P,3$L(')E2XF;F)S<#L@/"]P/CQS<&%N/CPO7!E.B!T97AT+VAT M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@ M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$ M)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@2UO=VYE9"!S=6)S:61I M87)Y+"!65DDL(&AA=F4@2!T:&4@9W)A;G0@9G5N9',N)FYBF4@=&AE6QE/3-$)U1%6%0M24Y$14Y4.C`N M-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$3$545$52 M+5-004-)3D6QE/3-$ M)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT M('-T>6QE/3-$3$545$52+5-004-)3D2!T97)M:6YA=&5D(&ET&ES=&EN9R!O8FQI M9V%T:6]N2!T:&5N(&5N=&5R M960@:6YT;R!A(&YE=RP@=&AR964M>65AF5D(&]F9FEC92!S<&%C97,N M)FYB2!L97-S M('1H870@=&AE('!R979I;W5S(&QE87-E+"!A=F5R86=I;F<@)#65A65A6QE/3-$)U1%6%0M M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQB/CQI/D-A2!D86UA M9V5S+"!P=6YI=&EV92!D86UA9V5S+"!A='1O7,F(S$T-CL@9F5E6UE($QA8F]R871O6UE(BDN)FYB6UE(&9I;&5D(&9O2!J=61G;65N="!I M;B!T:&4@4V]U=&AE2XF;F)S<#L@3VX@4V5P=&5M8F5R(#$R M+"`R,#`V+"!T:&4@1&ES=')I8W0@0V]U6UE(&)E(&%D9&5D(&%S(&1E9F5N M9&%N=',@=&\@=&AE($-A6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I M;B`P<'0G/B9N8G-P.SPO<#X@/'`@GEM92!R97%U97-T960@=&AE(%5N:71E9"!3=&%T97,@4&%T96YT(&%N M9"!42!T:&4@55-05$\@;VX@1&5C96UB97(@,30L(#(P M,#8N)FYB&%M:6YE2!T:&4@0E!!22!O;B!$96-E;6)E'!E9&ET92!F=7)T M:&5R(&%C=&EO;B!O;B!T:&4@8V%S92!W:71H:6X@=&AE(%534%1/+"!W:&EC M:"!W87,@=&\@:&%V92!B965N(&AA;F1L960@=VET:"!S<&5C:6%L(&1I6QE/3-$)U1% M6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO M<#X@/'`@2`R,#`U+"!/4TA!(&9O=6YD('!R;V)A8FQE(&-A M=7-E('1O('-U<'!O65E)B,Q-#8[2XF;F)S<#L@/"]P/B`\<"!S='EL93TS1"=415A4+4E. M1$5.5#HP+C5I;CL@34%21TE..C!I;B`P:6X@,'!T)SXF;F)S<#L\+W`^(#QP M('-T>6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P M<'0G/D]N($]C=&]B97(@-2P@,C`P-2P@=&AE($%,2B!W:&\@8V]N9'5C=&5D M('1H92!H96%R:6YG(&]N($-45$,F(S$T-CMS(&%P<&5A;"!O9B!T:&4@3U-( M02!F:6YD:6YG28C,30V.W,@<')E M;&EM:6YA6QE/3-$)U1%6%0M24Y$ M14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/DEN($UA7-I2!T:&4@ M05)"+B9N8G-P.R!);B!*86YU87)Y(#(P,#DL('1H92!!3$H@:7-S=65D(&$@ M2!-87D@,S$L(#(P,3(N)FYB M2!T:&4@4V]L:6-I=&]R)W,@3V9F:6-E M(&]F('1H92!5+E,N($1E<&%R=&UE;G0@;V8@3&%B;W(@86YD($-45$,@87)E M(&1U92!B>2!*=6QY(#,P+"`R,#$R+B9N8G-P.R!.;R!D871E(&AA6QE/3-$)U1%6%0M M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@ M/'`@6QE/3-$)U1%6%0M M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/D]N(%-E<'1E;6)E M6UE;G0@8V]N M=')A8W0@=VET:"!T:&4@0V]M<&%N>2!H860@8V%L;&5D(&9O6QE M/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/D]N M(%-E<'1E;6)E2!W87,@6QE/3-$3$545$52+5-004-)3D2!S=6)M:71T960@82!S=6UM87)Y(&QI;6ET960@:6X@;&5N9W1H M('-T871I;F<@=&AE:7(@<&]S:71I;VYS+B9N8G-P.R`\+V9O;G0^/"]P/B`\ M<"!S='EL93TS1"=415A4+4E.1$5.5#HP+C5I;CL@34%21TE..C!I;B`P:6X@ M,'!T)SXF;F)S<#L\+W`^(#QP('-T>6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN M.R!-05)'24XZ,&EN(#!I;B`P<'0G/E!R:6]R('1O('1H92!C;VYC;'5S:6]N M(&]F('1H92!A2!A;'-O(')E<75E2=S M('-T2!E>&5R8VES960@:71S(')E87-O;F%B;&4@9&ES8W)E M=&EO;B!U;F1E&5C=71I=F4F(S$T-CMS(&%C=&EO;G,@=V5R92!C875S92!F;W(@96UP M;&]Y;65N="!T97)M:6YA=&EO;B!U;F1E6QE/3-$)U1%6%0M M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/DEN($IA;G5A2=S(&UO=&EO;B!T M;R!V86-A=&4@=&AE(&%R8FET2!I;G1E2!A;F0@86QL(&-L86EM6QE/3-$)U1%6%0M24Y$ M14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@ M'!E8W1A=&EO;G,@86YD(&-O;G1R86-T2!I;B!C;VYN96-T:6]N('=I=&@@ M=&AE:7(@<'5R8VAA6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN M(#!I;B`P<'0G/B9N8G-P.SPO<#X@/'`@3PO:3X@)B,Q M-3`[(%=E(&UA>2!B92!A('!A2P@;W(@<&]S2!P;W1E M;G1I86P@:G5D9VUE;G0@;&]S&-E<'1I;VX@ M;V8@=&AE(&%C8W)U960@97AP96YS97,@6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)' M24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$3$545$52+5-004-)3D'1087)T7V,R M-V0T8F8P7S,Q,6%?-#`W9%\Y-3DY7S$U-C=B,31D8V%B9@T*0V]N=&5N="U, M;V-A=&EO;CH@9FEL93HO+R]#.B]C,C=D-&)F,%\S,3%A7S0P-V1?.34Y.5\Q M-38W8C$T9&-A8F8O5V]R:W-H965T'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P M="<^/&(^,3$N)FYB2!E>'1E;F1E M9"!F;W(@86X@861D:71I;VYA;"`S,"!D87ES(&EN($UA2XF;F)S<#L@)FYB2!I28C,30V.W,@8V]M;6]N('-T;V-K(&%T('1H92!R871E(&]F("0Q M+C`U('!E3X-"CPO:'1M;#X-"@T*+2TM M+2TM/5].97AT4&%R=%]C,C=D-&)F,%\S,3%A7S0P-V1?.34Y.5\Q-38W8C$T M9&-A8F8-"D-O;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(W9#1B9C!? M,S$Q85\T,#=D7SDU.3E?,34V-V(Q-&1C86)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R M3QB3PO'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@ M("`@/'1R(&-L87-S/3-$2!.;W1E($1I'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\(2TM96=X+2T^/'`@6QE/3-$ M)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$3$545$52+5-004-) M3D2`R+"`R,#$Q('1H92!#;VUP86YY(&%D;W!T960@ M86YD(&5X96-U=&5D('1H92!%;7!L;WEE97,F(S$T-CL@1&ER96-T;W)S)B,Q M-#8[(&%N9"!#;VYS=6QT86YT2!V M97-T960@=7!O;B!G6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)' M24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$3$545$52+5-004-)3D6QE/3-$)U1%6%0M24Y$ M14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$ M3$545$52+5-004-)3D'!I2!E:71H97(@-2!O'!I7,@9F]L;&]W:6YG('1H92!";V%R9"!M96UB97)S)B,Q-#8[('1E2!C;VYS:61E'1E;G-I;VX@87,@82!M;V1I9FEC871I;VX@=&\@=&AE(&]P=&EO;B!A9W)E M96UE;G1S(')E8V]R9&EN9R!I;F-R96UE;G1A;"!C;VUP96YS871I;VX@;V8@ M)#@P+#`P,"!F;W(@=&AE('1H6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!- M05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE/3-$3$545$52+5-004-) M3D6QE/3-$)U1%6%0M M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G/CQF;VYT('-T>6QE M/3-$3$545$52+5-004-)3D6QE/3-$34%2 M1TE.+4Q%1E0Z,"XU:6X^17AP96-T960@=F]L871I;&ET>2`H,BD@)FYB2!O6QE M/3-$)U1%6%0M24Y$14Y4.BTP+C5I;CL@34%21TE.+4Q%1E0Z,6EN)SXH,BDF M;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#LF;F)S<#L@17-T M:6UA=&5D(&)A'!E8W1E9"!L:69E(&]F('1H92!O M<'1I;VYS(&=R86YT960N/"]P6QE/3-$)TU!4D=)3CHP:6X@ M,&EN(#!P="<^)FYB2!R96-O9VYI>F5D(&5X<&5N2!R96-O M9VYI>F5D(&5X<&5N6QE/3-$)U1%6%0M24Y$14Y4 M.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0[($)!0TM'4D]53D0Z=VAI=&4G M/CQF;VYT('-T>6QE/3-$3$545$52+5-004-)3D6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P M<'0[($)!0TM'4D]53D0Z=VAI=&4G/CQF;VYT('-T>6QE/3-$3$545$52+5-0 M04-)3D6QE/3-$)U1% M6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0[($)!0TM'4D]5 M3D0Z=VAI=&4G/CQF;VYT('-T>6QE/3-$3$545$52+5-004-)3D2=S($)O87)D(&]F M($1IF5D('1H92!I2!P;W-T960@8GD@0U140R!I;B!A M('!R96IU9&=M96YT(')E;65D>2!A8W1I;VX@6QE/3-$)U1%6%0M24Y$14Y4 M.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0[($)!0TM'4D]53D0Z=VAI=&4G M/CQF;VYT('-T>6QE/3-$3$545$52+5-004-)3D6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)' M24XZ,&EN(#!I;B`P<'0[($)!0TM'4D]53D0Z=VAI=&4G/CQF;VYT('-T>6QE M/3-$3$545$52+5-004-)3D2!O9B!I=',@:6YT96YT('1O(&-O;G9E6QE/3-$ M3$545$52+5-004-)3D6QE/3-$)U1%6%0M24Y$14Y4.C`N M-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0[($)!0TM'4D]53D0Z=VAI=&4G/CQF M;VYT('-T>6QE/3-$3$545$52+5-004-)3D6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="`P+C5I;B<^ M/&D^/&9O;G0@6QE/3-$3$54 M5$52+5-004-)3D6%B M;&4@;VX@=&AE(&QA2!T:&4@0V]M<&%N>28C,30V.W,@0F]A6QE/3-$3$545$52+5-004-)3D6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="`P+C5I M;CL@0D%#2T=23U5.1#IW:&ET92<^/&D^/&9O;G0@6QE/3-$3$545$52+5-004-)3D6QE/3-$)TU!4D=)3CHP:6X@,&EN M(#!P="`P+C5I;CL@0D%#2T=23U5.1#IW:&ET92<^/&D^/&9O;G0@2!A6QE/3-$ M3$545$52+5-004-)3D2!T:&4@0V]M<&%N>2!I;B!T:&4@979E;G0@=&AA="!T:&4@9G5N9',@=V5R M92!R96QE87-E9"!A;F0@6QE/3-$3$545$52+5-004-)3D2!W:6QL(&)E(')E M8V]R9&5D(&%T(&9A:7(@=F%L=64@;VX@96%C:"!R97!O2!C:&%N9V4@6QE/3-$3$545$52 M+5-004-)3D6QE/3-$ M)TU!4D=)3CHP:6X@,&EN(#!P="`P+C5I;B<^/&9O;G0@F5D(&QO"!M;VYT:',@96YD960@2G5N92`S,"P@,C`Q,2!R96QA M=&5D('1O('1H92!C;VYV97)T960@6QE/3-$ M)TU!4D=)3CHP:6X@,&EN(#!P="`P+C5I;B<^)FYB6QE/3-$3$545$52+5-004-)3D6QE/3-$3$545$52+5-004-)3D6QE/3-$)TU!4D=)3CHP:6X@ M,&EN(#!P="`P+C5I;CL@0D%#2T=23U5.1#IW:&ET92<^/&9O;G0@2!A="!-87)C:"`S,2P@,C`Q,B!A;F0@1&5C96UB M97(@,S$L(#(P,3$@8F5C875S92!T:&4@=F%R:6%B;&4@8V]N=F5R2!R97%U:7)E('1H92!#;VUP86YY('1O('-E='1L92!T:&4@ M8V]N=F5R'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA6QE/3-$3$545$52+5-004-)3D6QE/3-$)TU! M4D=)3CHP:6X@,&EN(#!P=#L@5$585"U!551/4U!!0T4Z:61E;V=R87!H+6YU M;65R:6,[('1A8BUS=&]P6QE/3-$)W!A9V4M8G)E86LM M:6YS:61E.B!A=F]I9#LG/B`\=&0@=VED=&@],T0R.#(@6QE/3-$3$545$52+5-004-)3D6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!-05)'24XZ,&EN M(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/CQF;VYT('-T>6QE/3-$3$545$52 M+5-004-)3D6QE/3-$)V)O6QE/3-$)U1%6%0M M04Q)1TXZ8V5N=&5R.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N M=&5R/CQB/CQF;VYT('-T>6QE/3-$3$545$52+5-004-)3D6QE/3-$)V)O6QE/3-$3$545$52+5-004-)3D6QE/3-$)V)O6QE/3-$)V)O6QE/3-$ M)TU!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S.G)I9VAT(#DY+C!P="<^ M/&(^)FYB6QE/3-$ M)V)O6QE/3-$)V)O6QE/3-$)V)O6QE M/3-$)V)O6QE/3-$)TQ)3D4M2$5)1TA4.FYO6QE/3-$)W!A9V4M8G)E86LM:6YS:61E M.B!A=F]I9#LG/B`\=&0@=VED=&@],T0R.#(@6QE/3-$)V)O'0@,7!T('-O;&ED.R!B;W)D97(M;&5F=#H@(V8P9C!F,#L@<&%D M9&EN9RUB;W1T;VTZ(#!I;CL@8F%C:V=R;W5N9"UC;VQO6QE/3-$)W!A9V4M8G)E86LM M:6YS:61E.B!A=F]I9#LG/B`\=&0@=VED=&@],T0R.#(@6QE/3-$)V)O6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S.G)I M9VAT(#DY+C!P="<^)FYB6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I M;B`P<'0G/CQF;VYT('-T>6QE/3-$0D%#2T=23U5.1#IW:&ET93Y);B!T:&4@ M<75A2!S=&]C:R!M971H;V0N)FYB2`S,"PP M,#`@;W!T:6]N7!E.B!T97AT M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^ M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT M/3-$)W1E>'0O:'1M;#L@8VAA'0@0FQO8VM=/"]T9#X-"B`@("`@ M("`@/'1D(&-L87-S/3-$=&5X=#X\(2TM96=X+2T^/'`@6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF M>3L@34%21TE..C!I;B`P:6X@,'!T.R!T86(M2!A6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@ M34%21TE..C!I;B`P:6X@,'!T.R!T86(M2!I;F-L=61E.CPO<#X@/'`@6QE/3-$ M)U1%6%0M04Q)1TXZ:G5S=&EF>3L@5$585"U)3D1%3E0Z+3$S+C5P=#L@34%2 M1TE..C9P="`P:6X@,'!T(#$Q,BXU<'0[(%1%6%0M05543U-004-%.CL@=&%B M+7-T;W!S.CDY+C!P="`Q,3(N-7!T(&1E8VEM86P@-2XQ:6X@-BXT:6XG/B8C M,30Y.SQF;VYT('-T>6QE/3-$)T9/3E0Z-W!T("=4:6UE3L\+W`^(#QP('-T M>6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@5$585"U)3D1%3E0Z+3$S+C5P M=#L@34%21TE..C9P="`P:6X@,'!T(#$Q,BXU<'0[(%1%6%0M05543U-004-% M.CL@=&%B+7-T;W!S.CDY+C!P="`Q,3(N-7!T(&1E8VEM86P@-2XQ:6X@-BXT M:6XG/B8C,30Y.SQF;VYT('-T>6QE/3-$)T9/3E0Z-W!T("=4:6UE2!T:&4@9G5L;"!T97)M(&]F('1H92!A6QE/3-$3$545$52+5-004-)3D2!I;G!U="!T:&%T(&ES('-I M9VYI9FEC86YT('1O('1H92!F86ER('9A;'5E(&UE87-UF4@ M=&AE('5S92!O9B!O8G-EF4@=&AE M('5S92!O9B!U;F]B6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@5$585"U)3D1%3E0Z,"XU:6X[ M($U!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S.C0Y+C5P="`Y.2XP<'0@ M,S`S+CAP="!D96-I;6%L(#4N,6EN(&QE9G0@,SDW+C1P="!D96-I;6%L(#8N M-&EN)SX\9F]N="!S='EL93TS1$Q%5%1%4BU34$%#24Y'.BTP+C%P=#XF;F)S M<#L\+V9O;G0^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..FIU2!A6QE/3-$)U1%6%0M04Q)1TXZ:G5S=&EF>3L@5$585"U)3D1%3E0Z M,"XU:6X[($U!4D=)3CHP:6X@,&EN(#!P=#L@=&%B+7-T;W!S.C0Y+C5P="`Y M.2XP<'0@,S`S+CAP="!D96-I;6%L(#4N,6EN(&QE9G0@,SDW+C1P="!D96-I M;6%L(#8N-&EN)SX\9F]N="!S='EL93TS1$Q%5%1%4BU34$%#24Y'.BTP+C%P M=#XF;F)S<#L\+V9O;G0^/"]P/B`\<"!S='EL93TS1"=415A4+4%,24=..FIU M6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ M,&EN(#!I;B`P<'0G/E1H92!#;VUP86YY(&-L87-S:69I960@=&AE(&1E6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I M;B`P<'0G/E1H92!C87)R>6EN9R!A;6]U;G1S(')E<&]R=&5D(&EN(&]U&EM871E(&9A:7(@=F%L=64@9'5E('1O('1H92!S M:&]R="UT97)M(&UA='5R:71Y(&]F('1H;W-E(&9I;F%N8VEA;"!I;G-T3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT M4&%R=%]C,C=D-&)F,%\S,3%A7S0P-V1?.34Y.5\Q-38W8C$T9&-A8F8-"D-O M;G1E;G0M3&]C871I;VXZ(&9I;&4Z+R\O0SHO8S(W9#1B9C!?,S$Q85\T,#=D M7SDU.3E?,34V-V(Q-&1C86)F+U=O'0O:'1M;#L@8VAA7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R2!D97!O3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^)FYB&-EF5D+"!N;R!S:&%R97,@:7-S=65D(&%N9"!O M=71S=&%N9&EN9SPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$:6YN97)&;V]T;F]T93X-"B`@("`@("`@/'1D('9A;&EG;CTS1'1O<#Y; M-%T\+W1D/@T*("`@("`@("`\=&0@8V]LF5D+"`Q-"PX,S`L,C`T('-H87)E'1087)T7V,R-V0T8F8P7S,Q M,6%?-#`W9%\Y-3DY7S$U-C=B,31D8V%B9@T*0V]N=&5N="U,;V-A=&EO;CH@ M9FEL93HO+R]#.B]C,C=D-&)F,%\S,3%A7S0P-V1?.34Y.5\Q-38W8C$T9&-A M8F8O5V]R:W-H965T'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA6%L=&EE'!E;G-E7!E.B!T97AT+VAT;6P[ M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@ M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E M>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@ M(#QT9"!C;&%S6%B;&4L(&=E;F5R86P@86YD(&%C M8W)U960@97AP96YS97,@*%-H87)E'!E;G-E(&9R;VT@ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O:F%V87-C3X-"B`@("`\=&%B;&4@8VQA'`I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X M=#X\'!E;G-E6%B;&4L(&%C M8W)U960@97AP96YS97,@86YD(&]T:&5R(&QI86)I;&ET:65S/"]T9#X-"B`@ M("`@("`@/'1D(&-L87-S/3-$;G5M/B@T,2PP-C,I/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S2!I;G9E6%B;&4\+W1D M/@T*("`@("`@("`\=&0@8VQA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@ M("`@("`@(#QT9"!C;&%S'0O:F%V M87-C3X-"B`@("`\=&%B M;&4@8VQA'0^/"$M+65G>"TM/CQP('-T>6QE/3-$)TU! M4D=)3CHP:6X@,&EN(#!P="<^/&(^,RX\+V(^)FYB6QE/3-$)U1%6%0M24Y$14Y4.C`N-6EN.R!-05)'24XZ,&EN(#!I;B`P<'0G M/CQF;VYT('-T>6QE/3-$0D%#2T=23U5.1#IW:&ET93XF;F)S<#L\+V9O;G0^ M/"]P/B`\<"!S='EL93TS1"=415A4+4E.1$5.5#HP+C5I;CL@34%21TE..C!I M;B`P:6X@,'!T)SX\9F]N="!S='EL93TS1$)!0TM'4D]53D0Z=VAI=&4^3F\@ M;F5W(&%C8V]U;G1I;F<@<')O;F]U;F-E;65N=',@:7-S=65D(&]R(&5F9F5C M=&EV92!D=7)I;F<@=&AE('1H7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S M8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC XML 17 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6
Receivables, Loans, Notes Receivable, and Others
3 Months Ended
Mar. 31, 2012
Receivables, Loans, Notes Receivable, and Others  
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

4.         RECEIVABLES

 

Receivables consist of the following:  

 

 

March 31, 2012

 

December 31, 2011

Calmare® Sales Receivable

  $         102,850

 

  $                24,444

Other Receivable

                 9,165

 

                    18,027

Royalties, net of allowance of $101,154

      at March 31, 2012 and December 31, 2011

                         -

 

 

Total receivables

  $         112,015

 

  $                42,471

XML 18 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Changes in Stockholders' Equity (USD $)
Preferred Stock
Common Stock
Capital in excess of par value
Accumulated deficit
Total shareholders' interest(deficit)
Balance - August 1, 2010 at Dec. 31, 2011          
Compensation expense from stock option grants     $ 138,630   $ 138,630
Common shares issued to settle accounts payable, general and accrued expenses   1,145 127,109   128,254
Common shares issued to settle accounts payable, general and accrued expenses (Shares)   114,415      
Balance - August 1, 2010 at Mar. 31, 2012 $ 60,675 $ 148,302 $ 45,036,867 $ (47,401,023) $ (2,155,179)
Share Balance - August 1, 2010 at Mar. 31, 2012 2,427 14,830,204      
XML 19 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6
Statement of Cash Flows, Supplemental Disclosures
3 Months Ended
Mar. 31, 2012
Statement of Cash Flows, Supplemental Disclosures  
Cash Flow, Supplemental Disclosures [Text Block]

Supplemental disclosure of non-cash investing and financing transactions:

 

During February 2012, the Company issued 14,415 shares at $1.19 per share to settle $17,154 of accrued liabilities.

 

During March 2012, the Company issued 100,000 common shares at $1.111 per share to settle $111,100 of accrued liabilities.

 

During February 2011, the Company canceled 10,000 common shares previously issued to Crisnic and canceled the related $9,000 receivable.  

 

During February 2011, the Company issued 10,000 common shares at $0.99 per share to settle $9,900 of deferred payroll.

 

During January 2011, the Company canceled 15,000 common shares previously issued to Crisnic and canceled the related $13,500 receivable.  

 

During January 2011, the Company issued 15,000 common shares at $1.09 per share to settle $16,350 of accrued liabilities.

ZIP 20 0001360865-12-000089-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001360865-12-000089-xbrl.zip M4$L#!!0````(`)*)LD`,WT7)@%<``.J?`@`1`!P`8W1T8RTR,#$R,#,S,2YX M;6Q55`D``T.[MD]#N[9/=7@+``$$)0X```0Y`0``[%UM<^,VDOY\5W7_@5N7 MQ-DJR2;U+D]FMSQ^F?@RL1W;F6P^I2`2DI"A"`8@+7M__74#I`12D$11"Y[&3BJAGW-Y\?[L M7J8LH8[DXV1.!&TX9\$3B;#?.9_%:0+=KJ.(/Y$$@&4#/OC'#7@6OP@VF2;. MM^=_=UJN.VBV7*]U[,SG\V,:3(A09(]]/G.:363I>21"!\80R=.`LK='TR2) M3T].\.MC2?WC"7\Z@0LVV=Y0U'[-PT1S)`\V8)BQA3S2A_O0XHHGJ MY;87?0KM%007$VCDMD]8)!,<7T[]6;)"ZWD[;^N=_.O'#P_^E,Y(<#@\44_SIBLMB_S@XQ&12\KPE.W`?RJ;$T+B18\QD2/5.GM@$2AH2Z?E M]3>!Z!9YAXA'43JSMP\2<9*\Q/0$&C6A%17,-\<2E.8ZP^B=Z(='H!O_\1T* MX50J4=_3L:/D=XI4WQY)-HM#'*WZ;BKH^.V1GR1^,Y_RXV<9'#DGB@XHT.D% M]X&+*'F$[H[/HX0^)_?8ZU>O]9-W]`_/;?[TW4FYY4KW.Q@(#RZCX((D5CI: MKFV0:Y%:H>."[!D\"O#Q54@F-G)C$DJJ*17:+BA<1J#S+_=TPF0B2)33B/8!\1#_F$4:DL5P/82)5PS@%>D/`Z"NCS#_3%!N3"_SRWY0T')M52 MQP79\U0('!*3/@E_I41L$&VS":+-Y;JN8YEA/IOQZ"'A_J>'*3@R>9LF:"GH M()TT8AI`/SHJ@%XJ4">@/IO!)+P]NKZY`C7I]+UN?S`LC&T#1HF=NW04,O\J MY"19HO_\<%&&]GYJK4"WW+[;[W2Z)K1!KX1TQ<"UGX-`)EQ8Y^D!2*/WOZ4.3S()*#+#@[5'6_C=K^]_4Y/W&@DI3"NNHUS79M5!\%1YM'*[R MUVF!*]Z%O>OH";[BZ"`B)J,]YL'D2;7+I=#H@E]X2V4YW7VC;@+V=@>\$ MC0D++I]C&DD*.G:;3*DXDY(FTCY!VP70[;4ZAEY4@#@H2Q;#MJ'8<+BQWM>;UB#A0?JIP)6\`N(,R3;?>A>O]4W]+Q$KC;47D!ZUFLH:6\X M-&U$T]F5M$TM.YU!J[.9L.]SB,SD'7E!]US7T+PV6'FO94!9Z>X+;5T(.ZYI M!!N`QRPL/WY_>?OC^>XSYO6[K19HQ3J*]>%6P=J#7@4P8_@BI<$'1D8LA(22 MUE]).L.N&1&MI7P`?,N\MB!"[+=WA;_A"=U7E]MN,12TT-P+TS+8'1$OZ)C" MM\$]A1@CK3W08<\$M1/=%]W#,+'*0J_G M]7L[L("&#W&3EI.J9.0-7W97;I7H:&>RAN9>F/41OB;M&*&7,\W,.B:%(&+CV^O#KJ>PF M@3^!FXUR691_ED5:6S')K$N4F^Y6-ND,VJX1I9:)'9"I:D:B*]85&3H+`H8[ M>B2\@Q3Z.CHG,4M(N'OXVG7;$*V;0;.=\M[HM@(-N$H(`7;#OJ<)81$-+HF( M6#21$`RFLS0D"0T@?F!^C02RV>EW<"ND;5:IMJ$VQUX_=HL*<69 M\C"@0F+J72-`:+:\;M?K&SG]*M%],"V(7@^21],*MB`:B^M9%!Q@S"L9^#:$ MP[%3(6O?B9D'$E*9Q=*;JSF_VN/#UK#?,8+3$KW:6)[-&P]:?;=;$>RW4873*K:&/CTV_'6PI4=M=GN],U%8B/UHE?F M+R3$C7*E1;N+M-5QS26A0*TND%7YW9[G5@+"G0298!'U.O+YK)99>YVAX5\M M%`N(JB:O']5`ZKN&ZAND:D'813&P/#VD4,(H1[45836H(?CL!*K"6,; M"^[7##;!+`O/80@10+9QLO-P!KUAQY!9D5I=(/ODN/UANQ+2!S+B`I:T>ZH" MFKI#:[>]MKG!;2>[+[)MK.T>Q++#G9#?TX@*$D*CLV"&.X.)4*6?NH/O=EOM MONDH-],_&"]67?9ZO7:_'B_70%R`4ZHKAV'7:YL.KD"M-I)U0>QYO6I(/T>" MDI#]FP;&\K4H]FU>%*TNJ=4?&*YU"_F#L6(30@OD78^3VYBB%BP\PNYB``_3 M&IJ'1U9([@%HG?$AF'FO*IY>B5`(5X+/SH$ZBU)HG/7BD7Q'QUQ0W>Z1/%-Y M^0R6P47`(B)>KA,ZDS<\0KX$5\XS5[*=1=7L#[LMMZ"NK\;<9R$$NZYVVIT_ M7P005"VA]I^Y`KF:0!6DLQXF+T'<4:$.4KXCDOD&G`SR)Y7&YQZ[A@E;B1\( MWII?`+R["_PO%$_.T^#L";1D0F_2V8B*V_'*D=(26[:SJVOC9MSF-;SJ3I"O MQZPUR&L/6CVWVST$LV797[`P!4*OI5D9^8.Q4$.[;"RLD5_6=,?3T7MJV#K0 MUV38JF6=3J_7'_0/P_!JX0P<79ABNSL\ZLRCLR01;)0FN.W^R'=>??1&1)QO M@$C$6[&SM632DRMGPBO M4UYRMN&]`H=57:G7ZGMNV=3^`GZK3+/7&K3,C9Z#\:HMQ<+LVG!OFP9TO.TZ M4$(M;?__GNH]`_G(U^S9Y[D3#=0+C9%4^;0"NXU5:GU/P5E*EM`'*IZ83S7N M/?7Y)%(4#Z=&[4&O;1Y?_7/X_RQE5DF5/P-Y75!@TV>*"OP=4K601L'9#-?4 M?Y,J@UTMTG=ZAH56@3@L3]8-8J^[#T^&A/%%B[HU\_*4V\GNBVP;?Z??V@UW M^3J>:EP7M^FY[J!PXL=&MES)%!14_(+J?Z\CXV6VWOH^6'T*VOI=78 M`G=;K4V,5T%];<:M!9=^;Z-N'H#O_+7(.AK1;+6WJ81!_D",6*UGT(<9'AR& MD=(K/>CW5UYUV5U4'<_M;;3N*K"OS;E=!]V!V^\?E'5\YQ@\Q)W@3RR@P;N7 MGR%DN8X.X:6:D.4-S:WGZEBOP:+]+!6D5,/6WBR"N/-PT(>H3M"U+WO6D:)K M%@RK0[T&A_8%LYA!U>50<)_20&T]XFG'V[&^\@GWR6LZ[4Z[\#[5=H2=%O/= M!=4JO"^[C7X5(]#'U?:VTX*&58=Z#0ZM&[%]SSS55I-!<_K-UPAW/VQ2>B=Q M'>']T:U'B?8$-W/0RVD7)U630?O6*KB&4'4L-CP`+]]8K:.Q@K\/E&G?:[;5;K\;F+K?XN);3 MAWW7&VQC[I7O%EIS)-2\]J,Z7W@0]QT)\;8^D"+%_>4VWK7C;>:AXK;O6NI[ M86_>A-$OF+T.`3P=R&^O+KJ M_?_Q39B\^5NS22?/S>8WD^0-?HX=F;R$].TW?Z0\>?-X^:_'YO7-Q>7-XZE[ MW&71&^?'L_OWUS>G+HL<]?\XT4V1@,F$$RRX61ZM.20*G'&^ MW#EX@Z,DOHH>3I&3DQA).GLS]0V9Q6^BD8S?')*JWB-RKNA(I$2\.'A77L-) MIC2_E=!A:B_)\3H-R)(XZI]QKM+L5'$\QM*ZR)A<6\G=XESF5\H)*7[`X MV^_$L\$2ZU54(AG\=L\E_'G??+@[.[^^>7_:=(^]KMG;LVK3YK^<=VZ,$C_@Y+R<+KM8J596Q%T>Z\P!+ZEU@\$"Z_@AJS?"X M')NA"@2XX13@7Y*'+%!6G(55$(6Q:,S%3&_)QUJ+X#F01.,`A=;F@;:SE90$ M_5/:+)7[B+#HY$PI)!H!`L#Y1<7W(QKI]/'V1S$J_$"FIK M2E,=R&UF_F'90RFDD:HY4P)F-:(T@NEF,T#._,N2(VCV5\3GJS.^*TZ=&?\% MA1$R"D*94W`@('%0;X!6+,O%L?A$O!E2?Q7B$9J+?5@[5_-/86#G0 M71C*\J@B2)F&0!WHJB;@@BA(``0XE0X%[H(L,6Q#:(;)H8.!%CB$A4!8J$W? M5^_(HC`2@VXRA3@-8E:0KT.?T2'A^#*P".(@9YR"I,?J-GGGA1*!J#BBO'RR M0#ZN;HV?:6PE5R'3J`J*11S))A$;@WL!S@I1$+H:H2\8`?\E^$QIW#D)9^"B<#`RC1?"_&^O MW]'RR[Z%6$U[14'B%V=&`Q4&!10CL;*3A`P38\A^8H%,193!_`JQMT MU#0F4TA,C/@9P6$5"2F1R7+=2.;<7#8*0>7W?`Z4A=(BS'(?%I24%!%$S9BTX),DW1 M68-$/\51(0M,K,3*G[$S^'+T/M:*A[;W1TH$ M+*4PRQ!"Z\`K^Z4[L`N5%8%*)8[>.,O-=LP$$,BZHJYHNR1C_)C16<\%)6#- M>6=((WV:ZSW^E%G95^6CFA+06?()(GR9T%CIK^%)(68#+.!;9FA9=;_AH19MD\!E+C\;)'OCIHK>'C M,?I)&:.S\+E,['X,98X^4(?6NBLX=1TIA_`4<^XL)E.Y(O@\2`>RM"X[L@': MN.?DY9.&\3_W06$+8IJ1%_5$)9@+SZ*# M,2P-R=2T%Q_/.000)^KHK:#Q.H_6V_>@G81)JFH^"P,3DMT'KE:A;+4`\R&9%2A7+Z*RI5E#Y8`K$>1YNYE!`G5!QV&^%L9@ MW7C1,$@DP>U6.A[CHT7^Y'.\&R#C3!6.0@(]QBK1THI']$%+7!YGRT2_V$[J M>L_R'+/*R'"J=(J6+[F0N:6);XAH`-O9*YS M>EI7]0[+M`%%8U?G?6-HA!XG0*OG,39H(/9F1G@09TC7E0M4+=&:3"!9;&PJA3J M5F.SP**J6W,6AA"7TZ3@S`SF$;:`-8)0$3T'S?SS8H@-M9&$'P,Z4N79$XSY MU.ONC?QCG`K=9N$6,_7/S:Q0U45+FD\A.<404W6EI3IO@-?$86*@C#7&!!@/ MFN31M`Y_9T!?11'P=`Q).%?6MR;\>\3D.R^F1!SY2@5N!VJ;-EVQ$MX(':&/ M4AVGN*>`GZ;H9P"L0/B*L##5^V>95H$.KE.J+3JU<.ASM1A%=$)TY@'ASCCW M?18?O/2F^:VH_R>=SBOQ9?:Y!*,E:MU$8,NIDX>R_!43_]C*P9/J.4UNH@8[T<=/447=T(:]_9 M*?H)6?J;$4 MVA7!343L=3:!E%"]A:,4ZB/DA;@V7J5J9AK.AP_G MB^U%_2PO22(A'\]Q"*PG+(]M./G.(T8"$=97$PR!9R0B$[I427.6?\;D1/%K M8VQE45!F"_`YL_DBE\6=I=!DL8.T9+&XE('JZ&?@:9M3(\W'ES8E;Z<*?[[]0U?2\Z:Z2:<1BH#N3*MJF$\\XML>XDYE/4P(= MC"9"8K3837[]^RSG2$="V!B#+=OR*?=\?:A$DQ0?-H('K?A@5OC932(QGPLD1JXO`B;AKDRVQ^VM.S_SNF/AQ;9Q"123 MB!M_1:HPP^[>;GDL./LFGA(DY`=6$.:,_G7FH"0Q!1 M7I8L](5]RUIL!(>0(8=CI8"#*'"P$-D\R]LP*`=V@;[_S9>FH5N\#_@OK?;K<=]H6_7W?WPPQA[<.[+/!RC-;TQ% M7K+"%3`26\&`,@F0(E%2PROAHVC@Y,27XGX>O`;RN4985]&-$&.72`3UV#T* M:J!(Q$X:J$A?\T<3`7LF0H#28ULL;(#.@4%'CO\8VLL?D*(,19!XIC$$[7%J M_`.D&]LLXOR#?+QWT&\SDX/Q7&OJ3!4U?#BF%]&-3R<[,I>QW%:N(;*C^<9[ MJ_Z!_<-FZI`!J:_#5!-.PL/X;?:QC?,4&Z5,1$K--!7`75TS3=DCVH,=K4CQ M"@J)3X6/R8FFD]V\\32]9#07H7MM,R;DJ8E-QA8,3TF$HFUOM7TF3'!0)3/8/D>;4LD$X;Z6>NF,>:99$ ML<0:H!:A-%EQLGBJ*CFI5J,"A.%'/`U)5F`!H0O*Q>)%(%2EUG7B2R*ND[F1 M&-LS&4!SZV?0$(2:3D'1XG&(H71PT00:5IOI'H6KBNSF,WO739Y9241:-DRK MC)?"NYIN-O=LIM1I$`BZ)@2FK*5F.Q;WTH@]8&?7QAB#;%&<4V(="4.`+\JW M([6HZ\2GT6ZO5*P M/+\16H":U961H7=X+R(,)\+KY`#/5+#:-,!3=X'QF#`)*:?7*)SY!!/P#_N] M)4U*U>UC@4(5/0/`B-48L1:J$B=*'OE-P%X0M/J3B>WF8SZ':OJ88H(XL\FU M9;R5@N,YH>)80C$\31&7TB-X.Y6*MR[)I*&A2V>&6,/)%K'N)K_#'K4^^+P9 M&/Y=&%CL)#T]A(_;P+BU%]&G_'FIVBC2U^JJH-HL[(*\T1Y&)D3,]`P5T(P$ M.N>#QILGWS73(Q60J\)W4_?L!-O]3863>JP+GF:,TPJ==/6W4^&GXGU*8B7D MA)1_1[",H)-FYXP6E&V$@(Y+RS#*-B9"!G>@>NM^%QR*Z0BI/8"0;,)?'J;6 ML7Y%47FA?"ZWPRP@%+`1W^-D1/)#J3`S%WF)'04X\H+C2YX@,W3-(9Y"Q&9& M;^4]EQCX"5AOHP0KFU_D;W:.]=2B2+,E%Z#$EJ:5>>C.,-.=U*@@Y-!\S"8C M;0?HAKQ+#E7B6$O-ZD>4)90A0_KEIMH3!TD82>8.6\YH^!V_)!T;@!,+,>$4KECKZ9QEC2_)Q+H$$X-F-0?6-_F!SD8R;!/CW M.*PE/8>ER"O43$W&5*8%*5XK,D"I;9Y'81X8Q9?+$P%5>AHX;,O2LEZS`@0/ MKR5P9^^O1U8<6*>^@&'5\#<+64.>#6Q>:Z!1Z@2_!VW/!E?&R=G1^:\#X_WI M^7#XP;@87!KP]Z_G9\;PE_[E8)GIW5]XH.P(B"7VOUV=XP8&GP#5@^O0GD\/ M_`2`QAWKA[1\+*^&:U/\%E4\HBZ M]FGI$N\QX^M"#$@_O^ATXU(R()39.@W$_;18SR.F[Y>[Z2MXX=6,""NC$ M4SGNH=60-O,2$+83)*7IOUH6I_,L32>?RW'JVN_8,["TB_9"L/<0B[Z/P\.OEP.^O\`T!R>'`\^V3>!ZWPV MM*C-X@A.;H.-;MD&Y0Z^G%]=G?_ZZ2^3.OXOW=CIX.M5]N5%__@8SEP]7$?, M^-(_^L?/E^??SH[Q%,XO/U&:R1QUY#A[@\9IRT/[_>3XZI=/#0O(WEQ[YI+V MH1[*!:/*U5R=7RRMD-]:6B(^6E>PA"%.P,/DC@'0"@?UW)H#?8J=51=GM0^K M='&6U:GBM3&9.3WY^>S3F%3VU53;T,?EA[?%?:\PR4UCK'JJZ;TL]#XXZ%8* M#)K51-]MPL$>U5\]JF^&X??@=?&J^6.XY^W/#3DODK>#BN`$MZB!&A;HC%1K M9(_]S\SH\S'0>]:^Q]X]]E:>=^<#)W;.MQOM6KO]*EFWW-F686<4Q'$PNQ]\ MI&WNH",7M0Q`1J=0Q_!8,ZFAW?I>TQEF"V)\%WJ"T.5[+53=7"UW\#7+]<]V MQ7<;SBGHSNB5Y/V,GM[==8]5W6J9G7;#;+2MMR$25`AD5O+X/;96`%N?'35U M)&V:W<:A66^W=Z*ZMVK=URD"R)V](!&`7%PW>J$@O7:`$7`/M]=,)9[MSEX- M3W\V,G7VL?\VA(AG@]$G\&>_"5'D55U@]068'=*7/^FJK`RUNSD%3E MW%^6D$`]Q0\/S4ZW#(T#>TW\;)\/AM\&QT3\Z`E2\`GYL M7%R>G\'GH\&O\,30*!,:]T3J\UE`Y:ARO59U4%)-ZK&C"`$X@KKS@+:(5)D! M,1<+!T59EU2@`]QZ!:@8=N_$ON!`0;*JX?T(&.0<4_DOL_K:QVXT!FZ:["!#O03)6ANDD]^#6HA1)[_UOYP.AFNBS/.X M9A^/*=JMJ:;':>E]E?S]:27YJ>)Q<-[T&AG22N5Y]@SINRUYS;J:[]FTQY9F MR&NT*6)]67]L52#9(@GO8^MI3R49 M3`^T>#V[X:6EVUVD[^45W=0&F-2J+"99]5[M\)7=T%*_]2VZH_9\ZVGYUMJ% M&[E.8B;:;97-/=V=58>SW7UC7"B+S=.=SKUN)./=]NW.]8;9;=?W''*'-[YS MKO>$YUPA1K<^:O4:JSP_V\>H+>%EHV6V6JT]RZTXE*UFN639VG/2BG+2:GXR M>J9UV-[SXCTO?HN\^"5^,JRN66_<&[.QY].5Y=.7JEZ\22$=P02+.`>WJMOL M.ZMNF5:[=;?38@OVY'4!KCSR93UCS=X^O9<]GHPR'NSEF)^#M^A%U0GC:XL;W]X,;^;_V34XQM//AZ M?GDP[)\.C/[9L3'XY[>3JW\;P\'1M\N3JY.U(Q\KDJA24EAUJ9N-[8:(C4G: M.4O0E1M1>N?&K3"FPG,X_'ULQ^(Z"-T_,5\S,NP;V_404@XF07B`G:&T-TU^ MY4\1!J:*I!34HUQ&P,,N)&PMC!/?#VXX&07U_G_AAPMX;&:/1<)=.8^"R M%1AW[:8MPDZ#28Q]1;FC)R=._.YZV)HGQA%^[>^\B=P#P>0$#WP>LT6E4:_W M\')MG^.?'=6)>I;F!-G&?P,7-H^MS7#'E-U`5Z/=A=9P>#;#%`P@[G^F0V"V MTQQ.Q\<#F@G/]H-Q$,8N7K/M!=>)4!W>!#>4C,1W[!/L+*()K"H%B&`D(K@B M_>*I@S(U_O.Q%1O<>V0%3W- M$>VO@+6_(=)F#SY)[L;A]BGOU_[)I?%;__3;P/AUT!]^NQS\ND%B!D>%_3>) M8G>R*`^KUM2F#GQWV"#!TFC6F[4N2E9B[,[@?D'W@U\],8&?>EU^1OUV6&MM M&GU>6.!::+N+-5]I&5DSRN="],N8`*+E&)OZD9F8T/TJF+MCH]NH*]3YVA]^ M,;+<"&.(>&2'3@0C.VES0]68O#\\X@\?3(,_(/0:!+[&K[P$V5@6S;T90$M1 M,1L&UY`.Q=E@DBA'V#,TV\34%2%:DA?<1!2P.D!T^Y,;+,(>YX#\F&B"C_-B MJ5NC^S\D1M2[#7Z4QZ,-7,..B-KHU]1V.J;OKJ>`]FHJ:OF8^+:#%TZ-T(.8 MFJE2WAZ=,>7+<)X>TS\7N0R1&)MH`-(KS^46I&1CY/4EC&V\K@66N[ M21>T$AC7`;UE@"6\RF=W,B*HEKJ843+&[K!W2T`O'0K:]5IC!13HB][2W3?@ M[M>Y<)GH_7`$S`&X*D8AMW8(JU,`;ED-_JV0JU2R9_EH8<]EM_$7J]4KUV.^ MGL-Z.C`(M[>^DBWI%_28G\=V[F. M]-1!+@-HI]O`?&7;`U5V$@8S/'60ZL-@A+HK/#!:Z#&*KYNNP_?>JG7IB>Q]`^`]G M)KVJ^"Q)R\8,-F&,EF`Y2D9H.HA=.EZ2DA//HU&4V+R\A-!N;UJU]!'P1E58B*<$FN3ACD8!$P=@EX2"M871CAR[!"U=%BLC8+VQR!SPU0C$G M]\&U+&B5,T.`7C!.0'*19CE[AC9*LNP'Z('`.C$YGT!JQTBW45SZF.ICR:I0 M@#>`A[D]Z"<3A#.8W'B/U=.DEP"6*7>9.MF*Y=_8A@=OQN[<:IUMC3TX&E;:5E$5RF;H=LW>89TNY]WAH6EU#M=-*##Q..<,/][" MQ%-5:N`=3I"J>?;QS,9V&"ZH+B'QO4C>.06$O^!L*2LK^A`="+!>)/Y9K/0JB.#JRYVZ,Y$DXL`EDE"H@ZSG"I-:E MW[D"[IT2PK#Y:%N/%D@W=W$YN.B?'!N#?UT,SH:#(85KG5_],K@TCKY=7@+2 M&/WA<'!5C-AZ/,5[U/'>)11LO0:EA$$JK9CB'',J&32C#.>KJ]QM,T1M%=WC MZG1Z;&R[4]:I847-.DN/6VTU>C6]/7I5*]A5H!>%GO*PJA7%TP?[ZE42N='] MW=)N765`-.ID9#,:4JIM]NH4P6QT:O5-Q-JU\7:]8._[K_O9\I(.44&HPMV7 M%/C:*3BL5W%O(X`I*=-W%[&_#WPZ%2(65A-UOCV\E,#+T].5YOV9<\^5X]S9 MDY5M@4EY$OR=T,(?MYNGN1=:UA!:=E/:6^VVWMAIW+@VK664Y`K*:L\8?FWRH@G%;K8IR8_ M1J-M-KK-O313*6GF3C=#:*-KA'U@LYD;D>?;=FY0)GE`E8F]4++NV3],:EQ/ M2'EV.6$#4M%LF^WZ1N6<]_+$KB%MB0V5F/KWTD&5KZE"GW1,W\L!E0*][''R M:N_='Y5%]=?%^ZV>V>WM>7\E(>V)>/^;]V*\/4&@E!3TS%:WO9<-J@>-R[Z* M>^..=B8_/'6MO,J($'N?QKT$I'UH-EI[)T7UX._%."F>L?QM9:21"EWTDSLM M.G6S<=A]D-."/R[7[WQL^'@N%OTB#.8BC!<7GNUCV3D,VY]CD/O3QIUWMU\D M[N+R_&)P>?7OM"CG!9:(*R/;&T=SY^G&#F*Q^6Y(%A+J8J@SA_FZPJ_WP=OC-CN5+UTQ#7X\.#J_[%^=G)]]\@,?Y"4\[@,J)NBYOJ`O\^-$ M<1CXU^JO!#^4!%8G*0SDG]\`4BHEU3=JO3<`&E@ZZ>#W?.SDAN"2E%"+Y!'0 ML#=+OC+8*(^C7A-$]O;%RM@7RV7IZS"(]B%(E7(TK.&&?#[SH-%H=T2\0V&@U$W;TCL(*PE#W>'X^3&97CPG)`\U!@?3'5 MS\.>83D:[A.R5^4KB]\O-I`(Y/N6V6N]_*BA/7??J^=5O[/GPW'+;'4.]V)` M]>#LX7!BW.$DVX<*/;>OYPV&"K4:9J?>>5VA0I61)BH40;(/%7HC%_WT^T2HT`[C/AXUZO%=ZKR*_#5N[9F<"[3 MR,`NJTZA7JM);RW7:%UJ_EHHW_F00*ACOH M=7QT!.3D:@BX_6]L>6P:/P_.!I?]TR>.I^*XH_LCC"0T5CZFJ%SU2VIC>'E6)KZ;U7Q? MKX*BHNIY4D`?M#">!TK5W0JAF]6D/DQOZG(W,=BUJXN>5E52*)[J`LMC89[& MB/9&6>4HB.-@MA-N>2JNX?(G0D3&G(77K7+-IPR$J0ZC?(">VEW64Y\YSL7H M=-MFN]G:\]:G-G)ODQ\^)>)5A@4^`.^:SQ%]HB-9LVEVV]T][WS!O%-:?;!Q MSIZ!5I>!5NF38=6;9K.W4>CHGKGNF6NESOGAS+6:GXQFSVP\:7&8/2_>-B_& MOG38"77/B_>\>&TG:Z-MUAM[17?/B_>\^'F$8:MNMJUM,M[/A@P8H5MY/6Q8 MW]7+8)'\ MO-&JF\U6;\_/7RD_7^[6_K/P16A[.V/M3YUE\2:X^_9=7(9E-AN'9O?PE4=D M50H"GI1+/S4BOF)&O2WT`Z2S&BVS+D7CQZ0&[*;4Y5JC6O5'1:IC5/KEM\&Q M,?C7Q>!L.!A2J<_SJU\&E\;I2?_+R>G)U76'(>J5+F#1JL:%O(X(]4KE?5:F1'RE`]2;547.7N]%X>8:]_.,\>=OE0_N MT*1P&2QL#],C-_#85ZFD1H68X`-TE%[EHL]U:V(7ZS!U]QRTLB:$^[G>TQUS M=1C=`_"O\3PU$*UZ6EU@SS=?)M]4#6"PFSK63-A^.<0][WPL[WS9GXRN6>_V M]MQWSWW?'/=]:Y^,@[TL\()E`5EKR+#S^6A[:6`O#6Q&#@[;9KN^-UWO6?^> M]3\K'O::9KOQ;.%T+XA3O]!PNG#DPO:I\F$DXM@36&OP51O"7T;HSFMBYD^H M/[Q66>$9@5:O@:L:V3VV-'_MT;$H+T?^>&575VT9QNATVF:]7M\++*]48.%\ M/EN:&[RLMO'K#V/;"RX[I1Q6KV[V#JV]&/%J#!!5C'>KU`V\(+YNM7HF\/8] M7W^E?%TY$`;U[^_,CZ MFMGYXU#4L,Q&HVNV.LW[V#)_W#3[KP2B-A_B*);'A!S&VZ'&2,74B M3D)\9:T.1#310MBA_'4I:>%AC8DV["^4ZU%T+$9E?8QVV(/(LAZ7VGEV?C5( MNPV5L9/=P/)#^V1YZ[46T]\Y\3.(8&A`J#H*9G/;7QAN%%$XA]&K'P"`(A@* MY14RXL`8!6$8W!KOK'H=S6TZ\%Q-[9B?QQ9:`9`@U[<];V'`#3,D8A,MVS

(=,*]&ZT#HB%(`F^$6'L(I@` MHLW@B2"4>+^,[P]`/,3Z8SD8_6/A3;A:^AM7=M7/"V6@*^!#A-'((.KJ_6*W#S_CV;(:. M^1B9I!W33'30\/@[JU9OTW'0$+4RGKV"W^9X\A`'Y\U&V&PP7B#)>&(NW7@< MEQ[^TK\<_')^"H+V,#L_X^0,T&,PO#*>CG%O&X5`S7:".@A>'*.TQ8`IH>.8SAJ#7KTO$D05'B!D@! MO)/,8:4T`$RN+Z?O18&)?!2'G(,4[@9)Y&63J5EXR""<"+<@7O\/1`6D#F4; MR,_D&4$21W"$Q/'4R%/[!FF;\.6*95M1IU8I%E%1SO5P:/H2V* #$%]$S< MQ-_A^%T9YN38*%"1#(IW)^^K!$B0M(.0Z(@Y@`*NAR>9$;,@616F"JY]$O94 M9U@7Z+$(;Y`U:-`$9-H-:'TSV[>OX2_@FV1_H)?S_!(X:`:@+JR1%D^#R!F4 M4&T`A,X,%)'4VXO5L8!.;%-[*%$)/E3>L3]J28/PD\ M+[A5AY,[5HT^X>9@E]FEU32Y[THC(<"8(A?X5WK70@!(("UO+&!((YAD"$TB4C2,+YX]_N-@.`91!N4I>OP`M#,L3(0P(#P" M51X_A;];@18RY*(@I@%B`LA$R8R1;W]W:RSKBC#@5\:``6)`7NK.H\-&&R_? M+NTV+*MPQ3;<>C[&[!@)HD"+F"L\QWAO?7A^I^9K_J21:J->J_^5+RX4&UP= MN@3)^GD3>$")/5!1C/>-#^5&@*?=VO-_,KJ'MI M<\J#'*ODZ[7TR]T:\S!`\B%%$;T\9"4=V]'4<"2OBLA.E81Y.Q#(.Z!<6+TN M\%14X<=)B"Y,$*^=@`:B$>>@JY,6/;<7*-\[8NRAY34_08T,`.)_"0U@@CC$ M=G46\!F"U<.IY>E/$0:I!(Q2FJV)2UL[X\:VSGB0BI8C\JK),YVZ<)PA*B:T MU=`5:#(T?LMX#+HOTE=*'S>"&S1'*O4.SM&%\\`$&JEGB(P,3)"PLHZUY9/: M%GTVOJC-XM*_U88UXRH4=I2$K&*AE0CTUQC4VGB1YQ(L6MNLCY(Z%L5X#*G$ MG3\(:5152JY4N'/'\HQ^M:5X^,<8)I2.*DT%?PI'F8)(GVQWS<,FZY.,W>I, M,B=49@;3#`H2Z27DE5I/'V*3L]9:;,OL-.KFG8L5RO98N_,>GNXJLZB/3[=3 M-Q:/-L>F3E.K34=7+W>LO&O5E?4Q9_4O<6KFG`)(=*+Q5#B)QR=*"$<>BZ(# MOR&QSB>'"!"F/$K"C;7_NFT==ML'6KCLZBZT[.9S2//_['D0?8[*+)%V$D^! M=_PIK1L((S9QCXG1:=Z`S4 MZFJKVDI7>*\+)CG<@-RQ/0)&N1(EV!$&/ZKQ4:J!LQ.P"RD1(?5IMO.VMU#, M9`1-,UU:83E`M\C(:H\U<[\/(T>1&]O2QAN*.;!L-YJ6W68`!-8FXR^M@QT1 M4]MAT[X3VK?P[P#^-5K0Z^\Z?_ M)LXU)=^B]=%9&+QHAE&'T,!%0/Q[,/6-+S7CS/8#XZ9&"Q:Q2U=^)<93/_"" M:X`BTSCQQS63,(E>-(X!>D1LG`7PTF]`M]KU1J]I=8WWPX382`AC)6%L&E]" MU[D6\P`_'UU],(T(F`<%$@#-&0DON*5+<$1LNUY4SGPJCLXOB>[\/?'AY#N* M4=^+RR8ZP-U(XI["2`SWB"/B$2R?*C\U1HU,;6^BGEB'")E&L].6.&?R8)F& M8BIZQ#-$RGZ/$_!>#GDO!:)#T2!62^VS3ZF'P-V8[%TA(L,:6(_&?^`K#!91 M&T3.:4=_,%(3=6))";=`]G_R].4!LPFDW&H[EC2PM%IBJ!2M[@6D("JOJVK72]C;1O/@K?[0/&/4U]72WOHUE31"T!/1S;HXL58*:GB$[)C=*=R MLDW<"`T<*O;A=HHR#AN.'"7AE(0ID!#SO)TJ56-Y#0TK9E:6")):C1#]H;T82O%6IX!F]@0FZ(IBGFN MG^8>XP\!.<2U+.0'T+U5`%QEY+IO;1LCPF\!"=F,;%M$,!UO?^$@-TE'HP=C M'CSN>0Q9-_IR"W8_ULYN*&P70S:*ZMI]D]&JZ'V49*X%@5@J:V1KUH64/=1M MM,A3%V[.X>B.G8+>-Q214$CUM!D9"-<%/;QUAL`1:K6"U%>["'RY<-+,9P"_ ML$0)?FBOMANE+,+U*<3.*K=(M0>,*.)-L+19R$O@R1(]6& M1M'9]2_!+0P6FL5Q<)EL-J%`,[D:')3\7T$22QZ[I&5IYUY:6M:#_0KQ]B;6O&&]OEROM^77D7@)JC&&9 M@=+;2%-:?F<]PB#LRAFTB:8BURL+@%;4E*7E]P>.U(K!@" M9Z:[#LD8RLF:J;,3K=Q3&\A&]K:DHD.T+1-Y@N6>LP49S<\V'5+BPX%YY`VX M!OIBO`=HB,C$HBW1]:,X3'",V@-,J>OIQ-71SCUXS)YB9=,!:R8.6SR.R)L=(8$5B\&9WOEOFMHGU17=Y,P4HY&RE:AE!2^G946!XU^P=PDV5260;0*6>4F(O M6SXHV_+PT+0ZA[N:I"41+1$EE9<39:P MN'8R8BZ%$55=-Z8\CK[OP"DBJQ;^N+PBP0[S&%/@\.RT&_+7R^Q!J[E\`FN] M^+CTR'1]1^=G5Y?]HZMOE_U3X_S+Z1()+L[8,3,_F^`47,'P2VJS5$RBES'M<.%:?SVVXG) M1L5,WPQ&GGO-0J-)X$KP'+.GC2(CYB1;HF_3ICPT*C-BRG`&P.5DCI_?6;V> M6:\?RNS\>M-L=;KYK'HTBZ<)5&F>$^?7H-I.9DX5BP&/PH@M+F'2Z[5UW.98 M!J!27A2H#;`8@>LI)"]W:JP>N91Y)1?O3E"H-J5V(-V]H69G1550[MCUT5)! M4G64S%$ZSSP4V>)SQ`<.&M=7MC0.=(?U6-JZ?%#-(MOC'[))YF&`Q5@B2II; MV@4OW@.%RB<5;_D]M4]]:;^++.1.F@4U$&`_S*U0]Y#.51`(5^Q;'QR@H-5H M,S@T6^W,%*Y/MYP%6^ZIX:H7^2C".RO*5"5G:6>4Y=':S5EP(RNR-$I"S-*, M2,%4)0M.(MM<9D5CQ=]W/!!I*CN$!9\*E0Q,&J$*X8H8X:'ZOZ(C;@ M!`4SA$(<4&6AX@I0DZ%G9FAML^<`]/,015-O`=H-PE\PF:"U(9K;X^4Z$?KJ MR.?F`M1B[`:%MP,J1IEM4@54\S M:Y?&)6\@GFPBP\)SF!DDGJ/E>M..OU.X.2PX+8Y26(F-A"5-D'V(@O]VD2-? MOZ<0KUR`TO@VX%MFH!23"9,DXZL8A32$$H\I"SPKUZ,#9Z:5$P\@>YHJV05Z MT@2KYQA'(.)Z01P#G)P=Y<*9-"!))&RYD<)3F6OZKM%9`:AJ`PRFN[R'5(9S M2RX_->BN(>H]>NXC.PP\H&X&>^7@;,4,J!;K1K+$#-DR@"_;WJKUT8>:\?X( M#WHN2(#YD'_$37?P,=LT6Y^!!,L21(T>@DB]33DQ$XKELLG/X=DN>2!L--$9 M:R[:>,\[+SS.7WY0=L-O/E6A(/-A9!S3...8HS)3V$B_)A\?4'C;"4PD\H*( MW]RF^#[7GR`33ZV0F/$B?QICT@H^.@UFP7@1Q<+UR9-D+R*V+$1"_,%9TR`# M(;HX]@S@%7Z=)SY'FJ;?V'$?91FD M?AS,W'&D!I/OR>$*H8Y9S2$*J*O#O]4\#&N3-&4+IUP8:7"P,C$'">[?SX.# M[;GPHN_:3-B4?1K>88&18EG2<>7Z_<`_R($+*2T^UJ)T"N:_W,JMAEIZ#BP9 M6I$V2N`T0DYE0+8W@EOCDV=[A=SS2.`%B>(5J=I*!1P;`VJO;91\*%G:8O)) M3K(['\F]$V3OH`MBRAWBEWRM\_G+1?]$_=6%K2=S\G+' M5+Y+(VZ\WT(D;P;)L.*N*=/4;!"PR?^(3BQ?F>AX`),JIATJS,"7$#-=MM<[H-HMJ(LF8!-WO(BE(1_]DO0J M1SRCNBU7JLV?OS&N:U8O'`!Y%S)A*EU<0,XU\DUI:Q3%)=+L]!1/7PR4EF(5 MPV,T#]B60#CMHG9]*T?/BW)X,IS/$/A"46!.I%$,@D$2!H++GE."&LPD"B>E MO(9(+/0:-?2RBJ_&+>`XJ?P^1:5)V=&IG`TYDSG2XO/'@3]Q4<6]UK!.\[(`WW)GD8+4',1]3VE`)4'?8AZU)T8<$Y&):(1PY\-?^IDDFVKZZ2!I M+)-F!Z%X#/^:-7\V9:*9#1$NYHSC)%7MAW8XLGU@(>??/;$P^BPUP9(;QOOA M^;\^%"A8JBVR'D"KFP2)3[:\$7M2V+D2*#M?;KTZ>],T!U]Y?<8A2]>P!A(N M#71`>.BHNK*E" M75(7NIH4L?[JZD@_'YT5D-C@*.0#[J,B/@0D+'[X9B\)1ZB/.0^&Y M>"YXPJ$LY;GB9,EB+L$$HUED<$&,<6+IA8U33_'434N-*=`D^%5CO3CZK833 MMM)Y<6]PV8"N@59]?*T[5)?-Z.+ZS/-80'*77YK8-U0-FB,G9E)_@]O'#-%L MM#MQ*E^/,9X&R?4T?STVX+U#`@5RA7G`9??8GY+%/\E=ZW-DX@Y&2F%$(SQ$ MADA%T93LC!`J44S*8*VE-@;8I91Z(99Y6%:XUNSA3UO%0D(S4 M%?V9'ASQ!-0>*FMM>PO,UB)/PY_JR5$"R_0/HJD[B:7QV7>0?F!54A6N)DD. M[&]ET7NEE>/,:9D*I%@1"0E,YZ1&E])BBGE,-TAFO$P[S)-8754$TNK MREF15'3;\OT@\T#M*UT93DXW9D]T+6$%Q3;(54[WBO_(3:B7UN8G.0J!P3NY M?2+MEK'#Z;RC+-3\0111U1:(4CDP=[XQTR:"L``D<\+NT!43O'LDQ&75B2]) M\08)C)Z,%)@,`\\=NZ!2J\5+DY)2L''9QU3V5MF/64!EZ1+C&F0-?QA/L_OD MYSX+6$+%'9'4'@FF3@%:2^WPFL-;JT]'EI6I?`V&Z+XB#,:!H?=99^6*H$T` M[GXH4ZITI2N/+[I?N*36B$IA9T6%]1-9D(G$MHEQXU*)*S+^XH11,LH<(O*/ MB0LBGTNF_P33&K,R]YE+`X%!'XL?P+F/TH8`1X$CV%'!6AG+>;,`31ZY0^30 M:`;#5!3(>7U<8K&PH[D]EJF6JPS3]YT1,_I*'M#*PUFR@MU].%REB79GWK$] MHB;%O>0R>3F=)@L44:54R`N3Q)[L/F)\!87?Z![\`XD42?QI*.IP<(2TN.Q^ M\(2T[SO+9LI?0WD&:*K3:JC0"4QM8`-V>K3+-VUB&"5&-DG!Z6B*]')`Q?(1 M535XPWMY6?+W"IA/3VP4HAX4D_RG41^RH:6<6=78T.E37\83I^(`^CD+QZ-F M40Q$9.8E5)Q#`),,`G3;+A8"EV8;;57*()LNGNWOR+U5D9X(#:6&:JHQ`086 MEP)*Q+LN9,$)WK?@C)'@-K4+R?%XQ51.43ZGWBLS.N'.,%.-\*NV(ZZS>Z!I M-$LJF%$!,A$B$5(M3O`D=()D2BV>KUZ:^A0V+N';+S+$ M?!Z,9$OA-Y/_5L)PLA2H9&?3JR82KE=(`))D/359Y:LLX:/Y.DM%ZK-.A$R[ MH.]D\6-+L6,8%XCQ?^E!(E-9/O)BGF@1B;-4N03D2E8)4,*3'>ZD0Y'[1!F4 M4\+J?%K)BT]H.5*]+'Z]#NJU1[E>T52(>.D:U-XOR%SG5D=D.&=O#YU&F%JC="I,3T11;;.;SN;$ M*5V,R2"1.AL_L^]>VQ2LSXW*\*0_ZQ%/ZCENBD&0K```=0H\B]1-6&[O1=6- MDN1075A@://,C2DW'3[/9BA6H'4FEDXNX5^C:RVVE2;LAJD];IU<@:H2U@M" M[2PU"[!!3TPKN9NH@)]$0"+4!%&<$@X%E3"M4%QX'9:]"DG%QU;K+-.]N7HK7T6 MC-7*[`?W'(ZB7IA_KDT-I;E MR0-(25M\-J7RT:7B,/G1&$\Q,7:2>,8,9M!TM^L04Q=]<>VYU\)/TXR5HTZ- ME+.=L\V:`T8<$$`Z]FW1;A;VA-R?1W^YO9"V304*U2@ MC;8V9B`L):*!(Q,2R]:3MJ@Z)0VG8&Y"*[,W+$7#;BS@![.]*9-A(@T MG(&0B(!9.M7S[G+-&JW"'=(5P!!LG<\&R7E8=!]03-V*L$T2O\Q%["2$LVM1 MNA%=+0:J+)NPTM3]9*E[*)P,[TN+$BH@?/EQ:H2)[P=1DYQ@,I-$D1F0F_-6 M`,(_#LXJJE^:/"H+)N"5E]]?'E`S!Q>!!"?[<=(`QKTD)!8@>.A+4XIW2O;T MA=:,BR3$%/VT"GI6N4/.0M4=5$$1>"A5WO2:(/AF*JTZ@H0$X92X4NXZ#/:& M+%=7K?$@E"V1;T6KFIB2&I16'$$4SIY1;5`Q,0BP-*$0355]>;D&K7K\_;M. MAP;_D&F5:36Q>S)NKW+GF#64GB4Q5IQ0O3CEJ=+2B/_Z?)&%B@QY`C)%4QM^W,)_@OXG/*2\AR9G+#7G5 MUGVN,ZRTA@A3T-:IGTGM=]$DFK@X>@@,"*G M=B18[J12/#$U901I>P($3F3OX:VD@001EC)/XMQ8<"`S6"=2M!$*\9%2^M6# M%+Z,V:1I%L2MNVPX4,-)^V4QTR*KF:-=$06<4LXMQQXD#&9TBD#\%)A1H1Q4 M/E"B7X:PD@-5AU]JW4`)CS5<6?.FO&7[%[YA:IZ9ZT4;Q>X\D;A"'$;)(AR8 M:$JY1*8!I$0=DW]Q>AG!H]P9=&;9_4C[4GKF<$+S9.2YT93",?(/"[CI6\R" M-,DIZ5&G'-1^0I<[7N(VI;*!I-U<"E_BC#'T-#B9TX$P537"D+3']F;D-!78 M&M3$(X,##CB(GY.9-==.[N$/)O6J1DACY@W3<2TH8F(+&?5(M$;3']"NDL"] MX)'!LTD6AI@8$3 M/H6N:[`>LSO>U'ORC$4N\TK)HNF>"@GF),&,*2M6<\4Y7&(CKU_^KJIB98.5 M@RF684U0\F(;,E;?=;8+DH\SL#Y[$FQN7;^G)@J$G;$=AM@''(O.Q7I!(A!F MDA#MYAI98NXCR97^!%PH\)+\6Q2F0:4J`IE%"T!@^]<$O3;`72S)G,K"DV_B M+?K2\AUPIB%0GE2^RJ"8])(QJ2Y2-2&&:]\R,)`\PF*_%$`H\<*F3E2@70J5 MR53&J-+2DU1UBW1K0E[R(2:I1<8G:H_*D0R(IQU]Q)W3M%P)FEU56B*ZQ'N4 M][438+V!A)L)5>$FK(RH*[LAVR\4'.@%*@2$`,V',F55\3'E2/&IIS+Q)"(0 M=BJQ8+,'$:9ISEG+.!]VBZ5FT5N1$@1E:J=*#8G'.FR0E:@CMT8T-298-EZV M)E%Q9F':;:H<)[(R/@\KR$.U?$`H_\0E:X=4-NB$HL"N@B&IH/WQF%3H"RY@ M+E,N8>P^DZR!(C(H-5%AGV_#XQ^6*_W\ATL342VO'\CV,0-I[V\_G)Q]_>$G MRVJU?_RXG84\Y9XRPP2:,P!P[;D;V][R_AH=J]Y[B3M$=2444ZRIUM#XW'_*@-^B,3$SD!""IA?`S$ZB=4(P[J%OS_CQ^S;_DIH(W:,\V#IH5#.ND3 M/W[,!OWQH]S9TBX'S[9+EYLHYM:OOGO(^JU_-IY[_7!!AP?-^H;K?_[5PP5L M=OK_AM.O`(Y8:^"(M3F.+!.DG>T8-B9(H_GIQ^^CT'/<3Z`R4'SRKVS!^N]$//^ER"!!*7#^/]>/'TBE^@F.4:Z@0 MG;J;N[_$^^BG>[F`O9SX1[R7%WLWF!R$`;#")AM1]"(OY5)N8B`W\6)OHTQ* M?(D7I[SGK MD]&./<]\DM.N/[?.6]]'DH1#FI!>/T1J^1]Q)\_XH/R7.@=+QCGQH2_<5%JR&F(WL*_2)C[SR4U MA$!/7W0FXB-N7?T?ENS==!V>/1)>"L]WO@2/_F!\W/IZ-EC-QFN9N-Y_SMIY M46G5D=SQ['9G7W_N1\W,G:2^K+_YNU[8P3H>N(HMK.%(ZZGUT&.Y]]W=KF[S MM3T:CS5)^#?L@7@?25GQ_/97\;`UE*Q`$>]^F%^)'8[5N/#Q'LHMG_@XL[F^KLI7L_<5V7S[ZH'=RQ M_MSB,7P["<>XA)GWB9I&_B#\@V_#HI!4PK765\C2C?Y$V4,3#!`/;FT9!_[. MJENFU6ZMZLF[E,+[X\?WS7:&-\-W>Z-HUFV^PUZJIQL)W$TR#$ MKFVP%[/5Z*@?T@JJCMXT^*FVVMIPJ_5:O6[INVUP:GG);K&,6!6V>KCA5BUN M*Y9MM=,NW:?6);I\H^OV&7ZJ`^EN>""ULIM?=?M6R^PVZV:CWMKH<.#UCM4V M.]W>_:^O!```GBT` M`!4`'`!C='1C+3(P,3(P,S,Q7V-A;"YX;6Q55`D``T.[MD]#N[9/=7@+``$$ M)0X```0Y`0``S5I1;QHY$'Y.I?Z'O=Q#>E*6#O_NTV]Q'+653`L*:=2;1,W"<%#1'1E' M7Y0L\JC0V"ZZOOK2Z.B"&8BT[)LQ47`8-=(1$;9=4P[SPF"S6R'DB!@$UH?X M0&N'^"Z?*#;(3/2A^4=T?'1T&A\?U8]KT7@\KD$Z(,J9K5$YC.+84N),?#^W M/SVB(<+."'VQGQF3GR>);73?4[PFU2!!8R?)M.+^^W=[>Z[R^;UF"PW&)]/J M]>3?KW==FL&0Q$QH8^D_--3L7+OR.TE=!TI`1B_6L$_QM%ILB^+Z<7Q2K]WK M=(YHG_$%&/1!#H89-@(#-*L),(EUUM')27VNF36\ID=^:?+HD_K9V5GBWL[7 M1G.I>:H^;_UC\O#R66VV@LZ3GU';O0=QE>30@7YD_[]U;DO[(+$-$I:J_ZXD M+88@S/2_(=)K@:TFMZ(OU=`IN!^YCIV;20X7^YH-^E;2>SWE#":<%=\1T^+Z#"O0&10CK%M1UXJ^XZ1LDR2E5ZOHES6W*6$@-I MU^"OY:-;_69&Q`#TK>@:2;]GDJ<8@:[_Q[D]V52(3:#\ZK()0_\R71)N)V`W M`S"Z"C$6#89S^2*/L.._E8-Z6/FJ'NYSEG=C=,\1"AQSB,YNN!Q7[O*9X=WP M^(R/'X<_8<]!=XLESUV@A4(S5O#ZQ#AENW7F/F6HRF'0V8>SR8QR;8)'HAJLM<5MD,)L(*2_W6Y5T$\ M=U;"K:(]_U%ZN[/I7^R$\IW74^6%"9"#T`[E,?JX'*B;$0671&,*1"85G3JL M@14P'I2EN"M*=="((Q)1`M<1W0;EQDT%L>FY MQ6!1ZCD1W[Z](4S]0W@!7X&XHUM[.=WP[G73WGA)"PX-91CE@'7_Q)PUQ3`(Z=.1]]Q5@E:_`P.&6PQ2 MQ5'!M@1"";@M;V_?1A_XO,47_]_\Z^AJA@#ZO_#)`:8@=4"'T]8`5C.9O MX]C4HZJK21M#[I)&UL550)``-#N[9/0[NV3W5X"P`! M!"4.```$.0$``.U=;7/;.)+^/%NU_\$W^\%W5>,X3C9WD]3FMF3+<;G*L5RV MLW/?IB@2DC%+$1J0=*SY]0N`I,47-`A*E-C8TY>\V`VPGW[PCN[&W_[^L@B/ MG@F/*8L^'Y^]>7M\1"*?!32:?SZF,3OY^>B*LW1YE,:BW-'E^&IT'Z3 M=V_/WKTY^O[]^QL2S#VNJGWCL\71R8E4*:31/S_)/Z9>3(X$F"C^_.-3DBP_ MG9[*0B]3'KYA?'XJ*GM_6@C^^.<__?"#$O[T$M-*@>_O"_&ST__[>O/@/Y&% M=T*C.)'J9P5C^BE6/[]AO@)@\S([RO_Y[?ZZ^3T:):&/YXI)3]E*R6Y/./,5TL0U+\[(F3&:A'H;@DXX.DX2^RMM.M=7H2BG`_ MG9(3\5,2R3[7HXZZVK?7^;6NDX#,O#1,>M2X67>O^K*%1_LT<*/J'K15%9TL MR&)*>)^J5NHMZ5DH6=>P;40Y5>K2@/\Z9GXJ[)`4?X^BX#(2I5;7T8SQA1H/ MVY'X2>*?%)4KE:WK+J$1S89&5/[T1ORW\E'RDI`H($'Q6:G_KM`JA4XU&O5I M]PLQ3[*0!EY"@H=$_"G5B2>SBR=>?%4=;8T/IE[WE*I=$K")"Y^ MHHQX\O8LG[?_DO_XUU?M'KUI2(HOA-Z4A)^/`:'3@57-#";7:2R2=AV]T+A- M-L`9JV^#"SA2"6M$(=MI2*>^'Q M$>.B2>4+Y6S0_>2S*!'M^C)4M7P^CLE<_F,H&FLPQFHF`.C3R^Z.MOH,VL*9 MJ2&6*00@P]2Y2LVO9_LA)UN-[9(=@<2]KG4GZB*(*H$\KND/N MRNL]/6_&QE?F2X\276<22!8L:F>B*><I\>@[>#^(3^BQ7-%\$@`M.XXCZ6JNW2>.V M=RM6O:7_.ER/N">)P$""2X]'-)K'QJX`"./FI`VIGI(/@TX42TZ>Y-KFF5Q' M8H=)VB8,0-X-8@QX]=S\]W#N1W;)(+F,%S4*5^;58T'(2)R#,7BH?M*'"G%:WW?V8$=VZ M].')$YI-TD3>9$@X$-4-.1=8:X)#MRB]XVQ&DQL60V-)2<`!DY?A]+BP['$P MO([CE`3CE,N^2SAEP3^\,"7J=Q.E;'SY0KA/8Q*8QKU.]3C`W`;&0;>>!3!D MXT`/#)LJ9)<3NCMP'0`<42Q)\@3>U[676&X75NLQBCD2K]]\^&XS1&ZAO=T[Y%(YUXHXS4?G@A)XC[BC:H5#A955%7C M$#OT[^?'-8IC0>UH&B?<\R%_K)J0`\-C'18Z_ZA,P8M4C-Q18F7^NJPS+#1` MHO.5NO#BIU$4R+^D$]ZS%ZI(GN3"XWPE5D5JV0OYR5J5=8`L2R.@<[ZZCGQ. MQ"IU3+*_KZ-[(EH:]<7\)<%\87RR)%PL7J/YR!>3G^G$;,/*'*!W4S.A\\72 M`2EB([K0NB[C*'LET.BN8R3)%5`HPL[:.HK-I-+CP;C M?$MY^2*W_43,"NH<+YO.K=FSJLQ)6NW,U*,/U`[6G#9K31?8J8'"YPN5W3:M MQF3)8@I&O-2D'#!\`Q@Z3Z8[SL2*)EG=A5Z6LD8L:Y<2URV!>#`6<8`4,V1\ MODK&*<6=*<(\Y`_I-G1#O2D-U5I>-(=FN%G+T8-U<0=(LC<%/B>ADNYV9T:& M`FY197EZ-*3OSLCW61HE\9VW,AQ1UZ43KQGWL<7\7'4W M*3Z^TDS1D"1BZQH!`K>6`VZ>K6=H-Z=F^SGYW<`)^&@6K2QO3UDD+]!(Y,.# MCJF$`[08`0/\#!U>T^7(P^U#CN['&N]ZS,AW^Z$Z?&JFA88(8J/J(0%F['$3 M_$#DC>%YJRWU`#SIY#)[>HK&^ME_$ND**#!Y"` M^%)YP\MD%PAJAP[05=\"'V*O=O`*5.[!+'[;]Z-/I9I1O/%4TN<0EF6K:J,/ MH`W+RN]7V@*S&F(.C*!-:.B"LQZ\D,2YGK"O8%W*`=LW@.$+Q6)Q,IE=,1;$ M#V)>!3?_52D'3-\`ABZ0ZHJS.,[R;`-F+TLX8/(*H![CF/2;>N7[G_LR>Q>Z.>%6G=AHRARR\(0T44+W;.5%R8KL]M+ M30BQ]2%8Z*)V9`Q9E@X[>\4&7I#H)!U@0`L071R/&@,S!0'SER4<,'L%$+K8 M':6=W3I<*^H*`98K\B%C=%[#PO,XQ[9-*2SO`BDP6'S!/0]$/0.5JPIM4ZM" M#G!0AX4P',>;,CZ*@GNB[DO,!`#"#A`!P<07@G-%(M%O0Z'K*%@(4\H^*T]6 MSID?_%X_R++_N[%OT1(*YO/XM MG,NO(]&>4G7E`-*T<85.,+JYN?"%#S76-K8+.!>HTH!#&4TDMEOR%4/E&Z-\ MIU.A\_HV[YS,&,_?JWWT7DA\^2)&=*$ZC3R^4N@[/:6ZRR\ZT"IV:G!\L4^O M,/).<"Y6!_!Q/B3M#*\:H'U&0/44M$F2=2L$F*C*.&#_&BA\L5&'E-!6*:&' MC)RJM*'1LT?#[(WKDI=T[EIU[L4-_]A-:W&`R,Z&P1=U53B5WA%>I)$'&=3+ M.L`3`++/,*M^V/B%T/E30H+1LUCUS,EM*I$7STF6GC$WL=2M#@?8ZVB4/J.^ M=M/'QC1,$_#E:4C:`:9`H'W&C.VTI^4:-]I6M[X&UN(`AYT-8QF8=G"CWH$; MM,*ULG":?3-,FV3AN>F6Y4J0/< M;VLV=&[CH^"W-/,A4Z>UHETK[(_LG@@`/@U)95,M]M*]C`P[_ZP#;6GWID?G M*3\F2TY\JBX0Q+]#HDB)@M%"=J(_3`\)6A5U@'4[$Z![/$3YW.7-U.Q_H)-T M@!T*(Z:K MJQGPQ1M\BSCQ0OH'"=88UMZ/T"#65LH!REJ!XPM1:+JNONZQ\TQG+6<;'2IP M@,$NYL`7WG!XXW2`-TZ'C9$X/')J]\@IKFB*PP.:5KQN\X#FD!$4AV=M;9^U MQ?5F2^WI)7E.W7CWQYH^J\JG"T,57D+KE&\^"+UA!S@KKC?V0C__>4<@(^-0R=9=M7X`"I M77VP8\U-%#N&'1_)'PQ9A,P:UA>T%G&:S"Q_>@TCU9YEM9*ZI`<0<( M@J'B>V+)?D6U]4+3!>JZF,/R`:9]/FHA5)=O)4N?_-]3^NR%LA'>$4Y94-_: M`G1VJL(!0KN9!*!TP,,8O?XCT4HY7XD&:7RZU*JLLR0VC`"P-^#9S$.Z7&81 M^%Y8!(%?1S/&%\J9O^V%<,O2#C!H;0B`PT&=;[)H5/EZ*WCT61)Q@(TJ),#D MAPP8/6;`>-6WE`RBW"?&-/9#%J>"E4US873YQ%ZS8G11;"]DK#\XX7,ORJ-( MU\D[L@A3L0^.I7[ROY-9O@+TPG5>CTV)ZNOS>R6Q+Z7W3'#N::3R#H34IYMW M+V.=`U&AT63/]BTYSMXP+XIO62*?&2E^6'A:]F!UZR\-Q(6U?GMF:/WJ42S/ M('*/@63U0/R4JYWL]MQ8?&,@5BPTVS,?A=.GIIN MGQN(I6Y*[IDPT.%F>W+@J@-@-%\_OK,^X>QCSF[[Q&"3=9MB>R9#WJ92-4_)@:R7/[U_??TUV0N^;"CECWK M="^%RV\O/=_V6\.-!+8:(N'I7E3"U6%&_A;(#GG2?`L93QH-]ST6U9)V]S`J MU6L<:GRJZ[%GR[X^0?:5>.IT5DS6/9Q3VW]@(+NWJ;7W=;KJ;G>>V)?U:GZH MXL'6Y'IU]FSNA\N+!_^)!&E(1CRA?DB$[%_%(C60H>/!ZYEVZ?929D2:JQC;5NV]T/RJ3CE3^[D72A>ZAR>RQ8F;17U]KLXZ9NXI-20>8LC(`NGSF-@0Y1X65T8>- MU]1['H@1%X[F@XLX0(D9INYG' MMK69`_*(";$`BR^EMHK'L!IZ=)(.L*$%B"]I=BUIL)D*0-@!-B"8^)):K]^7 ML1ZUC$6<(,<$N<\LUOJ)NIIBJ=!AI9FK(4G$1C8"Q)=4VKK1N]G4[1OX9DF? M]0T<=O`']F.6A1`;W!8VOB3-G4\[W#[?Z'ZBL5DR9GW/N/U@3#RH%4%L5#VD M/I,DZ\WX0.2C,.>MMM3+(34/+J5>-;HR MU<404P%#PY<,>!0$-%-'YD^ZCO*`=>B$!Y!V@`P0*+YTO_(V3T9V3*A3WO6X;+#*T88F/"T-"% MN5P)I#>"\DDTIK%RV56QY$8?67,9Q+Q8@D87^W+/5EZ8K,SO8M>$'*"A#@M= M\,HZX>EU)/8@AG6-3M(!!K0`T86SJ*$T4Q`P?UG"`;-7`/48FZ*?9!]9XH7E MZ4@SPS9E$)L1`(4OTN3U*?@\:*]M:PK+(V;#`BR^$)4'$H9K5:'-:E7(`0[J ML!`&E7A3QM=)8LT$`,(.$`'!Q!=(SIX;,W-2E'."B`0Q?,,JWB),LD7YI]_CJ^@QME=M*.LL%/C3@\`6F9)L;V5CDP[J9]VXJ=%Y?P9V3&9-/BDBY1^^%Q)"?*$R<:V MT91VAE<-T#X#:WH*"B3)NA4"3%1E'+!_#12^D)MZ8NMS+Z8^8'V]K`,L`"#[ MC+WIAXU?")T_R<=/GL6P.R>WJ40^F2FEXTF:Q(D7B0%W;F*I6QT.L-?1*/B" M>NK-;TS#5."Q[&6%M`-,@4#[C.79:4_+-6ZTK6Y]#:S%`0X[&\8RP.C@E[DS MO\S)[.+)B^8DOHX4/Q7'V=WX:9H_B[)M]!AJ!5*%,5:3!;3^ MT,KN<.8JR#H)*FH!G)D:8F4MHH>,SO%U:VI^/=L/.63FI6&R2W8$$O>Z5C5$ M]6ME_=7,)-P4'71):&Q\M>S!&I3H.E,I9-7(1%/.#1HT^-"YDP.1JD8^S&7< MX*8%=X^^YWH_K75F?'6$SVD<45]K]39IW/9NQ8KP889J1+"Q*P#"N#EI0XK. M;UUB$9M!N;9YSB^UVB8,0-X-8@QXT;FK[S5V4#^6YH^SC<4P(XWT7OSZ[$PS MBNKE$)_R&<#UN)@#,MID5R]VEC4(#V+>UE;QFL3&@!+=>KD99R_&AC"5![MW MC"NS)@FGTS21<^TCZ^12T5/E@]'=WE[-&28V,R6^-F)Y%X+NMJ//IEUAVO8. M9$#2_A\[4_2;.9-EUP;Q=1RG)'AD#R1)0E)/@;[V!<[2<`..@SU5BIBJOLRV M\]WR]DIF97?"<%[UOSW/A0G1[=A'P6]I%M@8/S+@8*?P))(7CPN)1_E)JFEG MHJ#$]T3,.S%-R`/AS]0G=X13%MP3G\TS*L'3L/U\'7'[VCL1=B<4!R>&72:7 MDD^L?@G9]]WEEEI_`9&+0D6O@T<"IM.AWA;CDN`[SIZI:$SGJV^B*5Q'KY$8 M(U^TGRSUG3G`=X.*'!CC-S'/8`#@HGNQO60Q-DZ=&@ M>.PU7VV)S8E*\V=+_UG88+Q'8Q![XD=8#V69KG'BZJ M3!6Y2Z[1//BRVXD1IO"G\']/*2<"CVB>R4J>&Z2:S0/OC1ZY6GAEB6D MV%59S(45<0<(@Z'BRX-7F:U+[KF7+X3[-`8SXK67`L``00E#@``!#D!``#=/6MSY+:1GY.J^P\XIRZ[ MKI)6*V]\%3MV4EH]-JIH5RI)3B[ENG)1)&:$F"+G0(Y6\M7]]\.#G.$#+[)! M#N0OR7H$=#<:#;#1S^_^\O20HD=,"Y)GW[\Z?//V%<)9G"O_O+G?_OM=_^^OX^N:)ZL8YR@NV=TO"Y33-%%]!E]H/EZA=8%FX=. M3SX<71=K4F)4Y(OR(FOLBJ1!Z(*D+32,!RM M(('SV_)YA;__HB`/JQ1_4?UV3_%"#2ZE](#//\CP,BIQPAG[#6?LX7]RQOZN M^ODBNL/I%XB/_.'Z7$O9-RU884KRY#0;1VQG]LQ4WY01+0%T-^;/ M1ODMNP[Q*)H;,^>C-B^C=!RUVYF26GF9\A\NV+]:1..G$F<)3FJR.1S#.19H MQ$W!`=>0\[@)\U7*;\^O+(,/FJ3S&2WB*2[R M-8UQ!R;[OY_L?V#\MI%4C#N*"A MR9"9!5T9K_4I(1=,`?N):;\K3,OG*\;*\BA+3O]G358/#.'A MT5U1TBCNWC&.DT;+R3"B(/)28]E#`L\>BK($;5"%(C3#^%$+SYA=FN\BNL8, M/XG9%_NFS..?3Y]6."NZPF`9#+Z(S$0`/V9TS2Z?@L-%;&\9GKLU?U:AUPFA M.&9L+:J_XJ?5EZ&(FAMGNO>3R_[,J"_`BTOG/D_9+A;\"U<^:XZH8B#X4.F10XZ! M>,:BXCZBN(+]^VB5%W]B,EYB1E6)7I_@!8E)&=RG0\^0KCS:MF.\2MMY='TX MO?QXK%!BE<-`:JL)L=_'L0`=RM[;EM[42>U,G_'FP/&:,KD[P>QP$=V7O3L* M?F>HT4($I`:)$@DSN!>O9LV].\'$ZSGM)#'%48%/L/S_\XQ](S%YY!*K-Y>8 MYGBPFCB0!!&A!KC0A,=I[7VKB?-^S"=83)U:D)*K5QHI:@P`BTP?&40^F'*( MN.:-]M$SCB@2MG/$N(L?[C!%[P[W$%OT86BRTV="5U!T+)]3@XV8)LX4\PN2 M8:&4:S78WD`/&JP..>B#5$-%/W*X2`#^[]"$0[_VOK)JYOR<]HV$<$M2E%Y% MA+W(CJ,58:^%C^(8:HT3ICD>+`L.)$&DJ0+(G_CX*<;L$LH73!>FZ#%*US@T MJ7)B1_]U[KQ%0V6MP/&;9?YXD&`BQ8S]HRM=[*>?3K.2J5Z5B^J::6"4/_2Y MY*^[%Y)U^&B9:>"+.Q M7S/8CZ%&2P3H4\?--/L\XBA!(H(I*T0$%5.4I(4_%UB#$2LWCBBM-99]&6^Q M.<:'%6:PWNSM.`EESW(D"?=LV6`KA?VPA0O][^'\FN=G= M-XU+VLQ^SD?$)Z6=YC6KF@ MS,J`:B18_`SH(;)V@A>8:5T)H@&*DV'-7=FQ\GP^03F-:,:NUN(*4Z%DG9!T M7>)$(RRZT6"!L9`!$AH)JN/:9F=5.O]"$R,+)[JBY+0CNQ.G]U%!8D=ADF.] MBU*+!(@@"4`O58Q:7+`)D6(G9G4,5>$19VQ%4O5;,^JJL`CVRGN/%SG%F$3(.DRRBS\)RR"]7'A*6IXR^Y7GETM>[E2;#Z,,I-34[8/'`S>-P M)TBISTC)B0GM8,S`3X6;;![YFM.M+\BPV)G:@SPX]55(83Y]`9$'B'*0P0FK M>L5]C[Z>S^/M13>8LM?V,1/71_:N(7?']C`O[%DSL)<9, MW8O2\RS!3W_#W8AK_3@??F$U:A\.80D9"="(P0Y%2JR+5[B`38R?\V81Q^XJ MHN7S+8VR@B=FL"OOA!0Q>Y:M*;[%3^7[M*^SC8'@X0X:3"XLYE)>2@(?:B)$ M6XSH1XX3":3!15"-8%C_,ANYP2!W\\9-7Z$_SHNR8/BM+B? MAP*!NJ-'$@UT3V\C&FIY%7CWT!8SJE&'(I\PAG6,FSJ7`+'W&=S-M`_U)N9R`K+<4LQHG$?.?A/:_= MA8OB!!*IQ4CF_H."N\1QPY$:JL*(&6G$(!&+^ MDF^B#EKVQS.P*_;0[0>8.>NH\\L%3\8]2_//QSYD+%&"?"[\2M9+Q('J,Z M?WC(,Y41WWV>C\PI-]*`U6<$$L2%`!51NK64AB*8@_FAR*T:LE>[$;XAYGO[ M/*_"-YEQOBU\6&>J#UD0!]GB!^[;?(+8JKEQ]!B1E*O6MWGCC%0U$DSA2D.A M@(5T)-G0!-1V@%-4RKI*XJE6YCS[@B%OU_5E$Z-]Y MTM[EXH?L'B=+G)Q@2GC1Y$?V9Z:1K$7:@#X::BS`"3+PARX&(OT_9`QI2G[! M"5I&O-11AI(-+D0VR$(3>#C7[(G]XV1@WK*;LO*2/+3L]&KENS_22\%-#7I8 M=%T-MKJ6PQ,][;I5)3:-?-]!,0!9$XF;G_.,2^_1$['6!5#.\5\Q+7MW^%YW!KN]56L(L3? M8SACT.M":Z$(D2L73,]>_7[,)TY;M:SA,C*7LC=.`8N5"T&PK,"-CIY6")Y] M)77[7H,QI5NUD-!.APLCNB?$7;SF/"4RXOD:/^)L;6GUH!GLX628B/"4*2M` M^S\/4,HM)Z%-?GBGP+3\OOS;Q6>\`[,9V^7FK+3-`#DF'9+-G;I"QCDN1 M-\+HK([?MNKZD`#J$:#\--<8N0#8_=O`*V2]OI&WJ%^*P$-XJ&S2`9*"\5K` MUKI:G."[NA--^5Q5>V;(3;V&ALP&:0X:3_$%(%<"=R M_Y`Q05(_WH?F:"8%(B[6KB.ODT";CEC9HE`"7;8($+DK2]6D/."MKI'^[I#G M.RN^<(;!L#A<*Q&@<%L.'57@T?ZP4O#S+V/5:;[[:UE1W0;9]WIF#X"V\J05 MY^QX9`!],:6GI*BS7*+4J*4:A\-Z83H0`O)^5?"WR4X,0TB2X<*`5MM+YZV8 M,:J#+#/"/IZ\$:?,HN+U(/*4<+N#[07O.!D>YS&(2-"W8XL);5&A&E?0K_)A M7.I%@XS8RQE5W:BXYU8Q7ON3/HY0_UF3=DF[G^`?>$A&:W(YA54]O'KVYNVW>53>HY81KY-8Z;9(67BK" M8$8E"9M+9A%Z4SA7AKBT]M)OU8Z2BNK"V\F:FUCQ45%@;5B[PT2_:45&XOPG MM5&9>AEQ-*$)H3M?C#E%#KNVRRMPT[>WZBMDL6\.`##!M6@C%N0)O6?_Q31, M=C\*<93/GG0;^Q-UFE@27$E#&1WO[P]ND`7YT?OSR_.;\]/;]#1 MIQ-T\]>CZ]._7EZG-[?H]BUQG[@EZ)V%F,KM(H MEI4W0K(J#^:48P%7W2Z&(9;RY[.H3F;(/]K7442W>::UKEU MMQA>KW%;PK%9_..:6VL+4N+J%,@#LS\[G?.WH'\CAM??$SDF)ZS'3+94[UU<7;HSS4%E>B M!66VR\KB`BZJ`8PYGU(S7NL6T=3ZV*36GT$Z MM0H1+!7T+AB'D&Y]3658S\E=5!,JSK,JCOYC1'_&H@Y:-Z*>>^LQY>U";FF4 M\-P/X?5P3Q^:#)W'ND;3,,)3<@)1!652)+YY4O) M69IZ4_25FZ84SQD](7F4%:)4!Z>0UU@7ED:FAF/R*,(:W8_N.%APGPED"9!# M)Q#O(8%Z3QP@6<%?^N<:^%_*80)QLN=C@4O#O(&(O'BUIG:U-:/;=;J7`,0A MA()L)'5-2BO5-&'PW=U1K=,@ZZ:UO-LD=,'\2BPQ-RXSH:[8H:1 M"8KS;HKI1GQ1`UMH,CJ0.3VGRYA-G#.5L2@O%Q_R/"EN\E17Y+P[RD/:HA(M MS%YA-QOR/]=$G8"MH9JD\8]&N:D09S.2X*]^FHDPD.= M1D6!CE$#'=IJ;8+8H.+OO+)Q2+CG0-$`-=;F_8=$;*"DY3:_$0&WG;O^`\XP MC=)M"]E3&?*EBA'U`!3:>-O3HN:(9ZY4@CVTE-0(#TA4]3"N`NL*7R67YV>/ ML32S5QZ%^NPR.R&%2&X7=YLQR=H\!_QM="() M<@%P!`7O^Z7*J@Y&6@>QH_L-&[!%,Y?BW=06Z%>_T(B;=9J?$KL.A'E*`!/U M33R7ZO>Y!..7H;..T$Z+*Q^457V=A6Q./U.6\`]$+JXC? M73Q@,LJ>+[/TV3VFQ0=D#_XL;\L#OH8D&6A#1].URK\1DA14T8(X,2\E^,4C MD_L.-\]"--_)VO2Z'!`-8YX#/@U.)$'DG"-``L.+"75QXDE7+`?LT_@G^FE$ M,Y(M>=$NH?F;BEKJQX(>U%820!DW%7#$H,L\A5!DPVGIS?>9(_MG+'#%"R;G M61TZ>)4S<\>B0LR)+1\-#AX,2S@0D!^98F[$9G:1H]J_"_E0PUE M9J^NEA>QV$W9-VY&X36)6W;6MN===Q@&0O%:$&X`V?ZKPZW:@1;!B?WUF%^9'PXW>6TY-\?5<8C)>[3$G]:\9'M=5N)R718E^R`R;>=]5)!8(VG# M8(!%;Q3),%ED@-#G"BV*)%Z4"<3\JHQ;#HY\2T)PL8JC>->58\!^0TK8U`DQ M_*JNRITH'D?J<<"2-0;4,#-N#5A^>BO0H0B-=>WM@C16OL_;?[(JHR%>[EJK M96>8EQZ2*L0^7,PA:F&Z]:K:.^HYO9.*EE5/74LPO6&"SRJ6&F)`8B-!HHN` MB^C:.6`H26G760L-X$N>,68U* M86:[7&Q<8U=5'(8U&W\3W.%FG^(C)L4`C3^I%S299217P0>1D21IR21]3RRA'TZ"QZ(+6G84+91LXQ=8ST! M!IT3OXN#'),F)>)<;&D1S\0F-?Q8;,_+EJ"0#HA?SC;/QQ1R,VO";?Z`-P39 M>Y$I1_M(LC61`;KP-\SFUL6+C1+\+O(%[A M=%1S]T:9IT_>8Q&&;X M,P&:M$*"F?@I]U)'J^YHG1&BIA]%P11 M9^RWKJG:/!9DG;.2`*IA50%'$CJ2X)&`'XJT.3&A:8!SW(CQUH0J$I-WWY7- MB-DU?$II3H]SRL\K?RB8C`;#YH-L`Z-(]5#9BKNXZT[-_$,M<*(&TE"D:S23 MFJ]YP(;.&!A>-R_)CV*F)U!\17/VKBV?KU)N<6,4LU]7?(CF/[T0LQ'[N:,>N0@77$J?7`RG4\Z:F4+IK@! M>V\3)!YB&.=`O6X"W=R6#CGV,N M@]N^SUA9:5OJ*7D@F7"HE>015]E1&J&VS8)75W(C"U1?J5D+K(4DN))@`[G2 M*[,T9+=F-.>+,D]NT?+JL7!3OHD$'S'R$D%P=YQQW3U+MYWW%26/48D1>_G%LH+%RPT?;?%L4(BH8D=W$+=_ M:ZALWQGD+Q;_UE==^PU$]*.`&5RI$_62M2'V"D9/&QK\#YRF?\ORS]D-CHH\ MPXF0UNX-91_O(2#80HJ'6&".8?]GC@+5.)!$$HK8.'.C'P#LM#.`CM&5DX,; MZ@0^>Y\ZYVFP#M,#"//BNA+N!2E0`;:E&\J25K/JP9LUH]J.[TKW0F&ZT7!E MW4P&2,!X39D74L'+PH:>FNZR'9`"'$PVUW$I5"PFO-%#6X2A"-4X[K0K?(S;PSDCF&64&`_UT]Q9K2$> M8I7[",'Y\QP88I^$3>_#4$3(M.I^3+*.S_.)PR=<QN=9 M%7O/9'@CN1:SY@A`8-$:3SQ8`!=I_KDJ!KBHT:%H@R\X,^EX5G6E%KK1\\EV ME;R0+34=>O3CP)*I10T1O-NT\ M]7(MXUJV#;*26S9[6NOHU?HN)?%9FD==_4L]QH,55('2@^530D4";"A"9%QS MW[ZIY?.GC M*FA!=ACSG6WH>7W&S$/G189RFD8PJ5\$>J"0`GJ*B,0Q8R>1S@A8_Q`U.M#% M*D"&LON&1;;Z@YB8.FO)>'7D]X!.($-`^"@I/YA@V!4K\>TA@5&ZG&J<+\5' M,(9IBKKT([=YU]T\+O)L>8OI`W=]Z&78-G&BGATJXH#RVFC302H\/&H[RTM< M=\\-4$`=>>/6FD._A[,_Q6?]32U!_@JG"".QP!&:L+GP MP5!YT[(S@$I57,>[QH\X6V-3W2G5,%@5*0-B4$THH:17@$.1`MN"6Z6:K*R> M,;F#YD7!;KL%T=T>S1'PI(T^.E""!@?'$RP9//EI8O].UG$I.DD%=T4H5M]+ MQ-!Q>\:D"]G0O5_M7B,@^O'PY`L;*<#$<@Y<90%(MPA#DR$K2WJY&6[;,W,6 MKD-:Y`2)CY.D-@J@J"X/OH^.ULMU4:+#/6[1?^O3/@8BWUI[_T6MP]@QH;N2 MC^Q\W:-W$#BU9<\O`*IPDK3][*4S31.0EH)<##&77=0M5 MU9OILW3\,V#32?HCCD0;Z:,L:325-KP,7&>"'@L#R8.(1:-W>(U,?/H;Z$(1 MEA&<:3XT1NVO9T`M;M&S"?')SG3]':?E< M&58T,M,9!)87-5)88'\9$9ZX1@7H@*X7\YJ[@F'B]*P1'8V0N8^8EUC1>FL4 M0WW$;&@)\)/T?Q-2,*/+LA5A"1;&SQFW_[GQ2:1YQOXI4]BY\E05XSO/FF-( M%I-5B@N;1]L+:`^Q_?X6"/HDXL^HJ4JU*!'Z>%WMD63M@34Y87]`/;*YGRG@ M6Y#&Z_PB=K[IT%!H^OTQ(/U>BQ*>`R"MOU2"]17=!J;9&,>F(#R4LV!<>/,1 M8A$00$Y[]6$YSHNRJ,KODU]P4@7"M2/@3$GNH^#`LMXAI,.RE"N]0F#>0PW< M>ZC"OB5TFREM+M:H&0SOY&$D`O3\8=_$/,NP M+,[(=JY8IT(_#+4PHYD5O8X<#ALRHV6E,DF<1I2W&B^89KE^6`O*JI8H.FN+ M?2+<`N-,'-#J6T-%B03K._O![T*,2J-B-:&=%W=N]`Q/`X5N)QV8S"$U4\32 M3!-$(Y\?=<9,P'$S[@$SX43*G&!11Y$\X@9-&I%1C_50#LE``NR940/>2$TP MR39.B^^70+)NP(R/@;S$Q96,RM>]!9I#X$\!!4+02X##"S6O0+78WB-`R]ZY MRV=K]K_ZHZ<"V5Z^)9>W1Q?HZ.;F]/8FM"UOKU)=_WJ'S7,IC@I\@N7_GV>5 M@:*V7R@3/C5B,1*8C]:[@$7,DNX^$"*D'S"G\6?1A4?V4Z> MMNA(C\@YBHU4']0]M&RVMN@&PMLEV)Z/,9 M2=ESO2-)^G$>JI!H4'NH1+*!C"3H4(3(NO9^11(CWW>CS)OM!JJ17E5[CY:# MEH;OVY8&I-EH/'LQ3Q.+G<,J+#,:QAJ)U;8P&O58N'G,1`)$SCG@?290#TC4 M?PXY:,7(@YZ9S+X/NWP"5=$OM8#SSE:]1#CG)Y`3L`F>0$,6X2&FO:$?]G3" M%Y$<">.@_44T7`YV7G%X4Q446G'8!&BJBL,.Q(->39V*PWF-[@56''9@E6/% M8>>-GK^XNCF*H3O*6XEUCW$+-5JTX_W7YG: M:RVZ0(-:K(NVUJC>]DW,1.YR)>&F>Q7CLTS0!+D0,Y4#-A!5Z&V#<1 MA"9<#KSHBI?SWNRHA:W1%>>O:HKO@K#M((\PG2%.!5"!I4XG=5V(1&WQM\N5 MR*,\?<(T)DPE&^;%,,"9RJ%A)QWV\9/`>/JL;'";2RPOJ6*ZG46.[@K7[=U) M14)!UWV>,I87LA2M>VE"PUR?-0KM)()J`6W:E3)A;:+Z?;3*BS^AL(H*CV*/ MH8:AZQ9.ZU6[QDO1OSXK/T4/JHHURF$>?&IJQ!Y<:EO`B$,.17QL*^\[U$P\ MG^_"J@.#V84JG+\VCX-^//ABLI("DIX*.&+099ONH+T/5EYT;Q['?1F?/LB> M$_R5*LI:5)D8(A5,8'O/FYU?1<_RM:'/'1P!!)0X.)YHX,MR@W73B;+*(*S+ ML?'F\#7N4(0/QK%FLB!TGV=^@+0^T]P5[%Z:WWV^GP?'$%)ARIM&7T,H&BTL8#K@&MN:]?8N.1.?QVN,-Y@R$7MO[9>I M'@?2^XRH09]%`1B]#[E_IG'Q32W-@?$!M$G2WP_&*=.U0?)W3M-(<3Z>Y<$3`OE^;HR*,,DTF MM][(O+7.W$F]O.%FK84FE(.X.,3YZRE5#18SE6?V@KK]<5[BHY2H/8AAD'5T MM0M6A3X9F#UU\K6[S&W%Y=S(E/LB+>YLP4<=_RKEJMYD?T%!GFM<% M!O.UW.1X^ZQRNPMN&=757W=:_!0L[W@T)SB"3FA\RBF69WP\1R7@)U\ML6]M+]S2SS0)+ MDB-9$)G:HD"\^"YB-V>RK=)&,O9P%JI$:++FR)JNU`W:LED-ME7I8/:O=)V( MUDR41Y4E@4U#,N:TJC M14Y1>8^1["09FC3[897"M.M-`&;,[^,)YVZ.<^50>%:?@0!X1DV071MJZM<9AX+>@#8"('+`8?/O+`^EX"D#5,`/ M+,7*A0G-=X/;-NS-<=GW\Y;=]&9VQU1U34F0D5AK=;:-!5Z`#&7X>LXC#1Q6"4$3* MD0/-*]!Y)Z:RRQ^QAUK"'VMG:;3L[&K_[R`[O!(5R"->`T0<8BA2H%UJT]IN M8.OX2Z!J9'_"9(H+T+M#?M\JCK]Z'.C@&U%#]K@"C/91#1N].]RS?DEFI5V^ M#V_*B)8Z`_/+6<9IEGA>Q-Q7L)$1S7SQN=^OPJ<$^5!QBXL\R@I1EG3[8TV'*<5R,`A/RO`P M@KVY>P36/23KT&[_TA#TH$P'8_FEUJ?'[/#.4]/.2,:^2(#4-!6`J5+3#,2" M[`D\+6U5X4)WSVA1XWEYB6D&%CDFIEDW=$XW^:I*3+Y<-(OZ:CWEFN$>G.5F M0F`7:`6;6UDSGLX;:`%O&Q/ZOG.7[=CY#7B>/>("DIRK`C#5#6@@UDMR;O,6 MW";J-G\E-04O[VXT,,_Q;K1N=8C2/*ZHL@G0C-(]95%EE2B_E*+*#JP:+].[ MUE6Y1X/;2:JZ74R'_D=$>6VFXBRG-Y@^DA@7E_0XCCS>YSAA;8ONFZT MIS@[+1G`W/U'4G`9>WTGHUUST*)`KPP7*?/:B1^<&\G"AK;5T6$;=EFWS6.$ ML"?@$U1\VU7$\-8M>K1>KHL229_H6Y]I^O.O=I!3^]>W<"9B6SC03,\ MRKP+S55=L'^QW^J?V/_<105FO_P_4$L#!!0````(`)*)LD!O1<^DT!X``'L* M`@`5`!P`8W1T8RTR,#$R,#,S,5]P&UL550)``-#N[9/0[NV3W5X"P`! M!"4.```$.0$``.U=W7/;.))_WJW:_\$W^Y"[JG$<)S,W'[5S6_)7RK5)I+(] M.W=/*9J$9.S0A`8D'6O^^@-`2N('&@0I2D#O^"56I`;8W3^@"32Z&W_[^_-C M?/1$>$I9\M.KT]=O7AV1)&01318_O:(I._[^^V]_.#Y]]??_^#^Y27.:D:.4S;,O`2=? M'TVBIR"1[<[9XS+/1+/K)&%/028>G'XM_A.^_EK\MEQQNGC(CO[S_+^.WKYY M\_WQVS>G;U\???GRY36)%@%7W;X.V>/1\;%D*:;)KS_*?^Z#E!P)89+TIZ\> MLFSYX\F);/1\S^/7C"].1&?O3M:$7_WESW_ZDR+^\3FEM09?WJW)3T_^]^.' MV_"!/`;'-$DSR7[1,*4_INK[#RQ4`E@\\@BDD/\[7I,=RZ^.3]\>OSM]_9Q& M%4;G-*X]1NA@23*:T2>2D?#A=4*R$ZFL-^_>G5::R8Y[:J35I-3)Z0\__'"B M?JU2B^ZB;$->[?W;D^+'!C4UL+/1L\#V3P6XG,7DALR/Y-^?;ZZM=7`B&YS0 MB'^^8&'^2))L_7>21)>):+6Z3N:,/RH$OSI2@OV8K9;DIZ]2^KB,R?J[!T[F M/WT59EEXO.Y<8O-7Z[Y/MM(L.4D%F?K^@_BB]ECRG)$D(M'ZP5*"?-5+$-OR(+*IR;9I^"1-!@&R:H,5G&= M\#JS`0_778J/"M17X`PH*4Z6PFHFV7'X0.-HW7K.V6,/!:Z98`89A,D6W+"E M;!C$KXX8CP@O7@0'T?]:D#O1K4;OM9^1Z;LNFE[/;P^MYQGAE`D9HHL@,RF\ M3H=4\PUA]1"\.Q0$$\%2)-FZBH.%1O7UWY&IO"&<7M7?'$K5!=OG@AT>Q-?B ME?K\#[("S7J3#IGJ`6'U$'Q[*`C.'G8L(N&(??%G4JE*IO"*I7_@\'MDZ%\;PA M2\8S,15OA1[S%+9+>G*4<$"B`UNS-X<%YI\LSH46>3%J8$2:="BA:`D+8'"P M_7'!UB\DCO^1L"_)+0E2EI#H.DUSPD$L('J4F(#"`]@5ON9!YJ`]^R*,.[)(?PN(N$V<> MI/=J#.;I\2((EL7L(7&6KK]I3J/RZ\\;[J;S-D^`2[]?VYTLP@B"W07W<=,- M`1`YL@B#L)!F`9)U3T[^$<`H9)%GPN+-+J;$Y)DVC;9=&U^@JHTN+29ZD;V# M:";Z(F)C$JFA]Y$\WK<6G$927P`QC;`J/GIYO8.EXKXR8M*FPP:(1M(]':(- M1V,21;3@9A;0Z#HY#Y8T"V(C,N8VV%#JT,"(9V[Z"(0;$A+Z)(WNE1#DG-,T MH:%6_UW46#3?*?6>#M^&SY(;D@54;-PO`Y[09)$:IP=`C`6=+IGW="RWTPM% MZ/.!)*G8PEPG8C]#NEXL`#TVB`R2[^G`;H0%L]BADFOQL7.5O"7T!9?NI7%% M..]>]>T=F!@R<2Z/#6?2;R_TF669%/..?6)B1"694))@97&=9$2H'MXY MC]*Y+TBW!FD=[7$4"2_-CY;KM?R'0LV@;(5@RG4FF.>9HG\986#GGT__2&-, M2&NP0X-&V642N1UC'9$?,!T.W&TC.MYA!7#&V9QF'U@*+0`J!"@@JPKDW4SX2%-262ROKWZ08'=`/5XM_\!9"@L MR0@8FSK"#+)10=[MGR;1O_(T4Z=N=PSP62F)S@(A@-P9BFVAPJ(JX0T1:XF4 M9N26\"<:DD(3-R1DBT3U"+K\#O-T%./I8%",&,L)^1ZSG"?3>3$5[ECIA]/Z M'?647@-F%''$B,U>RBW^:Z_BDAZKHM?B[BE&YJ: M.P(+=8(965`Q^PI+W<^4/6=)68AC.B\^9_0^%NO;4%!F=-`4[NX3,_"V:NL* MA_5F'!0C>>2!8-LIYI%@K3A@*/CG?U)C>YH]@.?PW>TP`UH5'\#,Z6F\810. M`*W:$#-J-04`L.V<2[LG;[[6XS3$G:_O"#.L1@4!,.^,3Y>$![)XSB04:SB3EW1@9R@`'JHH[^(N M=8*L,][Z`+MM@Q:_BMC>Q4ZV^;U.GH20C/>9?]4V2&&JB>U=\&.;WQDGRX!& M%^6JZO)9NGF(>#Q6MF+`=&[B)=U-Y0 M*4CFM4YAX?R+11-\\IQ$[7D(#VZ`WFM(+,3U+^;L$\M(AZVID:!`H"Z4?Q%C M;8?`VA-P0YY(`AX:=+=#`8^%^/Z%?UT03N6]DD^D,K&A:"`M+0IL`#''#-+2 MOZGK84?KASJU?HXA=T54^;!*L-P=^XV`2$(#!<5E66B2URQ-6EL@C M-I*$L.DQM4`!C%%D`"'7677]JIGC=GWT=W:\';$NZZ=OZT94\WIHD7BM5KU0 M@")'W!C?$GFJ>-:I33V=]RH%Q`/T.FAO;-+K>25/S%+%AB9(M&T2&E"\PXUO MI0ZX,4ZK2>8U&+!P```N#Y/U-7H@GQ!`C0(.4%0`E>\/&YS:HP2ZQGSIZ;S& MQ2`>@(C#`^AFR>])&.:/>2R312[(G(9@0(!%0Z]1ZJ,`(+CT#<8H[_8*VWHK M@0-0G8``@!X?>`\\Z,8!4;?P`&";K;C#R^#*8&3QZ]AWOU5Z=I@C"'#D["R# M/9(-2QW>#XC:=1H:GI3`#GV_9`&^9`'V6ERJ`[>N/,`6F2_:[U@X-H7S3O^W M04S2DD\XH+1)A4+[+='\R]]C:3:=OVO^,2A4IYQ=@OD$RK]4)"S=BIII>I^\#FDP3:;FF M\QNIE%@;66XD]5ZWL)#>I9C=L%409RMS5%2#R&O]0X)YE^HE4P^+ MG.@H46"@%=&[Y"]E"0L&`0"J%"@47Q/)NX0OQ9W=NEQ+B@<"RQ6ZR\2N35V! M,D6V:Z,*T^.`!1;7OXRP6Z*NM2M9A;:N=2(4*#0%\S"'*[AG?))$-T0=@YDA M`(A10`$)ZE_>UGN2B+D;"UXGT2--J)RWTJ=OQJ:K%0J0.D7WKU+Z^BY.,SI- M*A1HM$3S+R&LG0!R%5!>%.>>_YP\D&@AS_;7F0C7B1A1N3KP@H^5AG:(!-/A M"O,OYZRURK%=S.$`2R.>EREH8OLE[T=5X4\JS#X7/&_/D\_(G/'R`ON[X)FD ME\_"K@O6:1+PE9*^UU71^WPBBG&Q5Y7[ES"W$:.ZDI;UM3WJ%'HS:*)D\!C65PQQVKA-.747!G M0=H*AA[:"PHH>ZO&OU2]=?SPC/#U710@AGI:%$@!8HZ9FS<.'K\0NGC(2#1Y M$NN?!?F4/]X3OKZJ=IIG:18D8N6S,.'4KP\4^/54RYBI@ON99QJNG*9G08^Z[J<1$>) M`AFMB/[="Y2FN;P<=3I7_F8Q%?SLC/"2=!3'\GT5:&;=PJ9,JZ6J$`K5-T_]),VF''FUUW6<*P MN]R/;07&X]M;SSV*R/FY2[=`]REZS(+YN66 M:_M;KOVZK*EQ[YKT8+>N_+(&T*HSI,C:*.U5X.,MY@ MJKA++Y\)#VD*ILAUMT,!HH7X_MU25F5Z&VA5R7JVP$S?#AUF@/B&.\P\P\SN M2L:AO:#&L^_%C0X=/7H1/K!D<4?XXP6Y![>*W0T18UA7@.$^-&8&S5%C&,+34`^'W3_S+0 MI1HA@CF>.;T2=._X?S[]-QH!0AAH#'P[=`Q<)I';2V'SY3)6^@GB==&#ZV3. M^&,!4D?A"`TYJ?(B);7@(-.]0H)"CSJ0@%*W[AP#E`;1U<2!Z^7T86V<1)D>3S1<5#:D%X>O8\D?P-Z=0/(L MACU+ULT=3?\=,6V^K^TTU5$LY`!F8\O7E"^"I$Q(WY:?*I+59Q4.IO-R4QC$ MV\I40TW*6(\_L+D9B^UQ3-%./)R:KE$F66VB=K71HXN$SFDH MH[U:W'6M+"P;.YS2%OC4]GJ6VO"NU-A9GHH]4YI>D#3D=%D:+5FS-Y4Q85N= M=T$ZH",\\`[14DUD]R9M*M.1S' MT-L^SF#]>W?AZK:_#7-W/(@V?%78WZ+094Z&]>70H@S%N7:+X#`%^K0@W%Y6 MG,J#Y#(0/%O=DC#GZC!R=QMC\0QGUL6"MW'L2O>#3`O*/JV=^:`W+,K$+L7D MQX#_2E0-SR:[\K"%\"R@B9PZ\O1;1;';&YR]/,[2+"VK8\CJ)V6^=CU!>W?CU>]QSNQ8/S;',6F]GFDP;L/Z<59QM0>S]N9L MYVX=FJV=QD&]D.NNNO7)4($9=KL;);AK9P8(9FD<8P/V;UHV631R%VVLY\S> M9/3JPJ%YL$>N$8W<0T%>S?NB*D6Z+DL1Q",L0W2=NIOK&F9&FN7MGHWSVT3N MZ@H`B^(D]I-\:&\NY[L%AK6R_4,5YM.D5[F]>9B)S9782271#8GEQ5+;F.XQ M7+5=CW#HH^UB;2SG;,=S3,:B1V.7];%-'-K;C4%=.77']D6V56^[M^)\LA\R M]9$JWXWTRZ@[W!>`WM"W,XMAX&D<4P$_P&`B+!JY"@W<<)8V6;,W"CT[ M<6@.[-&K107V5))/!D#Z:\?P5MX[]`&HIX_E6[S/C"[#RL_./('W/7;K$+53 MOUU;QW5W'""@=U$QU5S8[I-J':WCC(B.L50_=-;*ZI,M*XZ:=K=F93_.[%GY M_'$L6M&9:8/2I'!V:ZP84`\L%@,H+5B2(0[VELZ^O4/;!Z!1OV#66@\^3;[J M'5#E/DB=IVQOB5K7`AQE9V'[+)<[#5L>1]MY6#[0O!/IVXFK9=`V46-NSW7G MY9U-TO"X7YO4?N`` MFV3HQ-7IJF"SB/E6`0,SP25O,=GCI'5H=QY:H6[$:Z>P@Q7ID_FY#'A"DX4L MS*),Y@@[DV:/[O8H34Y&VJTTNC7N6T!:1]._R5#7_(;I7>Y0NA"HSE.#Q#Y- MQ*N`*%7G>8<>?)KKY:)C%O!L->H"#6IJ'*D.\3U&#?@]-8!BO$Z@$,/73CTRR_O3R_#1](E,=DPC,:QD30?G/. MQ`1+4A)MZB=4"FG)"Z$75.IBC%#H71EP9C5V97RD&DN[<6&JNS12S\X"+HR, MSI0%D)OL(%E-DWAE;\7&Z-EE!:=Q1TP]?F,$G;NWCALQMK5E2'06Q+*@]NT# MV2$MS:+G`]LS"XY?U*] M4[`M@2D]Q-0,!6C=PNOQ&E"QW[W=K%05DC>)%(8%A%='BP13K9AZ(!W>K2B+ MK22B[Y58T])4[(??,Q9!TPT@1@$()*@>$:?7(*HJ$9?/,NYA4XRK]AZ&XCLL M6J+`RDH%>N"^PV@3;"NA\5)Z3!?/FR^7/W69\[6M#B%F8SM9H\.U M8-T+K!^\OO+Z<=SS8FZELQKU<+"`4IUN*%O%QWJ'.H`O=>06(@+8.-P:Z]J M;%L9(!TE"CRT(@)(H-RKKXM[WI`GDN0=,`+$*)"$!`7`_!XGF)P^!3(VQ-I> M&IL@`=8D-`#O#X>%%RJ>6CY?[0S6W*\T:PR(TFN`C"(")ZX.G0/64P;K1+&? M'F\'.1#<5?SR3N6V@@/J?XOQY=/;UX/=N]/?G_-VD,-`/Z\^?5NWK9I9U"+Q M6JUZH0!%CKC-OQ7K!Y*>=6I33^>]2@'Q`+T.VNF;]'HN+-\3X1D5&RA+%1N: M(-&V26A`\0ZW\?)%Q1+%GC&LK$GF-1BP<```WSGT<441+=B9!32Z3LH[-B`/ M%T"-`@Y05``5E-OP&R+O;R+1.OU_$H;Y8ZY2"2_(G(;@N:]%0Q0HVR@``/S` M&_-]+7VME[PX`-4)"`3=^K&#UQZW#CQSQ@%1M_``8,YS\+:7N%=O:!\U&0]X MA`]9>0!KKL)GA21DPU+'!AZB=IWXA2<)KT/?+WEW+WEWO=:=ZFBK*_.N1>:+ M]CO6E$WAO-/_;1#+RZH5GW#,;9,*A?9;HOF7,Y M8^\#FGP0H$^3"YHNRU((T[DQ:-S2YEW;IO%:D8!8AB0L=&[VTCV6+,I,VJZ-+DSO-9(6XOJ7]W5+XGC+ M*K3UK1.A0*$IF(>96L$]X]OK5+>)99\9G285"C1:HOF7X?5SPDD0T]])5-F) M;F+ZH8UW5RL4Z'2*[E_.5VM18KOVPH&(1CQ#MIR6W27*X7`D1B]#R7/"\ M/3X^(W/&24%W%SR3]/)9F&'!.DT"OE+2?V+BUR03VI/+F[6=,)[T[N>)*,;% M7E5N2$%S.L*$&.4T*.^4,HZ.-C4B9#6B&C+'7.7;DFP[#@$LZC0H$&B(Y5]F M6/,:I[,@I2&@?STM"AP`,<=,$1L'CU\(73R(#>#D21C?!?F4/]X3/ITKIM-I MGJ59D`BSNS#AU*\/%/CU5(LA]\R3>79!XUS(8SG3UM0HL`)%'3-Q;*^SK>2X M-;KZS3>P%Q0H]E9-5S:;\Q#%$\X;R\L<`;W%K+(VWY8(H/6)\^T,\Y7V\87J+I#?O4B>P=1 M/='T(Y'O(@`9+:DO@)A&6*.JLD9>[V"I)*`:,6G380-$(ZEW4<)`_JD1&7,; M;"AU:,"[T.)F+JD1*H`8&T:0S".&(8]FW(0^'\2*62RK"R=>EY$#Z+%!9)#< MN\#FE\RLX:\=??Q@>97B!0D5YN_$SZ>GFAA"/9TO.M7Z-@SBC7;=V9)PRN2V MFF>C%M3;"9;/6('Y#$(SH(Y8`8(>.@=A[@$R"PDNK`V/TI"86K M\NU,E1+2&R)V2BG-R"WA3S0D,_52NB$A6R2J1]";STV#PZ%=[F$[?,1 M\=:-=ZQ7N.)(G:,80F,I$DYR1+DZM8U+0!IY8!U; M,*">G@Y`YX$)Z70NKQ&^BMF7_94&VS[!J["#&F?.HPPVK-@'%[2;N/:$HHPI M`#6/,Y3@C^V-=HB`O,%;#*499T]4V*ZSU<_"\EPGF]R722C,55%)TCS%!W3D M"X)=/J#>"O(1Y3^L?\YIA,%F2R>7VF(8*5'NF-R/)2&-24V".S;.5-S[8U$, MCOTKW[OXB`LBT`BIPD)\CHD")8DFCW+W]WM@<,58-46!NYT2O`N?J#AQY/WE M'<4S],0H\($$]2Y4XH:(B4[#K(PJ-","$*-`!!+4NW)O+U7Y[*OR.?3GOE1Q MZ%O%P6UZMV`YE1$*ZF]ES5,>.G17?K?M``6$?10R8G&Z?:$I5KM$#+_[&)QX MYC9(,:N);2A\YQ%.ZY>P&U)9IPL`QJM;Z,N MUUUBJZ+*-AI7-0,[0PJYG:+\J\;7ED36E$W$T_I,YFH;I`#6Q/:O1%^;X49( MT#86J'*UDC6`5ITA1=9.4?[5^;-WZ^]\WH$#VCX*\:]P(,!]4<)[A&,L4T>8 MX34JR+^*@\+*K`/DPM]RRHF01PS0;"4]B?)N=1GUM)0D`+P].D`!:Q^%^%>\ M4#`;$A*I.GKR5J'I7'P3Y7(H$N/RUZ(A#O@L%.!E14#CGFS@-A4'9-W">UDL MT-+X[_Q6Q`%B'X7X5X,0X/Z*)D$2CK#8,76$&5ZC@OPK;5A].7QB&5GOL2S> MB35R%)#!POI7F[#VUJ[D7EP^$Q[2%*Q2V-T.'52`^/Y5+K0W"3O;2APH]E%( M5ZE"!\5&!.MB=R/_R!W.DU@[2R>4RE9HKM``0'MU@0+2?DH!0'7HQ-'S/Q'C ME/.5&)+_#&+PDC^[MHAA;*D!P&]`&NKN)3B0X.][68^^PD!CX#LTB5X7-`UC MEN9\G80MHRR*NJK2><4YX^=,"!&J%<;09*^>3SEPPE=/[L8I*6#SJ%/#[OW5FFH6/R(497>"7#/!&N_@LO!$;IV9(P& MXU]?/XZAVXY,&=@"E;_(?^[%%"0`` M.EH``!$`'`!C='1C+3(P,3(P,S,Q+GAS9%54"0`#0[NV3T.[MD]U>`L``00E M#@``!#D!``#M7&UOX[@1_GP%^A_8?*A;P*_)9F^3QGO(.ME%@.PZB+=%ORUH MB;:)HTD=2>7E?GV'E&3)D41)<>YL%/H4R9QYAL.'0PY),1>_/*T9>B!24<'' MG5%_V$&$>\*G?#GN4"5Z'SZ,`: M#*LNO'C]+I0%SY(N5QK]8_)/=#PJ9* MREN1-4;@!5?G/J'CSDKKX'PP>)I+UE?$ZR_%PP`*!@:H-QSU3D:=6'Q!V4;< M&`#4@&BJZ0/1Q%OU.=%6:WAB=+#6DLZAYI^%7%^1!0Z9'G="_EN(&5U0XD/+ M,;(F7&\)9(HUEDNBO^$U40'V2`/;MKY;\H\G?2&7(#(<#?[[]79FFR%Q[(E1 M_FN1^.CL[&Q@2Q/1G*1MMQCZ9&"*YUB1#3*44H<\Y4H;FK/ROMXF)18^'42% MB6BH>DN,@XWL`JNYE8T+"@CD@O-P75P=7\N!?@[(`(1Z($4D]3K08WZZP-#O MM.UWYA7>@X#RA;`O/UT8C\\3M^_)`MGF.C=0XR-%UP$C1_%O*TD6XR-/:Z^7 M4/4CD*0/E4M$I&"@5MI#\1U\0.;AW_FBC!\\;8)1%3D44$@N4@E\,7J)FC86`,^4?[?/+\(\U M8Y$RK>T(JZ?S@O@"I?BGA+PW)O2**H\)%4IRC26'3$'=$3E;07J0\N>0<=$U M-'2ENO"2J"/01Q:@I<1%R>QZ8I((/V3D$@+;8P1DWVUZ_6?*85ZGF-W`5"G7 MML;3Q3U94J4EYKJ(P5TA782?Y`@':R@Q!^EF9!"9E.%=-Q.]&ZLH8];$;FJX M[2BO&(PG6*T^,_'89"Q.=5Q4__RJH=A@(PO>TEE(9Y,I=8>9=/BN@+YV_MQM ML)[*)>;T=UN5M#GAY9+[=YGVF"XVPUW:T$5#]6Z`+OI_S@W465M=M&4-8>ZC MK#W3*=(1.S79=@]W3'_"S"S#9RM"=$DH;XNX*#QQ1G",@R*@EAA7W%YZG@BY MAKQTLL)\212$U[640DZ$E,1[,?`VU"NC$-8RPWQ^G$*B&-,>5%&=B6T*;) M$.0U48/><+ON6`GF$ZFN?PNI?JZ;';E!7.G2^Z;IDLV6XBY`."' MHAC<`*,8&5GH;C2:(HN.$OB69!?)T$IXSFR*`SF*##$K9+-(S$5;?L,H0;`# M9X+1IN'+7/*D& M#5DXE.!9"C.(+8.OF3/O`43:%.03X>!ALSFS0-L5K&>-YLP4'"7H+<<-4MG- MPE$+[]?RU6=C95>Z>]PDW'9S8%D#3(+@R#ZZ@BSPH&YB9*+ MX-RVPO;^P68%`REO!KT=IVL?B;\(T%R):WS-;[*W453:Y,(+3>=,_IJM5`Y: MSYGSX`P-=:1=<1.E-+%V]M'NMEJH[$ETRYAS;1A]=O1\QW!$!?3RP+1FX0JQ M5-@52L?Y=6*,`XL(@Q0M(39@+6$NPF[X`U%V>U)=D7G"@GZ>$2^45)?LCM;0 M()2&6+62*\+>Y5C;PK/1E2SJ4LB61C>-MKWN,$PU M%5LL9:*NK97\O)809&':1+W^'NB\,-VPO[N"YGW!CN6\S1_JGJ^7?])2)>L* MBZ*OTXI.R]NO7)J,9!ZA#_9LY59@KKX)353Z8[+)7S*TU=1U)17Y[<8,;!=9 MX"ZRT)F2S-G`_Q'!%X/,_29XV;K\=$'7@9`:1;?H;H5G2QSWN\Q;+[GDU3,_ M]4;'O9-1_TGY'<0+K[:5W!`;-*U`>J,KNLUES)\9\Z/WM@#"MDE]ZZ9V\LBHXK_'5KLK+BYSF MH89QYR70R'A\9Q-QRI@9!<8=R&/-_45ST_$<%OY4^":8QAT_C+Y-[B![.:L3 MW3X\]\4:4WX#$X@1ZY@QK;.@[$)7]S;HK%?U^UL\4Z`BC_4^'(]_3I)W"HN.T@W[F3\88(][+JE M>$X9\)!X4EI\D,Y\.]VN;^)%_O>#K/X,5(GZ5.Q#2>$!.S*!-0.TKW"F=$Y;>YYB+;+AGOR0'A(JH;D8MF#G.^_0&HSY3/,B+F9:4YTHZ^F M$E?*R_?*1H-#[RJR7@6UWZZXRUVN467G?2/TO391_I"BTF^GREZ=J;ME4N5A M!W87AN@]#"_DN0ZFOMU+?\E>[533IT] M#T<5)XN5SC5!V*NKY;>XJERLH[GG`0?&P\IQ)"NSU^I&XW9ES\J)[;O[U+R0 M5*,[-48Z2-?SWY6_UG47TGZ[ZHO_:U3=:+=_S%2Y9'XK^(/<$ODN(%W.;N$D;A<4_"D.--Q:B[]DN(*%G3EH M.@%N1J/$AY+"-^ZMA34N.[V)YS!'I5T2![+-4/YO.QIL/-0".FNB/Z1 MA;I1*B3^=S$C6C/R\AP'YFJ)6;*L(?[UDYG=:YS`I7GUKH;^V,/(W6M8\TCR MK1HD,6>:Y6(0'=+#X_\`4$L!`AX#%`````@`DHFR0`S?1&UL550%``-#N[9/=7@+ M``$$)0X```0Y`0``4$L!`AX#%`````@`DHFR0%H!_$2>!```GBT``!4`&``` M`````0```*2!RU<``&-T=&,M,C`Q,C`S,S%?8V%L+GAM;%54!0`#0[NV3W5X M"P`!!"4.```$.0$``%!+`0(>`Q0````(`)*)LD!#C!<8;AD``+2N`0`5`!@` M``````$```"D@;A<``!C='1C+3(P,3(P,S,Q7V1E9BYX;6Q55`4``T.[MD]U M>`L``00E#@``!#D!``!02P$"'@,4````"`"2B;)`UC+!?QTF``#-ZP$`%0`8 M```````!````I(%U=@``8W1T8RTR,#$R,#,S,5]L86(N>&UL550%``-#N[9/ M=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`DHFR0&]%SZ30'@``>PH"`!4` M&````````0```*2!X9P``&-T=&,M,C`Q,C`S,S%?<')E+GAM;%54!0`#0[NV M3W5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`)*)LD!=J$&WA0D``#I:```1 M`!@```````$```"D@0"\``!C='1C+3(P,3(P,S,Q+GAS9%54!0`#0[NV3W5X C"P`!!"4.```$.0$``%!+!08`````!@`&`!H"``#0Q0`````` ` end XML 21 R22.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting Changes and Error Corrections
3 Months Ended
Mar. 31, 2012
Accounting Changes and Error Corrections  
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

3.         RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

 

No new accounting pronouncements issued or effective during the three months ended March 31, 2012 has had or is expected to have a material impact on the consolidated financial statements.

XML 22 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "

"+ text.join( "

\n" ) +"

"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "

" + text[p] + "

\n"; } } }else{ formatted = '

' + raw + '

'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+' '+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } }
XML 23 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6
Accounting Policies
3 Months Ended
Mar. 31, 2012
Accounting Policies  
Business Description and Basis of Presentation [Text Block]

1.      BASIS OF PRESENTATION

 

The interim condensed consolidated financial information presented in the accompanying condensed consolidated financial statements and notes hereto is unaudited.

 

Competitive Technologies, Inc. ("CTTC") and its majority-owned subsidiary, Vector Vision, Inc. ("VVI"), (collectively, "we" or "us") provide patent and technology licensing and commercialization services throughout the world, with concentrations in the U.S., Europe and Asia, with respect to a broad range of life and physical sciences, electronics, and nanotechnologies originally invented by individuals, corporations and universities. 

 

These consolidated financial statements include the accounts of CTTC and VVI.  Inter-company accounts and transactions have been eliminated in consolidation.

 

We believe we made all adjustments necessary, consisting only of normal recurring adjustments, to present the unaudited condensed consolidated financial statements in conformity with accounting principles generally accepted in the U.S.  The results for the three months ended March 31, 2012 are not necessarily indicative of the results that can be expected for the next full fiscal year ending December 31, 2012.

 

The interim unaudited condensed consolidated financial statements and notes thereto, should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission ("SEC") on April 16, 2012.

 

During the three months ended March 31, 2012, and the three months ended March 31, 2011, we had a significant concentration of revenues from our Calmare® pain therapy medical device.  The percentages of gross revenue attributed to sales and rentals of Calmare® devices were 92% and 97% in the three months ended March 31, 2012 and March 31, 2011, respectively.  We continue to expand our sales activities for the Calmare® device and expect the majority of our revenues to come from this technology for at least the next two fiscal years.  However, we continue to seek revenue from new or existing technologies or products to mitigate the concentration of revenues, and replace revenues from expiring licenses and patents on other technologies. 

 

The Company incurred operating losses for the past three quarters, having produced marginal net income in the first quarter of 2011, after having incurred operating losses each quarter since fiscal 2006.  The Company has taken steps to significantly reduce its operating expenses going forward and expects revenue from sales of Calmare® medical devices to grow.  During the five month transitional period ended December 31, 2010; the Company undertook a major reduction of its operating expenses through staff reductions and reduced office space costs.  However, even at the reduced spending levels, should the anticipated increase in revenue from sales of Calmare® devices not occur the Company may not have sufficient cash flow to fund operating expenses beyond the fourth quarter of calendar 2012.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern.  The financial statements do not include adjustments to reflect the possible future effect of the recoverability and classification of assets or amounts and classifications of liabilities that may result from the outcome of this uncertainty.

 

The Company's continuation as a going concern is dependent upon its developing recurring revenue streams sufficient to cover operating costs.  The company does not have any significant individual cash or capital requirements in the budget going forward.  If necessary, CTTC will meet anticipated operating cash requirements by further reducing costs, issuing debt and/or equity, and/or pursuing sales of certain assets and technologies while we pursue licensing and distribution opportunities for our remaining portfolio of technologies.  There can be no assurance that the Company will be successful in such efforts.  Failure to develop a recurring revenue stream sufficient to cover operating expenses would negatively affect the Company’s financial position.

 

Our liquidity requirements arise principally from our working capital needs, including funds needed to sell our current technologies and obtain new technologies or products, and protect and enforce our intellectual property rights, if necessary.  We fund our liquidity requirements with a combination of cash on hand, cash flows from operations, if any, including royalty legal awards, short term borrowing, and sales of common stock.  At March 31, 2012, we had no outstanding long-term debt. 

 

During the fiscal 2011, the Company entered into a Factoring Agreement with Versant Funding, LLC ("Versant") to accelerate receivable collection and better manage cash flow.  Under the Factoring Agreement the Company will sell to Versant certain of the Company's accounts receivables.  For those accounts receivable the Company tenders to Versant and Versant chooses to purchase, Versant will advance 75% of the face value to the Company, and will submit a percentage of the remainder to the Company upon collection on the account.  The percentage is based on the time it takes Versant to collect on the account.   As part of the Factoring Agreement, the Company and Versant entered into a Security Agreement whereby the Company granted Versant a security interest in certain of the Company’s assets to secure the Company’s performance of the representations made with respect to the purchase of the accounts receivable.  At March 31, 2012, no receivables were factored.

                                                  

Sales of our Calmare® pain therapy medical device continue to be the major source of revenue for the Company.  The Company acquired the exclusive, worldwide rights to the "Scrambler Therapy" technology in 2007.  The Company's agreement with Giuseppe Marineo, the inventor of "Scrambler Therapy" technology, and Delta Research and Development ("Delta"), authorizes CTTC to manufacture and sell worldwide the device developed from the patented "Scrambler Therapy" technology.  The "Scrambler Therapy™" technology is patented in Italy and applications for patents have been filed in the U.S. and internationally and are pending approval.  The Calmare® device has CE Mark certification from the European Union as well as U.S. FDA 510(k) clearance.

 

The agreement with Professor Marineo and Delta enabled the Company to establish an agreement with GEOMC Co., Ltd. ("GEOMC", formerly Daeyang E & C Co., Ltd.) of Seoul, South Korea, to manufacture the Calmare® pain therapy medical device, based on Prof. Marineo's "Scrambler Therapy™" technology.  The GEOMC agreement is for a period of ten (10) years, through 2017, and outlines each company's specific financial obligations.

 

The Company has entered into a number of international distribution agreements, at one time covering nearly 40 countries.  The Company conducted a review of its distribution partners during the five-month period ending December 31, 2010, leading to the termination of CTTC's agreement with Life Epistéme Group, srl ("LEG").  LEG had the distribution rights in 34 countries, but had not met its minimum obligations to CTTC, and the Company had no indication that LEG would meet its commitments in the foreseeable future. 

           

 

During the quarter ended March 31, 2011, CTTC negotiated a new distribution agreement with Life Episteme Italia ("LEI") for the countries of Italy and Malta. The distribution agreement with LEI contained quarterly and annual marketing and sales requirements which LEI must meet in order to retain continued exclusivity within LEI's territory. 

 

In 2010, the Company became its own distributor in the U.S, contracting with 15 commissioned sales representatives.  During 2011, the Company and its representatives developed plans to increase awareness of the Calmare device among critical medical specialties and have begun to implement those plans targeting specific customers and locations in fiscal 2012.

 

Over the past 18 months, the Company entered into several sales agreements for the Calmare® device, including sales to U.S. government entities within the U.S. Department of Defense and the U.S. Department of Veterans Affairs.  Sales to these physicians and medical practices and to others with whom the Company had existing sales agreements are generating revenue for the Company. 

 

We earn revenue in two ways: retained royalties from licensing our clients' and our own technologies to our customer licensees, and sales of finished products.  We record revenue when the terms of the sales arrangement are accepted by all parties including a fee that is fixed and determinable, delivery has occurred and our customer has taken title, and collectability is reasonably assured.

 

            In 2011 the Company took greater control of the sales process, worldwide.  We are the primary obligor, responsible for delivering devices as well as for training our customers in the proper use of the device.  We deal directly with customers, setting pricing and providing training; work directly with the inventor of the technology to develop specifications and any changes thereto and to select and contract with manufacturing partners; and retain significant credit risk for amounts billed to customers.  Therefore, all product sales are recorded following a gross revenue methodology.

XML 24 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Balance Sheets (USD $)
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Dec. 31, 2011
Dec. 31, 2010
Cash and cash equivalents $ 1,570 $ 331,386 $ 28,485 $ 557,018
Restricted cash 750,000      
Receivables (69,544) (1,152,853)    
Inventory (230,000) (870,228)    
Prepaid expenses and other current assets 14,022 1,764    
Total current assets 4,609,986   5,101,380  
Security deposits 17,275   17,275  
Property and equipment, net 42,707   26,169  
TOTAL ASSETS 4,669,968   5,144,824  
Accounts payable, GEOMC 4,175,225   3,865,225  
Accrued expenses and other liabilities 549,500   1,228,473  
Preferred stock liability 375,000   375,000  
Total current liabilities 6,825,147   6,771,681  
5% preferred stock 60,675 [1]   60,675 [1]  
Series B preferred stock    [2]      [2]  
Series C convertible preferred stock    [3]      [3]  
Common stock 148,302 [4]   147,157 [4]  
Capital in excess of par value 45,036,867   44,771,128  
Accumulated deficit (47,401,023)   (46,605,817)  
Total shareholders' interest (Deficit) (2,155,179)   (1,626,857)  
TOTAL LIABILITIES AND SHAREHOLDERS' INTEREST (DEFICIT) $ 4,669,968   $ 5,144,824  
[1] $25 par value, 35,920 shares authorized, 2,427 shares issued and outstanding
[2] $0.001 par value, 20,000 shares authorized, no shares issued and outstanding
[3] $1,000 par value, 750 shares authorized, 375 shares issued and outstanding at March 31, 2012 and December 31, 2011
[4] $.01 par value, 20,000,000 shares authorized, 14,830,204 shares issued and outstanding at March 31, 2012 and 14,715,789 shares issued and outstanding at December 31, 2011
XML 25 R17.htm IDEA: XBRL DOCUMENT v2.4.0.6
Fair Value Measures and Disclosures
3 Months Ended
Mar. 31, 2012
Fair Value Measures and Disclosures  
Fair Value Disclosures [Text Block]

6.         FAIR VALUE MEASUREMEMENTS

 

The Company measures fair value in accordance with Topic 820 of the FASB Accounting Standards Codification ("ASC"), "Fair Value Measurements and Disclosures" ("ASC 820"), which provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described as follows:

 

Level 1 -   Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access.

 

Level 2 - Inputs to the valuation methodology include:

       Quoted prices for similar assets or liabilities in active markets;

       Quoted prices for identical or similar assets or liabilities in inactive markets;

       Inputs other than quoted prices that are observable for the asset or liability;

       Inputs that are derived principally from or corroborated by observable market data by correlation or other means.

If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

 

Level 3 - Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

 

The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.  Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs.

 

The Company values its derivative liability associated with the variable conversion feature on its Series C Convertible Preferred Stock (Note 12) based on the market price of its common stock.  For each reporting period the Company calculates the amount of potential common stock that the Series C Preferred Stock could convert into based on the conversion formula (incorporating market value of our common stock) and multiplies those converted shares by the market price of its common stock on that reporting date.  The total converted value is subtracted by the consideration paid to determine the fair value of the derivative liability.

 

The method described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value could result in a different fair value measurement at the reporting date.

 

The Company classified the derivative liability of $88,960 and $66,176 at March 31, 2012 and December 31, 2011, respectively, in Level 2 of the fair value hierarchy.

 

The carrying amounts reported in our Condensed Consolidated Balance Sheet for Cash and Cash Equivalents, Accounts Receivable, Accounts Payable, Notes Payable, Accrued Expenses and Other Liabilities and Preferred Stock Liability approximate fair value due to the short-term maturity of those financial instruments.

XML 26 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6
Document and Entity Information (USD $)
3 Months Ended
Mar. 31, 2012
Jun. 30, 2011
Document and Entity Information    
Entity Registrant Name Competitive Technologies Inc.  
Document Type 10-Q  
Document Period End Date Mar. 31, 2012  
Amendment Flag false  
Entity Central Index Key 0000102198  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding 14,715,789  
Entity Public Float   $ 20,707,445
Entity Filer Category Smaller Reporting Company  
Entity Current Reporting Status Yes  
Entity Voluntary Filers No  
Entity Well-known Seasoned Issuer No  
Document Fiscal Year Focus 2012  
Document Fiscal Period Focus Q1  
XML 27 R18.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Balance Sheets (USD $)
Mar. 31, 2012
Dec. 31, 2011
Cash and cash equivalents $ 1,570 $ 28,485
Restricted cash   750,000
Receivables, net 112,015 [1] 42,471 [1]
Inventory, Finished Goods 4,440,156 4,210,156
Prepaid expenses and other current assets 56,245 70,268
Total current assets 4,609,986 5,101,380
Property and equipment, net 42,707 26,169
Security deposits 17,275 17,275
TOTAL ASSETS 4,669,968 5,144,824
Accounts payable, general 1,326,862 1,124,007
Accounts payable, GEOMC 4,175,225 3,865,225
Accrued expenses and other liabilities 549,500 1,228,473
Notes payable 300,000 100,000
Deferred revenue 9,600 12,800
Derivative liability 88,960 66,176
Preferred stock liability 375,000 375,000
Total current liabilities 6,825,147 6,771,681
5% preferred stock 60,675 [2] 60,675 [2]
Series B preferred stock    [3]    [3]
Series C convertible preferred stock    [4]    [4]
Common stock 148,302 [5] 147,157 [5]
Capital in excess of par value 45,036,867 44,771,128
Accumulated deficit (47,401,023) (46,605,817)
Total shareholders' interest (Deficit) (2,155,179) (1,626,857)
TOTAL LIABILITIES AND SHAREHOLDERS' INTEREST (DEFICIT) $ 4,669,968 $ 5,144,824
[1] net of allowance of $101,154 at March 31, 2012, and December 31, 2011
[2] $25 par value, 35,920 shares authorized, 2,427 shares issued and outstanding
[3] $0.001 par value, 20,000 shares authorized, no shares issued and outstanding
[4] $1,000 par value, 750 shares authorized, 375 shares issued and outstanding at March 31, 2012 and December 31, 2011
[5] $.01 par value, 20,000,000 shares authorized, 14,830,204 shares issued and outstanding at March 31, 2012 and 14,715,789 shares issued and outstanding at December 31, 2011
XML 28 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations (USD $)
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Product sales $ 329,746 $ 1,827,056
Cost of product sales 150,571 856,754
Gross profit from product sales 179,175 970,302
Retained royalties 12,403 10,610
Investment income 1,497  
Other income 14,704 10,910
Selling expenses 86,940 100,793
Personnel and consulting expenses 331,370 367,119
General and administrative expenses 552,378 516,637
Interest expense 9,513 9,616
Total Expenses 1,002,985 997,116
Income (loss) before income taxes (795,206) 29,434
Net income (loss) $ (795,206) $ 29,434
Basic income (loss) per share $ (0.05) $ 0.00
Basic weighted average number of common shares outstanding: 14,752,251 13,826,055
Diluted income (loss) per share $ (0.05) $ 0.00
Diluted weighted average number of common shares outstanding: 14,752,251 14,466,787
XML 29 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6
Payables and Accruals
3 Months Ended
Mar. 31, 2012
Payables and Accruals  
Accounts Payable and Accrued Liabilities Disclosure [Text Block]

9.         ACCOUNTS PAYABLE, GENERAL

 

 

March 31, 2012

 

December 31, 2011

Legal fees payable

  $            785,534

 

  $           733,858

Accounting fees payable

                103,397

 

                 39,285

Consulting fees payable

                225,024

 

               110,515

Other payables

                212,907

 

               240,349

Accounts Payable, General

  $         1,326,862

 

  $        1,124,007

 

10.       ACCRUED EXPENSES AND OTHER LIABILITIES

 

 

March 31, 2012

 

December 31, 2011

Royalties payable

  $             284,948

 

  $          210,169

Deferred compensation

                     8,089

 

                          -

Accrued accounting fees

                   65,502

 

                93,529

Arbitration settlement payable

                             -

 

              775,000

Other accrued liabilities

                 190,961

 

              149,775

Accrued Expenses and Other Liabilities

  $             549,500

 

  $       1,228,473

 

            Deferred revenue includes 12 and 16 training days which were purchased but not conducted during the three months ended March 31, 2012 and year ended December 31, 2011, respectively. 

XML 30 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6
Property, Plant, and Equipment
3 Months Ended
Mar. 31, 2012
Property, Plant, and Equipment  
Property, Plant and Equipment Disclosure [Text Block]

8.         PROPERTY AND EQUIPMENT

 

Property and equipment, net, consist of the following:

 

 

March 31, 2012

 

December 31, 2011

Property and equipment, gross

  $             247,647

 

  $          227,645

Accumulated depreciation and amortization

                 204,940

 

              201,476

     Property and equipment, net

  $               42,707

 

  $            26,169

 

Depreciation and amortization expense was $3,464 and $8,154 for the three months ended March 31, 2012, and 2011, respectively. 

XML 31 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Operations (USD $)
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Product sales $ 329,746 $ 1,827,056
Cost of product sales 150,571 856,754
Gross profit from product sales 179,175 970,302
Gains on sale of rental assets   (34,728)
Retained royalties 12,403 10,610
Investment income 1,497  
Other income 14,704 10,910
Total other revenue 28,604 56,248
Selling expenses 86,940 100,793
Personnel and consulting expenses 331,370 367,119
General and administrative expenses 552,378 516,637
Interest expense 9,513 9,616
Unrealized loss on derivative instrument 22,784 2,951
Total Expenses 1,002,985 997,116
Income (loss) before income taxes (795,206) 29,434
Net income (loss) $ (795,206) $ 29,434
Basic income (loss) per share $ (0.05) $ 0.00
Basic weighted average number of common shares outstanding: 14,752,251 13,826,055
Diluted income (loss) per share $ (0.05) $ 0.00
Diluted weighted average number of common shares outstanding: 14,752,251 14,466,787
XML 32 R15.htm IDEA: XBRL DOCUMENT v2.4.0.6
Equity
3 Months Ended
Mar. 31, 2012
Equity  
Stockholders' Equity Note Disclosure [Text Block]

12.       SHAREHOLDERS’ INTEREST

 

On May 2, 2011 the Company adopted and executed the Employees’ Directors’ and Consultants Stock Option Plan (the “Plan”).  During the three months ended March 31, 2012, the Company granted 70,000 options to directors which were fully vested upon granting.  Also, 10,000 previously granted options were forfeited during the quarter ended March 31, 2012.  All outstanding options have been fully expensed.

 

During the three months ended March 31, 2012, the Board of Directors extended the expiration dates for all options previously granted to two departing Board members in recognition for their service during the period of managerial transition.  Those options will expire per their original term specified in each individual option agreement, typically either 5 or 10 years from the date of granting, rather than expiring within the specified time period, typically 90 days following the Board members’ termination dates.  The Company considered the extension as a modification to the option agreements recording incremental compensation of $80,000 for the three months ended March 31, 2012.

 

We estimated the fair value of each option on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions.

 

Three Months Ended March 31, 2012

Dividend yield (1)                                      0.0%
Expected volatility (2)                             86.7% - 87.1%
Risk-free interest rates (3)                          0.89%
Expected lives (2)                                    5 YEARS
 
(1)        We have not paid cash dividends on our common stock since 1981, and currently do not have plans to pay or declare cash dividends. Consequently, we used an expected dividend rate of zero for the valuations.
(2)        Estimated based on our historical experience. Volatility was based on historical experience over a period equivalent to the expected life in years.
(3)        Based on the U.S. Treasury constant maturity interest rate with a term consistent with the expected life of the options granted.

 

During the three months ended March 31, 2012, the Company recognized expense of $58,630 for stock options issued to directors during the current period.   During the three months ended March 31, 2011, the Company recognized expense of $4,720, for stock options issued to employees.

 

On December 15, 2010 the Company issued a $400,000 promissory note.  The promissory note was scheduled to mature on December 31, 2012 with an annual interest rate of 5%.

 

On December 15, 2010, the Company's Board of Directors authorized the issuance of 750 shares of Series C Convertible Preferred Stock ($1,000 par value) with a 5% cumulative dividend to William R. Waters, Ltd. of Canada.  On December 30, 2010, 750 shares were issued.  The Company converted the above $400,000 promissory note into 400 shares and received cash of $350,000 for the remaining 350 shares.  These transactions were necessitated to replenish the Company's operating cash which had been drawn down by the $750,000 cash collateral previously posted by CTTC in a prejudgment remedy action styled John B. Nano v. Competitive Technologies, Inc., Docket No. CV10 5029318 (Superior Court, Bridgeport, CT), see Note 12 below for details.  

 

On June 17, 2011, William R. Waters, Ltd. of Canada, advised the Company of its intent to convert one half of its Series C Convertible Preferred Stock, 375 shares, to common stock, with a conversion date of June 16, 2011.  On July 14, 2011, American Stock Transfer & Trust Company was asked to issue the certificate for 315,126 shares of CTTC common stock.  In accordance with the conversion rights detailed below, the conversion price for these shares was $1.19, which is 85% of the mid-point of the last bid price ($1.35) and the last ask price ($1.45) on June 16, 2011, the agreed upon conversion date.

 

The rights of the Series C Convertible Preferred Stock are as follows:

 

Dividend rights – The shares of Series C Convertible Preferred Stock accrue a 5% cumulative dividend on a quarterly basis and is payable on the last day of each fiscal quarter when declared by the Company’s Board.  Dividends declared for the three months ended March 31, 2012 were $4,623.  At March 31, 2012, $14,075 dividends declared have not been paid, including the $4,623 declared in the current quarter, and are shown in accrued and other liabilities.

 

Voting rights – Holders of these shares of Series C Convertible Preferred Stock shall have voting rights equivalent to 1,000 votes per $1,000 par value Series C Convertible Preferred share voted together with the shares of common stock

 

Liquidation rights – Upon any liquidation these Series C Convertible Preferred Stock shares shall be treated as equivalent to shares of Common stock to which they are convertible.

 

Redemption rights – The redemption rights were associated with the $750,000 that had been held in escrow by the Company in the event that the funds were released and returned to the company.  However, the funds were withdrawn from escrow and paid out in accordance with the settlement agreement (see Note 13 for details).  Therefore the redemption rights no longer apply to the remaining Series C Convertible Preferred Stock.

 

Conversion rights – Holder has right to convert each share of Series C Convertible Preferred Stock at any time into shares of the Company's common stock at a conversion price for each share of common stock equal to 85% of the lower of (1) the closing market price at the date of notice of conversion or (2) the mid-point of the last bid price and the last ask price on the date of the notice of conversion.  The variable conversion feature creates an embedded derivative that was bifurcated from the Series C Convertible Preferred Stock on the date of issuance and was recorded at fair value.  The derivative liability will be recorded at fair value on each reporting date with any change recorded in the Statement of Operations as an unrealized gain (loss) on derivative instrument.

 

On the date of conversion of the 375 shares of Series C Convertible Preferred Stock the Company calculated the value of the derivative liability to be $81,933 and recorded an unrealized loss of $15,678 for the six months ended June 30, 2011 related to the converted shares.  Upon conversion, the $81,933 derivative liability was reclassified to equity. 

 

The Company recorded a convertible preferred stock derivative liability of $88,960, associated with the 375 shares of Series C Convertible Preferred Stock outstanding at March 31, 2012, and $66,176, associated with the 375 shares of Series C Convertible Preferred Stock outstanding at December 31, 2011. 

 

The Company has classified the Series C Convertible Preferred Stock as a liability at March 31, 2012 and December 31, 2011 because the variable conversion feature may require the Company to settle the conversion in a variable number of its common shares. 

XML 33 R13.htm IDEA: XBRL DOCUMENT v2.4.0.6
Commitment and Contingencies
3 Months Ended
Mar. 31, 2012
Commitments and Contingencies {1}  
Commitments and Contingencies Disclosure [Text Block]

13.       CONTRACTURAL OBLIGATIONS AND CONTINGENCIES

 

As of March 31, 2012, CTTC and its majority-owned subsidiary, VVI, have remaining obligations, contingent upon receipt of certain revenue, to repay up to $199,006 and $203,478, respectively, in consideration of grant funding received in 1994 and 1995.  CTTC is also obligated to pay at the rate of 7.5% of its revenue, if any, from transferring rights to certain inventions supported by the grant funds.  VVI is obligated to pay at rates of 1.5% of its net sales of supported products or 15% of its revenue from licensing supported products, if any.  We recognize these obligations when we receive revenue related to the grant funds.  We recognized $425 and $345 of these obligations during the quarters ended March 31, 2012and March 31, 2011, respectively. 

 

On November 22, 2010, the Company terminated its operating lease and paid the landlord all existing obligations thereto.  The Company then entered into a new, three-year operating lease for new, more appropriately sized office spaces.  The obligations are significantly less that the previous lease, averaging $70,000 per year for the three-year term.  Under the previous lease, rent and utility obligations would have been approximately $300,000 per year for that same period.

 

In January 2011, the Company entered into a two-year lease effective February 1, 2011 for additional office space for the sales and training staff in Charlotte, NC.  Obligations under this lease average $27,000 per year for the two-year term.

 

Carolina Liquid Chemistries Corporation, et al. (Case pending) – On August 29, 2005, we filed a complaint against Carolina Liquid Chemistries Corporation ("Carolina Liquid") in the United States District Court for the District of Colorado, alleging patent infringement of our patent covering homocysteine assays, and seeking monetary damages, punitive damages, attorneys’ fees, court costs and other remuneration at the option of the court.  As we became aware of other infringers, we amended our complaint to add as defendants Catch, Inc. ("Catch") and the Diazyme Laboratories Division of General Atomics ("Diazyme").  On September 6, 2006, Diazyme filed for declaratory judgment in the Southern District of California for a change in venue and a declaration of non-infringement and invalidity.  On September 12, 2006, the District Court in Colorado ruled that both Catch and Diazyme be added as defendants to the Carolina Liquid case. 

 

On October 23, 2006, Diazyme requested the United States Patent and Trademark Office (the "USPTO") to re-evaluate the validity of our patent and this request was granted by the USPTO on December 14, 2006.  On July 30, 2009, the U.S. Patent and Trademark Office’s Board of Patent Appeals and Interferences (“BPAI”) upheld the homocysteine patent.  In September 2008, the examiner had denied the patent, but that denial was overruled by the BPAI.  While the examiner had appealed that BPAI decision, delaying further action, that appeal was also denied by the BPAI on December 13, 2010.  In June 2011, the examiner once again appealed the BPAI decision, was again denied.  In addition to responding to this new appeal, the Company had petitioned the Director of the USPTO to help expedite further action on the case within the USPTO, which was to have been handled with special dispatch according to USPTO requirements for handling reexamination proceedings of patents involved in litigation. 

 

On March 13, 2012, the USPTO issued the Ex Parte Reexamination Certificate confirming the patentability of claims examined.  Future action on this case pends its return to the District Court in Colorado. 

 

Employment matters – former employee (case pends) – In September 2003, a former employee filed a whistleblower complaint with OSHA alleging that the employee had been terminated for engaging in conduct protected under the Sarbanes Oxley Act of 2002 (SOX).  In February 2005, OSHA found probable cause to support the employee’s complaint and the Secretary of Labor ordered reinstatement and back wages since the date of termination and CTCC requested de novo review and a hearing before an administrative law judge (“ALJ”).  In July 2005, after the close of the hearing on CTTC’s appeal, the U.S. district court for Connecticut enforced the Secretary’s preliminary order of reinstatement and back pay under threat of contempt and the company rehired the employee with back pay. 

 

On October 5, 2005, the ALJ who conducted the hearing on CTTC’s appeal of the OSHA findings ruled in CTTC’s favor and recommended dismissal of the employee’s complaint.  Although the employee abandoned his position upon notice of the ALJ’s decision, he nevertheless filed a request for review by the DOL Administrative Review Board ("ARB"). 

 

In May 2006, the U.S. Court of Appeals for the Second Circuit vacated the order of the district court enforcing the Secretary’s preliminary order of reinstatement and back pay.  The employee also filed a new SOX retaliation complaint with OSHA based on alleged black listing action by CTTC following his termination.  OSHA dismissed the complaint and the employee filed a request for a hearing by an administrative law judge. Ultimately, the employee voluntarily dismissed the appeal.

 

In March 2008, the ARB issued an order of remand in the employee’s appeal of the October 2005 dismissal of his termination complaint, directing the ALJ to clarify her analysis utilizing the burden-shifting standard articulated by the ARB.  In January 2009, the ALJ issued a revised decision again recommending dismissal and once again the employee appealed the ruling to the ARB.  On September 30, 2011, the ARB issued a final decision and order affirming the ALJ’s decision on remand and dismissing the employee’s complaint.  The employee has appealed the ARB's decision before the U.S. Court of Appeals for the Second Circuit which has ordered the employee to file his opening brief by May 31, 2012.  Response briefs by the Solicitor's Office of the U.S. Department of Labor and CTTC are due by July 30, 2012.  No date has been set for oral argument.

 

John B. Nano vs. Competitive Technologies, Inc. - Arbitration (case completed) – On September 3, 2010, the Board of Directors of CTTC found cause consisting of violation of fiduciary duties to the Corporation and violation of the CTTC Corporate Code of Conduct and removed John B. Nano as an Officer of the Corporation, in all capacities.  On September 13, 2010, the Board of Directors also found cause consisting of violation of fiduciary duties to the Corporation and violation of the CTTC Corporate Code of Conduct removed John B. Nano as a Director of the Corporation, in all capacities, for cause, consisting of violation of his fiduciary duties.  Details of these actions are outlined in Form 8-K filings with the SEC on September 13, 2010, and September 17, 2010.  Mr. Nano was previously the Chairman of the Board of Directors, President and Chief Executive Officer of CTTC. 

 

On September 13, 2010, Mr. Nano brought an arbitration claim to the American Arbitration Association against CTTC.  Mr. Nano's employment contract with the Company had called for arbitration, which Mr. Nano had demanded to resolve this conflict.  Mr. Nano sought $750,000 that he claimed was owed under his contract and claimed that he had been terminated without cause. 

 

On September 23, 2010 the Company was served notice that John B. Nano, CTTC's former Chairman, President and CEO had filed a Notice of Application for Prejudgment Remedy/Claim of $750,000 and an Application for an Order Pendente Lite claiming we had breached Mr. Nano’s employment contract with us.  The applications were filed in the State of Connecticut Superior Court in Bridgeport, CT.  In November 2010, the Company funded $750,000 as a Prejudgment Remedy held in escrow with the Company's counsel and has included this amount as restricted cash on the December 31, 2011 and December 31, 2010 balance sheets.  The Company did not believe it was liable to the former Chairman, President and CEO, believing he was terminated for cause.  The case proceeded through the arbitration process.  The initial arbitration hearing began in April 2011; additional hearing dates were held in May and June 2011.  In July 2011, each party submitted a summary limited in length stating their positions. 

 

Prior to the conclusion of the arbitration hearings, the Company filed suit in Federal Court against the American Arbitration Association.  The Company requested a temporary restraining order to halt the arbitration, which was denied by the court.  The Company also requested a hearing before the court to review the arbitration proceedings.  In August 2011, the American Arbitration Association's assigned arbitrator gave award to the Company's former Chairman, President and CEO, despite the Company's strongly held belief that the Board of Directors properly exercised its reasonable discretion under the employment agreement in finding that the former executive engaged in willful misconduct and gross negligence and that the executive’s actions were cause for employment termination under the employment agreement and governing law.  The former executive had requested a payment of $750,000, which he believed was due under his employment agreement.  Following the notification of award, the former employee filed a motion with the State of Connecticut Superior Court in Bridgeport, CT to have the award confirmed.  CTTC followed with a motion to vacate the award.  A hearing on those two motions was held before a judge in October 2011. 

 

In January 2012, the judge denied the Company's motion to vacate the arbitration award in favor of its former CEO John B. Nano and granted Mr. Nano's application to confirm the award.  Following the decision, CTTC settled all disputes with its former Chairman and CEO, John B. Nano. Pursuant to the settlement, CTTC has released to Mr. Nano from escrow the $750,000 deposited by CTTC following Mr. Nano's application for a prejudgment remedy. CTTC paid an additional $25,000 as settlement of additional amounts of statutory interest.  These amounts ($775,000) had been accrued at December 31, 2011.  The settlement includes mutual general releases of any and all claims either party has or had against the other. The settlement agreement also includes a provision that neither CTTC nor Mr. Nano would disparage the other. Should any such disparagement occur and litigation ensue, they further agreed that the prevailing party would be entitled to recover its costs and expenses, including reasonable attorney's fees. CTTC's payments to Mr. Nano were completed in the quarter ended March 31, 2012.

 

Unfair Trade Practices; U.S. District Court of Connecticut (case completed) – In September 2011, the Company filed a complaint against an individual in U.S. District Court of Connecticut for (1) violation of the Connecticut Unfair Trade Practices Act, (2) tortious interference with business and economic expectancy, (3) libel and (4) injunctive relief.  The complaint noted that the individual named in the civil action has, for more than a year, engaged in a systematic campaign to destroy the Company's trades and business, interfere with the Company's expectations and contracts and libel the Company by disseminating materially false and libelous statements about the Company on message boards throughout the Internet and otherwise.  The Company sought punitive damages from the individual for his alleged unfair trade practices and wrongful interference with the Company's business.  The case was concluded in March 2012.  By the parties’ stipulation settling the matter, the defendant agreed to cease his posting of any statements on the Internet or publishing any statements elsewhere, orally or in writing, concerning CTTC, CTTC’s officers, directors, and employees, the Calmare device, Marineo (the inventor of the Calmare device), or any other person or entity in connection with their purchase or use of the Calmare device.

 

Summary – We may be a party to other legal actions and proceedings from time to time.  We are unable to estimate legal expenses or losses we may incur, if any, or possible damages we may recover, and have not recorded any potential judgment losses or proceeds in our financial statements to date, with the exception of the accrued expenses related to the Nano case, previously disclosed.  We record expenses in connection with these suits as incurred.

 

We believe we carry adequate liability insurance, directors and officers insurance, casualty insurance, for owned or leased tangible assets, and other insurance as needed to cover us against potential and actual claims and lawsuits that occur in the ordinary course of our business.  However, an unfavorable resolution of any or all matters, and/or our incurrence of significant legal fees and other costs to defend or prosecute any of these actions and proceedings may, depending on the amount and timing, have a material adverse effect on our consolidated financial position, results of operations or cash flows in a particular period.

XML 34 R14.htm IDEA: XBRL DOCUMENT v2.4.0.6
Debt
3 Months Ended
Mar. 31, 2012
Debt  
Debt Disclosure [Text Block]

11.       NOTES PAYABLE

 

In December 2011, the Company issued a 90-day note payable to borrow $100,000.  That note was originally extended for an additional 30 days in March 2012.  The proceeds were used for general corporate purposes.  In January 2012, two additional notes were issued to borrow $50,000 each.  In April and May, 2012 additional notes totaling $125,000 were issued.  On May 10, 2012 all notes totaling $325,000 were combined into one note.  Note payable bears simple of interest at 6.00% per annum.  Principal amounts totaling $300,000 and $25,000 including all unpaid interest are due on July 2, 2012 and August 1, 2012, respectively.    

 

In March 2012, the Company issued a 24-month convertible promissory note to borrow $100,000 for general corporate purposes.  The convertible promissory note bears simple interest of 6.00% simple interest per annum and is payable monthly in advance. At any time on or after September 13, 2012 the holder of the note may elect by notice to the Company to convert this convertible promissory note into shares of Company’s common stock at the rate of $1.05 per share.

XML 35 R16.htm IDEA: XBRL DOCUMENT v2.4.0.6
Earnings Per Share
3 Months Ended
Mar. 31, 2012
Earnings Per Share  
Earnings Per Share [Text Block]

2.      NET INCOME (LOSS) PER COMMON SHARE

 

The following sets forth the denominator used in the calculations of basic net income (loss) per share and net income (loss) per share assuming dilution:

 

 

Three  months ended

 

Three months ended

 

March 31, 2012

 

March 31, 2011

Denominator for basic net income (loss) per share, weighted average shares outstanding

               14,752,251

 

               13,826,055

Dilutive effect of common stock options

                           N/A

 

                        8,212

Dilutive Effect of Series C convertible preferred stock

                           N/A

 

                    632,520

Denominator for diluted net income (loss) per share, weighted average shares outstanding

               14,752,251

 

               14,466,787

 

Options to purchase 373,000 shares of our common stock outstanding at March 31, 2012 and 375 shares of convertible preferred stock at March 31, 2012 were not included in the computation of diluted net income (loss) per share because they were anti-dilutive. 

 

In the quarter ended March 31, 2011, those options with exercise prices less than $1.28, (average market price for the period) if exercised, would have resulted in dilution using the treasury stock method.  At March 31, 2011 the Company had 280,000 outstanding options to purchase its common stock, of which only 30,000 options had an exercise price less than $1.28.  In addition, 750 shares of convertible preferred stock were outstanding at March 31, 2011, with the dilutive effect of 632,520 shares of common stock.

XML 36 R21.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statements of Cash Flows (USD $)
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Net income (loss) $ (795,206) $ 29,434
Depreciation and amortization 3,464 8,154
Share-based compensation - stock options 138,630 4,720
Accrued stock contribution (directors stock exp)   (10,083)
Gains on sale of rental assets   (34,728)
Unrealized loss on derivative instrument 22,784 2,951
Receivables (69,544) (1,152,853)
Restricted cash 750,000  
Prepaid expenses and other current assets 14,022 1,764
Inventory (230,000) (870,228)
Accounts payable, accrued expenses and other liabilities (41,063) 1,708,077
Net cash (used in) operating activities (206,913) (312,792)
Purchase of property and equipment (20,002) (14,415)
Proceeds from sale of rental asset   43,800
Increase in security deposits   (2,275)
Net cash provided by (used in) provided by investing activities (20,002) 27,110
Proceeds from note payable 200,000 50,000
Proceeds from exercise of stock options   10,050
Cash provided by financing activities 200,000 60,050
Net (decrease) in cash and cash equivalents (26,915) (225,632)
Cash and cash equivalents at beginning of year 28,485 557,018
Cash and cash equivalents at end of year $ 1,570 $ 331,386
XML 37 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
3 Months Ended
Mar. 31, 2012
Mar. 31, 2011
Depreciation and amortization $ 3,464 $ 8,154
Accrued stock contribution (directors stock exp)   (10,083)
Unrealized loss on derivative instrument 22,784 2,951
Restricted cash 750,000  
Receivables (69,544) (1,152,853)
Prepaid expenses and other current assets 14,022 1,764
Inventory (230,000) (870,228)
Accounts payable, accrued expenses and other liabilities (41,063) 1,708,077
Net cash (used in) operating activities (206,913) (312,792)
Purchase of property and equipment (20,002) (14,415)
Proceeds from sale of rental asset   43,800
Increase in security deposits   (2,275)
Net cash provided by (used in) provided by investing activities (20,002) 27,110
Proceeds from exercise of stock options   10,050
Cash provided by financing activities 200,000 60,050
Net (decrease) in cash and cash equivalents (26,915) (225,632)
Cash and cash equivalents at beginning of year 28,485 557,018
Cash and cash equivalents at end of year $ 1,570 $ 331,386
XML 38 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6
Deferred Costs, Capitalized, Prepaid, and Other Assets
3 Months Ended
Mar. 31, 2012
Deferred Costs, Capitalized, Prepaid, and Other Assets  
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]

7.         PREPAID EXPENSES AND OTHER CURRENT ASSETS

 

Prepaid expenses and other current assets consist of the following:

 

 

March 31, 2012

 

December 31, 2011

Prepaid insurance

  $                    855

 

  $            25,283

Travel and commission advances

                   35,500

 

                35,500

Other

                   19,890

 

                  9,485

Prepaid expenses and other current assets

  $               56,245

 

  $            70,268

XML 39 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 21 98 1 true 5 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.competitivetech.net/20120331/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information false false R2.htm 000020 - Statement - Consolidated Statements of Changes in Stockholders' Equity Sheet http://www.competitivetech.net/20120331/role/idr_ConsolidatedStatementsOfChangesInStockholdersEquity Consolidated Statements of Changes in Stockholders' Equity true false R3.htm 000030 - Statement - Consolidated Balance Sheets Sheet http://www.competitivetech.net/20120331/role/idr_ConsolidatedBalanceSheets Consolidated Balance Sheets false false R4.htm 000040 - Statement - Consolidated Statements of Operations Sheet http://www.competitivetech.net/20120331/role/idr_ConsolidatedStatementsOfOperations Consolidated Statements of Operations false false R5.htm 000050 - Statement - Consolidated Statements of Cash Flows Sheet http://www.competitivetech.net/20120331/role/idr_ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows false false R6.htm 000060 - Statement - Statement of Cash Flows, Supplemental Disclosures Sheet http://www.competitivetech.net/20120331/role/idr_StatementOfCashFlowsSupplementalDisclosures Statement of Cash Flows, Supplemental Disclosures false false R7.htm 000080 - Disclosure - Accounting Policies Sheet http://www.competitivetech.net/20120331/role/idr_DisclosureAccountingPolicies Accounting Policies false false R8.htm 000090 - Disclosure - Receivables, Loans, Notes Receivable, and Others Notes http://www.competitivetech.net/20120331/role/idr_DisclosureReceivablesLoansNotesReceivableAndOthers Receivables, Loans, Notes Receivable, and Others false false R9.htm 000100 - Disclosure - Investments, Debt and Equity Securities Sheet http://www.competitivetech.net/20120331/role/idr_DisclosureInvestmentsDebtAndEquitySecurities Investments, Debt and Equity Securities false false R10.htm 000110 - Disclosure - Deferred Costs, Capitalized, Prepaid, and Other Assets Sheet http://www.competitivetech.net/20120331/role/idr_DisclosureDeferredCostsCapitalizedPrepaidAndOtherAssets Deferred Costs, Capitalized, Prepaid, and Other Assets false false R11.htm 000120 - Disclosure - Property, Plant, and Equipment Sheet http://www.competitivetech.net/20120331/role/idr_DisclosurePropertyPlantAndEquipment Property, Plant, and Equipment false false R12.htm 000130 - Disclosure - Payables and Accruals Sheet http://www.competitivetech.net/20120331/role/idr_DisclosurePayablesAndAccruals Payables and Accruals false false R13.htm 000150 - Disclosure - Commitment and Contingencies Sheet http://www.competitivetech.net/20120331/role/idr_DisclosureCommitmentAndContingencies Commitment and Contingencies false false R14.htm 000160 - Disclosure - Debt Sheet http://www.competitivetech.net/20120331/role/idr_DisclosureDebt Debt false false R15.htm 000170 - Disclosure - Equity Sheet http://www.competitivetech.net/20120331/role/idr_DisclosureEquity Equity false false R16.htm 000200 - Disclosure - Earnings Per Share Sheet http://www.competitivetech.net/20120331/role/idr_DisclosureEarningsPerShare Earnings Per Share false false R17.htm 000210 - Disclosure - Fair Value Measures and Disclosures Sheet http://www.competitivetech.net/20120331/role/idr_DisclosureFairValueMeasuresAndDisclosures Fair Value Measures and Disclosures false false R18.htm 000240 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.competitivetech.net/20120331/role/idr_CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets false false R19.htm 000250 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.competitivetech.net/20120331/role/idr_CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations false false R20.htm 000260 - Statement - Condensed Consolidated Statement of Changes in Shareholders' Equity Sheet http://www.competitivetech.net/20120331/role/idr_CondensedConsolidatedStatementOfChangesInShareholdersEquity Condensed Consolidated Statement of Changes in Shareholders' Equity false false R21.htm 000270 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.competitivetech.net/20120331/role/idr_CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows false false R22.htm 250000 - Disclosure - Accounting Changes and Error Corrections Sheet http://www.competitivetech.net/20120331/role/idr_DisclosureAccountingChangesAndErrorCorrections Accounting Changes and Error Corrections false false All Reports Book All Reports Process Flow-Through: 000030 - Statement - Consolidated Balance Sheets Process Flow-Through: 000040 - Statement - Consolidated Statements of Operations Process Flow-Through: 000050 - Statement - Consolidated Statements of Cash Flows Process Flow-Through: 000060 - Statement - Statement of Cash Flows, Supplemental Disclosures Process Flow-Through: 000240 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Mar. 31, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 000250 - Statement - Condensed Consolidated Statements of Operations Process Flow-Through: 000270 - Statement - Condensed Consolidated Statements of Cash Flows cttc-20120331.xml cttc-20120331.xsd cttc-20120331_cal.xml cttc-20120331_def.xml cttc-20120331_lab.xml cttc-20120331_pre.xml true true XML 40 R20.htm IDEA: XBRL DOCUMENT v2.4.0.6
Condensed Consolidated Statement of Changes in Shareholders' Equity (USD $)
Preferred Stock
Common Stock
Capital in excess of par value
Accumulated deficit
Total shareholders' interest(deficit)
Balance - December 31, 2011 at Dec. 31, 2011 $ 60,675 $ 147,157 $ 44,771,128 $ (46,605,817) $ (1,626,857)
Net income (loss)       (795,206) (795,206)
Common shares issued to settle accounts payable, general and accrued expenses   1,145 127,109   128,254
Common shares issued to settle accounts payable, general and accrued expenses (Shares)   114,415      
Compensation expense from stock option grants     138,630   138,630
Balance - August 1, 2010 at Mar. 31, 2012 $ 60,675 $ 148,302 $ 45,036,867 $ (47,401,023) $ (2,155,179)
Share Balance - August 1, 2010 at Mar. 31, 2012 2,427 14,830,204